1
00:00:05,600 --> 00:00:08,600
>> WELCOME BACK, EVERYONE
TODAY

2
00:00:08,600 --> 00:00:10,320
TO THE SECOND DAY OF THE STATE

3
00:00:10,320 --> 00:00:12,800
OF SCIENCE AND TRANSFUSION

4
00:00:12,800 --> 00:00:16,960
MEDICINE SYMPOSIUM. I'M HAPPY TO

5
00:00:16,960 --> 00:00:18,840
SEE YOU JOIN AGAIN, AS OTHERS

6
00:00:18,840 --> 00:00:22,800
ARE JOINING NOW. YESTERDAY WE

7
00:00:22,800 --> 00:00:24,800
HEARD AND DISCUSSED RESEARCH

8
00:00:24,800 --> 00:00:26,880
PRIORITIES FROM THREE WORKS

9
00:00:26,880 --> 00:00:28,800
GROUPS FOCUSED ON BLOOD DONORS

10
00:00:28,800 --> 00:00:30,840
AND SUPPLY, OPTIMIZING

11
00:00:30,840 --> 00:00:32,800
TRANSFUSION OUTCOMES AND

12
00:00:32,800 --> 00:00:34,200
RECIPIENTS AND EMERGING

13
00:00:34,200 --> 00:00:36,280
INFECTIONS. TODAY YOU WILL HEAR

14
00:00:36,280 --> 00:00:38,240
PRESENTATION RESEARCH PRIORITIES

15
00:00:38,240 --> 00:00:39,120
FROM THREE MORE STATE OF THE

16
00:00:39,120 --> 00:00:40,800
SCIENCE WORKING GROUPS FOCUSED

17
00:00:40,800 --> 00:00:42,760
ON MECHANISTIC ASPECT OF

18
00:00:42,760 --> 00:00:44,640
COMPONENTS IN TRANSFUSION, NEW

19
00:00:44,640 --> 00:00:46,880
METHODS IN TRANSFUSION SCIENCE,

20
00:00:46,880 --> 00:00:48,920
AND DONOR AND RECIPIENT HEALTH

21
00:00:48,920 --> 00:00:51,440
DISPARITIES. AS REMINDER FOR

22
00:00:51,440 --> 00:00:53,720
THOSE WHO ARE NOT WITH US

23
00:00:53,720 --> 00:00:54,760
YESTERDAY WE ASK DURING THE

24
00:00:54,760 --> 00:00:56,400
PRESENTATIONS YOUR MICROPHONES

25
00:00:56,400 --> 00:00:58,280
REMAIN MUTED AND YOU UTILIZE THE

26
00:00:58,280 --> 00:01:01,800
ZOOM CHAT BOX TO ASK QUESTIONS.

27
00:01:01,800 --> 00:01:04,000
OR MAKE COMMENTS. MANY OF YOU

28
00:01:04,000 --> 00:01:08,080
SHOULD HAVE RECEIVED BIOSKETCHES

29
00:01:08,080 --> 00:01:11,480
ON OUR SPEAKERS. YESTERDAY AND

30
00:01:11,480 --> 00:01:14,720
IN PARALLEL WITH YESTERDAY'S

31
00:01:14,720 --> 00:01:16,160
AGENDA FOLLOWING THE THREE

32
00:01:16,160 --> 00:01:18,600
PRESENTATIONS BY THE WORKING

33
00:01:18,600 --> 00:01:20,120
GROUP CO-CHAIRS, WHETHER HE HAVE

34
00:01:20,120 --> 00:01:21,600
A LUNCH BREAK THEN RETURN TO

35
00:01:21,600 --> 00:01:24,920
PARTICIPATE IN ONE OF THREE

36
00:01:24,920 --> 00:01:26,160
SIMULTANEOUSLY OCCURRING BREAK

37
00:01:26,160 --> 00:01:28,600
OUT SESSIONS.  LUNCH BREAK WE'LL

38
00:01:28,600 --> 00:01:29,600
PROVIDE INSTRUCTIONS THOUSAND

39
00:01:29,600 --> 00:01:31,080
ENTER THE BREAK OUT ROOMS AND

40
00:01:31,080 --> 00:01:32,240
DURING THE THE BREAK OUT

41
00:01:32,240 --> 00:01:33,160
SESSIONS YOU WILL HAVE THE

42
00:01:33,160 --> 00:01:34,920
OPPORTUNITY TO ASK QUESTIONS OR

43
00:01:34,920 --> 00:01:37,360
MAKE COMMENTS VIA THE CHAT BOX

44
00:01:37,360 --> 00:01:38,920
OR RAISE YOUR HAND THROUGH THE

45
00:01:38,920 --> 00:01:40,760
ZOOM PORTAL TO BE CALLED ON TO

46
00:01:40,760 --> 00:01:45,080
SPEAK. IN PARALLEL WITH

47
00:01:45,080 --> 00:01:47,080
YESTERDAY'S PRESENTATION, AFTER

48
00:01:47,080 --> 00:01:48,880
THE BREAK OUT SESSIONS EACH

49
00:01:48,880 --> 00:01:50,520
WORKING GROUP WILL PRESENT A

50
00:01:50,520 --> 00:01:52,720
SUMMARY OF THE DISCUSSION. WE

51
00:01:52,720 --> 00:01:54,640
ALSO HOPE TO HAVE SOME TIME FOR

52
00:01:54,640 --> 00:01:56,160
OPEN DISCOURSE AND PRESENT SOME

53
00:01:56,160 --> 00:01:59,760
FINAL THOUGHTS PRIOR TO CLOSING

54
00:01:59,760 --> 00:02:01,680
THE MEETING THIS AFTERNOON. WE

55
00:02:01,680 --> 00:02:03,840
ARE PLEASED TO HAVE TWO KEYNOTE

56
00:02:03,840 --> 00:02:05,280
SPEAKERS TO SHARE PERSPECTIVES

57
00:02:05,280 --> 00:02:06,560
ON STATE OF THE SCIENCE IN

58
00:02:06,560 --> 00:02:07,800
TRANSFUSION MEDICINE AND I WILL

59
00:02:07,800 --> 00:02:09,440
TURN IT OVER TO BRIAN TO

60
00:02:09,440 --> 00:02:10,680
INTRODUCE OUR FIRST KEYNOTE

61
00:02:10,680 --> 00:02:15,040
SPEAKER FOR TODAY. 

62
00:02:15,040 --> 00:02:18,920
>> THANK YOU SO MUCH,
NAREG.

63
00:02:18,920 --> 00:02:20,480
APPRECIATE HANDING OVER TO ME

64
00:02:20,480 --> 00:02:22,600
AND THANKS TO EVERYBODY FOR

65
00:02:22,600 --> 00:02:23,840
JOINING US AGAIN TODAY, VERY

66
00:02:23,840 --> 00:02:26,280
EXCITED FOR THE SECOND DAY OF

67
00:02:26,280 --> 00:02:28,120
THE WORKSHOP AND ALSO THE

68
00:02:28,120 --> 00:02:29,440
OPPORTUNITY TO BE ABLE TO

69
00:02:29,440 --> 00:02:30,760
INTRODUCE OUR FIRST KEYNOTE

70
00:02:30,760 --> 00:02:33,760
SPEAKER OF THE DAY. FIRST

71
00:02:33,760 --> 00:02:35,560
KEYNOTE SPEAKER IS DR. DANA

72
00:02:35,560 --> 00:02:36,520
DEVINE, DIRECTOR OF THE

73
00:02:36,520 --> 00:02:38,800
UNIVERSITY OF BRITISH COLUMBIA

74
00:02:38,800 --> 00:02:40,160
CENTER FOR BLOOD RESEARCH AND

75
00:02:40,160 --> 00:02:42,480
SHE IS THE CHIEF SCIENTIST AT

76
00:02:42,480 --> 00:02:44,800
CANADIAN BLOOD SERVICES. SHE WAS

77
00:02:44,800 --> 00:02:46,560
FORMALLY VICE PRESIDENT MEDICAL

78
00:02:46,560 --> 00:02:48,440
AND SCIENTIFIC SERVICES AT

79
00:02:48,440 --> 00:02:50,040
COMMUNITY BLOOD SERVICES,

80
00:02:50,040 --> 00:02:52,560
POSITION SHE HELD FOR 11 YEARS.

81
00:02:52,560 --> 00:02:54,760
BEFORE THAT SHE WAS DIRECTOR OF

82
00:02:54,760 --> 00:02:56,080
THE CANADIAN BLOOD SERVICES

83
00:02:56,080 --> 00:02:58,320
CENTER FOR INNOVATION. AS MANY

84
00:02:58,320 --> 00:03:00,000
OF YOU KNOW, SHE IS CURRENTLY

85
00:03:00,000 --> 00:03:01,960
THE PRESIDENT OF THE ASSOCIATION

86
00:03:01,960 --> 00:03:04,800
FOR THE ADVANCEMENT OF BLOOD AND

87
00:03:04,800 --> 00:03:09,480
BIOTHERAPIES.  WE ARE THRILLED

88
00:03:09,480 --> 00:03:11,160
THAT DANA WILL BE HERE TODAY. 

89
00:03:11,160 --> 00:03:12,600
SHE IS GOING TO PRESENT

90
00:03:12,600 --> 00:03:13,600
PRE-RECORDED REMARKS. HOWEVER

91
00:03:13,600 --> 00:03:14,840
SHE IS ONLINE AND WILL BE ABLE

92
00:03:14,840 --> 00:03:16,840
TO FOLLOW UP WITH ANY QUESTIONS

93
00:03:16,840 --> 00:03:20,480
ON -- AND ANSWER THOSE. WITHOUT

94
00:03:20,480 --> 00:03:22,040
ANY MORE WAITING LET'S PLEASE

95
00:03:22,040 --> 00:03:24,480
TURN IT OVER TO HEAR DR. DEVINE

96
00:03:24,480 --> 00:03:31,080
KEYNOTE ADDRESS. THANK YOU.

97
00:03:31,080 --> 00:03:32,560
>> GOOD MORNING OR GOOD

98
00:03:32,560 --> 00:03:33,440
AFTERNOON, WHEREVER YOU HAPPEN

99
00:03:33,440 --> 00:03:36,040
TO BE. THIS IS DANA DEVINE

100
00:03:36,040 --> 00:03:38,320
SPEAKING. I AM CURRENTLY THE

101
00:03:38,320 --> 00:03:41,120
DIRECTOR OF THE UNIVERSITY

102
00:03:41,120 --> 00:03:42,320
BRITISH COLUMBIA CENTER FOR

103
00:03:42,320 --> 00:03:43,760
BLOOD RESEARCH AND CHIEF

104
00:03:43,760 --> 00:03:44,920
SCIENTIST FOR CANADIAN BLOOD

105
00:03:44,920 --> 00:03:46,240
SERVICES. I WANT TO TALK TO YOU

106
00:03:46,240 --> 00:03:49,440
TODAY ABOUT THE IMPACT OF BLOOD

107
00:03:49,440 --> 00:03:51,840
DONOR VARIATION ON TRANSFUSION

108
00:03:51,840 --> 00:03:52,840
PRODUCT QUALITY. I THINK THIS IS

109
00:03:52,840 --> 00:03:57,560
AN AREA THAT IS HAS BECOME

110
00:03:57,560 --> 00:03:58,360
GREATER INTEREST IN RECENT

111
00:03:58,360 --> 00:04:02,680
YEARS. SO I HAVE A FEW

112
00:04:02,680 --> 00:04:04,560
DISCLOSURES. I AM A HALF TIME

113
00:04:04,560 --> 00:04:05,800
EMPLOYEE OF CANADIAN BLOOD

114
00:04:05,800 --> 00:04:07,840
SERVICES, I CHAIR THE BOARD OF

115
00:04:07,840 --> 00:04:11,120
MACRO PHARMA, CHAIR MEDICAL

116
00:04:11,120 --> 00:04:12,800
ADVISORY COMMITTEE OF RED CROSS

117
00:04:12,800 --> 00:04:13,800
AND MEMBER OF THE BOARD OF

118
00:04:13,800 --> 00:04:16,600
DIRECTORS OF STORM BIO, A BOSTON

119
00:04:16,600 --> 00:04:17,800
BASED STARTUP IN THE GENE

120
00:04:17,800 --> 00:04:18,960
THERAPY AREA WHICH WAS FOUNDED

121
00:04:18,960 --> 00:04:20,880
BY ONE OF MY FORMER GRADUATE

122
00:04:20,880 --> 00:04:24,360
STUDENTS. SO I GUESS THE

123
00:04:24,360 --> 00:04:27,440
QUESTION THAT WE ARE TRYING TO

124
00:04:27,440 --> 00:04:28,920
ANSWER FOR TODAY IS WHAT HAPPENS

125
00:04:28,920 --> 00:04:30,920
TO BLOOD CELLS IN STORAGE? I

126
00:04:30,920 --> 00:04:32,960
THINK THAT WE ALL ARE ALL WELL

127
00:04:32,960 --> 00:04:34,840
AWARE THAT CELLULAR BLOOD

128
00:04:34,840 --> 00:04:36,600
PRODUCTS DEVELOP STORAGE LESIONS

129
00:04:36,600 --> 00:04:37,840
OVER TIME AND THESE HAVE A

130
00:04:37,840 --> 00:04:42,760
NEGATIVE IMPACT ON BLOOD PRODUCT

131
00:04:42,760 --> 00:04:45,600
QUALITY. THIS CAN BE

132
00:04:45,600 --> 00:04:49,920
DEMONSTRATED BY A COLLECTION OF

133
00:04:49,920 --> 00:04:51,360
DATA THAT WAS PUT TOGETHER BY

134
00:04:51,360 --> 00:04:52,760
THE BEST COLLABORATIVE AND

135
00:04:52,760 --> 00:04:56,920
PUBLISHED IN 2008 IN

136
00:04:56,920 --> 00:04:58,280
TRANSFUSION. WHAT YOU CAN SEE IN

137
00:04:58,280 --> 00:05:02,440
THIS SLIDE IS SIMPLY THAT THE

138
00:05:02,440 --> 00:05:05,040
MINIMUM STANDARD FOR 24 HOUR

139
00:05:05,040 --> 00:05:10,000
RECOVERY FOR THE FDA IS 75%. YOU

140
00:05:10,000 --> 00:05:12,720
CAN SEE THAT THERE ARE NUMBER OF

141
00:05:12,720 --> 00:05:14,280
INDIVIDUALS WHO DON'T REACH THAT

142
00:05:14,280 --> 00:05:18,440
75%.  THIS IS A REFLECTION OF

143
00:05:18,440 --> 00:05:21,360
THE FACT THAT THERE'S A LOT OF

144
00:05:21,360 --> 00:05:24,680
VARIABILITY AMONG BLOOD DONORS

145
00:05:24,680 --> 00:05:27,080
AND THIS IS REFLECTED IN THE

146
00:05:27,080 --> 00:05:29,920
SURVIVAL RECOVERY OF THE RED

147
00:05:29,920 --> 00:05:33,440
CELLS. YOU CAN ALSO SEE IF YOU

148
00:05:33,440 --> 00:05:38,880
LOOK AT IMAGES OF RED CELLS IN

149
00:05:38,880 --> 00:05:45,800
STORAGE, THIS IS ADOPTED FROM

150
00:05:45,800 --> 00:05:52,520
ANOTHER TRANSFUSION PAPER. WHEN

151
00:05:52,520 --> 00:05:53,960
WE ARE TALKING BLOOD COMPONENT

152
00:05:53,960 --> 00:05:55,320
QUALITY WE ARE TALKING ABOUT THE

153
00:05:55,320 --> 00:05:58,000
IMAGES DAY ONE. BY THE THE TIME

154
00:05:58,000 --> 00:06:00,160
YOU HAVE GOTTEN TO DAY 21 YOU

155
00:06:00,160 --> 00:06:07,440
SEE A LOT OF RED CELL FORMS,

156
00:06:07,440 --> 00:06:11,640
THESE RED CELL FORMS ARE

157
00:06:11,640 --> 00:06:13,480
BLEVVING OFF FROM TIPS AND

158
00:06:13,480 --> 00:06:14,480
CREATING MICROPARTICLES IN THE

159
00:06:14,480 --> 00:06:21,280
UNIT. IF BY DAY 35 YOU HAVE RED

160
00:06:21,280 --> 00:06:29,280
CELLS THAT ARE SPE SPHERICAL AND

161
00:06:29,280 --> 00:06:31,360
COMPLETED THIS BLOOD BLEVVING

162
00:06:31,360 --> 00:06:33,400
PROCESS AND ON THE WAY TO LYSIS.

163
00:06:33,400 --> 00:06:35,400
SO THESE ARE NOT THE GREATEST

164
00:06:35,400 --> 00:06:37,280
RED CELLS TO TRANSPHUTS TO

165
00:06:37,280 --> 00:06:41,000
PATIENTS.  WE CAN SEE THESE

166
00:06:41,000 --> 00:06:45,640
STORAGE INDUCED

167
00:06:45,640 --> 00:06:46,280
MICROERYTHROCYTES AND HERE YOU

168
00:06:46,280 --> 00:06:48,960
HAVE -- THESE ARE DAY ONE, AND

169
00:06:48,960 --> 00:06:51,480
HERE YOU GO ON THROUGH VARIOUS

170
00:06:51,480 --> 00:06:54,160
WEEKS AND YOU CAN SEE THAT WE

171
00:06:54,160 --> 00:06:56,920
GET THESE VERY ROUND SPHERICAL

172
00:06:56,920 --> 00:07:01,440
CELLS BY 42 DAYS STORAGE, THESE

173
00:07:01,440 --> 00:07:04,640
CELLS ARE VERY DIFFICULT TO GET

174
00:07:04,640 --> 00:07:07,840
THROUGH SPLENIC SINUSES BECAUSE

175
00:07:07,840 --> 00:07:10,600
THEY ARE ROUND SO THEY DON'T

176
00:07:10,600 --> 00:07:12,160
HAVE THE DEFORMABILITY

177
00:07:12,160 --> 00:07:13,520
CAPABILITIES THAT FRESH RED

178
00:07:13,520 --> 00:07:20,240
CELLS DO. WE HAVE EXAMPLES IN

179
00:07:20,240 --> 00:07:23,040
THIS GRAPH OF HIGH STORAGE

180
00:07:23,040 --> 00:07:25,560
INDUCED MICROERYTHROCYTE FORMERS

181
00:07:25,560 --> 00:07:27,520
AND YOU CAN SEE SOMETIMES THIS

182
00:07:27,520 --> 00:07:32,760
IS VERY HIGH INDEED. WE HAVE LOW

183
00:07:32,760 --> 00:07:36,320
STORAGE INDUCED MICROERYTHROCYTE

184
00:07:36,320 --> 00:07:37,640
PERFORMERS WHICH ARE THE BETTER

185
00:07:37,640 --> 00:07:39,840
DONORS.  THERE IS ALSO AN IMPACT

186
00:07:39,840 --> 00:07:45,880
OF -- THIS IS DATA FROM KANIAS.

187
00:07:45,880 --> 00:07:53,000
THIS IS AN EXAMPLE OF STORAGE

188
00:07:53,000 --> 00:07:54,680
REMOLLSIS BY AGE. YOU CAN SEE

189
00:07:54,680 --> 00:07:57,800
THAT FEMALES ARE GENERALLY DOING

190
00:07:57,800 --> 00:08:01,880
BETTER IN STORAGE THAN GUYS ARE.

191
00:08:01,880 --> 00:08:06,720
SO THIS IS A GRAPH OF THE

192
00:08:06,720 --> 00:08:08,800
VARIABILITY YOU SEE IN BETWEEN

193
00:08:08,800 --> 00:08:15,720
THE GENDERS.  OVER HERE ON THIS

194
00:08:15,720 --> 00:08:18,240
OTHER SIDE ARE SOME DATA THAT

195
00:08:18,240 --> 00:08:20,120
LOOK AT OSMOTIC FRAGILITY. YOU

196
00:08:20,120 --> 00:08:23,960
CAN SEE THE OSMOTIC FRAGILITY IN

197
00:08:23,960 --> 00:08:28,080
MEN IS IS MARKEDLY DIFFERENT

198
00:08:28,080 --> 00:08:33,320
THAN IN WOMEN, AS IS THE PLASMA

199
00:08:33,320 --> 00:08:37,840
TAC WHICH IS TOTAL -- FORGOT

200
00:08:37,840 --> 00:08:39,040
WHAT THE ABBREVIATION STANDS

201
00:08:39,040 --> 00:08:43,640
FOR. SORRY. SO THIS IS JUST WHAT

202
00:08:43,640 --> 00:08:45,440
WE ARE LOOKING AT THE DIFFERENCE

203
00:08:45,440 --> 00:08:49,600
BETWEEN GENDERS. WE ALSO SEE

204
00:08:49,600 --> 00:08:50,920
THIS IS WORK OUT OF MY OWN

205
00:08:50,920 --> 00:09:01,120
LABORATORY. WE ALSO SEE THAT YOU

206
00:09:01,120 --> 00:09:02,680
CAN SEE SIGNIFICANT DIFFERENCE

207
00:09:02,680 --> 00:09:04,760
IN BODY MASS INDEX WHICH HAS

208
00:09:04,760 --> 00:09:06,320
SIGNIFICANT LEVEL OF STORAGE

209
00:09:06,320 --> 00:09:10,360
HEMOLYSIS SO HIGHER BMI THE MORE

210
00:09:10,360 --> 00:09:12,280
LIKELY YOUR RED CELLS ARE TO

211
00:09:12,280 --> 00:09:16,040
LYSE IN STORAGE. WE ALSO SEE

212
00:09:16,040 --> 00:09:18,480
THESE TRIGLYCERIDE LEVELS IN

213
00:09:18,480 --> 00:09:20,600
DIFFERENCE BETWEEN MALES AND

214
00:09:20,600 --> 00:09:23,480
FEMALES, IS PARTLY ACCOUNTS FOR

215
00:09:23,480 --> 00:09:32,040
SOME OF THE DIFFERENCE. WHAT

216
00:09:32,040 --> 00:09:32,840
ABOUT PLATELET?

217
00:09:32,840 --> 00:09:34,560
THIS IS AN INTERESTING DATA SET

218
00:09:34,560 --> 00:09:35,880
PUT TOGETHER BY THE BEST

219
00:09:35,880 --> 00:09:38,240
COLLABORATIVE. THESE ARE DONORS

220
00:09:38,240 --> 00:09:42,320
DOWN HERE IN THIS RED BOX WHOSE

221
00:09:42,320 --> 00:09:43,560
PLATELETS FAIL PH ON ONE

222
00:09:43,560 --> 00:09:44,680
DONATION AND THEY ARE MORE

223
00:09:44,680 --> 00:09:45,880
LIKELY TO FAIL ON A SECOND

224
00:09:45,880 --> 00:09:49,080
DONATION.  SO THESE ARE DONORS

225
00:09:49,080 --> 00:09:52,760
THAT WE PROBABLY DON'T WANT IN

226
00:09:52,760 --> 00:09:54,960
OUR SYSTEM. THEY ARE FAILING PH

227
00:09:54,960 --> 00:09:57,760
ON MULTIPLE OCCASIONS THROUGH

228
00:09:57,760 --> 00:10:00,520
SEVEN DAY QUALITY CONTROL OR

229
00:10:00,520 --> 00:10:02,520
FIVE DAY QUALITY CONTROL

230
00:10:02,520 --> 00:10:03,840
DEPENDING WHERE YOU ARE. THIS IS

231
00:10:03,840 --> 00:10:06,280
A SET OF POOL DATA ACROSS THE

232
00:10:06,280 --> 00:10:12,040
TWO CANADIAN BLOOD SERVICES, THE

233
00:10:12,040 --> 00:10:16,720
BRITT S OSSIES, DUTCH AND COUPLE

234
00:10:16,720 --> 00:10:20,360
OF AMERICAN OUTFITS. SO BLOOD

235
00:10:20,360 --> 00:10:22,560
SYSTEMS KNOWN AS VITALANT AS

236
00:10:22,560 --> 00:10:28,520
WELL AS EFS. SO THIS IS A VERY

237
00:10:28,520 --> 00:10:30,400
INFORMATIVE QUALITY CONTROL SET

238
00:10:30,400 --> 00:10:32,280
OF DATA THAT TELLS US THAT WE

239
00:10:32,280 --> 00:10:33,960
REALLY NEED TO GET THESE

240
00:10:33,960 --> 00:10:36,520
PLATELET DONORS, WHOSE PLATELETS

241
00:10:36,520 --> 00:10:38,840
ARE FAILING PH ON MULTIPLE

242
00:10:38,840 --> 00:10:43,560
DONATIONS OUT OF THE SYSTEM. SO

243
00:10:43,560 --> 00:10:45,120
ONE OF THE THINGS THAT MY GROUP

244
00:10:45,120 --> 00:10:47,120
HAS DONE IS STARTED TO CHASE

245
00:10:47,120 --> 00:10:50,240
AROUND BIOMARKERS TO TRY TO

246
00:10:50,240 --> 00:10:51,880
IDENTIFY POOR STORING DONORS. 

247
00:10:51,880 --> 00:10:55,640
WE HAVE TAKEN A COUPLE OF

248
00:10:55,640 --> 00:10:58,920
APPROACHES TO THIS, WE LOOKED BY

249
00:10:58,920 --> 00:11:00,680
PROTEOMIC METHODOLOGIES AND SOME

250
00:11:00,680 --> 00:11:07,120
OF THIS IS DONE IN COLLABORATION

251
00:11:07,120 --> 00:11:08,040
WITH D'ALESSANDRO. WE HAVE SEEN

252
00:11:08,040 --> 00:11:12,360
A STRONG CORRELATION BETWEEN RAP

253
00:11:12,360 --> 00:11:15,320
1 AND RHOGDI FOR THE ABILITY OF

254
00:11:15,320 --> 00:11:18,680
THESE PLATELETS TO GIVE

255
00:11:18,680 --> 00:11:20,560
REASONABLE NUMBERS ON SURVIVAL

256
00:11:20,560 --> 00:11:23,920
AND RECOVERY. THE OTHER QUESTION

257
00:11:23,920 --> 00:11:26,960
THAT BECOMES MORE RELEVANT IS DO

258
00:11:26,960 --> 00:11:28,080
THESE BIOMARKERS PREDICT

259
00:11:28,080 --> 00:11:31,160
TRANSFUSION OUTCOME IN PATIENTS 

260
00:11:31,160 --> 00:11:36,760
SO WHAT WE DID IS A PROJECT WITH

261
00:11:36,760 --> 00:11:38,480
CHERYL BEFORE SHE RETIRED, THIS

262
00:11:38,480 --> 00:11:41,040
WAS LOOKING AT DONORS WHO

263
00:11:41,040 --> 00:11:44,080
CURRENTLY MET SUCCESSFULLY MET

264
00:11:44,080 --> 00:11:46,720
SCREENING CRITERIA. THEN WE

265
00:11:46,720 --> 00:11:49,480
LOOKED AT THEIR OWN SURVIVAL

266
00:11:49,480 --> 00:11:51,080
RECOVERY. WE RADIO LABELED THE

267
00:11:51,080 --> 00:11:52,640
PLATELETS OF DONORS AND RETURNED

268
00:11:52,640 --> 00:12:00,480
THEM TO THE DONOR. WE LOOKED

269
00:12:00,480 --> 00:12:01,120
WITH WHETHER OR NOT THEY HAD A

270
00:12:01,120 --> 00:12:02,920
GOOD OR POOR OUTCOME. WE FOUND

271
00:12:02,920 --> 00:12:04,400
DONORS THAT DID NOT HAVE A GOOD

272
00:12:04,400 --> 00:12:10,400
OUTCOME. AND WOULD NOT HAVE

273
00:12:10,400 --> 00:12:12,480
PASSED THE FDA MINIMUM

274
00:12:12,480 --> 00:12:15,400
STANDARDS.  PROTEOMICS IS A VERY

275
00:12:15,400 --> 00:12:16,720
POWERFUL TECHNOLOGY AND OFFERS

276
00:12:16,720 --> 00:12:21,120
AN APPROACH TO IDENTIFY DONOR

277
00:12:21,120 --> 00:12:22,280
BIOMARKERS THAT ARE RELATED TO

278
00:12:22,280 --> 00:12:24,480
SUCCESSFUL STORAGE. WE USE

279
00:12:24,480 --> 00:12:26,120
PROTEOMICS TO IDENTIFY PUNITIVE

280
00:12:26,120 --> 00:12:28,120
BIOMARKERS AND WE NEED TO TEST

281
00:12:28,120 --> 00:12:32,240
THESE IN LARGE CLINICAL TRIALS. 

282
00:12:32,240 --> 00:12:33,360
THE QUESTION IS HOW DO WE

283
00:12:33,360 --> 00:12:36,920
OPTIMIZE QUALITY OF DONORS GIFT.

284
00:12:36,920 --> 00:12:39,560
WE NEED TO ENSURE THAT COMPONENT

285
00:12:39,560 --> 00:12:41,800
PRODUCTION STORAGE ARE OPTIMAL,

286
00:12:41,800 --> 00:12:44,000
WE CAN BE FOCUSED ON IMPROVING

287
00:12:44,000 --> 00:12:45,480
STORAGE CONTAINERS WHICH I HAVE

288
00:12:45,480 --> 00:12:47,440
A GRADUATE STUDENT IN MY GROUP

289
00:12:47,440 --> 00:12:49,160
WHO IS WORKING ON THAT

290
00:12:49,160 --> 00:12:53,120
PARTICULAR PROBLEM. THEN WE HAVE

291
00:12:53,120 --> 00:12:59,080
A SERIES OF STORAGE SOLUTIONS WE

292
00:12:59,080 --> 00:13:01,000
CAN ADD TO PLATELET CONCENTRATES

293
00:13:01,000 --> 00:13:03,080
OR RED CELL CONCENTRATES AND TRY

294
00:13:03,080 --> 00:13:04,000
TO UNDERSTAND WHETHER THEY ARE

295
00:13:04,000 --> 00:13:07,080
GOING TO CONTRIBUTE TO

296
00:13:07,080 --> 00:13:13,360
IMPROVEMENT OF QUALITY OF

297
00:13:13,360 --> 00:13:16,200
PRODUCT. WE NEED TO UNDERSTAND

298
00:13:16,200 --> 00:13:17,000
DONOR APPRECIATION TO PRODUCT

299
00:13:17,000 --> 00:13:18,400
QUALITY AND THAT WILL ALLOW

300
00:13:18,400 --> 00:13:20,000
STORAGE LESION DEVELOPMENT WELL

301
00:13:20,000 --> 00:13:21,880
ENOUGH TO HAVE BIOMARKERS THAT

302
00:13:21,880 --> 00:13:23,440
GUIDE DONOR MANAGEMENT. SO WHAT

303
00:13:23,440 --> 00:13:28,520
WE WANT TO BE ABLE TO DO IS LOOK

304
00:13:28,520 --> 00:13:29,720
AT OTHER APPROACHES TO QUALITY

305
00:13:29,720 --> 00:13:31,880
IMPROVEMENT, WORKING ON NOVEL

306
00:13:31,880 --> 00:13:33,120
ADDITIVE SOLUTIONS AND WORKING

307
00:13:33,120 --> 00:13:35,840
TO IDENTIFY BIOMARKERS THAT

308
00:13:35,840 --> 00:13:39,600
IDENTIFY POOR STORING DONORS.

309
00:13:39,600 --> 00:13:43,320
THERE IS A NICE PAPER THAT

310
00:13:43,320 --> 00:13:46,200
(INDISCERNIBLE) PUB -- NAREG

311
00:13:46,200 --> 00:13:48,200
ROUBINIAN PUBLISHED IN JCI

312
00:13:48,200 --> 00:13:50,080
INSIGHTS THAT LOOKED WHETHER YOU

313
00:13:50,080 --> 00:13:52,800
GOT -- WHAT WERE CONTRIBUTORS TO

314
00:13:52,800 --> 00:13:54,880
POOR-STORING DONORS. THEY FOUND

315
00:13:54,880 --> 00:13:58,520
THAT THE SEX, THE RH STATUS, THE

316
00:13:58,520 --> 00:13:59,960
FINGER STICK HEMOGLOBIN, WHETHER

317
00:13:59,960 --> 00:14:02,480
OR NOT THE DONOR SMOKED, THEN

318
00:14:02,480 --> 00:14:03,520
STORAGE DONATION WHETHER OR NOT

319
00:14:03,520 --> 00:14:07,600
YOU GAMMA IRRADIATED THE

320
00:14:07,600 --> 00:14:09,320
COMPONENT, WHETHER OR NOT IT WAS

321
00:14:09,320 --> 00:14:10,000
LEUKOREDUCED, WHETHER OR NOT IT

322
00:14:10,000 --> 00:14:11,520
WAS AN APHERESIS COLLECTION AND

323
00:14:11,520 --> 00:14:13,080
THE KIND OF STORAGE SOLUTION

324
00:14:13,080 --> 00:14:15,560
THAT WAS INVOLVED, WERE ALSO

325
00:14:15,560 --> 00:14:18,160
CONTRIBUTING FACTORS.  FOR THE

326
00:14:18,160 --> 00:14:19,600
RECIPIENT, THE SEX, THE BODY

327
00:14:19,600 --> 00:14:21,480
MASS INDEX, THE RACE AND

328
00:14:21,480 --> 00:14:24,160
ETHNICITY AND THE AGE, WERE ALL

329
00:14:24,160 --> 00:14:26,920
CHARACTERISTICS ASSOCIATED WITH

330
00:14:26,920 --> 00:14:31,560
HEMOGLOBIN. AND BILIRUBIN. SO

331
00:14:31,560 --> 00:14:33,000
THESE ARE THINGS WE NEED TO BE

332
00:14:33,000 --> 00:14:36,160
THINKING ABOUT. SO IN

333
00:14:36,160 --> 00:14:37,240
CONCLUSION, THE QUALITY OF BLOOD

334
00:14:37,240 --> 00:14:38,400
PRODUCTS IS REALLY VERY

335
00:14:38,400 --> 00:14:39,880
IMPORTANT FOR OUR PATIENTS, AND

336
00:14:39,880 --> 00:14:42,440
WE NEED TO WORK TO IMPROVE OUR

337
00:14:42,440 --> 00:14:44,480
APPROACH TO QUALITY ASSURANCE

338
00:14:44,480 --> 00:14:45,760
FOR BLOOD COMPONENTS. THIS

339
00:14:45,760 --> 00:14:46,960
EFFORT HAS TO INCLUDE THE

340
00:14:46,960 --> 00:14:49,120
DEVELOPMENT OF BETTER STANDARDS

341
00:14:49,120 --> 00:14:50,320
FOR COMPONENT QUALITY CONTROL

342
00:14:50,320 --> 00:14:52,320
AND THE IDENTIFICATION OF DONORS

343
00:14:52,320 --> 00:14:53,720
WHO HAVE CHARACTERISTICS THAT

344
00:14:53,720 --> 00:14:56,400
CAUSE REDUCED QUALITY. THOUGH I

345
00:14:56,400 --> 00:14:58,600
WOULD SAY THAT RIGHT NOW IN THE

346
00:14:58,600 --> 00:14:59,840
MIDDLE OF THE PANDEMIC WHEN WE

347
00:14:59,840 --> 00:15:02,280
ARE A LITTLE BIT SHORT OF DONORS

348
00:15:02,280 --> 00:15:04,520
MAYBE WE DON'T WANT TO IMPLEMENT

349
00:15:04,520 --> 00:15:05,800
THAT AT THIS PARTICULAR POINT IN

350
00:15:05,800 --> 00:15:09,880
TIME. SO THANK YOU FOR YOUR

351
00:15:09,880 --> 00:15:11,560
ATTENTION AND I AM MORE THAN

352
00:15:11,560 --> 00:15:22,120
HAPPY TO TAKE ANY QUESTIONS.  WE

353
00:15:34,240 --> 00:15:36,120
DO HAVE TIME, THIS IS AN

354
00:15:36,120 --> 00:15:37,920
ADDITIONAL CHANCE TO HAVE

355
00:15:37,920 --> 00:15:40,720
DIALOGUE. I SEE WE HAVE A HAND

356
00:15:40,720 --> 00:15:41,800
RAISED.  PLEASE GO AHEAD.

357
00:15:41,800 --> 00:15:44,240
>> THANK YOU FOR THAT
EXCELLENT

358
00:15:44,240 --> 00:15:46,360
PRESENTATION. I WAS CURIOUS,

359
00:15:46,360 --> 00:15:48,880
ABOUT THE DONORS THE PLATELET

360
00:15:48,880 --> 00:15:50,760
DONORS THAT ARE FAILING PH

361
00:15:50,760 --> 00:15:54,760
MULTIPLE TIMES, DO WE HAVE ANY

362
00:15:54,760 --> 00:15:57,600
KIND OF UNDERSTANDING OR

363
00:15:57,600 --> 00:16:01,840
SPECULATION EVEN AS TO WHY? THAT

364
00:16:01,840 --> 00:16:04,240
MIGHT BE? IS IT SOMETHING THAT

365
00:16:04,240 --> 00:16:10,160
HAS TO DO WITH FACTORS THAT ARE

366
00:16:10,160 --> 00:16:12,720
EXPRESSED ON THEIR PLATELETS OR

367
00:16:12,720 --> 00:16:22,480
IN THEIR PLASMA? I THINK MOST

368
00:16:22,480 --> 00:16:24,600
PLATELETS DONORS WHO ARE FAILING

369
00:16:24,600 --> 00:16:25,880
MULTIPLE TIMES ARE ACTIVATED. 

370
00:16:25,880 --> 00:16:28,440
THAT CAUSES THE PLATELETS TO

371
00:16:28,440 --> 00:16:32,400
HAVE A MUCH SHORTER ADULT LIFE

372
00:16:32,400 --> 00:16:33,920
THAN WHAT NORMALLY SEE.

373
00:16:33,920 --> 00:16:36,360
>> HAVE WE LOOKED AT
ACTIVATION

374
00:16:36,360 --> 00:16:38,160
MARKERS ON THESE PLATELETS?

375
00:16:38,160 --> 00:16:48,440
>> YES WE HAVE.

376
00:16:56,640 --> 00:16:58,120
>> THIS IS THE OPPORTUNITY
TO

377
00:16:58,120 --> 00:16:59,240
RAISE COMMENTS AT THIS POINT

378
00:16:59,240 --> 00:17:00,680
MORE BROADLY. THANK YOU. I SEE A

379
00:17:00,680 --> 00:17:03,320
HAND RAISED.  I APOLOGIZE. ALL I

380
00:17:03,320 --> 00:17:06,520
CAN SAY IS PLEASE GO AHEAD. I

381
00:17:06,520 --> 00:17:10,600
DON'T KNOW YOUR FULL NAME.

382
00:17:10,600 --> 00:17:16,480
>>

383
00:17:16,480 --> 00:17:19,240
>> I HAVE A QUESTION FOR
YOU.

384
00:17:19,240 --> 00:17:22,120
COULD YOU FOR SEE DIFFERENT

385
00:17:22,120 --> 00:17:23,560
DONORS YOU COULD HAVE DIFFERENT

386
00:17:23,560 --> 00:17:26,320
STORAGE TIMES THAT WOULD BE

387
00:17:26,320 --> 00:17:29,840
MANAGED BY IT?

388
00:17:29,840 --> 00:17:31,400
>> THAT IS WHERE WE ARE
GOING TO

389
00:17:31,400 --> 00:17:33,760
END UP GOING. I THINK THAT FOR

390
00:17:33,760 --> 00:17:37,200
SOME OF THESE DONORS, WHOSE

391
00:17:37,200 --> 00:17:38,080
PALATALLIES DON'T STORE WELL FOR

392
00:17:38,080 --> 00:17:39,960
INSTANCE WERE GOING TO HAVE

393
00:17:39,960 --> 00:17:43,080
SHORTER STORAGE PERIODS THAN SAY

394
00:17:43,080 --> 00:17:50,760
FIVE OR SEVEN DAYS.  AND THAT

395
00:17:50,760 --> 00:17:52,320
CREATES A SET OF CHALLENGES FOR

396
00:17:52,320 --> 00:17:53,080
THE HOSPITALS. 

397
00:17:53,080 --> 00:17:57,880
>> THANK YOU. LOOKS LIKE
WE HAVE

398
00:17:57,880 --> 00:17:58,960
MERLIN WHO RAISE THEIR HAND,

399
00:17:58,960 --> 00:18:01,960
THEN A CHAT THEN FOLLOW WITH YOU

400
00:18:01,960 --> 00:18:02,600
CASSANDRA.

401
00:18:02,600 --> 00:18:05,640
>> MANY THANKS. HOW DO YOU

402
00:18:05,640 --> 00:18:07,520
RECONCILE THE VALUE OF

403
00:18:07,520 --> 00:18:10,760
IDENTIFYING STORAGE LESIONS WHEN

404
00:18:10,760 --> 00:18:12,520
WE KNOW THAT SOME OF THEM ARE

405
00:18:12,520 --> 00:18:14,400
REPAIRED DURING CIRCULATION LIKE

406
00:18:14,400 --> 00:18:18,000
THE SODIUM POTASSIUM,

407
00:18:18,000 --> 00:18:23,080
CONCENTRATION OF D 3 PDG.

408
00:18:23,080 --> 00:18:26,440
>> I DO THINK THAT I'M A

409
00:18:26,440 --> 00:18:28,120
PLATELET BIOLOGIST PRIMARILY. SO

410
00:18:28,120 --> 00:18:30,080
I'M MORE FOCUSED ON WHAT IS

411
00:18:30,080 --> 00:18:31,960
GOING ON WITH THE PLATELET

412
00:18:31,960 --> 00:18:35,800
DONORS. I DO THINK THAT WHAT WE

413
00:18:35,800 --> 00:18:37,840
SEE IS A LARGE NUMBER OF

414
00:18:37,840 --> 00:18:44,000
ACTIVATED PLATELETS IN THESE

415
00:18:44,000 --> 00:18:50,240
DONORS THESE PLATELETS ARE

416
00:18:50,240 --> 00:18:55,360
ACTIVATED AND CLEARED QUICKLY IN

417
00:18:55,360 --> 00:18:56,240
CIRCULATION, SO I THIS I THEY

418
00:18:56,240 --> 00:19:02,440
ARE NOT A REALLY GOOD PRODUCT. 

419
00:19:02,440 --> 00:19:03,640
SOME OF THESE STORAGE LESIONS

420
00:19:03,640 --> 00:19:04,960
GET REPAIRED IN CIRCULATION.

421
00:19:04,960 --> 00:19:13,680
PARTICULARLY FOR RED CELLS.

422
00:19:13,680 --> 00:19:15,560
>> I'M GOING TO READ THE
CHAT

423
00:19:15,560 --> 00:19:17,440
QUESTIONS AND FOLLOW IN ORDER OF

424
00:19:17,440 --> 00:19:19,520
HANDS. MONICA, I DON'T KNOW YOUR

425
00:19:19,520 --> 00:19:21,080
LAST NAME. INTERESTING

426
00:19:21,080 --> 00:19:22,840
CHALLENGE, ARE POOR PLATELET

427
00:19:22,840 --> 00:19:25,040
DONORS ALSO POOR RED CELL

428
00:19:25,040 --> 00:19:25,440
DONORS?

429
00:19:25,440 --> 00:19:27,160
>> NOT NECESSARILY. IF YOU
ARE

430
00:19:27,160 --> 00:19:32,200
COLLECTING PLATELETS BY

431
00:19:32,200 --> 00:19:33,880
APHERESIS TECHNOLOGY YOU WILL

432
00:19:33,880 --> 00:19:37,200
SEE THIS PHENOMENON FOR PLATELET

433
00:19:37,200 --> 00:19:39,960
DONORS.  IT DOESN'T NECESSARILY

434
00:19:39,960 --> 00:19:41,760
ALSO MEAN THEY ARE POOR RED CELL

435
00:19:41,760 --> 00:19:44,720
DONORS.

436
00:19:44,720 --> 00:19:48,720
>> THANK YOU. DR.
JOSEPHSON

437
00:19:48,720 --> 00:19:48,960
PLEASE.

438
00:19:48,960 --> 00:19:52,880
>> GREAT TALK. CURIOUS
WHETHER,

439
00:19:52,880 --> 00:19:54,800
I DIDN'T SEE IT PRESENTED BUT

440
00:19:54,800 --> 00:19:56,800
YOU MIGHT HAVE LOOKED AT IT, BY

441
00:19:56,800 --> 00:19:58,200
DONORS AND PLATE LET'S, OPPOSED

442
00:19:58,200 --> 00:20:00,840
TO RED CELLS. WHETHER YOU FOUND

443
00:20:00,840 --> 00:20:02,760
OR INVESTIGATING THERE IS A

444
00:20:02,760 --> 00:20:03,800
SIMILAR DIFFERENCE OR NO

445
00:20:03,800 --> 00:20:05,440
DIFFERENCE AT ALL BETWEEN THE --

446
00:20:05,440 --> 00:20:07,120
AND THE AGE OF THE PLATELET,

447
00:20:07,120 --> 00:20:11,480
DOES THAT MATTER.

448
00:20:11,480 --> 00:20:13,720
>> WE HAVEN'T LOOKED AT
THAT

449
00:20:13,720 --> 00:20:16,400
THOUGH WE COULD. I HAVEN'T --

450
00:20:16,400 --> 00:20:17,520
THE WORK WE HAVE BEEN DOING

451
00:20:17,520 --> 00:20:20,840
ISN'T REALLY FOCUSED IN THAT

452
00:20:20,840 --> 00:20:22,280
DIRECTION. I COULD EASILY GO

453
00:20:22,280 --> 00:20:26,320
BACK AND COUNT UP THE NUMBER OF

454
00:20:26,320 --> 00:20:28,960
MALE AND FEMALE DONORS AND SEE

455
00:20:28,960 --> 00:20:30,400
THE SAME KIND OF DIFFERENCE WE

456
00:20:30,400 --> 00:20:33,160
DO FOR RED CELLS.

457
00:20:33,160 --> 00:20:41,520
>> NEXT UP IS DR. BUSCH.

458
00:20:41,520 --> 00:20:43,680
>> THE CONCEPT WHAT IS IN
THE

459
00:20:43,680 --> 00:20:47,880
BAG, WHICH IS ONE OF THE POINTS

460
00:20:47,880 --> 00:20:49,600
RAISED (INDISCERNIBLE) WE

461
00:20:49,600 --> 00:20:50,840
ACTUALLY DON'T MEASURE AT THE

462
00:20:50,840 --> 00:20:53,200
TIME OF ISSUE OR CERTAINLY TIME

463
00:20:53,200 --> 00:20:56,360
OF TRANSFUSION WHAT THE CONTENT

464
00:20:56,360 --> 00:20:58,120
OF RED CELLS OR PERHAPS

465
00:20:58,120 --> 00:20:59,000
PLATELETS ARE IN THE PRODUCTS

466
00:20:59,000 --> 00:21:08,440
THAT WE ISSUE. WE PACK IN A RED

467
00:21:08,440 --> 00:21:09,640
CELL AND NEVER QUANTIFY THE

468
00:21:09,640 --> 00:21:11,440
HEMOGLOBIN OR RED CELL CONTENT.

469
00:21:11,440 --> 00:21:14,080
SO BOTH IN TERMS OF DOSE OF RED

470
00:21:14,080 --> 00:21:16,640
CELLS AND PLATELETS AT THE TIME

471
00:21:16,640 --> 00:21:21,320
ISSUE FROM TRANSFUSION SERVICE

472
00:21:21,320 --> 00:21:23,640
OR QUALITY MEASURES. WHAT IS THE

473
00:21:23,640 --> 00:21:24,560
FUTURE DIRECTION IN THAT REGARD?

474
00:21:24,560 --> 00:21:28,720
>> I THINK AS PROBABLY
MOST

475
00:21:28,720 --> 00:21:36,720
PEOPLE KNOW, THE NUMBER OF UNITS

476
00:21:36,720 --> 00:21:38,040
IS HIGHLY VARIABLE AND WE ARE

477
00:21:38,040 --> 00:21:39,920
NOT GIVING STANDARD DOSE TO

478
00:21:39,920 --> 00:21:41,160
PATIENTS SO THAT IS A CONCERN

479
00:21:41,160 --> 00:21:42,640
THAT WE DON'T HAVE A STANDARD

480
00:21:42,640 --> 00:21:53,000
DELIVERY SYSTEM. WE ARE GO GOING

481
00:21:53,000 --> 00:21:54,520
TO END UP WITH QUALITY CROW

482
00:21:54,520 --> 00:21:56,040
FEATURES THAT WE HAVE GOT NOW. I

483
00:21:56,040 --> 00:21:58,520
THINK WE ARE -- WE JUST HAVE TO

484
00:21:58,520 --> 00:22:01,320
GO DOWN THAT PATH OF DEVELOPING

485
00:22:01,320 --> 00:22:09,240
NEW QUALITY CONTROL PARAMETERS. 

486
00:22:09,240 --> 00:22:11,880
>> THANK YOU. DR. KOR.

487
00:22:11,880 --> 00:22:15,840
>> FANTASTIC PRESENTATION.
THANK

488
00:22:15,840 --> 00:22:18,320
YOU. A QUICK QUESTION OF THE

489
00:22:18,320 --> 00:22:19,200
CLINICAL RELEVANCE OF THE

490
00:22:19,200 --> 00:22:20,240
STORAGE LESION. RED CELLS

491
00:22:20,240 --> 00:22:22,440
CLEARLY A LOT OF INTEREST OVER

492
00:22:22,440 --> 00:22:25,320
TEN PLUS YEARS, 20 YEARS AT THIS

493
00:22:25,320 --> 00:22:27,320
POINT BUT COULDN'T FIND IT MADE

494
00:22:27,320 --> 00:22:29,000
A BIG CLINICAL DIFFERENCE IN

495
00:22:29,000 --> 00:22:31,120
PATIENTS WHO RECEIVE EXTENDED

496
00:22:31,120 --> 00:22:32,840
STORE RED CELLS VERSUS SHORTER

497
00:22:32,840 --> 00:22:34,440
STORE RED CELLS. I'M WONDERING

498
00:22:34,440 --> 00:22:36,480
FROM A PLATELET PERSPECTIVE,

499
00:22:36,480 --> 00:22:39,680
CLEARLY YOU HAVE SHOWN NICELY

500
00:22:39,680 --> 00:22:40,800
THAT THERE ARE SUBOPTIMAL

501
00:22:40,800 --> 00:22:41,920
PLATELET COMPONENTS BUT ANY

502
00:22:41,920 --> 00:22:44,640
SENSE WHAT THE IMPACT OF

503
00:22:44,640 --> 00:22:46,280
TRANSFUSED THOSE COMPONENTS TO

504
00:22:46,280 --> 00:22:47,840
RECIPIENTS IS ON RECIPIENT

505
00:22:47,840 --> 00:22:48,440
OUTCOMES? ?

506
00:22:48,440 --> 00:22:50,240
>> NOSE PLATELETS ARE
ACTIVATED

507
00:22:50,240 --> 00:22:56,120
SO THEY GET CLEARED IMMEDIATELY 

508
00:22:56,120 --> 00:22:57,520
THEY HAVE ALL ACTIVATION

509
00:22:57,520 --> 00:22:59,080
RECEPTORS ARE TURNED ON AND THEY

510
00:22:59,080 --> 00:23:03,280
GET CLEARED OUT IN THE RECEPTORS

511
00:23:03,280 --> 00:23:07,560
IN THE LIVER AND ALSO BY

512
00:23:07,560 --> 00:23:09,120
MACROPHAGES IN THE SPLEEN. THE

513
00:23:09,120 --> 00:23:11,840
OTHER ISSUE ABOUT THE RED CELLS

514
00:23:11,840 --> 00:23:15,920
IS THAT HONESTLY, NOT SURE WE

515
00:23:15,920 --> 00:23:19,000
REALLY KNOW. I'M VERY INTERESTED

516
00:23:19,000 --> 00:23:21,040
IN GETTING INVOLVED IN SOME

517
00:23:21,040 --> 00:23:23,240
CLINICAL STUDIES THAT WOULD TELL

518
00:23:23,240 --> 00:23:29,080
US WHAT IS HAPPENING. BECAUSE IF

519
00:23:29,080 --> 00:23:30,160
YOU LOOK PARTICULARLY IN

520
00:23:30,160 --> 00:23:32,800
PATIENTS WHO ARE RECEIVING

521
00:23:32,800 --> 00:23:34,920
CHRONIC TRANSFUSION SUPPORT LIKE

522
00:23:34,920 --> 00:23:36,320
THALASSEMIA PATIENTS AND SICKLE

523
00:23:36,320 --> 00:23:38,760
CELL DISEASE PATIENTS, I THINK

524
00:23:38,760 --> 00:23:41,440
IF YOU GIVE THEM A BAD UNIT OF

525
00:23:41,440 --> 00:23:44,000
RED CELLS, THEY ARE COMING BACK

526
00:23:44,000 --> 00:23:45,800
FOR ANOTHER TRANSFUSION MUCH

527
00:23:45,800 --> 00:23:47,560
QUICKER THAN THEY WOULD BE IF WE

528
00:23:47,560 --> 00:23:56,240
GAVE THEM A GOOD UNIT.

529
00:23:56,240 --> 00:23:58,440
>> MOSTLY THINKING
INCREMENTS

530
00:23:58,440 --> 00:24:02,480
DANA, OPPOSED TO POTENTIAL

531
00:24:02,480 --> 00:24:04,680
INJURIOUS EFFECT TO AN ORGAN?

532
00:24:04,680 --> 00:24:09,600
>> YES, I'M THINKING 
THINKING T

533
00:24:09,600 --> 00:24:11,000
IS THE INCREMENT. I DON'T THINK

534
00:24:11,000 --> 00:24:12,720
WE HAVE ANY EVIDENCE THAT THESE

535
00:24:12,720 --> 00:24:17,880
CELLS ARE CAUSING DAMAGE TO END

536
00:24:17,880 --> 00:24:18,080
ORGANS

537
00:24:18,080 --> 00:24:18,880
>> THANK YOU.

538
00:24:18,880 --> 00:24:21,080
>> GREAT. WE DO SEE
ADDITIONAL

539
00:24:21,080 --> 00:24:27,800
HANDHANDHANDS. PLEASE GO AHEAD,E

540
00:24:27,800 --> 00:24:29,000
YOUR NAME SO WE CAN CATCH YOUR

541
00:24:29,000 --> 00:24:29,360
NAME PLEASE.

542
00:24:29,360 --> 00:24:33,600
>> THIS IS LARRY HORASCH,
CAN

543
00:24:33,600 --> 00:24:33,920
YOU HEAR ME?

544
00:24:33,920 --> 00:24:34,560
>> HI.

545
00:24:34,560 --> 00:24:36,400
>> HI, DANA, THANK YOU FOR
THAT

546
00:24:36,400 --> 00:24:39,840
SUMMARY. TWO QUESTIONS FOR YOU. 

547
00:24:39,840 --> 00:24:43,360
YOU PUT YOUR FINGER AND MIKE

548
00:24:43,360 --> 00:24:44,080
ALSO POINTED TO SOMETHING

549
00:24:44,080 --> 00:24:45,400
IMPORTANT IN A CLINICAL TRIAL WE

550
00:24:45,400 --> 00:24:50,920
DID SEVERAL YEARS AGO. WE HAD TO

551
00:24:50,920 --> 00:24:53,000
MEASURE HEMOGLOBIN IN THE BAG

552
00:24:53,000 --> 00:24:54,480
BECAUSE WE WERE INTERESTED IN

553
00:24:54,480 --> 00:24:57,240
CONSUMPTION IN THALASSEMIA

554
00:24:57,240 --> 00:24:58,760
PATIENTS. HEMOGLOBIN VARIED FROM

555
00:24:58,760 --> 00:25:01,040
38 TO 75 GRAMS, HUGE FROM

556
00:25:01,040 --> 00:25:04,160
ACCEPTED DONORS.  SO I THINK YOU

557
00:25:04,160 --> 00:25:05,400
ARE RIGHT ABOUT THAT. WE NEED TO

558
00:25:05,400 --> 00:25:08,480
BE MEASURING THE AMOUNT OF

559
00:25:08,480 --> 00:25:09,880
HEMOGLOBIN IN BAG. BUT WHAT

560
00:25:09,880 --> 00:25:11,640
ABOUT COLD STORED PLATELETS? WE

561
00:25:11,640 --> 00:25:13,400
KNOW THEY DON'T CIRCULATE WELL. 

562
00:25:13,400 --> 00:25:14,480
WHAT ABOUT THE QUALITY CONTROL

563
00:25:14,480 --> 00:25:16,560
OF THOSE?

564
00:25:16,560 --> 00:25:19,560
>> I THINK COLD STORED
PLATELETS

565
00:25:19,560 --> 00:25:21,080
HAVE BEEN SHOWN TO BE USEFUL FOR

566
00:25:21,080 --> 00:25:25,560
BLEEDING PATIENTS.  YOU

567
00:25:25,560 --> 00:25:27,200
SHOULDN'T BE USING A

568
00:25:27,200 --> 00:25:27,680
PROPHYLACTIC PLATELET

569
00:25:27,680 --> 00:25:35,840
TRANSFUSION.  THEY HAVE A ROLE

570
00:25:35,840 --> 00:25:37,520
BUT IT IS MORE FOR BLEEDING

571
00:25:37,520 --> 00:25:40,440
PATIENTS AND CARDIAC SURGERY,

572
00:25:40,440 --> 00:25:41,240
THAT SORT OF THING.

573
00:25:41,240 --> 00:25:44,280
>> I AGREE WITH THAT. TO
THE

574
00:25:44,280 --> 00:25:45,920
MARKERS YOU LOOK AT IN COLD

575
00:25:45,920 --> 00:25:48,120
STORED PLATELETS TELL YOU

576
00:25:48,120 --> 00:25:50,480
ANYTHING ABOUT THE QUALITY OF

577
00:25:50,480 --> 00:25:51,280
ROOM TEMPERATURE STORED

578
00:25:51,280 --> 00:25:51,520
PLATELETS?

579
00:25:51,520 --> 00:25:54,000
>> I HAD A GRADUATE
STUDENT WORK

580
00:25:54,000 --> 00:25:55,960
IN COLD STORED PLATELETS. HE'S

581
00:25:55,960 --> 00:25:59,400
FOUND VERY INTERESTING THINGS

582
00:25:59,400 --> 00:26:03,720
THEY WORK REALLY WELL IN -- HE'S

583
00:26:03,720 --> 00:26:05,480
BEEN DOING A LOT OF IN VITRO

584
00:26:05,480 --> 00:26:10,960
WORK AND THEY WORK WELL IN ROTEM

585
00:26:10,960 --> 00:26:12,480
(PHONETIC) ASSAYS BUT THEY DON'T

586
00:26:12,480 --> 00:26:19,120
WORK THAT WELL IN PLATELET

587
00:26:19,120 --> 00:26:20,080
AGGREGATION STUDIES AND THAT

588
00:26:20,080 --> 00:26:20,680
SORT OF THING.

589
00:26:20,680 --> 00:26:21,480
>> THANK YOU.

590
00:26:21,480 --> 00:26:23,280
>> DOCTOR, WE WILL COME
BACK TO

591
00:26:23,280 --> 00:26:24,360
YOU IN A SECOND. THE REASON I

592
00:26:24,360 --> 00:26:26,080
WANT TO MAYBE JUST TURN TO THE

593
00:26:26,080 --> 00:26:27,760
CHAT BOX IS THIS QUESTION THAT'S

594
00:26:27,760 --> 00:26:31,840
BEEN RAISED BY DR. SUNNY ZEKE IS

595
00:26:31,840 --> 00:26:32,840
VERY MUCH CONNECTED TO WHAT WE

596
00:26:32,840 --> 00:26:35,000
HAVE BEEN DISCUSSING WHICH IS

597
00:26:35,000 --> 00:26:36,400
ACTIVATED PLATELETS ARE

598
00:26:36,400 --> 00:26:37,800
PRESENTED AS AN ARGUMENT IN

599
00:26:37,800 --> 00:26:39,880
FAVOR OF COLD STORED PLATELETS.

600
00:26:39,880 --> 00:26:41,440
MIGHT THE FUTURE HAVE TWO KINDS

601
00:26:41,440 --> 00:26:43,680
OF PLATELET LABELS BLEEDING

602
00:26:43,680 --> 00:26:45,800
VERSUS PROPHYLAXIS? WONDERING

603
00:26:45,800 --> 00:26:47,800
WHAT YOU THINK ABOUT THAT, DR.

604
00:26:47,800 --> 00:26:48,080
DEVINE?

605
00:26:48,080 --> 00:26:51,400
>> YEAH, I'M PRETTY SURE
THAT

606
00:26:51,400 --> 00:26:54,520
MOST OF OUR HOSPITALS WILL END

607
00:26:54,520 --> 00:26:56,040
UP WITH DUAL INVENTORIES WHERE

608
00:26:56,040 --> 00:26:57,880
WE HAVE ONE SET OF COLD

609
00:26:57,880 --> 00:26:59,920
PLATELETS, WE ARE GOING BACK TO

610
00:26:59,920 --> 00:27:01,480
SOMETHING THAT ALL PLATELETS

611
00:27:01,480 --> 00:27:02,960
WERE STORED IN THE COLD

612
00:27:02,960 --> 00:27:04,040
INITIALLY WHEN FIRST DEVELOPED

613
00:27:04,040 --> 00:27:07,520
COMPONENT THERAPY. I THINK THAT

614
00:27:07,520 --> 00:27:09,200
THESE -- WE ARE GOING TO END UP

615
00:27:09,200 --> 00:27:10,640
GOING BACK THERE BECAUSE THESE

616
00:27:10,640 --> 00:27:13,440
PLATELETS ARE REALLY VERY GOOD

617
00:27:13,440 --> 00:27:16,080
AT PREVENTING -- HELPING

618
00:27:16,080 --> 00:27:20,520
PATIENTS STOP BLEEDING.  I THINK

619
00:27:20,520 --> 00:27:23,080
THAT WE WILL HAVE TWO DOUBLE

620
00:27:23,080 --> 00:27:23,960
INVENTORIES IN MANY THE

621
00:27:23,960 --> 00:27:25,280
HOSPITALS. ONE SET OF PLATELETS

622
00:27:25,280 --> 00:27:27,480
THAT STORED ROOM TEMPERATURE,

623
00:27:27,480 --> 00:27:28,520
PLATELET SHAKER AND THE OTHER

624
00:27:28,520 --> 00:27:29,880
SET THAT IS STORED IN THE

625
00:27:29,880 --> 00:27:33,080
REFRIGERATOR.

626
00:27:33,080 --> 00:27:38,240
>> THANK YOU. SO DR.
EICHBAUM

627
00:27:38,240 --> 00:27:39,400
PLEASE GO AHEAD.

628
00:27:39,400 --> 00:27:42,000
>> SIMILAR TO THE COLD
STORAGE

629
00:27:42,000 --> 00:27:43,680
PLATELETS, JUST A GENERAL

630
00:27:43,680 --> 00:27:45,560
FOLLOW-UP QUESTION ABOUT WHAT IS

631
00:27:45,560 --> 00:27:47,160
THIS TELL US ABOUT WHAT WE

632
00:27:47,160 --> 00:27:48,760
SHOULD BE TELLING CLINICIANS

633
00:27:48,760 --> 00:27:51,600
ABOUT THE RESULTS OF MANY

634
00:27:51,600 --> 00:27:52,840
MULTI-MILLION DOLLAR,

635
00:27:52,840 --> 00:27:54,200
MULTI-CENTER TRIALS THAT THOUGH

636
00:27:54,200 --> 00:27:55,680
THEY ARE PROBLEMS WITH THESE

637
00:27:55,680 --> 00:27:59,480
STUDIES MOST OF THE END POINTS

638
00:27:59,480 --> 00:28:00,480
WERE ABOUT MORTALITY MORBIDITY

639
00:28:00,480 --> 00:28:01,800
ABOUT THE RED CELL STORAGE

640
00:28:01,800 --> 00:28:03,600
LESION THAT THERE MAY NOT BE

641
00:28:03,600 --> 00:28:05,720
THAT BIG IMPACT. DO WE HAVE TO

642
00:28:05,720 --> 00:28:07,280
RE-EVALUATE ALL THESE STUDIES?

643
00:28:07,280 --> 00:28:10,920
HOW DO WE LOOK AT THESE -- ALL

644
00:28:10,920 --> 00:28:13,720
THESE STORAGE LESIONS STUDIES?

645
00:28:13,720 --> 00:28:16,600
>> I THINK WE NEED TO GO
BACK

646
00:28:16,600 --> 00:28:20,240
AND RE-EVALUATE THEM. I THINK

647
00:28:20,240 --> 00:28:22,320
THAT THEY ARE -- WE PUT A

648
00:28:22,320 --> 00:28:23,840
CERTAIN LEVEL OF INTERPRETATION

649
00:28:23,840 --> 00:28:25,720
ON THEM INITIALLY AND I THINK WE

650
00:28:25,720 --> 00:28:27,280
REALLY NEED TO GO BACK AND LOOK

651
00:28:27,280 --> 00:28:32,880
AT THEM AGAIN.

652
00:28:32,880 --> 00:28:39,920
>> THANKS.

653
00:28:39,920 --> 00:28:45,440
>> THANK YOU. WE HAVE
ADDITIONAL

654
00:28:45,440 --> 00:28:47,560
QUESTION FROM -- NEED TO SCROLL

655
00:28:47,560 --> 00:28:48,920
BACK UP. QUESTIONS ARE STARTING

656
00:28:48,920 --> 00:28:51,080
TO COME IN, WHICH IS GREAT,

657
00:28:51,080 --> 00:28:52,400
APPRECIATE THAT. RELATED

658
00:28:52,400 --> 00:28:53,720
QUESTION IS THE POSSIBLE IMPACT

659
00:28:53,720 --> 00:28:56,480
ON STORAGE NOT ONLY ON 24 HOUR

660
00:28:56,480 --> 00:28:58,240
RECOVERY BUT ALSO LONG TERM RED

661
00:28:58,240 --> 00:29:00,280
CELL SURVIVAL. ESPECIALLY

662
00:29:00,280 --> 00:29:01,560
CONSIDERING TRANSFUSION NEEDS OF

663
00:29:01,560 --> 00:29:02,760
PATIENTS WHO REQUIRE LONG TERM

664
00:29:02,760 --> 00:29:06,680
TRANSFUSION SUPPORT. MORE A

665
00:29:06,680 --> 00:29:07,880
COMMENT BUT WONDERING IF WILL IS

666
00:29:07,880 --> 00:29:10,920
ASOR IN I ASPECTS

667
00:29:10,920 --> 00:29:12,280
>> THIS IS AN IMPORTANT
ASPECT

668
00:29:12,280 --> 00:29:16,560
AND I THINK THAT IF WE LOOK AT

669
00:29:16,560 --> 00:29:21,760
WHAT IS GOING ON THERE WE SEE A

670
00:29:21,760 --> 00:29:25,960
SHORTENING OF SURVIVAL WITH RED

671
00:29:25,960 --> 00:29:28,480
BLOOD CELLS IN THESE PATIENTS

672
00:29:28,480 --> 00:29:29,880
WHO REQUIRE LONG TERM

673
00:29:29,880 --> 00:29:33,400
TRANSFUSION SUPPORT. IT IS

674
00:29:33,400 --> 00:29:36,280
RELATED TO DONORS.  IT IS

675
00:29:36,280 --> 00:29:37,360
RELATED TO THE CHARACTERISTICS

676
00:29:37,360 --> 00:29:42,200
OF THE DONOR.

677
00:29:42,200 --> 00:29:44,520
>> THANK YOU ALSO SEEING
QUITE A

678
00:29:44,520 --> 00:29:46,880
FEW QUESTIONS AROUND COLD STORE

679
00:29:46,880 --> 00:29:48,200
VERSUS NOT AND POTENTIALLY

680
00:29:48,200 --> 00:29:51,480
DIFFERENT ASPECT OF PLATELETS

681
00:29:51,480 --> 00:29:53,720
THEMSELVES. THAT IDEA OF

682
00:29:53,720 --> 00:29:55,040
POTENTIAL DUAL INVENTORY BOTH

683
00:29:55,040 --> 00:29:57,560
WHETHER THAT MIGHT BE PRIORITY

684
00:29:57,560 --> 00:29:58,200
IDENTIFIED COMING OUT OF THE

685
00:29:58,200 --> 00:30:00,960
STATE OF SCIENCE AND ADDITIONAL

686
00:30:00,960 --> 00:30:03,040
LITERATURE COMPARING PERFORMANCE

687
00:30:03,040 --> 00:30:04,720
IN DIFFERENT SETTINGS. SO FOR

688
00:30:04,720 --> 00:30:05,840
THOSE WHO ASKED THOSE QUESTIONS

689
00:30:05,840 --> 00:30:12,080
IF YOU DO WANT TO COME OFF AND

690
00:30:12,080 --> 00:30:15,320
FURTHER EXPLORE THAT, VERY HAPPY

691
00:30:15,320 --> 00:30:25,600
FOR YOU TO DO SO.

692
00:30:28,400 --> 00:30:34,400
>> I NOTICE THAT DR.
SPINELLA

693
00:30:34,400 --> 00:30:37,280
(PHONETIC) HAS A PROMOTIONAL

694
00:30:37,280 --> 00:30:40,040
THING FOR HIS

695
00:30:40,040 --> 00:30:41,000
>> TRIAL.

696
00:30:41,000 --> 00:30:42,680
>> HIS TRIAL IN THE CHAT
BOX AND

697
00:30:42,680 --> 00:30:44,560
I ENCOURAGE ALL OF YOU WHO ARE

698
00:30:44,560 --> 00:30:46,520
BASED IN THE STATES TO REALLY

699
00:30:46,520 --> 00:30:48,120
PILE IN AND TRY TO HELP THEM GET

700
00:30:48,120 --> 00:30:49,240
THAT TRIAL DONE. I THINK THAT IS

701
00:30:49,240 --> 00:30:52,040
GOING TO SHOW US SOME REALLY

702
00:30:52,040 --> 00:30:54,560
IMPORTANT INFORMATION. .

703
00:30:54,560 --> 00:31:00,000
>> THANK YOU, DR. DZIK.
PLEASE

704
00:31:00,000 --> 00:31:00,400
GO AHEAD.

705
00:31:00,400 --> 00:31:02,080
>> FOLLOW UP, IT IS A
GREAT

706
00:31:02,080 --> 00:31:05,000
TOPIC AND VERY INTERESTING AND

707
00:31:05,000 --> 00:31:07,040
YOU KNOW, THE POTENTIAL FOR DUAL

708
00:31:07,040 --> 00:31:11,080
INVENTORIES AND PROBL PROBLEMS T

709
00:31:11,080 --> 00:31:12,640
THAT WOULD PRESENT IN TERMS OF

710
00:31:12,640 --> 00:31:14,520
LOGISTICS AND CROSSING LINES AND

711
00:31:14,520 --> 00:31:17,240
THAT SORT OF THING MAKES IT --

712
00:31:17,240 --> 00:31:19,120
AND CONSEQUENCES FOR PATIENTS

713
00:31:19,120 --> 00:31:24,040
MAKES IT REALLY IMPORTANT WE

714
00:31:24,040 --> 00:31:26,400
DEMONSTRATE COLD STORED

715
00:31:26,400 --> 00:31:28,040
PLATELETS STOP BLEEDING IN

716
00:31:28,040 --> 00:31:30,960
PATIENTS.  DANA WHO I ADMIRE

717
00:31:30,960 --> 00:31:31,960
VERY MUCH TOSS THAT OFF. THE

718
00:31:31,960 --> 00:31:36,600
QUALITY OF THE EVIDENCE LOOKING

719
00:31:36,600 --> 00:31:39,200
AT CLINICAL BLEEDING OUTCOMES,

720
00:31:39,200 --> 00:31:42,640
WITH ONE PLATELET VERSUS ANOTHER

721
00:31:42,640 --> 00:31:45,760
IS NOT THAT ROBUST.  THIS IS

722
00:31:45,760 --> 00:31:47,280
SUCH AN IMPORTANT BIG ISSUE THAT

723
00:31:47,280 --> 00:31:49,840
I THINK IT COULD BE SOMETHING

724
00:31:49,840 --> 00:31:51,640
NHLBI MIGHT WANT TO GET BEHIND.

725
00:31:51,640 --> 00:31:53,160
THAT IS NOT TO SAY THE CHIPS ARE

726
00:31:53,160 --> 00:31:54,680
NOT INFORMATIVE, LOOKING FORWARD

727
00:31:54,680 --> 00:31:56,760
TO IT AS WELL AS ANYONE.  BUT

728
00:31:56,760 --> 00:31:59,880
MAY NOT BE THE FINAL ANSWER.  WE

729
00:31:59,880 --> 00:32:01,160
MAY NEED MORE STUDIES IN

730
00:32:01,160 --> 00:32:02,600
SETTINGS OTHER THAN CARDIAC

731
00:32:02,600 --> 00:32:05,880
SURGERY TO DEMONSTRATE THE

732
00:32:05,880 --> 00:32:08,960
EFFECT IN VIVO, LEST WE FALL

733
00:32:08,960 --> 00:32:11,680
INTO A TRAP WE HAVE FALLEN INTO

734
00:32:11,680 --> 00:32:12,720
A HUNDRED THOUSAND TIMES IN THE

735
00:32:12,720 --> 00:32:16,040
PAST WHICH IS TO USE LABORATORY

736
00:32:16,040 --> 00:32:19,120
MEASURES AS SOME SORT OF TRUTH

737
00:32:19,120 --> 00:32:20,840
SERUM REGARDING IN VIVO

738
00:32:20,840 --> 00:32:23,760
EFFECTIVENESS. WHICH --

739
00:32:23,760 --> 00:32:26,000
>> I COMPLETELY AGREE WITH
YOU,

740
00:32:26,000 --> 00:32:27,440
SUNNY.

741
00:32:27,440 --> 00:32:30,680
>> I DO THINK BY THE WAY
ADD ONE

742
00:32:30,680 --> 00:32:32,440
MORE THOUGHT THEN BE QUIET,

743
00:32:32,440 --> 00:32:33,760
WHICH EVERYONE WILL BE HAPPY

744
00:32:33,760 --> 00:32:35,800
ABOUT. DR. LARRY WHO IS LIKE

745
00:32:35,800 --> 00:32:37,720
MR. PLATELET FROM DECADES AGO,

746
00:32:37,720 --> 00:32:39,680
AND A GENIUS WHEN YOU LOOK BAT

747
00:32:39,680 --> 00:32:41,240
AT EARLIER WORK, THE GUY WAS WAY

748
00:32:41,240 --> 00:32:44,120
AHEAD OF HIS TIME.  NOTICE WHEN

749
00:32:44,120 --> 00:32:48,640
YOU PUT PLATELETS IN THE COLD

750
00:32:48,640 --> 00:32:49,840
THEY UNDERGO FORM OF ACTIVATION

751
00:32:49,840 --> 00:32:53,560
THAT CAUSES THEM TO RELEASE

752
00:32:53,560 --> 00:32:58,200
INTERIOR THINGS SUCH AS VWF. AND

753
00:32:58,200 --> 00:33:00,400
FIBRINOGEN. SO WHEN YOU THEN

754
00:33:00,400 --> 00:33:02,320
TAKE A COLD PLATELET WITH ITS

755
00:33:02,320 --> 00:33:05,840
PLASMA NOW ENRICHED WITH VWF AND

756
00:33:05,840 --> 00:33:08,040
STICK IT IN THE ROTA MACHINE, IT

757
00:33:08,040 --> 00:33:09,280
IS POSSIBLE THE EFFECT YOU

758
00:33:09,280 --> 00:33:10,720
OBSERVE HAS NOTHING TO DO WITH

759
00:33:10,720 --> 00:33:11,960
PLATELETS THEMSELVES BUT THE

760
00:33:11,960 --> 00:33:15,440
FACT YOU CHANGED THE PLASMA

761
00:33:15,440 --> 00:33:17,600
ENVIRONMENT OF THOSE PLACE LETS

762
00:33:17,600 --> 00:33:21,440
BY HAVING THEM ENRICH THAT

763
00:33:21,440 --> 00:33:24,520
PLASMA FOR VON WILLEBRANDE AND

764
00:33:24,520 --> 00:33:26,320
ALL, AN EFFECT WHICH IS

765
00:33:26,320 --> 00:33:29,600
SUBSTANTIAL AND A CLOSED TEST

766
00:33:29,600 --> 00:33:31,480
TUBE, BUT NOT NECESSARILY BE

767
00:33:31,480 --> 00:33:34,120
TRUE IN VIVO WHERE THAT FLUID

768
00:33:34,120 --> 00:33:36,000
GETS WASHED AWAY, IF YOU FOLLOW

769
00:33:36,000 --> 00:33:36,680
WHAT I'M TRYING TO SAY.

770
00:33:36,680 --> 00:33:45,080
>> YOU ARE EXACTLY RIGHT,
SUNNY 

771
00:33:45,080 --> 00:33:45,480
>> ALL RIGHT.

772
00:33:45,480 --> 00:33:48,400
>> PERFECT TIMING. I DO

773
00:33:48,400 --> 00:33:49,960
APOLOGIZE BUT IT IS A VALUABLE

774
00:33:49,960 --> 00:33:51,800
DISCUSSION AND THERE'S

775
00:33:51,800 --> 00:33:52,600
ADDITIONAL CHAT REMARKS COMING

776
00:33:52,600 --> 00:33:54,600
IN. WE ARE GOING TO RECORD ALL

777
00:33:54,600 --> 00:33:55,920
THOSE AND MAKE SURE THEY ARE

778
00:33:55,920 --> 00:33:57,840
AVAILABLE FOR THE SAKE OF TIME,

779
00:33:57,840 --> 00:33:59,040
WE WANT TO TRY TO STAY ON

780
00:33:59,040 --> 00:34:02,120
SCHEDULE SO WE WILL MOVE ON. I

781
00:34:02,120 --> 00:34:04,800
THINK WE WILL BE INTRODUCING THE

782
00:34:04,800 --> 00:34:07,560
NEXT GROUP WHICH WILL BE ONE OF

783
00:34:07,560 --> 00:34:10,480
THE ACTUAL WORKING GROUPS. 

784
00:34:10,480 --> 00:34:14,120
>> THANK YOU SO MUCH, DR.
DEVINE

785
00:34:14,120 --> 00:34:16,040
FOR YOUR TALK AND ALSO

786
00:34:16,040 --> 00:34:17,240
ENGAGEMENT WITH THE MEMBERS WHO

787
00:34:17,240 --> 00:34:21,360
ARE PARTICIPATING TODAY. 

788
00:34:21,360 --> 00:34:22,080
>> THANK YOU VERY MUCH FOR
THE

789
00:34:22,080 --> 00:34:24,440
INHAVE IATION. 

790
00:34:24,440 --> 00:34:27,160
>> THANK YOU, AGAIN, DANA.
AS

791
00:34:27,160 --> 00:34:28,840
WELL. AND WE DO HOPE TO COME

792
00:34:28,840 --> 00:34:33,240
BACK TO THESE QUESTIONS WE NOW

793
00:34:33,240 --> 00:34:35,280
BEGIN GENERAL SESSION WITH THE

794
00:34:35,280 --> 00:34:36,880
PRESENTATION OF DRAFT RESEARCH

795
00:34:36,880 --> 00:34:38,720
PRIORITIES BY WORKING GROUP

796
00:34:38,720 --> 00:34:41,560
CO-CHAIRS, IT IS MY PLEASURE TO

797
00:34:41,560 --> 00:34:43,320
INTRODUCE OUR FIRST GROUP OF

798
00:34:43,320 --> 00:34:44,520
CO-CHAIRS, FOCUSED ON

799
00:34:44,520 --> 00:34:45,920
MECHANISTIC ASPECT OF COMPONENTS

800
00:34:45,920 --> 00:34:48,160
AND TRANSFUSIONS, OMICS

801
00:34:48,160 --> 00:34:48,720
EFFECTIVENESS QUALITY AND

802
00:34:48,720 --> 00:34:57,840
SAFETY. DR. ELDAD HOD,

803
00:34:57,840 --> 00:35:01,360
DEPARTMENT OF PATHOLOGY CELL

804
00:35:01,360 --> 00:35:02,960
BIOLOGY CLEMSON UNIVERSITY.

805
00:35:02,960 --> 00:35:04,920
LEADER IN TRANSLATIONAL RESEARCH

806
00:35:04,920 --> 00:35:07,000
FOCUSED ON RED CELL BIOLOGY AND

807
00:35:07,000 --> 00:35:08,360
RECIPIENT OF SEVERAL GRANTS FROM

808
00:35:08,360 --> 00:35:10,360
THE NIH INCLUDING PRINCIPLE

809
00:35:10,360 --> 00:35:12,880
INVESTIGATOR FOR THE NEW YORK

810
00:35:12,880 --> 00:35:15,960
HUB PROGRAM. DR. ANGELA

811
00:35:15,960 --> 00:35:16,800
D'ALESSANDRO, PROFESSOR

812
00:35:16,800 --> 00:35:18,640
DEPARTMENT OF CHEMISTRY

813
00:35:18,640 --> 00:35:20,480
MOLECULAR GENETICS UNIVERSITY OF

814
00:35:20,480 --> 00:35:22,760
COLORADO, AMONG MANY OTHER ROLES

815
00:35:22,760 --> 00:35:24,840
HE FILLS HE IS DIRECTOR OF

816
00:35:24,840 --> 00:35:27,320
MEDICAL OMICS CORE AS WELL AS

817
00:35:27,320 --> 00:35:28,880
MASS SPECTROMETRY SHARED

818
00:35:28,880 --> 00:35:30,000
RESOURCE, UNIVERSITY OF

819
00:35:30,000 --> 00:35:35,960
COLORADO. WELCOME TO YOU BOTH.

820
00:35:35,960 --> 00:35:40,160
>> THANK YOU, THANKS TO
THE

821
00:35:40,160 --> 00:35:42,560
ORGANIZERS, NHLBI, BRIAN AND ART

822
00:35:42,560 --> 00:35:44,400
FOR GIVING US THE OPPORTUNITY TO

823
00:35:44,400 --> 00:35:48,280
CO-CHAIR THIS COMMITTEE. I

824
00:35:48,280 --> 00:35:49,720
APPRECIATE THE DISCUSSION WE

825
00:35:49,720 --> 00:35:51,640
JUST HAD BECAUSE IT GIVES US A

826
00:35:51,640 --> 00:35:52,640
GOOD INTRODUCTION TO THE WORK WE

827
00:35:52,640 --> 00:35:58,240
DID ON THIS COMMITTEE. SO JUST

828
00:35:58,240 --> 00:36:01,240
TO INTRODUCE YOU TO THE PROCESS

829
00:36:01,240 --> 00:36:04,440
WE UNDERTOOK WHEN DRAFTING

830
00:36:04,440 --> 00:36:07,440
PRIORITIES FOR THIS COMMITTEE.

831
00:36:07,440 --> 00:36:10,520
WE FORMED A COMMITTEE WITH -- IN

832
00:36:10,520 --> 00:36:12,440
ADDITION TO ANGLO AND MYSELF WE

833
00:36:12,440 --> 00:36:14,880
ASKED THE PEOPLE YOU SEE LISTED

834
00:36:14,880 --> 00:36:18,840
HERE TO JOIN US AND WE TRY TO

835
00:36:18,840 --> 00:36:19,760
GIVE PRESENTATION FROM BOTH

836
00:36:19,760 --> 00:36:21,120
PEOPLE WHO DO CLINICAL RESEARCH

837
00:36:21,120 --> 00:36:25,240
AND BASIC RESEARCH IMMUNOLOGY

838
00:36:25,240 --> 00:36:26,360
ALSO REPRESENTED AS WELL AS

839
00:36:26,360 --> 00:36:29,160
PEOPLE WITH FOCUS ON PEDIATRIC

840
00:36:29,160 --> 00:36:30,360
TRANSFUSION MEDICINE AS WELL AS

841
00:36:30,360 --> 00:36:33,720
ADULT AND PEOPLE WITH REGULATORY

842
00:36:33,720 --> 00:36:36,160
EXPERIENCE. WE MET SEVERAL TIMES

843
00:36:36,160 --> 00:36:40,840
BY ZOOM TO BRAINSTORM IDEAS AND

844
00:36:40,840 --> 00:36:43,840
IT BECAME APPARENT TO ANGLO AND

845
00:36:43,840 --> 00:36:46,040
I THAT FIVE BROAD THEMES EMERGED

846
00:36:46,040 --> 00:36:47,800
SO WE BROKE OUT FIVE SUBGROUPS

847
00:36:47,800 --> 00:36:49,760
TO DEVELOP THEMES INTO SEPARATE

848
00:36:49,760 --> 00:36:51,520
PRIORITY AND THEN MET BACK AGAIN

849
00:36:51,520 --> 00:36:53,320
LARGER GROUP TO REVIEW WHAT THE

850
00:36:53,320 --> 00:36:56,000
SUBGROUPS HAVE COME UP WITH AND

851
00:36:56,000 --> 00:36:57,320
WILL PRESENT FIVE THEMES OR

852
00:36:57,320 --> 00:37:00,760
DRAFT PRIORITIES TO YOU TODAY.  

853
00:37:00,760 --> 00:37:05,120
NEXT PLEASE. SO JUST TO OUTLINE

854
00:37:05,120 --> 00:37:06,320
THE BROAD FIVE THEMES BEFORE WE

855
00:37:06,320 --> 00:37:09,160
GO INTO THEM ONE BY ONE. THE

856
00:37:09,160 --> 00:37:10,600
FIRST THING I WANT TO MENTION IS

857
00:37:10,600 --> 00:37:12,600
THAT WHEN WE DID THIS WE WANTED

858
00:37:12,600 --> 00:37:15,080
EACH OF THE PRIORITIES -- WE

859
00:37:15,080 --> 00:37:16,640
DIDN'T WANT PRIORITY TO BE

860
00:37:16,640 --> 00:37:18,080
REFLECTIVE OF ONE BLOOD PRODUCT

861
00:37:18,080 --> 00:37:20,080
LIKE RED CELL OR PLATELET, WE

862
00:37:20,080 --> 00:37:21,880
WANTED THEM TO BE RELEVANT TO

863
00:37:21,880 --> 00:37:23,080
ALL BLOOD PRODUCTS SO THAT WAS

864
00:37:23,080 --> 00:37:25,400
ONE OF THE THINGS WE WENT IN

865
00:37:25,400 --> 00:37:26,600
THINKING ABOUT WHEN WE DID THIS

866
00:37:26,600 --> 00:37:28,720
AND WE ALSO DIDN'T WANT THEM TO

867
00:37:28,720 --> 00:37:31,400
JUST BE DEDICATED TO PARTICULAR

868
00:37:31,400 --> 00:37:32,840
POPULATION. SO IT WASN'T LIKE

869
00:37:32,840 --> 00:37:35,480
ONE PRIORITY FOR NEONATAL

870
00:37:35,480 --> 00:37:38,720
TRANSFUSION MEDICINE. WE WANTED

871
00:37:38,720 --> 00:37:40,160
THAT TO ENTERCOLLATE AND BE PART

872
00:37:40,160 --> 00:37:41,320
OF EACH OF THE PRIORITIES WE

873
00:37:41,320 --> 00:37:45,000
CAME UP WITH. SO AT THE END OF

874
00:37:45,000 --> 00:37:46,840
THE DAY FIVE PRIORITIES, FIRST

875
00:37:46,840 --> 00:37:49,200
HOW TO BETTER DEFINE BLOOD

876
00:37:49,200 --> 00:37:50,520
PRODUCT QUALITY AND WE HAD AN

877
00:37:50,520 --> 00:37:54,200
EXCELLENT DISCUSSION ABOUT THAT

878
00:37:54,200 --> 00:37:57,440
IN THE PRIOR FOLLOWING THE

879
00:37:57,440 --> 00:37:59,040
KEYNOTE SPEECH. THE NEXT IS ARE

880
00:37:59,040 --> 00:38:00,480
THERE BETTER WAYS TO EVALUATE

881
00:38:00,480 --> 00:38:01,280
TRANSFUSION NEEDS AND

882
00:38:01,280 --> 00:38:03,680
EFFECTIVENESS. THE THIRD HAS

883
00:38:03,680 --> 00:38:07,120
SOME OVERLAP WITH THE SIX

884
00:38:07,120 --> 00:38:09,320
PRIORITY FROM YESTERDAY SECOND

885
00:38:09,320 --> 00:38:12,160
COMMITTEE CHAIRED BY CASSANDRA

886
00:38:12,160 --> 00:38:14,400
AND DARRELL, NON-INFECTIOUS

887
00:38:14,400 --> 00:38:16,920
SAFETY OF BLOOD PRODUCTS BE

888
00:38:16,920 --> 00:38:18,600
IMPROVED. THE FOURTH IS MORE

889
00:38:18,600 --> 00:38:20,160
IMMUNOLOGY BASED PRIORITY, WHAT

890
00:38:20,160 --> 00:38:21,400
STRATEGIES CAN BE EMPLOYED TO

891
00:38:21,400 --> 00:38:23,200
REDUCE RESPONSES TO RED BLOOD

892
00:38:23,200 --> 00:38:25,160
CELL OR OTHER ANTIGENS IN

893
00:38:25,160 --> 00:38:26,760
CONSEQUENCES OF ANTIBODIES IN

894
00:38:26,760 --> 00:38:30,080
TRANSFUSION AND PREGNANCY. AND

895
00:38:30,080 --> 00:38:31,760
THEN THE FIFTH IS HOW TO DESIGN

896
00:38:31,760 --> 00:38:32,880
AND TEST NEXT GENERATION OF

897
00:38:32,880 --> 00:38:34,920
BLOOD PRODUCTS, BLOOD DERIVED

898
00:38:34,920 --> 00:38:36,280
THERAPEUTICS AND HOW WE ENSURE

899
00:38:36,280 --> 00:38:38,200
SAFETY OF BLOOD PRODUCTS

900
00:38:38,200 --> 00:38:39,840
REPURPOSED FOR NON-TRANSFUSION

901
00:38:39,840 --> 00:38:41,560
INDICATIONS.  ALSO MENTION THESE

902
00:38:41,560 --> 00:38:43,280
ARE IN NO PARTICULAR ORDER WE

903
00:38:43,280 --> 00:38:44,600
WILL PRESENT THEM IN THE ORDER

904
00:38:44,600 --> 00:38:46,040
THEY ARE HERE BUT THAT DOESN'T

905
00:38:46,040 --> 00:38:48,680
MEAN WE ARE PRIORITIZING ONE

906
00:38:48,680 --> 00:38:49,960
OVER THE OTHER. IN THE

907
00:38:49,960 --> 00:38:51,520
DISCUSSION WE WOULD LOVE TO HEAR

908
00:38:51,520 --> 00:38:53,520
FROM YOU, IF YOU THINK SOME ARE

909
00:38:53,520 --> 00:38:54,760
MORE IMPORTANT THAN OTHERS IF

910
00:38:54,760 --> 00:38:56,440
YOU DON'T AGREE WITH PRIORITIES 

911
00:38:56,440 --> 00:39:01,760
NEXT PLEASE.  I WILL PRESENT THE

912
00:39:01,760 --> 00:39:04,880
FIRST ONE, HOW TO BETTER DEFINE

913
00:39:04,880 --> 00:39:07,720
BLOOD PRODUCT QUALITY. WHAT THIS

914
00:39:07,720 --> 00:39:08,960
ENCOMPASSES IS THREE THINGS, THE

915
00:39:08,960 --> 00:39:12,080
FIRST IS INNOVATIVE METHODS TO

916
00:39:12,080 --> 00:39:13,280
ASSESS BLOOD PRODUCT QUALITY

917
00:39:13,280 --> 00:39:14,320
INCLUDING DEVELOPING

918
00:39:14,320 --> 00:39:15,400
ALTERNATIVES TO CURRENT MEASURES

919
00:39:15,400 --> 00:39:16,840
USED FOR QUALITY CONTROL AND

920
00:39:16,840 --> 00:39:18,520
REGULATORY PURPOSES. A LOT OF

921
00:39:18,520 --> 00:39:20,040
WHAT WE WERE TALKING ABOUT IN

922
00:39:20,040 --> 00:39:22,920
THE PRIOR DISCUSSION SESSION.

923
00:39:22,920 --> 00:39:25,240
UNDERSTANDING MECHANISMS FOR HOW

924
00:39:25,240 --> 00:39:26,920
QUALITY MARKERS AFFECT DIFFERENT

925
00:39:26,920 --> 00:39:31,720
OUTCOMES AT THE MOLECULAR AND

926
00:39:31,720 --> 00:39:33,920
FUNCTIONAL LEVEL AND USING NOVEL

927
00:39:33,920 --> 00:39:37,440
STRATEGIES TO IMPROVE QUALITY

928
00:39:37,440 --> 00:39:38,480
USING PERCHIZE TRANSFUSION

929
00:39:38,480 --> 00:39:40,920
MEDICINE APPROACHES SO THIS WILL

930
00:39:40,920 --> 00:39:42,800
ENCOMPASS THESE THREE IDEAS. SO

931
00:39:42,800 --> 00:39:46,200
WHY IS THIS AN ISSUE AND I

932
00:39:46,200 --> 00:39:48,000
DIDN'T PLAN THIS WITH DANA, SHE

933
00:39:48,000 --> 00:39:49,240
SHOWED THE SAME FIGURE FROM THE

934
00:39:49,240 --> 00:39:50,760
SAME PAPER SHOWING EFFECTIVELY

935
00:39:50,760 --> 00:39:52,640
WHAT HAPPENS WITH THE RED CELL

936
00:39:52,640 --> 00:39:54,680
STORAGE LESION IS AS YOU PUT RED

937
00:39:54,680 --> 00:39:57,360
CELLS IN A BAG, THEY START TO

938
00:39:57,360 --> 00:40:01,200
DETERIORATE AND WE CAN NOW

939
00:40:01,200 --> 00:40:03,640
MEASURE MICROERYTHROCYTES IN A

940
00:40:03,640 --> 00:40:05,640
RELATIVELY AUTOMATED WAY, USING

941
00:40:05,640 --> 00:40:09,840
FLOW CYTOMETRY. THAT IS WHERE

942
00:40:09,840 --> 00:40:11,080
THEY ARE SO FAR DAMAGED THEY

943
00:40:11,080 --> 00:40:16,320
DON'T CIRCULATE WELL. WE CAN ME

944
00:40:16,320 --> 00:40:18,400
MEASURE THESE THINGS, SINCE LAST

945
00:40:18,400 --> 00:40:20,120
DAY OF THE SCIENCE WE DEVELOPED

946
00:40:20,120 --> 00:40:21,560
NOVEL METHODS FOR MEASURE THESE

947
00:40:21,560 --> 00:40:24,160
THINGS. WE HAVE OMICS TOOLS, ME

948
00:40:24,160 --> 00:40:29,640
TAB ONLYIC, PROTEOMICS. THINGS

949
00:40:29,640 --> 00:40:31,880
MY CO-CHAIR IS EXPERT ON THAT

950
00:40:31,880 --> 00:40:36,400
CAN REALLY -- WE CAN DEFINE

951
00:40:36,400 --> 00:40:38,200
STORAGE LESION. THE GAP IN

952
00:40:38,200 --> 00:40:39,440
KNOWLEDGE WE STILL FACE IS WHICH

953
00:40:39,440 --> 00:40:41,000
OF THESE MEASURES AFFECT OR

954
00:40:41,000 --> 00:40:42,000
PREDICT TRANSFUSION

955
00:40:42,000 --> 00:40:44,480
EFFECTIVENESS. THAT IS THE ONE

956
00:40:44,480 --> 00:40:46,800
OF THE GOALS OF THIS PRIORITY.

957
00:40:46,800 --> 00:40:49,440
NEXT PLEASE.

958
00:40:49,440 --> 00:40:54,080
SO WHY IS THIS AN ISSUE? THE

959
00:40:54,080 --> 00:40:56,160
POST TRANSFUSION RECOVERY STUDY,

960
00:40:56,160 --> 00:40:58,600
THE CURRENT FDA GOLD STANDARD

961
00:40:58,600 --> 00:41:01,440
FOR RED CELLS AND PLATELETS AS

962
00:41:01,440 --> 00:41:03,800
WELL, THERE ARE LOT OF METHOD

963
00:41:03,800 --> 00:41:05,480
LOGICAL ISSUES WHETHER YOU USE

964
00:41:05,480 --> 00:41:08,120
CHROMIUM OR BIOTIN, THERE ARE

965
00:41:08,120 --> 00:41:11,280
ISSUES WITH IT THAT ARE

966
00:41:11,280 --> 00:41:12,360
PUBLISHED FROM HAVING DONE MANY

967
00:41:12,360 --> 00:41:16,000
OF THESE STUDIES THE WAY YOU

968
00:41:16,000 --> 00:41:17,600
EXTRAPOLATE TO T 0 AND DETERMINE

969
00:41:17,600 --> 00:41:20,240
WHAT STARTING POPULATION IS, IS

970
00:41:20,240 --> 00:41:22,320
A MATHEMATICAL CALCULATION AND

971
00:41:22,320 --> 00:41:23,560
SOMETIMES FLAWED ESPECIALLY WHEN

972
00:41:23,560 --> 00:41:31,040
YOU TAKE INTO ACCOUNT WHAT IS

973
00:41:31,040 --> 00:41:32,360
SPLEEN MIGHT DO AS THEY FIRST

974
00:41:32,360 --> 00:41:33,560
PASS THROUGH THE CIRCULATION.

975
00:41:33,560 --> 00:41:34,920
BUT IT IS THE GOLD STANDARD BUT

976
00:41:34,920 --> 00:41:38,440
IT DOESN'T NECESSARILY TELL US

977
00:41:38,440 --> 00:41:39,920
ANYTHING ABOUT OXYGEN DELIVERY,

978
00:41:39,920 --> 00:41:41,840
IMPORTANT FOR RED CELLS AND

979
00:41:41,840 --> 00:41:42,840
HEMOSTASIS WHICH SOMETIMES IS

980
00:41:42,840 --> 00:41:45,960
IMPORTANT FOR RED CELLS AND

981
00:41:45,960 --> 00:41:47,840
PLATELETS. OR PLASMA FOR THAT

982
00:41:47,840 --> 00:41:52,280
MATTER. SO IT IS THE GOLD

983
00:41:52,280 --> 00:41:53,480
STANDARD BUT DOESN'T TELL US

984
00:41:53,480 --> 00:41:54,120
WHAT IS IMPORTANT IN OUR

985
00:41:54,120 --> 00:42:03,200
PATIENTS.  THE OTHER LAYER TO

986
00:42:03,200 --> 00:42:04,400
THIS, THERE'S DIFFERENT MEASURES

987
00:42:04,400 --> 00:42:05,560
OF QUALITY THAT MIGHT BE

988
00:42:05,560 --> 00:42:09,040
IMPORTANT FOR DIFFERENT

989
00:42:09,040 --> 00:42:10,280
POPULATIONS TO GETS AT THE

990
00:42:10,280 --> 00:42:11,680
CONVERSATION ABOUT COLD STORED

991
00:42:11,680 --> 00:42:13,240
PLATELETS, POTENTIALLY IN

992
00:42:13,240 --> 00:42:14,640
TRAUMA, YOU DON'T CARE ABOUT

993
00:42:14,640 --> 00:42:17,360
WHETHER THE PLATELETS CIRCULATE

994
00:42:17,360 --> 00:42:18,840
FOR 24 HOURS BUT WHAT YOU CARE

995
00:42:18,840 --> 00:42:20,640
ABOUT IS DO THEY GO TO SITE OF

996
00:42:20,640 --> 00:42:21,880
BLEEDING AND STOP IT SO THE

997
00:42:21,880 --> 00:42:23,800
QUALITY MEASURE FOR PLATELETS

998
00:42:23,800 --> 00:42:25,440
MIGHT BE -- CURRENT GOLD

999
00:42:25,440 --> 00:42:26,200
STANDARD QUALITY MEASURES MIGHT

1000
00:42:26,200 --> 00:42:28,920
BE IRRELEVANT FOR COLD STORED

1001
00:42:28,920 --> 00:42:31,320
PLATELETS. DEFINING THOSE

1002
00:42:31,320 --> 00:42:33,840
MEASURES IN MORE OPTIMAL WAY IS

1003
00:42:33,840 --> 00:42:37,760
PART OF THIS PRIORITY. SIMILARLY

1004
00:42:37,760 --> 00:42:39,480
FOR CHRONIC RED CELL

1005
00:42:39,480 --> 00:42:43,160
TRANSFUSIONS OR SICKLE CELL, YOU

1006
00:42:43,160 --> 00:42:46,240
NEED BETTER LIFE SPAN FOR THOSE

1007
00:42:46,240 --> 00:42:50,600
RED CELLS. POTENTIALLY AS

1008
00:42:50,600 --> 00:42:52,600
QUESTIONED IN THE PRIOR SESSION

1009
00:42:52,600 --> 00:42:54,600
ALLUDED TO, MAYBE OUR MEASURES

1010
00:42:54,600 --> 00:42:56,880
ARE NOT OPTIMAL FOR THEM EITHER.

1011
00:42:56,880 --> 00:43:02,320
NEXT SLIDE.  WE ALSO NEED

1012
00:43:02,320 --> 00:43:04,040
QUALITY MEASURES AND BETTER

1013
00:43:04,040 --> 00:43:05,000
DEFINING THEM BECAUSE WE THINK

1014
00:43:05,000 --> 00:43:08,360
IT WILL HELP US TO DEVELOP NOVEL

1015
00:43:08,360 --> 00:43:09,560
PRODUCTS SO WITHOUT USEFUL

1016
00:43:09,560 --> 00:43:11,520
QUALITY MEASURES THAT ARE

1017
00:43:11,520 --> 00:43:13,280
REPRODUCIBLE AND EASIER TO

1018
00:43:13,280 --> 00:43:16,400
PERFORM THAN POST TRANSFUSION

1019
00:43:16,400 --> 00:43:18,880
RECOVERY THAT HINDERS OUR

1020
00:43:18,880 --> 00:43:20,000
ABILITY TO DEVELOP NOVEL

1021
00:43:20,000 --> 00:43:21,920
PRODUCTS AND ALLOW US TO BETTER

1022
00:43:21,920 --> 00:43:23,840
QC CURRENT PRODUCTS.  NEXT

1023
00:43:23,840 --> 00:43:32,080
SLIDE.  IN TERMS OF PROPOSED

1024
00:43:32,080 --> 00:43:35,720
APPROACH, IN ALL PRIORITIES IT

1025
00:43:35,720 --> 00:43:36,920
GOES BACK TO WHAT STEVE

1026
00:43:36,920 --> 00:43:38,120
MENTIONED YESTERDAY, WE NEED

1027
00:43:38,120 --> 00:43:41,160
GOOD STUDIES AND DOESN'T MATTER

1028
00:43:41,160 --> 00:43:42,600
-- WE NEED EVERYTHING ALL

1029
00:43:42,600 --> 00:43:44,960
TOGETHER CLINICAL STUDIES BASIC

1030
00:43:44,960 --> 00:43:47,800
STUDIES, PRE-CLINICAL STUDIES,

1031
00:43:47,800 --> 00:43:48,880
AND SO CLEARLY NEED MORE OF

1032
00:43:48,880 --> 00:43:50,760
THAT. WHAT THE GROUP DID WANT TO

1033
00:43:50,760 --> 00:43:53,840
HIGHLIGHT IS THAT THERE IS SOME

1034
00:43:53,840 --> 00:43:55,840
COMPARATIVE EFFECTIVENESS

1035
00:43:55,840 --> 00:43:58,920
RESEARCH AND THERE ARE DIFFERENT

1036
00:43:58,920 --> 00:44:02,320
POPULATIONS THAT WE THINK THE

1037
00:44:02,320 --> 00:44:03,680
QUALITY MEASURES MIGHT FUNCTION

1038
00:44:03,680 --> 00:44:05,600
DIFFERENTLY IN THEM. SO LOOK AT

1039
00:44:05,600 --> 00:44:07,920
THIS LIST AND IF YOU HAVE ANY

1040
00:44:07,920 --> 00:44:09,560
COMMENTS ON THEM OR ANOTHER

1041
00:44:09,560 --> 00:44:11,000
POPULATION IMPORTANT TO

1042
00:44:11,000 --> 00:44:12,320
HIGHLIGHT PLEASE LET US KNOW IN

1043
00:44:12,320 --> 00:44:14,360
THE DISCUSSION SECTION BUT WE

1044
00:44:14,360 --> 00:44:17,560
THINK THE FOCUS SHOULD BE ON THE

1045
00:44:17,560 --> 00:44:20,240
QUALITY -- LINKING QUALITY

1046
00:44:20,240 --> 00:44:21,080
MARKERS WITH TRANSFUSION FOR

1047
00:44:21,080 --> 00:44:22,320
DIFFERENT POPULATIONS AND

1048
00:44:22,320 --> 00:44:25,160
DIFFERENT TRANSFUSION INDICA 

1049
00:44:25,160 --> 00:44:31,040
INDICATIONS. WE ALREADY HAVE

1050
00:44:31,040 --> 00:44:34,280
STUDIES UNDERWAY THAT ARE TRYING

1051
00:44:34,280 --> 00:44:36,400
TO LINK GENETIC AND OMICS

1052
00:44:36,400 --> 00:44:39,840
MARKERS TO PREDICT BLOOD PRODUCT

1053
00:44:39,840 --> 00:44:41,800
QUALITY. THERE ARE STUDIES SHOWN

1054
00:44:41,800 --> 00:44:44,520
OBSERVATIONALLY THAT YOU CAN USE

1055
00:44:44,520 --> 00:44:46,440
HEMOGLOBIN PLATELET, BILIRUBIN

1056
00:44:46,440 --> 00:44:47,880
INCREMENTS TO ASSESS CERTAIN

1057
00:44:47,880 --> 00:44:50,360
PARTS OF THE STORAGE LESION SO

1058
00:44:50,360 --> 00:44:52,560
THEY CAN DIFFERENTIATE ON A

1059
00:44:52,560 --> 00:44:54,600
POPULATION LEVEL YOU CAN USE THE

1060
00:44:54,600 --> 00:44:57,520
INCREMENTS IN AN OBSERVATIONAL

1061
00:44:57,520 --> 00:45:02,200
DATA SET TO OBSERVE THAT OLDER

1062
00:45:02,200 --> 00:45:06,320
STORED UNITS RAISE THESE MARKERS

1063
00:45:06,320 --> 00:45:08,080
GREATER. THERE IS A MOUSE MODEL

1064
00:45:08,080 --> 00:45:10,960
OF RED CELL TRANSFUSION BUT WE

1065
00:45:10,960 --> 00:45:12,280
CERTAINLY NEED MORE WORK

1066
00:45:12,280 --> 00:45:14,320
DEVELOPING MODELS FOR THE OTHER

1067
00:45:14,320 --> 00:45:16,520
BLOOD COMPONENTS. AND MORE WORK

1068
00:45:16,520 --> 00:45:18,160
NEEDS TO BE DONE DEVELOPING IN

1069
00:45:18,160 --> 00:45:20,840
IN VITRO OR EXVIVO IN SILICO

1070
00:45:20,840 --> 00:45:22,520
MODELS TO ADDRESS THE QUESTIONS

1071
00:45:22,520 --> 00:45:26,240
FOR ALL BLOOD PRODUCTS.  I WILL

1072
00:45:26,240 --> 00:45:28,240
HAND IT OFF TO ANGLO FOR THE

1073
00:45:28,240 --> 00:45:30,480
NEXT PRIORITY.

1074
00:45:30,480 --> 00:45:34,160
>> THANK YOU, ELDAD. SO
THE

1075
00:45:34,160 --> 00:45:35,440
SECOND PRIORITY IS PRETTY MUCH

1076
00:45:35,440 --> 00:45:37,440
ALIGNED WITH THE FIRST ONE, WITH

1077
00:45:37,440 --> 00:45:39,640
THE MINOR DIFFERENCE THAT

1078
00:45:39,640 --> 00:45:44,240
SOMEWHAT FIRST PRIORITY NEEDS TO

1079
00:45:44,240 --> 00:45:48,200
THE BLOOD IN CERTAIN PRIORITY,

1080
00:45:48,200 --> 00:45:51,320
IDENTIFY THE FOCUS MORE ON

1081
00:45:51,320 --> 00:45:52,200
EFFECTIVENESS OF RECEIVED

1082
00:45:52,200 --> 00:45:54,280
PRODUCTS. SO SPECIFICALLY AMONG

1083
00:45:54,280 --> 00:45:56,280
THE PRIORITIES IN THE WORKING

1084
00:45:56,280 --> 00:45:57,640
GROUP CONSENSUS WAS REACHED ON

1085
00:45:57,640 --> 00:46:00,960
THE NEED TO IDENTIFY BETTER WAYS

1086
00:46:00,960 --> 00:46:03,400
TO TRANSFUSION EFFECTIVENESS. WE

1087
00:46:03,400 --> 00:46:05,040
BELIEVE THAT NOVEL METHODS

1088
00:46:05,040 --> 00:46:06,680
STRATEGIES NEED TO ASSESS BLOOD

1089
00:46:06,680 --> 00:46:09,040
PRODUCT EFFICACY INCLUDING

1090
00:46:09,040 --> 00:46:10,680
DEVELOPING ALTERNATIVE MEASURES

1091
00:46:10,680 --> 00:46:15,840
US.WE ALSO THINK IT IS IMPORTANO

1092
00:46:15,840 --> 00:46:18,280
UNDERSTAND MECHANISMS THAT

1093
00:46:18,280 --> 00:46:19,280
UNDERLIE THE (INAUDIBLE) ALL

1094
00:46:19,280 --> 00:46:21,080
BLOOD COMPONENTS. WHILE WE HAVE

1095
00:46:21,080 --> 00:46:23,960
A CHANCE TO GO INTO DETAILS THE

1096
00:46:23,960 --> 00:46:27,160
NEXT FEW SLIDES, OUTCOMES

1097
00:46:27,160 --> 00:46:29,960
IDENTIFY, WE (INAUDIBLE) BLOOD

1098
00:46:29,960 --> 00:46:31,160
CELLS POPULATION WITH INCREASE

1099
00:46:31,160 --> 00:46:34,680
FOR PLASMA AND OTHER COMPONENTS

1100
00:46:34,680 --> 00:46:36,800
THOUGH IT IS BEING INCLUSIVE

1101
00:46:36,800 --> 00:46:42,240
(INAUDIBLE) PLAY A ROLE ON

1102
00:46:42,240 --> 00:46:44,000
FORMATION, AT THAT POINT WORKING

1103
00:46:44,000 --> 00:46:45,520
GROUPS IN PARTICULAR THE ONE LED

1104
00:46:45,520 --> 00:46:50,880
BY DR. JOSEPHSON HAVE DISCUSSED

1105
00:46:50,880 --> 00:46:53,680
EXTENSIVELY THE IMPACT OF

1106
00:46:53,680 --> 00:46:55,320
ASPECTS OF -- THAT FORM THE

1107
00:46:55,320 --> 00:46:56,720
CONTEXT OF QUALITY CONTROL OF

1108
00:46:56,720 --> 00:47:00,360
BLOOD PRODUCTS AND EFFICACY. FOR

1109
00:47:00,360 --> 00:47:03,000
EXAMPLE YESTERDAY IT HAS BEEN

1110
00:47:03,000 --> 00:47:05,040
DISCUSSED THAT THE BREAK OUT

1111
00:47:05,040 --> 00:47:08,400
SESSION FOR THE WORKING GROUP

1112
00:47:08,400 --> 00:47:12,480
DISCUSS SIX MINUTE WALKING TEST

1113
00:47:12,480 --> 00:47:14,280
HEART RATE IMMUNE FUNCTION,

1114
00:47:14,280 --> 00:47:16,240
WORKING GROUP OPTIMIZING

1115
00:47:16,240 --> 00:47:19,040
OUTCOMES FOR RECIPIENTS. AS SUCH

1116
00:47:19,040 --> 00:47:23,080
THIS STUDY PRESENTATION FOCUS ON

1117
00:47:23,080 --> 00:47:28,040
POTENTIAL BLOOD MARKERS FOR

1118
00:47:28,040 --> 00:47:30,400
EFFECTIVENESS. SO THE NEED FOR

1119
00:47:30,400 --> 00:47:33,800
NOVEL STRATEGIES TO MEASURE

1120
00:47:33,800 --> 00:47:35,640
TRANSFUSION EFFICACY OF BLOOD

1121
00:47:35,640 --> 00:47:37,160
PRODUCTS IS IDENTIFIED BY

1122
00:47:37,160 --> 00:47:41,800
STRATEGIES LARGELY BASED ON FOR

1123
00:47:41,800 --> 00:47:44,160
EXAMPLE CELLS, -- FUNCTIONAL

1124
00:47:44,160 --> 00:47:47,200
MEASUREMENTS OF THE SUFFICIENCY

1125
00:47:47,200 --> 00:47:49,320
OF DELIVERY OR PHYSICAL

1126
00:47:49,320 --> 00:47:54,840
INTOLERANCE OR ANEMIA. THE GROUP

1127
00:47:54,840 --> 00:47:57,320
-- INDUCES BLOOD PRODUCTS AND WE

1128
00:47:57,320 --> 00:48:00,880
ARE TRYING TO MEASURE MODEL

1129
00:48:00,880 --> 00:48:02,720
CONTENT OR ALTERNATIVE MEASURES

1130
00:48:02,720 --> 00:48:05,200
OF POTENCY TIED TO EFFECTIVENESS

1131
00:48:05,200 --> 00:48:07,280
OF THE PRODUCT. THE SAME

1132
00:48:07,280 --> 00:48:09,640
CONSIDERATION APPLIES TO ACCOUNT

1133
00:48:09,640 --> 00:48:11,680
FOR THE HETEROGENEITY OF THE

1134
00:48:11,680 --> 00:48:13,120
BLOOD PRODUCTS. AS POINTED OUT

1135
00:48:13,120 --> 00:48:18,000
IN THE KEYNOTE ADDRESS P. AND

1136
00:48:18,000 --> 00:48:21,520
THE SESSION THAT FOLLOWED. AS

1137
00:48:21,520 --> 00:48:23,760
SUCH WORKING GROUP ON THE

1138
00:48:23,760 --> 00:48:25,280
URGENCY TO FIND NEW QUALIFIED

1139
00:48:25,280 --> 00:48:29,160
BIOMARKERS TO IMPROVE

1140
00:48:29,160 --> 00:48:30,440
PRECISIONS, IDENTIFY PATIENTS

1141
00:48:30,440 --> 00:48:31,680
WHO MOST LIKELY BENEFIT FROM

1142
00:48:31,680 --> 00:48:33,200
TRANSFUSION EITHER IN THE ACUTE

1143
00:48:33,200 --> 00:48:38,720
OR CHRONIC CARE SETTING.

1144
00:48:38,720 --> 00:48:39,600
PATIENTS (INAUDIBLE) SURGERY OR

1145
00:48:39,600 --> 00:48:42,560
PATIENTS WITH ACQUIRED GENETIC

1146
00:48:42,560 --> 00:48:47,640
ANEMIA OR THROMBOCYTOPENIA. AS I

1147
00:48:47,640 --> 00:48:48,440
PERSONALLY ADDRESS THESE

1148
00:48:48,440 --> 00:48:51,800
QUESTIONS, WE NOTED THAT NOVEL

1149
00:48:51,800 --> 00:48:54,720
BIOMARKERS EFFECTIVENESS CAN BE

1150
00:48:54,720 --> 00:48:59,040
IDENTIFIED BY TECHNOLOGY,

1151
00:48:59,040 --> 00:49:01,880
TARGETED BLOOD DEVICE TO ASSESS

1152
00:49:01,880 --> 00:49:04,960
FOR EXAMPLE MEASUREMENTS OF ALL

1153
00:49:04,960 --> 00:49:06,200
LEVELS FOR SPECIFICALLY

1154
00:49:06,200 --> 00:49:07,760
METABOLIC MARKERS OF HYPOXIA

1155
00:49:07,760 --> 00:49:10,640
MANY IN CONTEXT OF RED CELL

1156
00:49:10,640 --> 00:49:14,800
TRANSFUSION. ANTICIPATED FOR

1157
00:49:14,800 --> 00:49:18,960
NEED O FOR DEVELOPMENT OF LAB --

1158
00:49:18,960 --> 00:49:22,000
DEVICES, FOR EXAMPLE SENSORS FOR

1159
00:49:22,000 --> 00:49:26,800
METABOLITE TESTS, GAS

1160
00:49:26,800 --> 00:49:29,840
METABOLITES OR OTHER FUNCTION

1161
00:49:29,840 --> 00:49:31,760
BIOMARKERS OF EFFECTIVENESS WHO

1162
00:49:31,760 --> 00:49:33,720
PROVIDE MECHANISTIC INSIGHT TO

1163
00:49:33,720 --> 00:49:40,560
FUNCTIONAL IMPROVEM IMPROVEMENTS

1164
00:49:40,560 --> 00:49:42,320
(INDISCERNIBLE). MARKERS ALSO

1165
00:49:42,320 --> 00:49:43,880
GUIDE TRANSFUSION OF BLOOD

1166
00:49:43,880 --> 00:49:45,920
PRODUCTS AND RED BLOOD CELLS,

1167
00:49:45,920 --> 00:49:49,120
FOR EXAMPLE PLATELETS

1168
00:49:49,120 --> 00:49:50,680
TEMPERATURE COLD STORED

1169
00:49:50,680 --> 00:49:52,520
PLATELETS OR FREEZE-DRIED. WE

1170
00:49:52,520 --> 00:49:54,240
DISCUSS A LITTLE BIT OF THIS

1171
00:49:54,240 --> 00:49:57,920
THIS MORNING, PLASMA CAN BE --

1172
00:49:57,920 --> 00:49:59,880
FOR WHOLE BLOOD. NOVEL MARKERS

1173
00:49:59,880 --> 00:50:03,080
TRANSFUSION EFFICACY FOR THIS

1174
00:50:03,080 --> 00:50:04,840
PRODUCT, COULD COMPLIMENT

1175
00:50:04,840 --> 00:50:10,520
MEASUREMENTS. FOR EXAMPLE

1176
00:50:10,520 --> 00:50:12,560
DONATION THAT ACCOUNTS,

1177
00:50:12,560 --> 00:50:19,560
MENTIONED THAT, CLASSIC

1178
00:50:19,560 --> 00:50:20,640
(INDISCERNIBLE) POSITIVE

1179
00:50:20,640 --> 00:50:21,960
GENERATION OR POINT OF CARE

1180
00:50:21,960 --> 00:50:23,200
QUANTITATIVE MEASUREMENTS OF

1181
00:50:23,200 --> 00:50:26,160
CLOTTING FACTORS FOR FIBRINOGEN

1182
00:50:26,160 --> 00:50:27,800
LEVELS. ONE THING THE GROUP --

1183
00:50:27,800 --> 00:50:31,400
IS SUCH MARKERS NOVEL MARKERS

1184
00:50:31,400 --> 00:50:33,000
SHOULD MEET CLIA CERTIFIED

1185
00:50:33,000 --> 00:50:34,680
STANDARDS AND WHAT HAS BEEN

1186
00:50:34,680 --> 00:50:36,600
DEFINED BEST BIOMARKERS END

1187
00:50:36,600 --> 00:50:37,840
POINTS AND OTHER TOOLS, FOR

1188
00:50:37,840 --> 00:50:43,080
DEVICES AND BIOMARKERS. WE

1189
00:50:43,080 --> 00:50:44,440
BELIEVE THAT PROGRESS IN

1190
00:50:44,440 --> 00:50:49,560
ADDRESSING THESE ISSUES

1191
00:50:49,560 --> 00:50:51,400
EFFECTIVENESS AS OUTLINED WILL

1192
00:50:51,400 --> 00:50:53,600
BE FEASIBLE AT LEAST BEGIN TO BE

1193
00:50:53,600 --> 00:50:56,000
IN THE NEXT TEN YEAR YEARS. FOR

1194
00:50:56,000 --> 00:50:59,560
EXAMPLE, CONCEPTS SUCH AS ANEMIA

1195
00:50:59,560 --> 00:51:02,440
TOLERANCE AND IMPACT ON

1196
00:51:02,440 --> 00:51:04,400
TRANSFUSION REQUIREMENT ARE

1197
00:51:04,400 --> 00:51:06,400
BEING STUDIED AND DISCUSSED TO

1198
00:51:06,400 --> 00:51:09,360
OPTIMIZE TRANSFUSION TRIGGERS.

1199
00:51:09,360 --> 00:51:11,880
WE NEED TO BETTER DEFINE THE

1200
00:51:11,880 --> 00:51:13,320
QUALITY FOR EXAMPLE RED BLOOD

1201
00:51:13,320 --> 00:51:16,920
CELLS AS REPRODUCIBLY EFFECTIVE

1202
00:51:16,920 --> 00:51:19,480
OXYGEN THERAPEUTICS BEYOND

1203
00:51:19,480 --> 00:51:21,280
HEMOGLOBIN INCREMENTS. DEFINING

1204
00:51:21,280 --> 00:51:22,880
EFFECTIVE HOMEOSTASIS IN

1205
00:51:22,880 --> 00:51:25,760
CONJUNCTION WITH PLATELET,

1206
00:51:25,760 --> 00:51:27,280
CRYOPRECIPITATE WHOLE BLOOD

1207
00:51:27,280 --> 00:51:29,560
TRANSFUSION REQUIRE ADDITIONAL

1208
00:51:29,560 --> 00:51:32,040
REFINEMENT. SUGGESTING P BY

1209
00:51:32,040 --> 00:51:33,320
OTHER GROUPS THE IDENTIFICATION

1210
00:51:33,320 --> 00:51:36,400
OF MAGIC BULLET, THERE WAS A

1211
00:51:36,400 --> 00:51:38,000
NICE -- IN ONE OF THE BREAK OUT

1212
00:51:38,000 --> 00:51:40,000
SESSION. MAGIC BULLET MARKERS

1213
00:51:40,000 --> 00:51:43,560
NEEDED EFFECTIVENESS MAYBE BY

1214
00:51:43,560 --> 00:51:45,840
THE -- TRANSFUSED PRODUCT IN

1215
00:51:45,840 --> 00:51:47,600
SUCK COMPONENTS LIKE RED BLOOD

1216
00:51:47,600 --> 00:51:50,040
CELLS AND BEYOND HEMOSTASIS AND

1217
00:51:50,040 --> 00:51:52,360
GAS TRANSPORT. MEASUREMENTS MAY

1218
00:51:52,360 --> 00:51:54,560
NOT JUST BE RELATED TO ONE

1219
00:51:54,560 --> 00:51:56,240
PARAMETER, BUT A COMBINATION OF

1220
00:51:56,240 --> 00:51:58,400
MEASUREMENTS PERHAPS INFORMED BY

1221
00:51:58,400 --> 00:51:59,560
TRADITIONAL OMICS APPROACHES AND

1222
00:51:59,560 --> 00:52:02,440
CLINICAL MEASUREMENTS IDENTIFY

1223
00:52:02,440 --> 00:52:03,960
BY ACTIVATION INTELLIGENCE OR

1224
00:52:03,960 --> 00:52:06,280
MACHINE LEARNING OPERATIONS OF

1225
00:52:06,280 --> 00:52:07,600
AVAILABLE DATA AND WORKING GROUP

1226
00:52:07,600 --> 00:52:11,160
RELATED TO THAT. NEXT SLIDE

1227
00:52:11,160 --> 00:52:15,960
PLEASE.  FINALLY TRANSFUSION

1228
00:52:15,960 --> 00:52:18,640
BLOOD COMPONENTS MRI FOCUSING ON

1229
00:52:18,640 --> 00:52:21,640
DIFFERENT POPULATION AS RED

1230
00:52:21,640 --> 00:52:23,720
BLOOD CELL, FOR EXAMPLE FOCUSING

1231
00:52:23,720 --> 00:52:30,520
ON NEONATES, CONSIDERATION CAN

1232
00:52:30,520 --> 00:52:31,160
BE MADE FOR PATIENTS TRANSFUSION

1233
00:52:31,160 --> 00:52:34,360
MANY THE SETTING OF TRAUMA

1234
00:52:34,360 --> 00:52:39,520
PATIENTS OR UNDERGOING ELECTIVE

1235
00:52:39,520 --> 00:52:41,120
SURGERY, AS POINTED OUT IN THE

1236
00:52:41,120 --> 00:52:43,000
CHAT, CHRONIC TRANSFUSION, FOR

1237
00:52:43,000 --> 00:52:46,520
EXAMPLE PATIENT SUFFERING FROM

1238
00:52:46,520 --> 00:52:49,680
CRYOGENIC ANEMIA OR

1239
00:52:49,680 --> 00:52:51,440
THROMBOCYTOPENIA. ONE I HOLD

1240
00:52:51,440 --> 00:52:53,440
NEAR AND DEAR TO MY HEART IS

1241
00:52:53,440 --> 00:52:55,840
CONCEPT OF PRECISE TRANSFUSION

1242
00:52:55,840 --> 00:52:59,320
MEDICINE HAS BEEN PERSONALIZED

1243
00:52:59,320 --> 00:53:00,360
SINCE (INAUDIBLE) TRANSFUSION

1244
00:53:00,360 --> 00:53:03,480
EFFORTS BUT PRECISE MEDICINE

1245
00:53:03,480 --> 00:53:05,040
APPROACHES WILL BE CLINICAL

1246
00:53:05,040 --> 00:53:08,160
DEFINE AND VALIDATE NOVEL

1247
00:53:08,160 --> 00:53:09,760
BIOMARKERS. THE SAME

1248
00:53:09,760 --> 00:53:12,600
EFFECTIVENESS PARAMETERS IS

1249
00:53:12,600 --> 00:53:15,040
TRANSFUSION OF BLOOD PRODUCTS,

1250
00:53:15,040 --> 00:53:18,120
AGAIN IN OTHER WORDS GROUP NOTED

1251
00:53:18,120 --> 00:53:21,440
THAT THERE (INDISCERNIBLE)

1252
00:53:21,440 --> 00:53:23,520
TRANSDUCED PATIENTS IS BY LACK

1253
00:53:23,520 --> 00:53:25,040
OF MARKERS THAN EFFECTIVENESS.

1254
00:53:25,040 --> 00:53:31,080
IT IS NOTED THAT TRANSFUSION

1255
00:53:31,080 --> 00:53:31,840
(INDISCERNIBLE) RED CELL

1256
00:53:31,840 --> 00:53:34,640
PRODUCTS, THERE IS LIMITED BASIC

1257
00:53:34,640 --> 00:53:38,560
CLINICAL SCIENCE IN THIS SPACE

1258
00:53:38,560 --> 00:53:41,760
THE EXTENT TO TRY INDICATIONS

1259
00:53:41,760 --> 00:53:45,080
UNDERWENT TO STOP TRANSFUSION.

1260
00:53:45,080 --> 00:53:47,440
NEXT SLIDE. WITH THAT, ELDAD.

1261
00:53:47,440 --> 00:53:51,040
>> SO THIS IS OUR
NONINFECTIOUS

1262
00:53:51,040 --> 00:53:52,240
SAFETY TRANSFUSIONED BLOOD

1263
00:53:52,240 --> 00:53:56,760
PRODUCT PRIORITY. SO THIS ONE

1264
00:53:56,760 --> 00:53:57,800
ENCOMPASSES IDENTIFYING

1265
00:53:57,800 --> 00:53:59,240
COMPOUNDS AND TRANSFUSED BLOOD

1266
00:53:59,240 --> 00:54:00,760
PRODUCTS THAT LEAD TO ADVERSE

1267
00:54:00,760 --> 00:54:02,800
EFFECTS AND SUSCEPTIBLE

1268
00:54:02,800 --> 00:54:04,440
RECIPIENTS, NOT NECESSARILY ALL

1269
00:54:04,440 --> 00:54:06,280
RECIPIENTS. UNDERSTANDING THE

1270
00:54:06,280 --> 00:54:07,240
MECHANISMS FOR HOW BLOOD

1271
00:54:07,240 --> 00:54:09,560
PRODUCTS AND COMPOUNDS FOUND

1272
00:54:09,560 --> 00:54:12,120
THERE IN INTERACT WITH CELLS AND

1273
00:54:12,120 --> 00:54:13,240
ORGAN SYSTEMS AND NOVEL

1274
00:54:13,240 --> 00:54:14,800
STRATEGIES TO IMPROVE SAFETY BY

1275
00:54:14,800 --> 00:54:17,640
PREVENTING THE OCCURRENCE OF THE

1276
00:54:17,640 --> 00:54:20,760
WRONG PRODUCT GETTING INTO THE

1277
00:54:20,760 --> 00:54:22,080
RIGHT RECIPIENT OR THE RIGHT

1278
00:54:22,080 --> 00:54:23,280
PRODUCT GETTING TO THE WRONG

1279
00:54:23,280 --> 00:54:26,200
RECIPIENT. NEXT SLIDE. SO WHY IS

1280
00:54:26,200 --> 00:54:28,640
THIS AN ISSUE? THERE ARE

1281
00:54:28,640 --> 00:54:31,800
COMPOUNDS FOUND IN THE PRODUCT

1282
00:54:31,800 --> 00:54:33,320
THAT WE CAN THEORETICALLY

1283
00:54:33,320 --> 00:54:35,120
MEASURE AND THEY POTENTIALLY CAN

1284
00:54:35,120 --> 00:54:37,120
LEAD TO ADVERSE OUTCOMES IN

1285
00:54:37,120 --> 00:54:38,560
VULNERABLE PATIENTS AND THE

1286
00:54:38,560 --> 00:54:41,520
GROUP FEELS THERE SHOULD BE MORE

1287
00:54:41,520 --> 00:54:43,880
WORK DONE ON ESTABLISHING THIS,

1288
00:54:43,880 --> 00:54:45,680
SO AGAIN YOU WOULD LOOK AT THE

1289
00:54:45,680 --> 00:54:47,800
LIST WE PUT HERE AND IF THERE

1290
00:54:47,800 --> 00:54:50,240
ARE ANYTHING YOU THINK WE ARE

1291
00:54:50,240 --> 00:54:54,240
MISSING PLEASE LET US KNOW THESE

1292
00:54:54,240 --> 00:54:55,400
COMPOUNDS FOUND IN THE PRODUCT

1293
00:54:55,400 --> 00:54:57,160
COME FROM DONOR SUCH AS

1294
00:54:57,160 --> 00:54:58,160
ANTIBODIES, THIS IS WHERE WE

1295
00:54:58,160 --> 00:55:01,440
INCORPORATE THE ABO ANTIBODIES

1296
00:55:01,440 --> 00:55:03,760
OR HLA ANTIBODIES OR OTHER

1297
00:55:03,760 --> 00:55:04,440
ANTIBODIES THAT MIGHT BE IN THE

1298
00:55:04,440 --> 00:55:07,080
PRODUCT. THERE CUB PRESCRIPTION

1299
00:55:07,080 --> 00:55:09,120
AND NON-PRESCRIPTION DRUGS THAT

1300
00:55:09,120 --> 00:55:10,760
ARE FOUND IN THE PRODUCT,

1301
00:55:10,760 --> 00:55:13,200
HORMONES, HEAVY METALS, AND

1302
00:55:13,200 --> 00:55:15,120
GENETIC VARIANTS OF CELLULAR

1303
00:55:15,120 --> 00:55:16,560
ELEMENTS OR PROTEIN ELEMENTS

1304
00:55:16,560 --> 00:55:17,280
THAT COULD BE IN THE PRODUCT

1305
00:55:17,280 --> 00:55:19,600
FROM THE DONOR THAT MAY LEAD TO

1306
00:55:19,600 --> 00:55:21,920
ADVERSE OUTCOMES IN CERTAIN

1307
00:55:21,920 --> 00:55:23,360
RECIPIENTS. IN TERMS OF

1308
00:55:23,360 --> 00:55:24,480
MANUFACTURING, THERE'S THE

1309
00:55:24,480 --> 00:55:28,800
STORAGE SOLUTIONS WE USE,

1310
00:55:28,800 --> 00:55:30,120
THERE'SPLASTISIZERS AND OTHER

1311
00:55:30,120 --> 00:55:32,120
COMPOUNDS THAT MIGHT BE USED FOR

1312
00:55:32,120 --> 00:55:34,160
PATHOGEN INACTIVATION THAT MAY

1313
00:55:34,160 --> 00:55:36,200
OR MAY NOT LEAD TO ADVERSE

1314
00:55:36,200 --> 00:55:37,640
OUTCOMES.  FINALLY, THE PROCESS

1315
00:55:37,640 --> 00:55:42,080
OF STORAGE INCREASES OR CHANGES

1316
00:55:42,080 --> 00:55:44,200
WHAT IS IN THE BAG AND RELEASES

1317
00:55:44,200 --> 00:55:45,880
POTASSIUM TO THE SUPERNATANT,

1318
00:55:45,880 --> 00:55:47,680
THERE'S INCREASES IN

1319
00:55:47,680 --> 00:55:50,320
MICROVESICALS, EXOSOMES,

1320
00:55:50,320 --> 00:55:53,920
HEMOGLOBIN NOT IN THE RED CELL

1321
00:55:53,920 --> 00:55:55,160
BUT FOUND OUTSIDE THE RED CELL

1322
00:55:55,160 --> 00:56:02,720
AND OTHER RESPONSE MEDIATORS

1323
00:56:02,720 --> 00:56:04,080
LIKEOXILIPINS TO CAUSE OUTCOMES

1324
00:56:04,080 --> 00:56:05,600
-- ADVERSE OUTCOMES IN CERTAIN

1325
00:56:05,600 --> 00:56:07,960
MODEL SYSTEMS. THEN THERE IS A

1326
00:56:07,960 --> 00:56:10,400
CONCEPT OF TRIM, TRANSFUSION

1327
00:56:10,400 --> 00:56:12,040
RELATED IMMUNOMODULATION.  WE

1328
00:56:12,040 --> 00:56:14,040
DON'T UNDERSTAND IT, WE STILL

1329
00:56:14,040 --> 00:56:16,320
DON'T UNDERSTAND WHAT EXTENT IT

1330
00:56:16,320 --> 00:56:19,520
HAPPENS AND WHAT CAUSES IT. BUT

1331
00:56:19,520 --> 00:56:20,880
WE THINK THERE MIGHT BE

1332
00:56:20,880 --> 00:56:22,200
COMPOUNDS IN THE TRANSFUSED

1333
00:56:22,200 --> 00:56:23,600
PRODUCT THAT MAY INTERACT WITH

1334
00:56:23,600 --> 00:56:26,120
THE RECIPIENT, RECIPIENT CELLS

1335
00:56:26,120 --> 00:56:28,120
OR ORGAN SYSTEMS, AND THAT

1336
00:56:28,120 --> 00:56:30,560
STUDYING THE MECHANISMS AND THE

1337
00:56:30,560 --> 00:56:31,760
BIOLOGICAL CROSS TALK BETWEEN

1338
00:56:31,760 --> 00:56:34,760
THE DONOR PRODUCT AND RECIPIENT

1339
00:56:34,760 --> 00:56:36,560
SHOULD BE PRIORITY. NEXT SLIDE

1340
00:56:36,560 --> 00:56:44,040
PLEASE. IN TERMS OF PROPOSED

1341
00:56:44,040 --> 00:56:46,800
APPROACH. THE GROUP ALSO FELT

1342
00:56:46,800 --> 00:56:47,600
THERE ARE -- WE DON'T

1343
00:56:47,600 --> 00:56:49,200
NECESSARILY DO A GREAT JOB

1344
00:56:49,200 --> 00:56:52,480
MONITORING FOR ALL THE

1345
00:56:52,480 --> 00:56:54,360
TRANSFUSION -- HARMFUL EFFECTS

1346
00:56:54,360 --> 00:56:56,360
AND TRANSFUSION REACTS OCCUR

1347
00:56:56,360 --> 00:56:58,360
WITHOUT KNOWING SO NOVEL METHODS

1348
00:56:58,360 --> 00:57:00,040
TO MONITOR FOR HARMFUL EFFECTS

1349
00:57:00,040 --> 00:57:01,600
ARE NEEDED.  WE NEED TO

1350
00:57:01,600 --> 00:57:02,520
DETERMINE WHICH PATIENT

1351
00:57:02,520 --> 00:57:03,760
POPULATIONS ARE MOST VULNERABLE

1352
00:57:03,760 --> 00:57:05,400
TO THESE EFFECTS SO FOR SOME

1353
00:57:05,400 --> 00:57:08,520
LIKE HEAVY METALS, NEONATES

1354
00:57:08,520 --> 00:57:11,480
MIGHT BE MORE VULNERABLE. ALSO

1355
00:57:11,480 --> 00:57:14,360
INCORPORATING SEX, RACE,

1356
00:57:14,360 --> 00:57:15,640
ETHNICITY, GENETIC BACK GROWN OF

1357
00:57:15,640 --> 00:57:17,200
RECIPIENT AND DONOR MAY ALSO

1358
00:57:17,200 --> 00:57:20,640
IMPACT THIS. FROM THE REGULATORY

1359
00:57:20,640 --> 00:57:23,800
SIDE, WE THINK THERE MIGHT BE

1360
00:57:23,800 --> 00:57:25,040
NEED TO BE EXPOSURE LIMITS

1361
00:57:25,040 --> 00:57:27,000
ESTABLISHED AND STANDARDS FOR

1362
00:57:27,000 --> 00:57:30,240
CONCENTRATION OF POTENTIALLY

1363
00:57:30,240 --> 00:57:31,320
HARMFUL COMPOUNDS DEPENDSING

1364
00:57:31,320 --> 00:57:33,080
WHAT THE STUDIES SHOW. THEN

1365
00:57:33,080 --> 00:57:35,360
ADDITIONAL METHODS ARE NEEDED TO

1366
00:57:35,360 --> 00:57:37,240
IMPROVE BLOOD SAFETY TO REDUCE

1367
00:57:37,240 --> 00:57:39,520
ERRORS IN ALL STEPS OF TRANS

1368
00:57:39,520 --> 00:57:41,400
FUSION PRODUCT. WE SEE WRONG

1369
00:57:41,400 --> 00:57:45,280
BLOOD IN TUBE WAY TOO OFTEN THAN

1370
00:57:45,280 --> 00:57:47,640
IS -- MAKES ME FEEL COMFORTABLE.

1371
00:57:47,640 --> 00:57:53,720
NEXT SLIDE.  SO IN TERMS OF

1372
00:57:53,720 --> 00:57:54,920
BARRIERS, ONE OF THE MAIN

1373
00:57:54,920 --> 00:57:57,640
BARRIERS FOR ANY STUDIES IN

1374
00:57:57,640 --> 00:57:58,920
PARTICULARLY AS A RESULT

1375
00:57:58,920 --> 00:58:00,720
FORRABLE NEONATES AND CHILDREN

1376
00:58:00,720 --> 00:58:02,880
IS MIGHT REQUIRE LONG STANDING

1377
00:58:02,880 --> 00:58:04,120
SUPPORT FOR LONG RANGE STUDIES

1378
00:58:04,120 --> 00:58:05,760
TO LOOK AT THE LONG TERM

1379
00:58:05,760 --> 00:58:07,120
CONSEQUENCES. SO THAT IS A

1380
00:58:07,120 --> 00:58:09,880
BARRIER TO DOING THOSE KINDS OF

1381
00:58:09,880 --> 00:58:11,640
STUDIES BUT WE FEEL THAT THAT IS

1382
00:58:11,640 --> 00:58:13,000
-- MORE SUPPORT IS NEEDED FOR

1383
00:58:13,000 --> 00:58:18,480
THOSE TYPES OF STUDIES.  MORE

1384
00:58:18,480 --> 00:58:19,800
ANIMAL AND PRE-CLINICAL MODELS

1385
00:58:19,800 --> 00:58:21,640
FOR BLOOD PRODUCTS NEED TO BE

1386
00:58:21,640 --> 00:58:23,560
DEVELOPED AS IN THE OTHER

1387
00:58:23,560 --> 00:58:24,800
PRIORITIES WE HAVE, ADDITIONAL

1388
00:58:24,800 --> 00:58:27,280
OMICS APPROACHES, NEEDED TO PUT

1389
00:58:27,280 --> 00:58:30,880
ALL THIS TOGETHER AND

1390
00:58:30,880 --> 00:58:32,600
IMPLEMENTATION SCIENCE

1391
00:58:32,600 --> 00:58:36,320
APPROACHES FOR IMPROVING SAFETY 

1392
00:58:36,320 --> 00:58:38,720
WE MOVE ON TO DRAFT PRIORITY

1393
00:58:38,720 --> 00:58:40,640
FOUR WHICH IS WHAT STRATEGIES

1394
00:58:40,640 --> 00:58:42,360
CAN BE EMPLOYED TO INDUCE

1395
00:58:42,360 --> 00:58:43,560
RESPONSES TO RED BLOOD CELL OR

1396
00:58:43,560 --> 00:58:44,960
OTHER ANTIGENS AND CONSEQUENCES

1397
00:58:44,960 --> 00:58:46,360
OF ANTIBODIES IN TRANSFUSION AND

1398
00:58:46,360 --> 00:58:50,240
PREGNANCY. SO THIS ENCOMPASSES

1399
00:58:50,240 --> 00:58:51,600
THREE THINGS. FIRST IS

1400
00:58:51,600 --> 00:58:53,480
PREVENTION STRATEGIES AND THE

1401
00:58:53,480 --> 00:58:56,120
GROUP FELT STRONGLY THAT AN

1402
00:58:56,120 --> 00:58:58,120
OUNCE OF PREVENTION IS WORTH

1403
00:58:58,120 --> 00:59:00,120
POUND OF CURE AND WE SHOULD TRY

1404
00:59:00,120 --> 00:59:05,480
WHERE POSSIBLE TO AVOID ANTIBODY

1405
00:59:05,480 --> 00:59:08,280
FORMATION AND SO THAT WAS THE

1406
00:59:08,280 --> 00:59:09,920
FIRST PART, SECOND ONE WAS

1407
00:59:09,920 --> 00:59:11,240
UNDERSTANDING MECHANISMS, SO IT

1408
00:59:11,240 --> 00:59:14,880
IS STILL MORE WORK ON -- INTO

1409
00:59:14,880 --> 00:59:17,640
WHY SOME MAKE ANTIBODIES AND

1410
00:59:17,640 --> 00:59:19,960
SOME DON'T. FOR RED CELLS

1411
00:59:19,960 --> 00:59:21,960
PLATELETS AND ALSO SELF ANTIGENS

1412
00:59:21,960 --> 00:59:24,720
VERSUS ALLO ANTIGENS, AND

1413
00:59:24,720 --> 00:59:26,400
INCLUDING THE ROLE THAT DONOR

1414
00:59:26,400 --> 00:59:29,280
COMPONENT CHARACTERISTICS MAY

1415
00:59:29,280 --> 00:59:32,080
PLAY. NOVEL STRATEGIES AND

1416
00:59:32,080 --> 00:59:33,440
THERAPEUTICS TO MINIMIZE

1417
00:59:33,440 --> 00:59:34,680
COMPLICATIONS SO WHEN SOMEONE

1418
00:59:34,680 --> 00:59:36,680
HAS ANTIBODY TO SOMETHING HOW

1419
00:59:36,680 --> 00:59:40,160
CAN WE MINIMIZE THE

1420
00:59:40,160 --> 00:59:43,360
COMPLICATIONS OR HARM THEY DO.

1421
00:59:43,360 --> 00:59:44,920
THIS INCLUDES HYPERHEMOLYSIS

1422
00:59:44,920 --> 00:59:47,880
WHICH IS STILL POORLY

1423
00:59:47,880 --> 00:59:49,560
UNDERSTAND. AUTOANTIBODIES THE

1424
00:59:49,560 --> 00:59:51,280
TO RED CELL ANTIGENS AND

1425
00:59:51,280 --> 00:59:53,160
ANTI-BODY THES TO OTHER THINGS

1426
00:59:53,160 --> 00:59:57,160
LIKE PLASMA LIKE IGA OR

1427
00:59:57,160 --> 00:59:58,800
HAPTOGLOBIN TO BE INCLUSIVE OF

1428
00:59:58,800 --> 01:00:01,440
ALL BLOOD PRODUCTS. SO WHY AN

1429
01:00:01,440 --> 01:00:03,600
ISSUE? ALLO ANTIBODIES CAN

1430
01:00:03,600 --> 01:00:06,120
RESULT IN HEMOLYTIC TRANSFUSION

1431
01:00:06,120 --> 01:00:07,320
REACTIONS, DELAY OR PREVENT

1432
01:00:07,320 --> 01:00:09,280
FUTURE TRANSFUSION SUPPORT, IT

1433
01:00:09,280 --> 01:00:11,200
CAN POSE BARRIERS TO

1434
01:00:11,200 --> 01:00:12,280
TRANSPLANTATION AND CAUSE OTHER

1435
01:00:12,280 --> 01:00:14,400
SERIOUS ADVERSE EFFECTS, ONE OF

1436
01:00:14,400 --> 01:00:15,640
THE THINGS WE DIDN'T PUTS HERE

1437
01:00:15,640 --> 01:00:18,720
IS IT ALSO ADDS SIGNIFICANT COST

1438
01:00:18,720 --> 01:00:21,480
IF THERE WERE NO ALLO ANTIBODIES

1439
01:00:21,480 --> 01:00:23,120
WE WOULDN'T SPEND EFFORT AND

1440
01:00:23,120 --> 01:00:24,800
MONEY PERFORMING TIGHTENED

1441
01:00:24,800 --> 01:00:26,760
SCREENS, THINGS LIKE THAT. THERE

1442
01:00:26,760 --> 01:00:28,200
IS ALSO THIS CONCEPT OF

1443
01:00:28,200 --> 01:00:29,800
RESPONDER VERSUS NON-RESPONDSER

1444
01:00:29,800 --> 01:00:31,800
POPULATIONS WHERE SOME PEOPLE

1445
01:00:31,800 --> 01:00:33,560
TEND TO RESPOND AND MAKE

1446
01:00:33,560 --> 01:00:35,280
ANTIBODIES WHEN EXPOSED TO ALLO

1447
01:00:35,280 --> 01:00:36,680
ANTIGENS AND SOME DON'T. WE

1448
01:00:36,680 --> 01:00:40,880
STILL DON'T UNDERSTAND THAT.

1449
01:00:40,880 --> 01:00:42,120
THERE NEEDS TO BE MORE RESEARCH

1450
01:00:42,120 --> 01:00:44,080
INTO DEFINING WHO IS AND ISN'T A

1451
01:00:44,080 --> 01:00:49,120
RESPONDER. ALSO THE CONCEPT OF

1452
01:00:49,120 --> 01:00:53,600
ANTIBODIES OF INESSENCE, MANY

1453
01:00:53,600 --> 01:00:55,560
ANTIBODIES APPEAR AND THEN

1454
01:00:55,560 --> 01:00:57,400
DISAPPEAR NOT DETECTABLE BY

1455
01:00:57,400 --> 01:00:58,840
AGGLUTINATION METHODS SO WE

1456
01:00:58,840 --> 01:01:00,960
DON'T DETECT THEM IN BLOOD VEIN

1457
01:01:00,960 --> 01:01:02,360
AND AS PATIENTS GO FROM BLOOD

1458
01:01:02,360 --> 01:01:04,680
VAIN TO BLOOD VAIN IF WE DON'T

1459
01:01:04,680 --> 01:01:06,200
HAVE A METHOD FOR TRACKING

1460
01:01:06,200 --> 01:01:07,760
E. CXFC ANTIBODIES SOMETIMES

1461
01:01:07,760 --> 01:01:11,800
EXPOSE PEOPLE TO ANTIGENS THAT

1462
01:01:11,800 --> 01:01:14,040
HAD WE HAD THEIR HISTORY WE

1463
01:01:14,040 --> 01:01:17,680
COULD HAVE AVOIDED SO

1464
01:01:17,680 --> 01:01:21,880
UNDERSTANDING THE PROCESS OF

1465
01:01:21,880 --> 01:01:23,320
EVANESCENCE AND WHEN CLINICALLY

1466
01:01:23,320 --> 01:01:26,120
SIGNIFICANT IS IMPORTANT. WHEN

1467
01:01:26,120 --> 01:01:28,400
YOU CHALLENGE SOMEONE WHO HAS

1468
01:01:28,400 --> 01:01:31,960
ALLO ANTIBODIES, OR

1469
01:01:31,960 --> 01:01:33,320
AUTOANTIBODIES FOR THAT MATTER,

1470
01:01:33,320 --> 01:01:35,120
WHY SOME PEOPLE HAVE CLINICAL

1471
01:01:35,120 --> 01:01:39,000
SYMPTOMS WITH IT AND SOME DON'T,

1472
01:01:39,000 --> 01:01:40,560
WE STILL DON'T KNOW. SO

1473
01:01:40,560 --> 01:01:42,360
UNDERSTANDING THAT MECHANISTIC

1474
01:01:42,360 --> 01:01:43,680
IS ALSO THE GROUP FELT WAS

1475
01:01:43,680 --> 01:01:48,040
IMPORTANT. NEXT SLIDE.  SO THE

1476
01:01:48,040 --> 01:01:51,000
GROUP FELT AGAIN THAT PREVENTION

1477
01:01:51,000 --> 01:01:52,160
STRATEGIES ARE OUT MOST

1478
01:01:52,160 --> 01:01:55,160
IMPORTANCE. WE NEED MORE WORK

1479
01:01:55,160 --> 01:01:57,320
DONE ON BETTER MATCHING BASED ON

1480
01:01:57,320 --> 01:01:59,080
MOLECULAR PHENOTYPES AND MORE

1481
01:01:59,080 --> 01:02:00,800
WORK DONE ON MOLECULAR

1482
01:02:00,800 --> 01:02:02,840
GENOTYPING. ADDITIONAL BASIC

1483
01:02:02,840 --> 01:02:05,960
TRANSLATIONAL AND CLINICAL

1484
01:02:05,960 --> 01:02:08,600
STUDIES TO STUDY MECHANISMS

1485
01:02:08,600 --> 01:02:09,960
UNDERLYING IMMUNIZATION.

1486
01:02:09,960 --> 01:02:11,120
SEVERITY OF TRANSFUSION

1487
01:02:11,120 --> 01:02:12,680
REACTIONS AND THERAPEUTICS TO

1488
01:02:12,680 --> 01:02:13,800
MINIMIZE COMPLICATIONS. T NEXT

1489
01:02:13,800 --> 01:02:18,840
SLIDE.  TERMS OF BARRIERS, ONE

1490
01:02:18,840 --> 01:02:23,080
OF THE MAJOR BARRIERS IS THAT

1491
01:02:23,080 --> 01:02:24,760
ALLO IMMUNIZATION IS A

1492
01:02:24,760 --> 01:02:27,880
RELATIVELY RARE EVENT, HARD TO

1493
01:02:27,880 --> 01:02:29,960
PREDICT WHEN SOMEONE WILL HAVE

1494
01:02:29,960 --> 01:02:32,160
OCCURRENCE OF ALLO ANTIBODY. WE

1495
01:02:32,160 --> 01:02:36,000
NEED TO DO A BETTER JOB BUILDING

1496
01:02:36,000 --> 01:02:38,120
BIOBANKS WITH FLOW ANNOTATED

1497
01:02:38,120 --> 01:02:39,520
BIOSPECIMENS, SPECIMENS THAT ARE

1498
01:02:39,520 --> 01:02:40,680
AVAILABLE BEFORE SOMEONE MAKES

1499
01:02:40,680 --> 01:02:43,000
AN ANTIBODY. WE NEED BETTER

1500
01:02:43,000 --> 01:02:44,680
INFORMATION SYSTEMS AND DATA

1501
01:02:44,680 --> 01:02:47,200
SHARING TO DOCUMENT ANTIBODIES

1502
01:02:47,200 --> 01:02:49,200
ACROSS THE STATES. THINGS THAT

1503
01:02:49,200 --> 01:02:52,720
ARE MAYBE ROUTINE A IN OTHER

1504
01:02:52,720 --> 01:02:55,880
COUNTRIES.  WE NEED ADDITIONAL

1505
01:02:55,880 --> 01:02:56,640
HEMOTOLOGY GENOMICS TOOLS TO BE

1506
01:02:56,640 --> 01:02:58,200
ABLE TO DEAL WITH THIS

1507
01:02:58,200 --> 01:03:00,760
INFORMATION. FINALLY, AGAIN AS A

1508
01:03:00,760 --> 01:03:02,520
MAIN BARRIERS THAT WE NEED

1509
01:03:02,520 --> 01:03:04,200
COLLABORATIVE NETWORKS AND

1510
01:03:04,200 --> 01:03:07,720
POTENTIALLY REGISTRIES TO REALLY

1511
01:03:07,720 --> 01:03:09,760
MAKE A DIFFERENCE IN -- FOR THIS

1512
01:03:09,760 --> 01:03:14,400
PRIORITY. NEXT SLIDE. SWITCH

1513
01:03:14,400 --> 01:03:16,360
BACK TO ANGLO.

1514
01:03:16,360 --> 01:03:25,200
>> SO LAST BUT TESTING AND

1515
01:03:25,200 --> 01:03:27,480
DESIGN AND THE TEST THE NEXT

1516
01:03:27,480 --> 01:03:28,840
GENERATION OF BLOOD PRODUCTS

1517
01:03:28,840 --> 01:03:30,720
BLOOD DERIVED THERAPEUTIC. AND

1518
01:03:30,720 --> 01:03:32,240
IMMEDIATE TO ENSURE SAFETY OF

1519
01:03:32,240 --> 01:03:35,000
NOVEL BLOOD PRODUCTS OR EVEN

1520
01:03:35,000 --> 01:03:37,640
BLOOD PRODUCTS REPURPOSED FOR

1521
01:03:37,640 --> 01:03:40,440
NON-TRANSFUSION INHIBITIONS. --

1522
01:03:40,440 --> 01:03:43,440
INDICATIONS. AS NOTESSED BY

1523
01:03:43,440 --> 01:03:45,240
YESTERDAY, MULTIPLE WORKS GROUPS

1524
01:03:45,240 --> 01:03:48,480
PRIOR SESSIONS THE GLOBAL

1525
01:03:48,480 --> 01:03:50,120
PANDEMIC, COVID-19 PANDEMIC HAS

1526
01:03:50,120 --> 01:03:51,400
EXACERBATED ISSUES IN THE BLOOD

1527
01:03:51,400 --> 01:03:54,600
SUPPLY CHAIN. HURDLES IN DONOR

1528
01:03:54,600 --> 01:03:56,760
RECRUITMENT AND SUBSEQUENT

1529
01:03:56,760 --> 01:03:58,440
SCARCE BLOOD RESERVES HAVE

1530
01:03:58,440 --> 01:04:00,280
PERSISTED IN EARLY 2022 DESPITE

1531
01:04:00,280 --> 01:04:01,760
EASING OF THE PANDEMIC. EFFORT

1532
01:04:01,760 --> 01:04:05,520
TO DEVELOP NOVEL BLOOD PRODUCTS

1533
01:04:05,520 --> 01:04:08,560
EXTEND SHELF LIFE, QUOTHMENT OR

1534
01:04:08,560 --> 01:04:09,720
EVEN REPLACE CURRENT PRODUCTS

1535
01:04:09,720 --> 01:04:12,240
ARE OF INCREASED IMPORTANCE.

1536
01:04:12,240 --> 01:04:15,000
MULTIPLE APPROACH WERE

1537
01:04:15,000 --> 01:04:17,120
IDENTIFIED TO TRANSFER THE

1538
01:04:17,120 --> 01:04:19,000
BLOOD, DEVELOPMENT OF EXVIVO

1539
01:04:19,000 --> 01:04:20,360
GENERATED BLOOD CELLS FROM STEM

1540
01:04:20,360 --> 01:04:23,520
OR PROGENITOR CELLS OR INDUCED

1541
01:04:23,520 --> 01:04:26,200
PLURIPOTENT STEM CELLS OR ADULT

1542
01:04:26,200 --> 01:04:28,560
UMBILICAL CORD BLOOD ORIGIN,

1543
01:04:28,560 --> 01:04:29,840
SYNTHESIS OF ARTIFICIAL BLOOD

1544
01:04:29,840 --> 01:04:32,360
CELLS, ERYTHROCYTES OR

1545
01:04:32,360 --> 01:04:36,680
PLATELETS, THE USE OF BLOOD

1546
01:04:36,680 --> 01:04:38,360
CELLS AS TRANSFUSION WERE

1547
01:04:38,360 --> 01:04:41,880
NOTICED.  SUCH AS THE USE OF

1548
01:04:41,880 --> 01:04:44,720
BLOOD CELLS, SPECIAL EMPHASIS ON

1549
01:04:44,720 --> 01:04:46,200
BLOOD CELLS AS DELIVERY SYSTEMS.

1550
01:04:46,200 --> 01:04:48,640
FOR EXAMPLE ENZYME LOADED RED

1551
01:04:48,640 --> 01:04:50,200
BLOOD CELLS FOR METABOLIC

1552
01:04:50,200 --> 01:04:51,760
INTERVENTIONS IN CANCER. NEXT

1553
01:04:51,760 --> 01:04:56,280
SLIDE PLEASE.  THE DEVELOPMENT

1554
01:04:56,280 --> 01:05:00,480
OF BLOOD PRODUCTS ENCOMPASS

1555
01:05:00,480 --> 01:05:01,920
SIGNIFICANT GOALS, FORWARD TO

1556
01:05:01,920 --> 01:05:03,840
QUALITY SAFETY AND EFFICACY AND

1557
01:05:03,840 --> 01:05:10,960
PERHAPS SHELF LIFE OF FROM DR.

1558
01:05:10,960 --> 01:05:12,200
DEVINE BLOOD GIFT. AS PART OF

1559
01:05:12,200 --> 01:05:14,400
THE APPROACHES THE GROUP

1560
01:05:14,400 --> 01:05:15,800
INCLUDED HIGH THROUGH PUT OMICS

1561
01:05:15,800 --> 01:05:18,680
THAT ARE DEVELOPMENT OF NOVEL

1562
01:05:18,680 --> 01:05:21,120
STRATEGIES OR ADJUVANTS FOR RED

1563
01:05:21,120 --> 01:05:24,000
BLOOD CELLS PLATELETS WHOLE

1564
01:05:24,000 --> 01:05:26,600
BLOOD PRODUCTS. IN ADDITION THE

1565
01:05:26,600 --> 01:05:27,840
RESEARCH TEMPERATURE MENTIONED

1566
01:05:27,840 --> 01:05:31,200
IN MISPRESENTATION BEFORE, FOR

1567
01:05:31,200 --> 01:05:33,880
-- THROMBOSOMES, THE

1568
01:05:33,880 --> 01:05:34,920
OPTIMIZATION OF MANAGEMENT

1569
01:05:34,920 --> 01:05:37,880
APPROACHES FOR EXAMPLE HYPOXY

1570
01:05:37,880 --> 01:05:39,080
STORAGE RED BLOOD CELLS WHOLE

1571
01:05:39,080 --> 01:05:44,800
BLOOD. WHILE THE SARS COV-2

1572
01:05:44,800 --> 01:05:45,680
TRANSFUSION IS NOT REPRESENT

1573
01:05:45,680 --> 01:05:48,080
CRITICAL ISSUE IN THE LATEST

1574
01:05:48,080 --> 01:05:50,120
PANDEMIC, WE MAY NOT BE SO LUCKY

1575
01:05:50,120 --> 01:05:53,520
THE NEXT PANDEMIC. PROVIDED

1576
01:05:53,520 --> 01:05:54,200
IMPLEMENTATION OF PATHOGEN

1577
01:05:54,200 --> 01:05:58,160
RELEASED PRODUCTS WILL BE BY

1578
01:05:58,160 --> 01:05:59,840
DEVELOPMENT OF SPECIFIC --

1579
01:05:59,840 --> 01:06:01,600
POTENTIAL EMPHASIS OF PATHOGEN

1580
01:06:01,600 --> 01:06:06,640
REACTION PROCESS. AS PART OF THE

1581
01:06:06,640 --> 01:06:09,120
DISCUSSION WE ALSO BOTH CONTROL

1582
01:06:09,120 --> 01:06:11,440
-- BRIEFLY DISCUSS DEVELOPMENT

1583
01:06:11,440 --> 01:06:13,680
OF UNIVERSAL BLOOD PRODUCTS, FOR

1584
01:06:13,680 --> 01:06:17,240
EXAMPLE ENZYMATIC TREATMENTS IN

1585
01:06:17,240 --> 01:06:19,520
BLOOD GROUP ANTIGEN OR MORE

1586
01:06:19,520 --> 01:06:22,400
BRIEFLY, WE DISCUSS PERCENT

1587
01:06:22,400 --> 01:06:24,840
BLOOD GIVEN RECENT BREAK THROUGH

1588
01:06:24,840 --> 01:06:30,720
IN CONDITION TO HUMANS.  IN

1589
01:06:30,720 --> 01:06:33,080
PARALLEL TO DEVELOPMENT OF NOVEL

1590
01:06:33,080 --> 01:06:34,800
BLOOD PRODUCTS, NOVEL USE OF

1591
01:06:34,800 --> 01:06:38,320
CORED BLOOD PRODU PRODUCTS ARE

1592
01:06:38,320 --> 01:06:41,320
EMERGING. FOR EXAMPLE POOR

1593
01:06:41,320 --> 01:06:43,840
PLASMA OR PLATELET GELS IN

1594
01:06:43,840 --> 01:06:45,440
COSMETIC, RHEUMATOLOGY, SPORTS

1595
01:06:45,440 --> 01:06:47,680
MEDICINE, EMERGENCY MEDICINE. IN

1596
01:06:47,680 --> 01:06:48,680
BURN PATIENTS AND TRAUMA

1597
01:06:48,680 --> 01:06:53,480
PATIENTS. STUDIES BY RODENT

1598
01:06:53,480 --> 01:06:55,600
MODELS FOLLOWED BY MORE RECENT

1599
01:06:55,600 --> 01:06:58,800
STUDIES ON TRANSFUSION OF PLASMA

1600
01:06:58,800 --> 01:07:01,080
FROM YOUNG DAUGHTERS AND

1601
01:07:01,080 --> 01:07:02,360
RECIPIENTS PROVIDE TRANSFUSIONAL

1602
01:07:02,360 --> 01:07:03,720
BLOOD PRODUCTS FOR ANTI-AGING

1603
01:07:03,720 --> 01:07:08,680
PURPOSES. FINALLY, COVID-19

1604
01:07:08,680 --> 01:07:10,240
PANDEMIC REVIVED INTEREST IN USE

1605
01:07:10,240 --> 01:07:12,960
OF CONVALESCENT PLASMA FOR

1606
01:07:12,960 --> 01:07:16,600
PROPHYLACTIC OR ACUTE DISEASE,

1607
01:07:16,600 --> 01:07:20,720
OPENING KEYNOTE LECTURE NOTESSED

1608
01:07:20,720 --> 01:07:26,560
HOW (INAUDIBLE) IF NOT FOR THE

1609
01:07:26,560 --> 01:07:27,440
NEXT EPIDEMIC. NEXT SLIDE

1610
01:07:27,440 --> 01:07:32,880
PLEASE.  SO FOCUS THERE DESCRIBE

1611
01:07:32,880 --> 01:07:34,280
BEGINNING TO DESCRIBE WOULD BE

1612
01:07:34,280 --> 01:07:35,960
POSSIBLE WITHIN THE NEXT THREE

1613
01:07:35,960 --> 01:07:38,760
TO TEN YEARS, STUDIES WOULD NEED

1614
01:07:38,760 --> 01:07:39,960
TO (INAUDIBLE) AT THE TIME, AS

1615
01:07:39,960 --> 01:07:45,680
PART OF THE STUDIES EXISTING

1616
01:07:45,680 --> 01:07:47,560
ANIMAL MODELS ANIMAL MODELS

1617
01:07:47,560 --> 01:07:49,640
WOULD BE NECESSARY. CAN BE

1618
01:07:49,640 --> 01:07:53,160
UTILIZE THE DEVELOPMENT OF

1619
01:07:53,160 --> 01:07:54,760
PRODUCTS WHICH CAN BE TESTED IN

1620
01:07:54,760 --> 01:07:56,200
TRIALS. WITH RESPECT TO

1621
01:07:56,200 --> 01:07:58,280
DEVELOPMENT OF EXVIVO GENETIC

1622
01:07:58,280 --> 01:08:00,800
BLOOD PRODUCTS ONE ISSUE

1623
01:08:00,800 --> 01:08:04,000
IDENTIFIED RELATED TO FOR

1624
01:08:04,000 --> 01:08:05,120
EXAMPLE, HOW THOSE CELLS

1625
01:08:05,120 --> 01:08:06,880
FUNCTION INCLUDING COST

1626
01:08:06,880 --> 01:08:09,000
EFFECTIVENESS AND SAFETY,

1627
01:08:09,000 --> 01:08:11,000
DIFFERENTIATION AMONG -- FOR

1628
01:08:11,000 --> 01:08:17,160
EXAMPLE IN MANIPULATION --

1629
01:08:17,160 --> 01:08:19,000
ENUCLEATION OF ERYTHROID

1630
01:08:19,000 --> 01:08:20,640
PRECURSORS.  DEVELOPING

1631
01:08:20,640 --> 01:08:22,000
STANDARDS AND QUALITY CONTROL

1632
01:08:22,000 --> 01:08:23,440
METHODS FOR THESE NOVEL PRODUCTS

1633
01:08:23,440 --> 01:08:31,160
IS CRUCIAL. SO THIS FINAL SLIDE

1634
01:08:31,160 --> 01:08:32,360
SUMMARIZES THE PRIORITY OF

1635
01:08:32,360 --> 01:08:37,760
WORKING GROUP OF COURSE AS DR.

1636
01:08:37,760 --> 01:08:39,200
HOD MENTIONED, SEE THERE'S BEEN

1637
01:08:39,200 --> 01:08:40,320
ACTIVITY IN THE CHAT, AND WE

1638
01:08:40,320 --> 01:08:42,360
WILL BE HAPPY TO DISCUSS THIS IN

1639
01:08:42,360 --> 01:08:44,840
THE BREAK OUT SESSION. THAT

1640
01:08:44,840 --> 01:08:48,360
SHOULD BE AROUND 12:35 TO 1:35

1641
01:08:48,360 --> 01:08:50,600
P.M. AND THANK YOU ALL FOR YOUR

1642
01:08:50,600 --> 01:08:54,480
ATTENTION. THANKS FOR THE

1643
01:08:54,480 --> 01:08:55,840
OPPORTUNITY TO PRESENT TODAY AND

1644
01:08:55,840 --> 01:08:58,440
SPECIAL THANKS TO THE WORK TO

1645
01:08:58,440 --> 01:09:01,160
PUT ALL THIS TOGETHER AND OF

1646
01:09:01,160 --> 01:09:03,120
COURSE ADD TO THE PRIORITIES

1647
01:09:03,120 --> 01:09:06,080
ADDITIONAL PRIORITIES THAT WERE

1648
01:09:06,080 --> 01:09:07,880
IN THESE WELL IDENTIFIED AS

1649
01:09:07,880 --> 01:09:10,440
PARTS OF THE DISCUSSION AND PATH

1650
01:09:10,440 --> 01:09:20,800
FORWARD. THANK YOU. 

1651
01:09:23,760 --> 01:09:28,800
>> THANK YOU SO MUCH DR.
HOD AND

1652
01:09:28,800 --> 01:09:29,600
D'ALESSANDRO, LOTS OF

1653
01:09:29,600 --> 01:09:30,840
OPPORTUNITY TO COME BACK AND

1654
01:09:30,840 --> 01:09:31,840
DISCUSSION DURING THE BREAK OUT

1655
01:09:31,840 --> 01:09:33,400
SESSION AND LATER ON. I WILL

1656
01:09:33,400 --> 01:09:37,600
MOVE TO THE NEXT WORKING GROUP.

1657
01:09:37,600 --> 01:09:38,640
THAT IS AN INTERESTING WORKING

1658
01:09:38,640 --> 01:09:40,640
GROUP, WE ASK THEM TO TACKLE A

1659
01:09:40,640 --> 01:09:42,680
LOT OF DIFFERENT THINGS. THIS

1660
01:09:42,680 --> 01:09:45,200
WORKING GROUP IS BEING CHAIRED

1661
01:09:45,200 --> 01:09:48,320
BY DR. RUCHIKA GOEL AND DR.

1662
01:09:48,320 --> 01:09:50,200
JANSEN SEHEULT, NEW METHODS

1663
01:09:50,200 --> 01:09:52,360
TRANSFUSION SCIENCE, DATA

1664
01:09:52,360 --> 01:09:53,320
SCIENCE MULTI-FACTORIAL

1665
01:09:53,320 --> 01:09:55,080
ANALYSES, USE OF ARTIFICIAL

1666
01:09:55,080 --> 01:09:56,080
INTELLIGENCE AND MACHINE

1667
01:09:56,080 --> 01:09:57,840
LEARNING. SO AGAIN, THOSE ARE

1668
01:09:57,840 --> 01:10:02,040
THE CHAIRS, THE CO-CHAIRS, DR.

1669
01:10:02,040 --> 01:10:05,280
GOEL IS ASSOCIATE PROFESSOR IN

1670
01:10:05,280 --> 01:10:06,520
PEDIATRICS HEMATOLOGY ONCOLOGY

1671
01:10:06,520 --> 01:10:08,640
AT SIMMONS CANCER INSTITUTE AT

1672
01:10:08,640 --> 01:10:11,080
SIU AS WELL AS ADDITIONAL ROLES

1673
01:10:11,080 --> 01:10:12,680
AT JOHNS HOPKINS UNIVERSITY AND

1674
01:10:12,680 --> 01:10:16,080
IMPACT LIFE AND DR. SEHEULT IS

1675
01:10:16,080 --> 01:10:17,960
SENIOR CONSULTANT PROFESSOR IN

1676
01:10:17,960 --> 01:10:19,400
DIVISION OF PATHOLOGY,

1677
01:10:19,400 --> 01:10:20,920
COMPUTATIONAL PATHOLOGY AND

1678
01:10:20,920 --> 01:10:21,720
ARTIFICIAL INTELLIGENCE,

1679
01:10:21,720 --> 01:10:22,720
DEPARTMENT OF LABORATORY

1680
01:10:22,720 --> 01:10:24,480
MEDICINE AT THE MAYO WHICH I IN

1681
01:10:24,480 --> 01:10:25,920
THIS CASE IN ROCHESTER. SO THANK

1682
01:10:25,920 --> 01:10:30,000
YOU. PLEASE GO AHEAD. 

1683
01:10:30,000 --> 01:10:32,040
>>

1684
01:10:32,040 --> 01:10:34,640
THANK YOU SO MUCH, DR. CUSTER

1685
01:10:34,640 --> 01:10:37,800
FOR THE INTRODUCTION. WE ARE

1686
01:10:37,800 --> 01:10:40,120
GRATEFUL TO NHLBI FOR GETTING A

1687
01:10:40,120 --> 01:10:42,600
CHANCE TO CO-CHAIR A SUBGROUP.

1688
01:10:42,600 --> 01:10:44,640
AND ALSO WE ARE THANKFUL FOR

1689
01:10:44,640 --> 01:10:46,080
NOVEL EMERGING DATA SCIENCES AND

1690
01:10:46,080 --> 01:10:47,440
COMPUTATIONAL METHODS IN BLOOD

1691
01:10:47,440 --> 01:10:48,520
BANKING TRANSFUSION MEDICINE TO

1692
01:10:48,520 --> 01:10:50,720
BE RECOGNIZED AS AN INDEPENDENT

1693
01:10:50,720 --> 01:10:55,320
SUBGROUP.  NEXT SLIDE PLEASE.  

1694
01:10:55,320 --> 01:10:57,200
SO AS WE THINK ABOUT THE

1695
01:10:57,200 --> 01:10:58,440
RESEARCH PRIORITIES THE NEXT

1696
01:10:58,440 --> 01:11:02,800
FIVE TO TEN YEARS, WHY IS DATA

1697
01:11:02,800 --> 01:11:04,360
SCIENCE IMPORTANT? DOES IT

1698
01:11:04,360 --> 01:11:05,400
DESERVE A SEPARATE ROLE IN

1699
01:11:05,400 --> 01:11:06,640
IDENTIFICATION? SO JUST LOOKING

1700
01:11:06,640 --> 01:11:08,880
AT THE BACKGROUND, APPLICATIONS

1701
01:11:08,880 --> 01:11:13,000
OF THE VARIOUS NEW DATA SCIENCE

1702
01:11:13,000 --> 01:11:15,080
TECHNIQUES SUCH AS ANALYTICS,

1703
01:11:15,080 --> 01:11:16,680
ARTIFICIAL INTELLIGENCE AND MANY

1704
01:11:16,680 --> 01:11:18,640
SHEEN LEARNING AND MULTI-OMICS

1705
01:11:18,640 --> 01:11:20,080
TO BANKING TRANSFUSION MEDICINE

1706
01:11:20,080 --> 01:11:22,640
IS STILL IN THE RELATIVE

1707
01:11:22,640 --> 01:11:25,560
INFANCY, DATA ANALYTICS CAN BE

1708
01:11:25,560 --> 01:11:29,280
KEY TO PROPOSED ASSOCIATIONS FOR

1709
01:11:29,280 --> 01:11:30,400
BETTER MECHANIC DECISIONS AND

1710
01:11:30,400 --> 01:11:32,520
HELP IDENTIFY PREDICT PATTERNS

1711
01:11:32,520 --> 01:11:34,280
AND TRENDS THAT WERE PREVIOUSLY

1712
01:11:34,280 --> 01:11:36,080
UNKNOWN AND THOSE INFORM FUTURE

1713
01:11:36,080 --> 01:11:36,840
STUDIES AS WELL AS

1714
01:11:36,840 --> 01:11:39,320
INTERVENTIONS.  HOWEVER, DESPITE

1715
01:11:39,320 --> 01:11:42,000
A LOT OF BUZZ, LOTS OF NEWER

1716
01:11:42,000 --> 01:11:43,240
COMPUTATIONAL METHODS ARE

1717
01:11:43,240 --> 01:11:46,320
RELATIVELY UNDERUTILIZED ANDs

1718
01:11:46,320 --> 01:11:48,720
SEW TEARIC CONCEPT BUT ONLY IN

1719
01:11:48,720 --> 01:11:49,880
TRANSFUSION MEDICINE BLOOD

1720
01:11:49,880 --> 01:11:54,280
BANKING BUT IN GENERAL ADOPTION

1721
01:11:54,280 --> 01:11:56,160
IN HEALTHCARE IS SLOW AS

1722
01:11:56,160 --> 01:11:57,560
COMPARED TO COMPANIES WHICH ARE

1723
01:11:57,560 --> 01:11:59,120
TECH AND HIGHLY DATA DRIVEN

1724
01:11:59,120 --> 01:12:00,800
BUSINESS SECTORS WE HAVE ADAPTED

1725
01:12:00,800 --> 01:12:02,320
THEM MUCH FASTER. SO I THINK

1726
01:12:02,320 --> 01:12:04,880
TIME IS RIGHT TO IDENTIFY AND AS

1727
01:12:04,880 --> 01:12:08,080
WELL AS APPLY SOME OF THESE NEW

1728
01:12:08,080 --> 01:12:09,560
NOVEL TECHNOLOGIES AND DRIVE

1729
01:12:09,560 --> 01:12:11,760
INNOVATION IN THE FELTED. --

1730
01:12:11,760 --> 01:12:14,200
FEEL. OUR SUBGROUP -- FIELD. OUR

1731
01:12:14,200 --> 01:12:15,960
SUBGROUP AS SOME ATTENDEES WILL

1732
01:12:15,960 --> 01:12:17,280
NOTICE BRINGS TOGETHER A LOT OF

1733
01:12:17,280 --> 01:12:19,400
PROPOSED APPROACHES FROM MANY

1734
01:12:19,400 --> 01:12:20,600
STATE OF THE SCIENCE WORKING

1735
01:12:20,600 --> 01:12:22,400
GROUPS AND EXCELLENT

1736
01:12:22,400 --> 01:12:27,280
PROPROPOSALS PUT FORTH. AS DR.

1737
01:12:27,280 --> 01:12:28,520
CUSTER MENTIONED ONE CHALLENGE

1738
01:12:28,520 --> 01:12:30,000
WE FACE AS WE TRY TO COME UP

1739
01:12:30,000 --> 01:12:31,440
WITH DRAFTING RESEARCH

1740
01:12:31,440 --> 01:12:33,240
PRIORITIES WAS THAT DO WE USE

1741
01:12:33,240 --> 01:12:35,600
EACH DATA SCIENCE TECHNIQUE AND

1742
01:12:35,600 --> 01:12:36,960
PROPOSED THAT AT ITS OWN

1743
01:12:36,960 --> 01:12:38,960
RESEARCH PRIORITY OR IDENTIFY

1744
01:12:38,960 --> 01:12:40,160
RESEARCH GAPS WHERE THE DATA

1745
01:12:40,160 --> 01:12:43,200
SCIENCE TECHNIQUES COULD BE

1746
01:12:43,200 --> 01:12:44,640
APPLIED. WE HAVE COME WITH A

1747
01:12:44,640 --> 01:12:47,520
HYBRID MODEL, WE HAVE ONE

1748
01:12:47,520 --> 01:12:48,840
RESEARCH GAP THAT COULD BE SOLVE

1749
01:12:48,840 --> 01:12:50,720
BY PROPOSING VARIOUS DATA

1750
01:12:50,720 --> 01:12:52,200
SCIENCE TECHNIQUES OR ONE DATA

1751
01:12:52,200 --> 01:12:53,440
SCIENCE TECHNIQUE THAT COULD BE

1752
01:12:53,440 --> 01:12:56,680
APPLICABLE TO MORE THAN ONE

1753
01:12:56,680 --> 01:12:58,920
RESEARCH GAP COMING UP WITH

1754
01:12:58,920 --> 01:13:02,640
PROPOSED DELIVERABLES.  HERE IS

1755
01:13:02,640 --> 01:13:06,920
OUR WORKING GROUP AND WE HAVE

1756
01:13:06,920 --> 01:13:08,880
BEEN FORT MAT THE UNIQUE

1757
01:13:08,880 --> 01:13:09,800
STRENGTH OF THE GROUP IS HALF

1758
01:13:09,800 --> 01:13:11,720
THE TEAM MEMBERS ARE PRIMARILY

1759
01:13:11,720 --> 01:13:14,600
BASED IN CLINICAL TRANSFUSION

1760
01:13:14,600 --> 01:13:17,200
MEDICINE, OTHER IS COMPOSED OF

1761
01:13:17,200 --> 01:13:19,720
TECHNICAL DATA SCIENCE EXPERTS

1762
01:13:19,720 --> 01:13:21,480
RANGING FROM GENOMICS

1763
01:13:21,480 --> 01:13:22,480
INFORMATICS, BIOSTATISTICS AND

1764
01:13:22,480 --> 01:13:23,920
DATA SCIENCES, ARTIFICIAL

1765
01:13:23,920 --> 01:13:24,960
INTELLIGENCE AND MACHINE

1766
01:13:24,960 --> 01:13:25,960
LEARNING AND THESE ARE EXPERTS

1767
01:13:25,960 --> 01:13:27,640
FROM U.S. AND CANADA. SO THANK

1768
01:13:27,640 --> 01:13:32,760
YOU SO MUCH FOR ALL THEIR TIME.

1769
01:13:32,760 --> 01:13:34,880
NEXT SLIDE. FOR OUR METHODOLOGY

1770
01:13:34,880 --> 01:13:37,440
SIMILAR TO GROUP AS ELDAD

1771
01:13:37,440 --> 01:13:39,240
PRESENTED WE HAD A LOT OF

1772
01:13:39,240 --> 01:13:40,960
CONVERSATIONS FIVE THEMES THAT

1773
01:13:40,960 --> 01:13:42,800
BROADLY EMERGED.  BASED ON

1774
01:13:42,800 --> 01:13:44,000
COMBINATION OF APPLICATION AS

1775
01:13:44,000 --> 01:13:46,320
WELL AS ANALYTIC TECHNIQUES.  WE

1776
01:13:46,320 --> 01:13:48,440
IDENTIFIED SUBGROUP LEADS AND

1777
01:13:48,440 --> 01:13:50,120
RESPONSIBILITIES, AND LEADING

1778
01:13:50,120 --> 01:13:51,400
TEAMS WERE ARTIFICIAL

1779
01:13:51,400 --> 01:13:53,040
INTELLIGENCE AND MACHINE

1780
01:13:53,040 --> 01:13:56,640
LEARNING. INFORMATICS, DATABASE

1781
01:13:56,640 --> 01:13:57,640
CURATION, DATA VISUALIZATION AND

1782
01:13:57,640 --> 01:14:00,440
BIG DATA RESEARCH. DEMAND

1783
01:14:00,440 --> 01:14:01,640
FORECASTING AND BLOOD SUPPLY

1784
01:14:01,640 --> 01:14:04,000
CHAIN MANAGEMENT. PERSONALIZED

1785
01:14:04,000 --> 01:14:05,800
TRANSFUSION MEDICINE AND COST

1786
01:14:05,800 --> 01:14:09,640
EFFECTIVENESS. OMICS AND SYSTEMS

1787
01:14:09,640 --> 01:14:13,600
BIOLOGY IN BLOOD BANKING. SO

1788
01:14:13,600 --> 01:14:16,760
WHAT WE CAN SEE HERE IS WE TRY

1789
01:14:16,760 --> 01:14:20,640
TO -- DATA SCIENCE CATEGORIES TO

1790
01:14:20,640 --> 01:14:23,800
VARIOUS SUB MEMBERS NEXT SLIDE. 

1791
01:14:23,800 --> 01:14:27,520
BUT THIS LOT OF EXPERTISE AND

1792
01:14:27,520 --> 01:14:28,800
IDEAS ARE FLUID AND OVERLAPPING

1793
01:14:28,800 --> 01:14:30,520
BUT YOU WILL SEE AS WE PRESENT

1794
01:14:30,520 --> 01:14:32,040
RESEARCH PRIORITIES.  NEXT

1795
01:14:32,040 --> 01:14:35,880
SLIDE.  SO THIS IS THE SUMMARY

1796
01:14:35,880 --> 01:14:38,040
OF FOUR PRIORITIES.  RIGHT NOW

1797
01:14:38,040 --> 01:14:41,280
NO SPECIFIC ORDER. JANSEN WILL

1798
01:14:41,280 --> 01:14:42,840
GO OVER RANKING STRATEGY BUT

1799
01:14:42,840 --> 01:14:44,600
LOVE TO HEAR INPUT DURING THE

1800
01:14:44,600 --> 01:14:47,520
BREAK OUT SESSIONS AND BEYOND

1801
01:14:47,520 --> 01:14:48,960
AND THE RANKING SHOULD BE

1802
01:14:48,960 --> 01:14:50,880
FLEXIBLE. SO SUMMARIES ARE USE

1803
01:14:50,880 --> 01:14:53,320
OF INFORMATION COMMUNICATION

1804
01:14:53,320 --> 01:14:55,040
TECHNOLOGIES, ICT AND SOCIAL

1805
01:14:55,040 --> 01:14:56,840
MEDIA TO BETTER UNDERSTAND BLOOD

1806
01:14:56,840 --> 01:14:59,720
DONOR BEHAVIOR. DEVELOPMENT AND

1807
01:14:59,720 --> 01:15:01,760
USE OF MULTI-DIMENSIONAL RANGE

1808
01:15:01,760 --> 01:15:04,440
OF DATABASES AND VISUALIZATION

1809
01:15:04,440 --> 01:15:05,520
TECHNIQUES AND BLOOD BANKING IN

1810
01:15:05,520 --> 01:15:07,080
TRANSFUSION MEDICINE. DATA

1811
01:15:07,080 --> 01:15:08,760
DRIVEN ECONOMIC EVALUATIONS IN

1812
01:15:08,760 --> 01:15:10,880
BLOOD BANKING TRANSFUSION

1813
01:15:10,880 --> 01:15:13,840
MEDICINE.  DEPLOYING ROBUST

1814
01:15:13,840 --> 01:15:15,080
SCALABLE ARTIFICIAL INTELLIGENCE

1815
01:15:15,080 --> 01:15:17,520
MACHINE LEARNING WORK FLOWS.

1816
01:15:17,520 --> 01:15:18,840
INTEGRATING GENOMICS INTO

1817
01:15:18,840 --> 01:15:21,320
CLINICAL TRANSFUSION WORK FLOWS 

1818
01:15:21,320 --> 01:15:23,200
USE OF IN SILICO CLINICAL

1819
01:15:23,200 --> 01:15:25,360
TRIALS, AS WELL AS MULTI-MODAL

1820
01:15:25,360 --> 01:15:27,720
AI AND MACHINE LEARNING WITH

1821
01:15:27,720 --> 01:15:30,800
PHENOMMIC DATA. SO MOVING ON TO

1822
01:15:30,800 --> 01:15:34,560
FIRST PRIORITY. THIS USING

1823
01:15:34,560 --> 01:15:35,240
INFORMATION COMMUNICATION

1824
01:15:35,240 --> 01:15:37,680
TECHNOLOGIES OR ICT AND SOCIAL

1825
01:15:37,680 --> 01:15:39,440
MEDIA TO BETTER UNDERSTAND BLOOD

1826
01:15:39,440 --> 01:15:41,800
DONOR BEHAVIOR. ALTHOUGH ICT

1827
01:15:41,800 --> 01:15:44,040
SOCIAL MEDIA ARE CONCEPTUALLY

1828
01:15:44,040 --> 01:15:46,880
DIFFERENT THEY ARE INTERTWINED

1829
01:15:46,880 --> 01:15:48,200
AND INEXTRICABLY CONNECTED SO

1830
01:15:48,200 --> 01:15:51,240
OUR QUESTION IS, HOW CAN SOCIAL

1831
01:15:51,240 --> 01:15:52,600
MEDIA, AND OTHER ICT

1832
01:15:52,600 --> 01:15:54,720
TECHNOLOGIES BE USED TO BETTER

1833
01:15:54,720 --> 01:15:57,240
UNDERSTAND DONOR MOTIVATION,

1834
01:15:57,240 --> 01:15:59,000
VARIOUS DONATION AND HELPING

1835
01:15:59,000 --> 01:16:01,160
INCORPORATE THOSE TO FACILITATE

1836
01:16:01,160 --> 01:16:07,200
DONOR RECRUITMENT. WHY AN ISSUE?

1837
01:16:07,200 --> 01:16:08,560
COMMUNICATION TECHNOLOGY SUCH AS

1838
01:16:08,560 --> 01:16:10,680
MAIL, TELEPHONE TEXT MESSAGING

1839
01:16:10,680 --> 01:16:13,640
AND EMAIL USED IN RECRUITING

1840
01:16:13,640 --> 01:16:15,600
BLOOD DONORS FOR DECADES AND

1841
01:16:15,600 --> 01:16:19,400
THESE REMAIN PRIMARY CHANNELS OF

1842
01:16:19,400 --> 01:16:20,480
COMMUNICATION FOR BLOOD CENTERS

1843
01:16:20,480 --> 01:16:22,480
AND DONORS.  ACADEMIC AND

1844
01:16:22,480 --> 01:16:23,360
MARKETING AND SOCIOLOGY

1845
01:16:23,360 --> 01:16:25,720
DEVELOPED TECHNIQUES FOR

1846
01:16:25,720 --> 01:16:26,840
ADVANCING UNDERSTANDING HUMAN

1847
01:16:26,840 --> 01:16:27,960
BEHAVIOR THROUGH THE LENS OF

1848
01:16:27,960 --> 01:16:30,560
SOCIAL MEDIA. THESE TECHNOLOGIES

1849
01:16:30,560 --> 01:16:32,520
PROVIDE A NOVEL YET UNTAP

1850
01:16:32,520 --> 01:16:34,360
POTENTIAL TO UNDERSTAND DONOR

1851
01:16:34,360 --> 01:16:36,040
BEHAVIOR AS WELL AS ENGAGE IN

1852
01:16:36,040 --> 01:16:37,280
DONOR RECRUITMENT AND

1853
01:16:37,280 --> 01:16:41,360
COORDINATION.  WHAT IS PROPOSED

1854
01:16:41,360 --> 01:16:43,320
APPROACH? WE LIKE TO PRESENT A

1855
01:16:43,320 --> 01:16:45,880
RECENT EXAMPLE AS WELL.  WE CAN

1856
01:16:45,880 --> 01:16:49,000
USE THE ICT AND SOCIAL MEDIA

1857
01:16:49,000 --> 01:16:52,480
PLATFORMS, TO REPLACE, SAY

1858
01:16:52,480 --> 01:16:54,360
COMPLIMENT AND/OR REPLACE OLDER

1859
01:16:54,360 --> 01:16:56,720
COMMUNICATION TECHNOLOGIES AND

1860
01:16:56,720 --> 01:16:57,720
ESPECIALLY TARGET CERTAIN

1861
01:16:57,720 --> 01:17:01,360
GRAPHICS, THE YOUNGER DONORS AS

1862
01:17:01,360 --> 01:17:04,960
THESE PLATFORMS OFFER DEEPER

1863
01:17:04,960 --> 01:17:06,360
MORE INTEGRATED CONNECTIONS AND

1864
01:17:06,360 --> 01:17:08,560
AUTOMATION AND ADAPTED LEARNING

1865
01:17:08,560 --> 01:17:10,200
BETTER THAN THE OLDER

1866
01:17:10,200 --> 01:17:11,800
TECHNOLOGIES. THERE ARE RECENT

1867
01:17:11,800 --> 01:17:14,360
SUCCESSFUL EXAMPLES THE BLOOD

1868
01:17:14,360 --> 01:17:17,320
DONATION TOOL USED TO CONDUCT

1869
01:17:17,320 --> 01:17:20,240
THE FIRST LARGE SCALE

1870
01:17:20,240 --> 01:17:21,880
ALGORITHMIC MATCHING OF BLOOD

1871
01:17:21,880 --> 01:17:23,640
DONORS. I WILL SHOW THE NEXT

1872
01:17:23,640 --> 01:17:25,520
COUPLE OF SLIDES AND THIS SHOWS

1873
01:17:25,520 --> 01:17:29,960
THE FIRST MODEL OF DEPLOYMENT IN

1874
01:17:29,960 --> 01:17:31,840
BLOOD BANKING LARGE SCALE. THE

1875
01:17:31,840 --> 01:17:33,600
GOEL WILL BE TO USE THIS

1876
01:17:33,600 --> 01:17:34,520
PLATFORM AS OPPORTUNITIES FOR

1877
01:17:34,520 --> 01:17:36,040
THE BLOOD CENTERS TO RECRUIT

1878
01:17:36,040 --> 01:17:38,240
DONORS AND ALSO FOR THE DONORS

1879
01:17:38,240 --> 01:17:40,960
TO IDENTIFY COMMUNITY AMONG

1880
01:17:40,960 --> 01:17:43,600
THEMSELVES. THERE ARE ALSO NEWER

1881
01:17:43,600 --> 01:17:45,400
NOVEL TECHNOLOGIES SUCH AS

1882
01:17:45,400 --> 01:17:47,400
VIRTUAL OR AUGMENTED REALITIES

1883
01:17:47,400 --> 01:17:49,640
WE HAVE BRILLIANT EXAMPLES AND

1884
01:17:49,640 --> 01:17:53,160
NEWER TRIALS COMING UP FOR DONOR

1885
01:17:53,160 --> 01:17:54,360
ENGAGEMENT AND ENHANCED

1886
01:17:54,360 --> 01:17:57,480
EXPERIENCES.  NEXT SLIDE.  THIS

1887
01:17:57,480 --> 01:18:03,200
SLIDE IS ADAPTED FROM -- WHO LED

1888
01:18:03,200 --> 01:18:04,560
THIS WORK UNIVERSITY OF MARYLAND

1889
01:18:04,560 --> 01:18:06,280
AND FACEBOOK FOR DEVELOPING

1890
01:18:06,280 --> 01:18:08,160
LARGE SCALE ALGORITHMIC MATCHING

1891
01:18:08,160 --> 01:18:09,600
FOR BLOOD DONATION, WHERE THE

1892
01:18:09,600 --> 01:18:12,840
BLOOD DONORS AS THE NEED AROSE

1893
01:18:12,840 --> 01:18:15,360
RECEIVE NOTIFICATION ABOUT THE

1894
01:18:15,360 --> 01:18:16,280
DONATION OPPORTUNITIES AND HOW

1895
01:18:16,280 --> 01:18:22,560
AND WHERE TO DO SO. THIS DID

1896
01:18:22,560 --> 01:18:25,000
HAVE A GO LIVE IN 2017, STARTING

1897
01:18:25,000 --> 01:18:28,840
WITH INDIA AND TO DATE BY

1898
01:18:28,840 --> 01:18:30,080
EXAMPLE MORE THAN 35 MILLION

1899
01:18:30,080 --> 01:18:31,520
PEOPLE WHO DID SIGN UP TO BE

1900
01:18:31,520 --> 01:18:33,240
BLOOD DONORS ACROSS THE

1901
01:18:33,240 --> 01:18:35,280
COUNTRIES AS LISTED. FOLLOW-UP

1902
01:18:35,280 --> 01:18:36,920
IN PERSON SURVEYS IN SOME OF

1903
01:18:36,920 --> 01:18:38,520
THESE COUNTRIES HAVE SHOWN THAT

1904
01:18:38,520 --> 01:18:40,560
IN ONE TO FIVE DONOR SET THAT

1905
01:18:40,560 --> 01:18:43,520
THE BLOOD DONATION TOOL DID

1906
01:18:43,520 --> 01:18:44,280
INFLUENCE POSITION TO GIVE

1907
01:18:44,280 --> 01:18:50,280
BLOOD.  LOOK AT EXAMPLES

1908
01:18:50,280 --> 01:18:51,800
FEASIBILITY AS WELL AS BARRIERS,

1909
01:18:51,800 --> 01:18:54,200
YES, THERE IS FEESIBILITY

1910
01:18:54,200 --> 01:18:55,800
BECAUSE TECHNOLOGIES ALLOW

1911
01:18:55,800 --> 01:18:58,240
PERSON REAL TIME COMMUNICATION,

1912
01:18:58,240 --> 01:18:59,760
WITH ENORMOUS AUDIENCES TO

1913
01:18:59,760 --> 01:19:02,280
VARIETY OF MEDIA INCLUDING TEXT,

1914
01:19:02,280 --> 01:19:04,560
RADIO IMAGES AN OPPORTUNITY FOR

1915
01:19:04,560 --> 01:19:06,120
REACTION AND INDIVIDUAL IMPROVED

1916
01:19:06,120 --> 01:19:07,920
MESSAGES.  ON SOME OF THESE

1917
01:19:07,920 --> 01:19:09,640
MODERN PLATFORMS USERS TEND TO

1918
01:19:09,640 --> 01:19:11,760
ENGAGE WITH GROUPS RATHER THAN

1919
01:19:11,760 --> 01:19:12,640
INDIVIDUALS WHICH ALSO WAS

1920
01:19:12,640 --> 01:19:14,640
MENTIONED BY OUR BLOOD DONORS

1921
01:19:14,640 --> 01:19:18,600
AND SUPPLY SUBGROUP BY DR.

1922
01:19:18,600 --> 01:19:19,240
BRIGHT, THIS YOURS TRULY FOR

1923
01:19:19,240 --> 01:19:20,920
COLLECTIVE CONSCIOUSNESS FOR

1924
01:19:20,920 --> 01:19:24,120
NOVEL SOCIAL DYNAMICS. THERE ARE

1925
01:19:24,120 --> 01:19:26,320
BARRIERS, TO BE TAKEN CARE OF,

1926
01:19:26,320 --> 01:19:27,920
SO AS THESE TECHNOLOGIES ARE

1927
01:19:27,920 --> 01:19:29,680
CONSTANTLY EVOLVING, ONGOING

1928
01:19:29,680 --> 01:19:30,720
RESEARCH WILL BE NEEDED TO

1929
01:19:30,720 --> 01:19:32,160
UNDERSTAND THE CHANGING ONLINE

1930
01:19:32,160 --> 01:19:35,440
SOCIAL DYNAMICS.  ONLINE PRIVACY

1931
01:19:35,440 --> 01:19:38,320
BREACH OF INFORMATION FOR THESE

1932
01:19:38,320 --> 01:19:39,680
MODALITIES ALWAYS REMAINS

1933
01:19:39,680 --> 01:19:41,800
IMPORTANT ESPECIALLY SOME OF

1934
01:19:41,800 --> 01:19:44,000
THEM THERE IS CONCERN FOR DEEPLY

1935
01:19:44,000 --> 01:19:44,800
SHARING PERSONAL INFORMATION.

1936
01:19:44,800 --> 01:19:46,040
THERE IS ALSO A NEED TO ACCOUNT

1937
01:19:46,040 --> 01:19:48,680
FOR DONOR CONCERNS, PARTICULARLY

1938
01:19:48,680 --> 01:19:50,800
RELATES TO NOTIFICATION FATIGUE,

1939
01:19:50,800 --> 01:19:52,800
IN ADDITION SOME OF THESE

1940
01:19:52,800 --> 01:19:55,240
COLLECTIVE CONSCIOUSNESS

1941
01:19:55,240 --> 01:19:57,120
TECHNIQUES CAN HAVE POSITIVE AND

1942
01:19:57,120 --> 01:19:58,240
NEGATIVE EFFECTS ON INDIVIDUALS

1943
01:19:58,240 --> 01:19:59,800
AS WELL AS COMMUNITY SO LARGELY

1944
01:19:59,800 --> 01:20:02,920
REMAINS TO BE STUDIED WHY THESE

1945
01:20:02,920 --> 01:20:06,320
REMAIN INCORPORATED. OUR SECOND

1946
01:20:06,320 --> 01:20:09,200
PRIORITY IS USING

1947
01:20:09,200 --> 01:20:10,840
MULTI-DIMENSIONAL DATABASES AND

1948
01:20:10,840 --> 01:20:11,800
DATA VISUALIZATION TOOLS AND

1949
01:20:11,800 --> 01:20:13,800
BLOOD BANKING. THE QUESTIONS

1950
01:20:13,800 --> 01:20:16,080
ARE, HOW CAN SOME OF THE

1951
01:20:16,080 --> 01:20:17,320
MULTI-DIMENSIONAL DATABASES

1952
01:20:17,320 --> 01:20:20,880
FIRST BE CURATED AND UTILIZED TO

1953
01:20:20,880 --> 01:20:22,520
ANSWER RESEARCH QUESTIONS IN

1954
01:20:22,520 --> 01:20:26,600
SOME OF THE SPECIFIC

1955
01:20:26,600 --> 01:20:28,560
POPULATIONS, DR. -- MENTIONED

1956
01:20:28,560 --> 01:20:29,920
SEVERAL TIMES THE POPULATIONS OF

1957
01:20:29,920 --> 01:20:31,600
INTEREST AND THE SAME APPLIES,

1958
01:20:31,600 --> 01:20:35,320
ABILITY OF HAVING SOME BIG DATA

1959
01:20:35,320 --> 01:20:36,640
MULTI-DIMENSIONAL DATABASES DOES

1960
01:20:36,640 --> 01:20:39,280
ALLOW THAT TO BE STUDIED. WE CAN

1961
01:20:39,280 --> 01:20:42,160
ALSO STUDY RARE OUTCOMES AN

1962
01:20:42,160 --> 01:20:44,680
EXPOSURES. HOW CAN YOU BEST

1963
01:20:44,680 --> 01:20:45,800
UTILIZE DATA VISUALIZATION TOOLS

1964
01:20:45,800 --> 01:20:51,200
TO EVALUATE AS WELL AS IMPROVE

1965
01:20:51,200 --> 01:20:52,840
QUALITY IN DATA MANAGEMENT. SO

1966
01:20:52,840 --> 01:20:55,520
WHY IS THIS IMPORTANT? TO DATE

1967
01:20:55,520 --> 01:20:57,600
THERE IS LIMITED AVAILABILITY OF

1968
01:20:57,600 --> 01:20:59,680
COMPREHENSIVE VEIN TO VEIN

1969
01:20:59,680 --> 01:21:00,720
DATABASES WHICH CONTAIN

1970
01:21:00,720 --> 01:21:02,720
INFORMATION ON DONORS, BLOOD

1971
01:21:02,720 --> 01:21:04,720
COMPONENTS, AS WELL AS

1972
01:21:04,720 --> 01:21:06,400
TRANSFUSION RECIPIENTS.  THESE

1973
01:21:06,400 --> 01:21:08,000
DATABASES PROVIDE KEY

1974
01:21:08,000 --> 01:21:09,000
INFORMATION FROM MANY

1975
01:21:09,000 --> 01:21:10,880
OBSERVATIONAL STUDIES AND ENABLE

1976
01:21:10,880 --> 01:21:12,240
INVESTIGATORS TO ADDRESS

1977
01:21:12,240 --> 01:21:15,040
EMERGING RESEARCH QUESTIONS. AS

1978
01:21:15,040 --> 01:21:18,280
FAR AS DATA VISUALIZATION GOES

1979
01:21:18,280 --> 01:21:19,960
MANY CURRENT EXTEND DATA

1980
01:21:19,960 --> 01:21:21,320
VISUALIZATION TECHNIQUES HAVE

1981
01:21:21,320 --> 01:21:23,280
BEEN STATIC AND TEND TO FOCUS ON

1982
01:21:23,280 --> 01:21:25,000
SINGLE CENTER. WHILE THESE

1983
01:21:25,000 --> 01:21:27,360
PROVIDE USEFUL FOCUS SUMMARIES

1984
01:21:27,360 --> 01:21:29,480
ON PERFORMANCE DATA, THEY MAY

1985
01:21:29,480 --> 01:21:31,840
NOT ALLOW FOR ENHANCE CONTEXT OR

1986
01:21:31,840 --> 01:21:33,080
FLEXIBILITY AT HIERARCHICAL

1987
01:21:33,080 --> 01:21:36,280
LEVELS FOR A DEEPER

1988
01:21:36,280 --> 01:21:37,920
UNDERSTANDING.

1989
01:21:37,920 --> 01:21:40,480
WHAT IS THE PROPOSED APPROACH?

1990
01:21:40,480 --> 01:21:42,560
IT WOULD BE DEVELOPMENT OF

1991
01:21:42,560 --> 01:21:45,000
COMPREHENSIVE VEIN TO VEIN

1992
01:21:45,000 --> 01:21:46,880
DATABASES WHICH CONTAIN THIS

1993
01:21:46,880 --> 01:21:51,240
INFORMATION. INCLUSION OF

1994
01:21:51,240 --> 01:21:52,760
NON-TRANSFUSED CONTROLS IN

1995
01:21:52,760 --> 01:21:54,120
PATIENT DATABASE COMPARATIVE

1996
01:21:54,120 --> 01:21:56,200
EFFECTIVENESS STUDIES AREN PRO.

1997
01:21:56,200 --> 01:21:57,800
UTILIZING MODELS I WILL TALK IN

1998
01:21:57,800 --> 01:21:59,720
THE NEXT SLIDE INCLUDING

1999
01:21:59,720 --> 01:22:01,280
OBSERVATIONAL MEDICAL OUTCOMES

2000
01:22:01,280 --> 01:22:03,960
PARTNERSHIP OR OMOP COMMON DATA

2001
01:22:03,960 --> 01:22:06,360
MODEL TO ALLOW'S OF COMBINING

2002
01:22:06,360 --> 01:22:08,880
MULTIPLE VEIN TO VEIN DATABASES,

2003
01:22:08,880 --> 01:22:10,760
SO WELL DESIGNED DATABASES AND

2004
01:22:10,760 --> 01:22:13,400
THE DATA ANALYTICS PIPELINE CAN

2005
01:22:13,400 --> 01:22:15,400
REALLY ENABLE THE DEPLOYMENT OF

2006
01:22:15,400 --> 01:22:17,200
DATA VISUALIZATION TOOLS ACROSS

2007
01:22:17,200 --> 01:22:20,680
MULTIPLE CENTERS. AND THIS CAN

2008
01:22:20,680 --> 01:22:22,240
ALLOW INTRAAND INSTITUTIONAL

2009
01:22:22,240 --> 01:22:24,080
BENCHMARKING OF PERFORMANCES

2010
01:22:24,080 --> 01:22:26,600
USING A FEDERATED MODEL,

2011
01:22:26,600 --> 01:22:27,840
SOMETHING JANSEN WILL ELABORATE

2012
01:22:27,840 --> 01:22:30,480
ON. IN ADDITION, THE ADVANCE

2013
01:22:30,480 --> 01:22:31,520
DATA VISUALIZATION APPLICATIONS

2014
01:22:31,520 --> 01:22:34,760
FOR PATIENTS LIKE MINE, IT CAN

2015
01:22:34,760 --> 01:22:36,320
ALLOW VISUALIZE PERFORMANCE IN

2016
01:22:36,320 --> 01:22:38,320
OUTCOMES OF PAST PATIENTS, THAT

2017
01:22:38,320 --> 01:22:40,600
IS SIMILAR TO UPCOMING PATIENT

2018
01:22:40,600 --> 01:22:44,280
AND SERVE AS PERSONALIZE RISK

2019
01:22:44,280 --> 01:22:48,120
ASSESSMENT TOOL.  I WANT TO GIVE

2020
01:22:48,120 --> 01:22:50,520
THIS EXAMPLE, FROM THE ODYSSEY

2021
01:22:50,520 --> 01:22:53,240
WEBSITE SHOWING VERY SIMPLISTIC

2022
01:22:53,240 --> 01:22:55,400
VIEW OF THE OMOP COMMON DATA

2023
01:22:55,400 --> 01:22:57,080
MODEL WHICH ALLOWS SYSTEMATIC

2024
01:22:57,080 --> 01:23:00,080
ANALYSIS OF VARIOUS DISPARATE

2025
01:23:00,080 --> 01:23:01,200
OBSERVATIONAL DATABASES AND

2026
01:23:01,200 --> 01:23:02,880
TRANSFORMS THE DATA WITHIN THESE

2027
01:23:02,880 --> 01:23:04,960
DATABASES INTO A COMMON FORMAT

2028
01:23:04,960 --> 01:23:07,720
OR A DATA MODEL. AS WELL AS

2029
01:23:07,720 --> 01:23:09,840
COMMON REPRESENTATION USING THE

2030
01:23:09,840 --> 01:23:12,040
TERMINOLOGIES, VOCABULARIES AND

2031
01:23:12,040 --> 01:23:14,400
CODING SCHEMES. THEN NEXT STEP

2032
01:23:14,400 --> 01:23:16,040
PERFORMS SYSTEMATIC ANALYSIS,

2033
01:23:16,040 --> 01:23:17,720
USING A LIBRARY OF STANDARD

2034
01:23:17,720 --> 01:23:19,960
ANALYTIC ROUTINES.  THAT HAVE

2035
01:23:19,960 --> 01:23:21,400
BEEN BASED ON THIS COMMON

2036
01:23:21,400 --> 01:23:27,800
FORMATS.  ALSO WANT TO GIVE AN

2037
01:23:27,800 --> 01:23:29,640
EXAMPLE OF NON-STATIC PATIENT

2038
01:23:29,640 --> 01:23:31,520
LED MANAGEMENT DATA VISUALIZING

2039
01:23:31,520 --> 01:23:36,040
TOOL DEVELOPED BY (INAUDIBLE)

2040
01:23:36,040 --> 01:23:38,720
DR. (INAUDIBLE) TEAM WHICH

2041
01:23:38,720 --> 01:23:42,280
ALLOWS REAL TIME TRACKING AS

2042
01:23:42,280 --> 01:23:46,280
WELL AS TRANSFUSIONAL BENCH

2043
01:23:46,280 --> 01:23:49,480
MARKING. SO FEASIBILITY AND

2044
01:23:49,480 --> 01:23:51,120
BARRIERS, DATABASES HAVE BEEN

2045
01:23:51,120 --> 01:23:55,640
SUCCESSFULLY CREATED, THE RED

2046
01:23:55,640 --> 01:23:59,480
THREE STUDIES INCORPORATED IT

2047
01:23:59,480 --> 01:24:00,720
WELL, SO THERE ARE EXAMPLES. 

2048
01:24:00,720 --> 01:24:02,160
THE BENEFITS OF USING

2049
01:24:02,160 --> 01:24:03,360
INCORPORATING SOME OF THE NEWER

2050
01:24:03,360 --> 01:24:06,840
DESIGNS FOR EXAMPLE THE OMOP

2051
01:24:06,840 --> 01:24:07,760
COMMON DATA MODEL CURRENTLY

2052
01:24:07,760 --> 01:24:09,680
DOING, REALLY ALLOWS COMBINING

2053
01:24:09,680 --> 01:24:11,000
THE DATA FROM VARIOUS DATE

2054
01:24:11,000 --> 01:24:15,640
OPERADISPARATE SOURCES ONCE

2055
01:24:15,640 --> 01:24:17,640
INCORPORATED THE MODEL CAN BE

2056
01:24:17,640 --> 01:24:20,320
INTERROGATED BY IDENTIFYING NEW

2057
01:24:20,320 --> 01:24:21,800
DATA MAPPINGS SUCH AS LABORATORY

2058
01:24:21,800 --> 01:24:23,720
METHODS BEYOND CLINICAL

2059
01:24:23,720 --> 01:24:25,160
APPLICATIONS. FURTHER DEPLOYING

2060
01:24:25,160 --> 01:24:26,960
THE DATA VISUALIZATION TOOLS, IS

2061
01:24:26,960 --> 01:24:29,160
BECOMING INCREASINGLY FEASIBLE

2062
01:24:29,160 --> 01:24:31,560
WITH USE OF OPEN SOURCE AND/OR

2063
01:24:31,560 --> 01:24:32,800
CHILD BASE SOLUTIONS.  THIS CAN

2064
01:24:32,800 --> 01:24:35,480
BE FACILITATED BY STANDARDIZE

2065
01:24:35,480 --> 01:24:37,320
DATABASE STRUCTURE. THERE ARE

2066
01:24:37,320 --> 01:24:41,440
BARRIERS INCLUDING NEED FOR DATA

2067
01:24:41,440 --> 01:24:43,200
USE, SIGNIFICANT BARRIERS IN

2068
01:24:43,200 --> 01:24:47,320
HARMONIZING THE DATA SETS,

2069
01:24:47,320 --> 01:24:48,800
CURRENTLY USED NOVEL SYSTEMS

2070
01:24:48,800 --> 01:24:51,960
SUCH AS THE LOGIC OBSERVATIONAL

2071
01:24:51,960 --> 01:24:54,560
IDENTIFY FOR AGGREGATING THE

2072
01:24:54,560 --> 01:24:56,760
LABORATORY DATA AND ALSO

2073
01:24:56,760 --> 01:24:59,720
DEPLOYING REAL TIME DATA

2074
01:24:59,720 --> 01:25:01,080
AGGREGATION PIPELINES. IN

2075
01:25:01,080 --> 01:25:03,280
ADDITION ONCE THIS IS DONE

2076
01:25:03,280 --> 01:25:04,640
DEFINING VALIDATED METRICS TO I

2077
01:25:04,640 --> 01:25:06,720
ALLOW MEANINGFUL COMPARISON IS A

2078
01:25:06,720 --> 01:25:12,000
KEY CHALLENGE.  OUR NEXT

2079
01:25:12,000 --> 01:25:13,680
PRIORITY IS USE OF DATA DRIVEN

2080
01:25:13,680 --> 01:25:15,680
ECONOMIC EVALUATIONS AND BLOOD

2081
01:25:15,680 --> 01:25:20,360
BANKING AND TRANSFUSION

2082
01:25:20,360 --> 01:25:21,520
MEDICINE, AND HOW TO USE

2083
01:25:21,520 --> 01:25:22,880
APPROACHES TO IMPROVE ACCURACY

2084
01:25:22,880 --> 01:25:24,760
AS WELL AS APPLICABILITY

2085
01:25:24,760 --> 01:25:25,680
ECONOMIC EVALUATIONS TO OUR

2086
01:25:25,680 --> 01:25:32,800
COMMUNITY. WHY IS THIS AN ISSUE?

2087
01:25:32,800 --> 01:25:33,760
COST EFFECTIVE ANALYSES, PERFORM

2088
01:25:33,760 --> 01:25:35,960
FORMAL ASSESSMENT OF TRADE OFFS

2089
01:25:35,960 --> 01:25:39,640
WHICH INFORM BENEFITS, HARMS AND

2090
01:25:39,640 --> 01:25:43,440
COSTS INHERENT AS KEY IN ANY

2091
01:25:43,440 --> 01:25:45,320
ALTERNATIVE OPTIONS.  IT IS NOT

2092
01:25:45,320 --> 01:25:47,000
COMPLETELY NEW TO TRANSCRIPTION

2093
01:25:47,000 --> 01:25:49,080
MEDICINE BUT IN OTHER SCENARIOS

2094
01:25:49,080 --> 01:25:51,120
AS WELL IT IS USED TO INFORM

2095
01:25:51,120 --> 01:25:52,760
PUBLIC AND PRIVATE

2096
01:25:52,760 --> 01:25:55,200
ORGANIZATIONS, INCLUDING

2097
01:25:55,200 --> 01:25:56,520
DECISIONS BENEFIT DESIGNS AND

2098
01:25:56,520 --> 01:25:58,440
PRICE NEGOTIATIONS. MODEL BASE

2099
01:25:58,440 --> 01:26:01,640
ECONOMIC EVALUATION, SYNTHESIZE

2100
01:26:01,640 --> 01:26:03,320
EVIDENCE AND REVEAL TRADE OFFS

2101
01:26:03,320 --> 01:26:05,640
BETWEEN POLICY ALTERNATIVES WHEN

2102
01:26:05,640 --> 01:26:07,880
FORM -- AND USE ALLOW EFFECTIVE

2103
01:26:07,880 --> 01:26:09,640
AS WELL AS PATIENT USER HELD

2104
01:26:09,640 --> 01:26:14,240
RESOURCES AND ALLOCATIONS.  

2105
01:26:14,240 --> 01:26:15,400
THERE HAVE BEEN SEVERAL ECONOMIC

2106
01:26:15,400 --> 01:26:17,880
EVALUATIONS WHICH FOCUS

2107
01:26:17,880 --> 01:26:20,680
PRIMARILY TRANSFUSION INFECTIONS

2108
01:26:20,680 --> 01:26:22,800
ALL NOTABLY NON-INFECTIOUS

2109
01:26:22,800 --> 01:26:23,720
TRANSFUSION CAN ACCOUNTS FOR

2110
01:26:23,720 --> 01:26:25,960
MOST TRANSFUSION ASSOCIATED

2111
01:26:25,960 --> 01:26:30,360
MORBIDITY AND MORTALI MORTALITYS

2112
01:26:30,360 --> 01:26:32,000
AN EXAMPLE FROM PARTICIPANT,

2113
01:26:32,000 --> 01:26:33,480
THIS SLIDE ADAPTED FROM SOME OF

2114
01:26:33,480 --> 01:26:36,920
THE WORK ON (INAUDIBLE) ALSO AN

2115
01:26:36,920 --> 01:26:38,680
AWARDEE WORKING AT STUDYING THIS

2116
01:26:38,680 --> 01:26:40,640
ISSUE WHERE YOU SEE THAT THERE

2117
01:26:40,640 --> 01:26:44,160
ARE STUDIES DATING MORE THAN 20

2118
01:26:44,160 --> 01:26:45,840
YEARS PLUS WHICH ASSURE DATA

2119
01:26:45,840 --> 01:26:47,280
DRIVEN ECONOMIC EVALUATION FROM

2120
01:26:47,280 --> 01:26:49,480
COST ANALYSES CAN

2121
01:26:49,480 --> 01:26:50,640
REPRODUCIBILITY COMPARATIVE

2122
01:26:50,640 --> 01:26:53,440
EFFECTIVENESS STUDY, COST

2123
01:26:53,440 --> 01:26:54,520
CONSEQUENCE AND UTILITY

2124
01:26:54,520 --> 01:27:00,240
ANALYSIS.  SO WHAT WOULD BE THE

2125
01:27:00,240 --> 01:27:01,800
PROPOSED APPROACH? WOULD BE FOR

2126
01:27:01,800 --> 01:27:03,160
IN OUR TRANSFUSION MEDS SIN

2127
01:27:03,160 --> 01:27:05,800
BLOOD BANKING, DERIVE BETTER

2128
01:27:05,800 --> 01:27:07,280
MODEL BASE ECONOMIC EVALUATION,

2129
01:27:07,280 --> 01:27:10,280
TO SYNTHESIZE EVIDENCE AND TRADE

2130
01:27:10,280 --> 01:27:12,320
OFFS BETWEEN POLICY

2131
01:27:12,320 --> 01:27:14,600
ALTERNATIVES, USE DECISION TREES

2132
01:27:14,600 --> 01:27:17,320
AND MODELS WHICH MODEL DIFFUSION

2133
01:27:17,320 --> 01:27:19,120
RECIPIENTS AS A HOMOGENOUS

2134
01:27:19,120 --> 01:27:20,640
POPULATION AND MODELS AGAIN

2135
01:27:20,640 --> 01:27:23,280
RESOURCES FOR EXAMPLE

2136
01:27:23,280 --> 01:27:24,880
PUBLICATION AND LITERATURE. THE

2137
01:27:24,880 --> 01:27:26,080
DECISION MODELING CAN BE USED TO

2138
01:27:26,080 --> 01:27:28,880
INFORM DONOR ELIGIBILITY AND

2139
01:27:28,880 --> 01:27:30,360
DEFERRALS, MODELS CAN BE USED TO

2140
01:27:30,360 --> 01:27:32,800
CONTINUALLY REASSESS THE BLOOD

2141
01:27:32,800 --> 01:27:35,600
SAFETY PORTFOLIO. IN ADDITION

2142
01:27:35,600 --> 01:27:38,720
THE DATA APPROACHES DIRECTLY

2143
01:27:38,720 --> 01:27:39,840
ANALYZE PATIENT LEVEL DATA AS

2144
01:27:39,840 --> 01:27:41,600
PART OF THE DECISION ANALYTIC

2145
01:27:41,600 --> 01:27:43,480
MODEL. THESE APPROACHES CAN BE

2146
01:27:43,480 --> 01:27:45,440
REDUCE BIAS IN POPULATION LEVEL

2147
01:27:45,440 --> 01:27:49,400
ESTIMATES AND ENABLE ANALYSIS OF

2148
01:27:49,400 --> 01:27:52,080
POLICY IMPLICATIONS AS WELL AS

2149
01:27:52,080 --> 01:27:53,600
FACILITATE MODEL BASE ECONOMIC

2150
01:27:53,600 --> 01:27:56,160
EVALUATIONS OF INTERVENTIONS,

2151
01:27:56,160 --> 01:27:57,200
NON-INFECTIOUS TRANSFUSION

2152
01:27:57,200 --> 01:28:02,880
REACTIONS.  FEASIBILITY IS AS WE

2153
01:28:02,880 --> 01:28:05,120
MENTION SOME OF THESE STUDIES

2154
01:28:05,120 --> 01:28:06,920
HAVE BEEN ATTEMPTED IN VARIOUS

2155
01:28:06,920 --> 01:28:08,320
SCENARIOS PREVIOUSLY AND THERE

2156
01:28:08,320 --> 01:28:10,680
IS INCREASE AVAILABILITY OF HIGH

2157
01:28:10,680 --> 01:28:12,160
PERFORMANCE COMPUTERS AS WELL AS

2158
01:28:12,160 --> 01:28:14,040
CLINICAL AND ADMINISTRATIVE

2159
01:28:14,040 --> 01:28:17,000
BILLING DATA SYNCED ON

2160
01:28:17,000 --> 01:28:20,000
TRANSFUSIONED PATIENTS ENABLE

2161
01:28:20,000 --> 01:28:20,880
MORE DATA DRIVEN EVALUATIONS. 

2162
01:28:20,880 --> 01:28:23,200
RISK MODELS AND DECISION

2163
01:28:23,200 --> 01:28:24,840
ANALYSIS INFORM EFFECTIVE BLOOD

2164
01:28:24,840 --> 01:28:28,160
SAFETY POLICIES. SOME OF THE

2165
01:28:28,160 --> 01:28:31,240
BARRIERS ARE ACCESS WE NEED TO

2166
01:28:31,240 --> 01:28:32,920
LARGER DATA SETS, COMPONENT

2167
01:28:32,920 --> 01:28:36,560
EXPOSURE AND OUTCOMES.  DATA

2168
01:28:36,560 --> 01:28:37,920
DIRECTLY ESTIMATE ADVERSE EVENT

2169
01:28:37,920 --> 01:28:42,240
IN DONOR DATA AS WE THINK OF THE

2170
01:28:42,240 --> 01:28:44,000
LONG TERM IMPLICATIONS AND

2171
01:28:44,000 --> 01:28:45,560
ECONOMIC EVALUATION INTO

2172
01:28:45,560 --> 01:28:47,480
ACCOUNT, SOME DATA TAKES YEARS

2173
01:28:47,480 --> 01:28:49,120
TO ACCUMULATE ESPECIALLY --

2174
01:28:49,120 --> 01:28:50,800
THOSE ARE TOUGH ONES TO ACCOUNT

2175
01:28:50,800 --> 01:28:51,960
FOR BY COST EFFECTIVENESS

2176
01:28:51,960 --> 01:28:56,560
ANALYSIS.  ALSO IN THE U.S.

2177
01:28:56,560 --> 01:28:57,760
MULTI-CARE SYSTEM MULTI-SOURCES

2178
01:28:57,760 --> 01:29:03,640
MAYBE NEEDED TO AGGREGATE TO

2179
01:29:03,640 --> 01:29:06,280
ENSURE REPRESENTATIVENESS. NOW

2180
01:29:06,280 --> 01:29:10,880
PASS TO JANSEN TO DISCUSS

2181
01:29:10,880 --> 01:29:11,600
QUALITY.

2182
01:29:11,600 --> 01:29:13,480
>> WE HAD NUMBER OF AI AND

2183
01:29:13,480 --> 01:29:16,480
MACHINE LEARNING EXPERTS IN OUR

2184
01:29:16,480 --> 01:29:17,560
GRUEL IN CLINICAL DOMAIN AND

2185
01:29:17,560 --> 01:29:19,320
TECHNICAL EXPERTISE AN DATA

2186
01:29:19,320 --> 01:29:20,400
SCIENCE AN ENGINEERING.  WE

2187
01:29:20,400 --> 01:29:23,360
STRUGGLED WITH THE AI PRIORITY

2188
01:29:23,360 --> 01:29:27,480
AND FOCUS OF SCOPE BECAUSE AI IS

2189
01:29:27,480 --> 01:29:31,160
A LARGE FIELD RIGHT NOW. SO ONE

2190
01:29:31,160 --> 01:29:32,800
OF THE THINGS WE STRUGGLED WITH

2191
01:29:32,800 --> 01:29:35,240
IS AI IS NOT NOVEL OR NEW THOUGH

2192
01:29:35,240 --> 01:29:38,000
WE THINK OF IT AS A NEW CONCEPT,

2193
01:29:38,000 --> 01:29:39,600
NEW THING THAT IS HAPPENING IN

2194
01:29:39,600 --> 01:29:43,040
THE LAST DECADE, THE (INAUDIBLE)

2195
01:29:43,040 --> 01:29:45,360
WAS DEVELOPED IN THE 50s, BACK

2196
01:29:45,360 --> 01:29:46,920
PROPAGATION SINCE 1960s AND

2197
01:29:46,920 --> 01:29:49,000
MODIFIED IN 1980s. SO THE

2198
01:29:49,000 --> 01:29:50,240
CONCEPTS OF DEEP LEARNING AND

2199
01:29:50,240 --> 01:29:51,560
MACHINE LEARNING ARE NOT NEW,

2200
01:29:51,560 --> 01:29:52,280
THEY HAVE BEEN AROUND FOR

2201
01:29:52,280 --> 01:29:54,800
DECADES BUT WHAT WE DO HAVE ARE

2202
01:29:54,800 --> 01:29:56,960
IMPROVEMENT IN COMPUTATIONAL

2203
01:29:56,960 --> 01:30:00,280
POWER, AND ALSO ACCESS TO DATA

2204
01:30:00,280 --> 01:30:03,320
ON SCALE AND SHAPE NEVER SEEN

2205
01:30:03,320 --> 01:30:08,840
BEFORE. SO YOU CAN THINK OF AI

2206
01:30:08,840 --> 01:30:11,880
AS A PIPELINE, AI MODEL IS

2207
01:30:11,880 --> 01:30:13,680
INTEGRATED IN THIS PIPELINE THAT

2208
01:30:13,680 --> 01:30:15,800
INCLUDES PREANALYTICAL FACTORS

2209
01:30:15,800 --> 01:30:19,240
OR PRE-MODEL FACTORS. AND ALSO

2210
01:30:19,240 --> 01:30:20,920
POST MODEL FACTORS. WE WANT TO

2211
01:30:20,920 --> 01:30:23,200
TRY TO TAKE THIS FROM A BIRD'S

2212
01:30:23,200 --> 01:30:26,200
EYE VIEW HOLISTIC VIEW OF AI AND

2213
01:30:26,200 --> 01:30:27,160
BLOOD BANKING TRANSFUSION

2214
01:30:27,160 --> 01:30:29,000
MEDICINE AND COME UP WITH AN

2215
01:30:29,000 --> 01:30:33,520
OVERARCHING PRIORITY.  SO THE

2216
01:30:33,520 --> 01:30:35,280
QUESTION WE CAME UP WITH

2217
01:30:35,280 --> 01:30:37,320
CLINICAL SERVICES AND BLOOD

2218
01:30:37,320 --> 01:30:41,800
BANKS EVALUATE ADOPT AI TOOLS

2219
01:30:41,800 --> 01:30:42,440
PREDICTING PATIENT TRANSFUSION

2220
01:30:42,440 --> 01:30:43,120
REQUIREMENT, BLOOD UTILIZATION

2221
01:30:43,120 --> 01:30:45,080
AN DEMAND FORECASTING. HOW WE

2222
01:30:45,080 --> 01:30:47,200
CAN ENSURE THOSE TOOLS ARE

2223
01:30:47,200 --> 01:30:48,000
GENERALIZABLE ROBUST AN

2224
01:30:48,000 --> 01:30:52,640
SCALABLE. THIS HAS BEEN

2225
01:30:52,640 --> 01:30:53,880
FACILITATED BY THE IMPROVEMENT

2226
01:30:53,880 --> 01:30:56,760
IN COMPUTATIONAL POWER AND

2227
01:30:56,760 --> 01:30:58,440
CONNECTED INTEROPERABLE HEALTH

2228
01:30:58,440 --> 01:30:59,800
DATA PIPELINES.  WE ARE SEEING A

2229
01:30:59,800 --> 01:31:01,400
NUMBER OF RESEARCH AND

2230
01:31:01,400 --> 01:31:03,720
TRANSLATIONAL APPLICATION OF A

2231
01:31:03,720 --> 01:31:05,880
AI ML TRANSFUSION ANALYTICS AND

2232
01:31:05,880 --> 01:31:13,280
BLOOD DEMAND FORECASTING. TWO

2233
01:31:13,280 --> 01:31:15,960
MORE COLLISION.

2234
01:31:15,960 --> 01:31:17,680
THESE ARE -- CLICKS.  THESE ARE

2235
01:31:17,680 --> 01:31:19,640
DATA RESEARCH APPLICATIONS

2236
01:31:19,640 --> 01:31:20,480
PUBLISHED IN TRANSFUSION

2237
01:31:20,480 --> 01:31:22,200
MEDICINE DOMAIN, ARTIFICIAL

2238
01:31:22,200 --> 01:31:23,480
INTELLIGENCE BASE PREDICTION OF

2239
01:31:23,480 --> 01:31:26,920
TRANSFUSION IN ICU, APPLICATION

2240
01:31:26,920 --> 01:31:30,200
DECISION TREE ALGORITHMS,

2241
01:31:30,200 --> 01:31:34,120
PREDICTION MASSIVE TRANSFUSION

2242
01:31:34,120 --> 01:31:36,600
TRAUMA. THEN MORE TRANSLATIONAL,

2243
01:31:36,600 --> 01:31:38,120
SOMETHING THAT IS GOING FOR FDA

2244
01:31:38,120 --> 01:31:40,800
APPROVAL IS AI ENABLED ADVANCE

2245
01:31:40,800 --> 01:31:42,360
DEPLOYMENT, LOOKING AT

2246
01:31:42,360 --> 01:31:43,640
COMPENSATORY RESERVE MACHINE

2247
01:31:43,640 --> 01:31:48,840
LEARNING ALGORITHMS.  THERE ARE

2248
01:31:48,840 --> 01:31:50,360
ALSO FEW APPLICATIONS IN THE

2249
01:31:50,360 --> 01:31:53,040
BLOOD BANKING DOMAIN, THIS ONE

2250
01:31:53,040 --> 01:31:54,600
STUDY REDUCTION OF PLATELET

2251
01:31:54,600 --> 01:31:55,880
OUTDATING AND SHORTAGE BY

2252
01:31:55,880 --> 01:31:57,440
FORECASTING DEMAND WITH THE

2253
01:31:57,440 --> 01:31:58,840
COMBINATION OF STATISTICAL

2254
01:31:58,840 --> 01:31:59,960
LEARNING AND DEEP NEURAL

2255
01:31:59,960 --> 01:32:05,360
NETWORKS.  ONE OF OUR WORKING

2256
01:32:05,360 --> 01:32:07,680
GROUP MEMBERS PUBLISHED THIS

2257
01:32:07,680 --> 01:32:09,560
QUITE FANTASTIC PAPER ON DEMAND

2258
01:32:09,560 --> 01:32:11,920
FORECASTING WHICH INCORPORATED

2259
01:32:11,920 --> 01:32:14,360
BOTH STATISTICAL MODELING AND

2260
01:32:14,360 --> 01:32:17,560
MACHINE LEARNING FOR INVENTORY

2261
01:32:17,560 --> 01:32:19,120
OPTIMIZATION. THEN RUCHIKA

2262
01:32:19,120 --> 01:32:20,800
MENTIONED THE FACEBOOK AI BLOOD

2263
01:32:20,800 --> 01:32:22,600
DONATION TOOL.  THIS WAS A QUICK

2264
01:32:22,600 --> 01:32:24,680
OVERVIEW OF SOME OF THE RESEARCH

2265
01:32:24,680 --> 01:32:26,600
APPLICATIONS POPPING UP IN THE

2266
01:32:26,600 --> 01:32:31,560
LITERATURE. SO FOR THIS

2267
01:32:31,560 --> 01:32:33,120
OVERARCHING GOEL DEPLOYING

2268
01:32:33,120 --> 01:32:35,560
ROBUST SCALE GENERALIZABLE

2269
01:32:35,560 --> 01:32:37,320
RISK-BASED APPROACH IS IDEAL

2270
01:32:37,320 --> 01:32:38,880
WHICH BALANCES THE DISEASE

2271
01:32:38,880 --> 01:32:40,720
STATES SEVERITY AND DECISION

2272
01:32:40,720 --> 01:32:43,640
CONSEQUENCE. GOING ON TO FOCUS

2273
01:32:43,640 --> 01:32:47,600
PRIORITY ON IMPLEMENT -- PLEA

2274
01:32:47,600 --> 01:32:50,000
AGREEMENT TAKES RESEARCH ON DATA

2275
01:32:50,000 --> 01:32:51,440
AVAILABILITY SOURCING FOR

2276
01:32:51,440 --> 01:32:52,680
ALGORITHM EVALUATION. A

2277
01:32:52,680 --> 01:32:54,160
STATISTICAL FRAMEWORK FOR MODEL

2278
01:32:54,160 --> 01:32:55,600
VALIDATION VERIFICATION.

2279
01:32:55,600 --> 01:32:56,600
PERFORMANCE MONITORING FOR

2280
01:32:56,600 --> 01:32:59,480
DRIFTS OR SHIFTS OVER TIME. 

2281
01:32:59,480 --> 01:33:01,080
HUMAN COMPUTER INTERACTION AND

2282
01:33:01,080 --> 01:33:09,080
MODEL CHANGE CONTROL.  WE ALSO

2283
01:33:09,080 --> 01:33:11,000
WANT TO FOCUS ON TWO TECHNIQUES

2284
01:33:11,000 --> 01:33:15,080
WHICH ARE RELATIVELY NOVEL.

2285
01:33:15,080 --> 01:33:17,080
FIRST ONE AROUND ENSEMBLE

2286
01:33:17,080 --> 01:33:18,640
LEARNING BUT UTILIZED MORE IN

2287
01:33:18,640 --> 01:33:20,400
BLOOD BANKING AND TRANSFUSION

2288
01:33:20,400 --> 01:33:22,480
MEDICINE RECENTLY. SO USING

2289
01:33:22,480 --> 01:33:24,520
MULTIPLE MODELS WHICH ALL HAVE

2290
01:33:24,520 --> 01:33:26,720
THEIR OWN PROS AND CONS. TO

2291
01:33:26,720 --> 01:33:29,480
ARRIVE AT A BETTER PREDICTION.

2292
01:33:29,480 --> 01:33:30,680
WE ALSO WANT TO FOCUS ON

2293
01:33:30,680 --> 01:33:32,320
FEDERATED LEARNING SO THE

2294
01:33:32,320 --> 01:33:34,520
PRINCIPLES OF FEDERATED LEARNING

2295
01:33:34,520 --> 01:33:36,760
ARE DECENTRALIZATION,

2296
01:33:36,760 --> 01:33:38,320
DISTRIBUTION, SECURE

2297
01:33:38,320 --> 01:33:40,360
AGGREGATION, AND ALL THOSE

2298
01:33:40,360 --> 01:33:42,120
FACTORS CAN REDUCE CLIENT

2299
01:33:42,120 --> 01:33:45,680
LATENCY, IMPROVE THE HUMAN

2300
01:33:45,680 --> 01:33:47,240
COMPUTER INTERACTION, PROVIDES

2301
01:33:47,240 --> 01:33:51,360
TOOL FOR DOING VERIFICATION.

2302
01:33:51,360 --> 01:33:52,000
PROTECTS PRIVACY, HOUSING DATA

2303
01:33:52,000 --> 01:33:59,240
LOCALLY. MUSCLE ROBUSTNESS AND

2304
01:33:59,240 --> 01:34:00,640
GENERALIZABILITY, THE AIM WAS TO

2305
01:34:00,640 --> 01:34:02,840
FOCUS ON USE OF ENSEMBLE

2306
01:34:02,840 --> 01:34:04,640
LEARNING FEDERATED LEARNING

2307
01:34:04,640 --> 01:34:06,400
TECHNIQUES ACHIEVING THE

2308
01:34:06,400 --> 01:34:08,520
OVERASH.ING AIM OF ROBUST

2309
01:34:08,520 --> 01:34:12,440
SCALABLE AI. SO THE FEASIBILITY

2310
01:34:12,440 --> 01:34:14,440
ISSUES OF ROBUSTNESS SCALABILITY

2311
01:34:14,440 --> 01:34:17,520
RELIABILITY, WE THINK CAN BE

2312
01:34:17,520 --> 01:34:20,160
ADDRESSED WITHIN 3 TO 10 YEARS

2313
01:34:20,160 --> 01:34:20,960
BECAUSE DATA INFRASTRUCTURE

2314
01:34:20,960 --> 01:34:27,000
WIDELY AVAILABLE. EACH OUR

2315
01:34:27,000 --> 01:34:29,200
VENDORS -- EPISICK SEPSIS MODEL 

2316
01:34:29,200 --> 01:34:30,840
WE AREN'T AWARE OF KNOWN

2317
01:34:30,840 --> 01:34:32,240
IMPLEMENTATIONS IN BLOOD BANKING

2318
01:34:32,240 --> 01:34:34,560
AND TRANSFUSION MEDICINE. 

2319
01:34:34,560 --> 01:34:35,880
ENSEMBLE AND FEDERATED METHODS

2320
01:34:35,880 --> 01:34:38,040
ARE RELATIVELY NEW BUT THEY HAVE

2321
01:34:38,040 --> 01:34:39,560
BEEN APPLIED QUITE A LOOT

2322
01:34:39,560 --> 01:34:41,280
MEDICAL IMAGING AND OTHER

2323
01:34:41,280 --> 01:34:43,000
CLINICAL USE CASES, THEY DO HOLD

2324
01:34:43,000 --> 01:34:44,600
SIGNIFICANT PROMISE FOR

2325
01:34:44,600 --> 01:34:46,560
TRANSFUSION MEDICINE BLOOD

2326
01:34:46,560 --> 01:34:48,440
BANKING. THERE ARE PROBLEMS WITH

2327
01:34:48,440 --> 01:34:49,320
INTEROPERABILITY AND

2328
01:34:49,320 --> 01:34:50,760
AGGREGATION, SOME ALLEVIATED BY

2329
01:34:50,760 --> 01:34:52,920
HAVING BETTER DATABASE DESIGN.

2330
01:34:52,920 --> 01:34:54,600
SOME WILL ALSO BE ALLEVIATED AS

2331
01:34:54,600 --> 01:34:56,960
SOFTWARE VENDORS GRAPPLE WITH

2332
01:34:56,960 --> 01:34:57,720
COMPLIANCE WITH THE FIREMAN

2333
01:34:57,720 --> 01:35:01,680
DATE.  THE REACH OF THE MANDATE

2334
01:35:01,680 --> 01:35:02,760
MAY NOT EXTEND BEYOND PATIENTS

2335
01:35:02,760 --> 01:35:05,080
TO BLOOD DONOR AND REIMBURSEMENT

2336
01:35:05,080 --> 01:35:07,240
IS ONGOING CONCERN AND PATHOLOGY

2337
01:35:07,240 --> 01:35:10,720
AND RADIOLOGY RIGHT NOW. MOSTLY

2338
01:35:10,720 --> 01:35:14,320
IM ALGORITHMS RECEIVE CATEGORY 3

2339
01:35:14,320 --> 01:35:15,880
CPT INITIALLY AND GETTING PAIRS

2340
01:35:15,880 --> 01:35:18,040
TO REBUST FOR THESE MODELS IS

2341
01:35:18,040 --> 01:35:22,160
CHALLENGING. FOR THE FIFTH

2342
01:35:22,160 --> 01:35:25,560
PRIORITY WE LEVERAGE EXPERTISE

2343
01:35:25,560 --> 01:35:28,920
OF OUR TWO GENOMICS EXPERTS,

2344
01:35:28,920 --> 01:35:30,560
SELENA AND BILL, I DON'T HAVE

2345
01:35:30,560 --> 01:35:31,840
EXPERTISE BUT I WILL PRESENT

2346
01:35:31,840 --> 01:35:34,200
THEIR PRIORITY THEY DRAFTED FOR

2347
01:35:34,200 --> 01:35:36,480
US. SO THE QUESTION HOW CAN WE

2348
01:35:36,480 --> 01:35:38,200
BETTER INTEGRATE GENOMICS

2349
01:35:38,200 --> 01:35:39,520
CLINICAL TRANSFUSION WORKFORCE

2350
01:35:39,520 --> 01:35:40,760
WITH OBJECTIVE PROVIDING THE

2351
01:35:40,760 --> 01:35:43,440
BEST DONOR FOR RECIPIENT, IN

2352
01:35:43,440 --> 01:35:44,960
CLINICAL TRANSFUSION? GENOMICS

2353
01:35:44,960 --> 01:35:46,760
HAS POTENTIAL TO ENHANCE

2354
01:35:46,760 --> 01:35:48,440
NATIONAL RARE BLOOD INVENTORY

2355
01:35:48,440 --> 01:35:51,080
IMPROVE ALLEGATION OF BLOOD

2356
01:35:51,080 --> 01:35:53,520
DECREASE UTILIZATION, OPTIMIZE

2357
01:35:53,520 --> 01:35:54,520
CLINICAL RESPONSE AN SAFETY.

2358
01:35:54,520 --> 01:35:56,680
>> TWO MINUTE WARNING.

2359
01:35:56,680 --> 01:35:58,960
>> GROWING EVIDENCE BASED

2360
01:35:58,960 --> 01:35:59,960
DEMONSTRATED ADVANTAGES OF

2361
01:35:59,960 --> 01:36:02,320
GENOMIC TESTING, CRITICAL

2362
01:36:02,320 --> 01:36:05,200
FACTORS FOR BROAD UPTAKE OPTIMAL

2363
01:36:05,200 --> 01:36:06,240
BIOINFORMATICS PIPELINE CREATION

2364
01:36:06,240 --> 01:36:08,200
OF VALIDATION DATA SETS WITH

2365
01:36:08,200 --> 01:36:11,440
RARE DIVERSE SAMPLES, ISSUES OF

2366
01:36:11,440 --> 01:36:13,400
EQUITY AND RACIAL DIVERSITY,

2367
01:36:13,400 --> 01:36:14,920
INCORPORATION OF LONG RANGE

2368
01:36:14,920 --> 01:36:16,640
SEQUENCING GLOBAL CURATED ALLELE

2369
01:36:16,640 --> 01:36:19,880
FREQUENCY DATABASES AND

2370
01:36:19,880 --> 01:36:23,240
INTEROPERABILITY. APPLICABILITY

2371
01:36:23,240 --> 01:36:25,120
OF THE PIPELINES TOOLS AN

2372
01:36:25,120 --> 01:36:26,120
APPROACHES NEED TO BE

2373
01:36:26,120 --> 01:36:27,760
SYSTEMATICALLY TESTED, THERE ARE

2374
01:36:27,760 --> 01:36:29,920
POTENTIALLY UNTAPPED GENOMICS

2375
01:36:29,920 --> 01:36:31,280
APPLICATIONS SUCH AS ALLO

2376
01:36:31,280 --> 01:36:33,520
ORGANIZATION, AUTO-IMMUNITY,

2377
01:36:33,520 --> 01:36:35,080
HYPERHEMOLYSIS, PERMIZED BLOOD

2378
01:36:35,080 --> 01:36:37,360
DONATION SCHEDULES, DISCOVERY

2379
01:36:37,360 --> 01:36:39,040
DATA SCIENCE CAN BE CROWD

2380
01:36:39,040 --> 01:36:41,320
SOURCED USING GRAND CHALLENGES

2381
01:36:41,320 --> 01:36:42,960
THOUGH WE HAVE TO GET AROUND

2382
01:36:42,960 --> 01:36:45,400
PRIVACY. THERE IS A ROLE FOR

2383
01:36:45,400 --> 01:36:50,080
MULTI-CENTER CLINICAL TRIAL. 

2384
01:36:50,080 --> 01:36:50,880
FEASIBILITIES, TOOLS ARE

2385
01:36:50,880 --> 01:36:54,480
AVAILABLE IN OTHER DOMAINS AND

2386
01:36:54,480 --> 01:36:56,840
INCREASELY AVAILABLE IN BLOOD

2387
01:36:56,840 --> 01:36:58,800
BANGING TRANSFUSION BUT AT SLOW

2388
01:36:58,800 --> 01:37:00,440
PACE.  THERE ARE PLATFORMS

2389
01:37:00,440 --> 01:37:02,760
AVAILABLE FOR CROWD SOURCE GRAND

2390
01:37:02,760 --> 01:37:03,560
CHALLENGES, THERE ARE CONCERNS

2391
01:37:03,560 --> 01:37:05,560
ABOUT PRIVACY, INTEROPERABILITY

2392
01:37:05,560 --> 01:37:09,360
AND AGGREGATION. QUICKLY GLANCE

2393
01:37:09,360 --> 01:37:11,640
OVER TWO ADDITIONAL PRIORITIES. 

2394
01:37:11,640 --> 01:37:13,320
FIRST WAS IN SILICO CLINICAL

2395
01:37:13,320 --> 01:37:15,320
TRIALS, THE FADS PLACED A LARGE

2396
01:37:15,320 --> 01:37:17,920
EMPHASIS ON -- FDA PLACED LARGE

2397
01:37:17,920 --> 01:37:19,120
MODELING AND SIMULATION IN

2398
01:37:19,120 --> 01:37:20,040
DEVICE APPROVAL PROCESS AN

2399
01:37:20,040 --> 01:37:25,120
CLINICAL TRIALS. THIS ONE IN

2400
01:37:25,120 --> 01:37:26,600
SILICO TRIALS OFFER INNOVATIVE

2401
01:37:26,600 --> 01:37:28,360
APPROACH TO EVALUATING

2402
01:37:28,360 --> 01:37:30,080
COMPARATIVE EFFICACY AND SAFETY,

2403
01:37:30,080 --> 01:37:31,960
MODELING AND SIMULATION USE TO

2404
01:37:31,960 --> 01:37:33,440
PREDICT PERFORMANCE, EXPLORE

2405
01:37:33,440 --> 01:37:35,560
ALTERNATIVE STUDY DESIGNS, NOVEL

2406
01:37:35,560 --> 01:37:37,160
EFFECTIVE THERAPEUTICS, SO THE

2407
01:37:37,160 --> 01:37:39,040
QUESTION HERE WAS CAN IN SILICO

2408
01:37:39,040 --> 01:37:40,960
CLINICAL TRIALS BE US YEW TO

2409
01:37:40,960 --> 01:37:42,760
IDENTIFY PATIENT SUB GROUPS MOST

2410
01:37:42,760 --> 01:37:44,840
LIKELY TO BENEFIT FROM RECESS

2411
01:37:44,840 --> 01:37:46,720
STATION STRATEGIES, GUIDE

2412
01:37:46,720 --> 01:37:48,600
INCLUSION AND EXCLUSION CRITERIA

2413
01:37:48,600 --> 01:37:50,200
FOR CLINICAL TRIALS AND IMPROVE

2414
01:37:50,200 --> 01:37:54,440
STATISTICAL POWER.  THE OTHER

2415
01:37:54,440 --> 01:37:55,560
PRIORITY WAS CHANGING THE

2416
01:37:55,560 --> 01:37:58,440
PARADIGM OF AI ML, WE HAVE A TOP

2417
01:37:58,440 --> 01:38:00,800
DOWN APPROACH, WE FRAGMENT THE

2418
01:38:00,800 --> 01:38:03,400
PROBLEM TO SMALLER PROBLEMS,

2419
01:38:03,400 --> 01:38:05,040
REFORMULATING THAT BOTTOM OR

2420
01:38:05,040 --> 01:38:06,520
CONNECTIONIST APPROACH,

2421
01:38:06,520 --> 01:38:07,720
COMBINING SINGLE MODEL AND

2422
01:38:07,720 --> 01:38:10,520
SYSTEMS THAT BUILD UP TO FORM

2423
01:38:10,520 --> 01:38:13,360
MORE COMPLEX MODELS.  SO JAMES

2424
01:38:13,360 --> 01:38:15,560
WORKED ON THIS PRIORITY FOR US,

2425
01:38:15,560 --> 01:38:18,800
A SYSTEMS BY BIOLOGY EXPERT, HOW

2426
01:38:18,800 --> 01:38:22,400
TO CREATE MULTI-MODAL AI THAT

2427
01:38:22,400 --> 01:38:23,520
LEVERAGES DATA USING SYSTEMS

2428
01:38:23,520 --> 01:38:25,400
BIOLOGY.  TO INTEGRATE KNOWN

2429
01:38:25,400 --> 01:38:26,840
MECHANISTIC DATA AND MOLECULAR

2430
01:38:26,840 --> 01:38:29,120
DATA. HOW CAN THIS BE USED TO

2431
01:38:29,120 --> 01:38:30,800
INTEGRATE DOMAIN KNOWLEDGE OF

2432
01:38:30,800 --> 01:38:33,240
BIOCHEMICAL PATHWAYS AND IMPROVE

2433
01:38:33,240 --> 01:38:37,160
PREDICTIVE ANALYTICS. WHAT WE

2434
01:38:37,160 --> 01:38:39,920
USED WAS THE RICE SCORING

2435
01:38:39,920 --> 01:38:40,800
METHOD, USED IN

2436
01:38:40,800 --> 01:38:41,920
TELECOMMUNICATION, WE ADAPTED IT

2437
01:38:41,920 --> 01:38:43,360
SLIGHTLY BUT USES FOUR FACTORS

2438
01:38:43,360 --> 01:38:45,160
THE REACH, NUMBER OF INDIVIDUALS

2439
01:38:45,160 --> 01:38:49,360
PRIORITIES LIKELY TO EFFECT THE

2440
01:38:49,360 --> 01:38:51,480
IMPACT CONFIDENCE OF FEASIBILITY

2441
01:38:51,480 --> 01:38:52,400
ACCOMPLISHED AND EFFORT

2442
01:38:52,400 --> 01:38:53,800
NECESSARY TO IMPLEMENT PRIORITY.

2443
01:38:53,800 --> 01:38:56,200
WE MADE A SLIGHT MODIFICATION BY

2444
01:38:56,200 --> 01:38:57,120
SWEARING THE EFFORT TO GET

2445
01:38:57,120 --> 01:38:58,840
VALUES TO BE CLOSER TO VALUE OF

2446
01:38:58,840 --> 01:39:04,600
1. THIS ADDRESSES STRIP PLOT HOW

2447
01:39:04,600 --> 01:39:06,840
OUR WORKING GROUP MEMBERS RANKED

2448
01:39:06,840 --> 01:39:08,800
ALL THESE SEVEN PRIORITIES IN

2449
01:39:08,800 --> 01:39:10,880
ORDER THEY WERE PRESENTED TODAY 

2450
01:39:10,880 --> 01:39:13,000
SO THE FIRST FIVE PRESENTED WERE

2451
01:39:13,000 --> 01:39:16,320
RANKED HIGHEST. LAST TWO ARE

2452
01:39:16,320 --> 01:39:17,520
CONSIDERING ADDITIONAL

2453
01:39:17,520 --> 01:39:22,360
PRIORITIES.  SOME VARIABILITY,

2454
01:39:22,360 --> 01:39:24,080
TECHNICAL EXPERTS RANKED IN

2455
01:39:24,080 --> 01:39:25,640
SILICO CLINICAL TRIALS HIGHER

2456
01:39:25,640 --> 01:39:27,120
THAN OTHER PRIORITIES BUT IN THE

2457
01:39:27,120 --> 01:39:29,560
END WE CAME UP WITH A GOOD

2458
01:39:29,560 --> 01:39:31,040
OVERALL RANKING FOR THE SERVE

2459
01:39:31,040 --> 01:39:34,360
PRIORITIES.  SO THIS HERE IS

2460
01:39:34,360 --> 01:39:36,360
ANOTHER SUMMARY, THESE ARE

2461
01:39:36,360 --> 01:39:38,200
OBVIOUSLY OPEN FOR

2462
01:39:38,200 --> 01:39:39,080
REPRIORITIZATION BASED ON

2463
01:39:39,080 --> 01:39:40,200
DISCUSSION MANY THE BREAK OUT

2464
01:39:40,200 --> 01:39:45,800
SESSION.  WE WANT THE THANK OUR

2465
01:39:45,800 --> 01:39:50,200
11 WORKING GROUP MEMBERS, THEY

2466
01:39:50,200 --> 01:39:52,240
CRIBBED TO DISCUSSION AND

2467
01:39:52,240 --> 01:39:54,960
HELPING DRAFT PRIORITIES.  WE

2468
01:39:54,960 --> 01:39:55,960
WELCOME DISCUSSION AND QUESTIONS

2469
01:39:55,960 --> 01:39:56,680
IN THE BREAK OUT SESSION.  THANK

2470
01:39:56,680 --> 01:39:58,960
YOU. 

2471
01:39:58,960 --> 01:40:07,120
>>

2472
01:40:07,120 --> 01:40:11,440
>> THANK YOU CLEAR
RESEARCH

2473
01:40:11,440 --> 01:40:13,320
PRIORITIES WHICH ENCOMPASS THE

2474
01:40:13,320 --> 01:40:16,640
EXPERTISE OF YOUR WORKING GROUP 

2475
01:40:16,640 --> 01:40:20,240
I NOW ARE HAVE THE PRIVILEGE OF

2476
01:40:20,240 --> 01:40:22,680
INTRODUCING DR. YVETTE MILLER

2477
01:40:22,680 --> 01:40:26,640
AND MEGHAN DELANEY, DONORS IN

2478
01:40:26,640 --> 01:40:32,600
TRANSFUSION MEDICINE. DR. -- IN

2479
01:40:32,600 --> 01:40:34,560
CHARLOTTE, NICK NICK SHE SERVED

2480
01:40:34,560 --> 01:40:35,640
IN MULTIPLE LEADER SHIP ROLES

2481
01:40:35,640 --> 01:40:37,640
FOR THE AMERICAN RED CROSS AND

2482
01:40:37,640 --> 01:40:39,040
AABB AND RECOGNIZED FOR HER LONG

2483
01:40:39,040 --> 01:40:41,040
STANDING COMMITMENT TO

2484
01:40:41,040 --> 01:40:42,560
ADDRESSING HEALTH DISPARITIES

2485
01:40:42,560 --> 01:40:43,800
AND STRUCTURAL RACISM AND BIAS

2486
01:40:43,800 --> 01:40:46,880
IN HEALTHCARE. DR. MEGHAN

2487
01:40:46,880 --> 01:40:51,280
DELANEY IS CHIEF DIVISION OF

2488
01:40:51,280 --> 01:40:53,800
PATHOLOGY, DIRECTOR OF

2489
01:40:53,800 --> 01:40:55,800
CHILDREN'S NATIONAL HOSPITAL AND

2490
01:40:55,800 --> 01:40:56,520
PEDIATRICS GEORGE WASHINGTON

2491
01:40:56,520 --> 01:40:59,040
UNIVERSITY.  WELCOME TO BOTH.

2492
01:40:59,040 --> 01:41:02,160
>> GREAT. THANK YOU. SO
MUCH.

2493
01:41:02,160 --> 01:41:06,200
AGAIN WE WANT TO -- WE WANT TO

2494
01:41:06,200 --> 01:41:08,120
THANK NHLBI FOR TAPPING US TO

2495
01:41:08,120 --> 01:41:11,040
TALK ABOUT THIS IMPORTANT TOPIC

2496
01:41:11,040 --> 01:41:14,040
ON DONOR BLOOD RECIPIENT HEALTH

2497
01:41:14,040 --> 01:41:17,440
DISPARITIES. THIS IS A SPECIAL

2498
01:41:17,440 --> 01:41:19,480
TIME AND SPECIAL PLACE TO BE TO

2499
01:41:19,480 --> 01:41:22,320
HAVE THIS DISCUSSION IN GENERAL

2500
01:41:22,320 --> 01:41:24,200
IN THE SCIENTIFIC LITERATURE,

2501
01:41:24,200 --> 01:41:25,560
AND SPECIFICALLY IN TRANSFUSION

2502
01:41:25,560 --> 01:41:27,000
MEDICINE, THERE HAS NOT BEEN

2503
01:41:27,000 --> 01:41:30,200
MUCH DISCUSSION AROUND HEALTH

2504
01:41:30,200 --> 01:41:31,320
DISPARITIES AND INHE CAN IS SO

2505
01:41:31,320 --> 01:41:35,360
WE UNDERSTAND THAT THIS IS AN

2506
01:41:35,360 --> 01:41:37,440
INCREDIBLE OPPORTUNITY TO BE

2507
01:41:37,440 --> 01:41:38,360
INNOVATED TO HAVE THIS

2508
01:41:38,360 --> 01:41:40,880
DISCUSSION. WE WANT TO THANK

2509
01:41:40,880 --> 01:41:42,760
NHLBI AND BRIAN FOR TAPPING US

2510
01:41:42,760 --> 01:41:51,240
AND INVITING US TO THIS SPACE.  

2511
01:41:51,240 --> 01:41:52,040
NONE OF THIS COULD HAVE BEEN

2512
01:41:52,040 --> 01:41:57,560
DONE. WITHOUT THIS FANTASTIC

2513
01:41:57,560 --> 01:41:58,840
GROUP OF INDIVIDUALS THAT HELP

2514
01:41:58,840 --> 01:42:02,880
US THAT WORKED WITH US TO PUT

2515
01:42:02,880 --> 01:42:04,120
THIS INFORMATION TOGETHER. 

2516
01:42:04,120 --> 01:42:05,640
MEGHAN AND I WERE DELIBERATE AN

2517
01:42:05,640 --> 01:42:09,320
INTENTIONAL AND FOCUSED ON

2518
01:42:09,320 --> 01:42:10,960
PUTTING A CROSS CULTURAL TEAM OF

2519
01:42:10,960 --> 01:42:12,200
VICTIMS THAT HE WANT ARED

2520
01:42:12,200 --> 01:42:14,840
DIFFERENT AREAS OF CERTAIN

2521
01:42:14,840 --> 01:42:16,560
DIVERSITY IN TERMS OF ETHNICITY

2522
01:42:16,560 --> 01:42:19,080
AND BACKGROUND BUT ALSO

2523
01:42:19,080 --> 01:42:22,040
EDUCATION AND EXPERIEN EXPERIENL

2524
01:42:22,040 --> 01:42:23,360
THESE INDIVIDUALS REPRESENT

2525
01:42:23,360 --> 01:42:30,080
EXCELLENCE IN THEIR FIELDS. 

2526
01:42:30,080 --> 01:42:32,880
SO FIRST PRIORITY WAS REGARDING

2527
01:42:32,880 --> 01:42:34,920
INCLUSION AND RESEARCH. HOW CAN

2528
01:42:34,920 --> 01:42:36,280
DIVERSITY OF RESEARCH

2529
01:42:36,280 --> 01:42:38,400
PARTICIPANTS FOR EXAMPLE RACE

2530
01:42:38,400 --> 01:42:39,600
SOCIOECONOMIC STATUS AN

2531
01:42:39,600 --> 01:42:44,160
LANGUAGE, BE INCREASED FOR BOTH

2532
01:42:44,160 --> 01:42:46,720
BLOOD DONOR STUDIES AND STUDIES

2533
01:42:46,720 --> 01:42:48,080
OF PATIENTS. WHAT IS THE PROBLEM

2534
01:42:48,080 --> 01:42:50,840
WE ARE DESCRIBING? RACIALIZED

2535
01:42:50,840 --> 01:42:52,240
ECONOMICALLY DEPRIVED

2536
01:42:52,240 --> 01:42:53,240
COMMUNITIES HAVE POOR HEALTH

2537
01:42:53,240 --> 01:42:55,640
OUTCOMES.  THIS IS SOMETHING WE

2538
01:42:55,640 --> 01:42:57,320
KNOW FROM THE LITERATURE, THE

2539
01:42:57,320 --> 01:42:58,760
PUBLIC HEALTH LITERATURE AS WELL

2540
01:42:58,760 --> 01:43:00,080
AS ASPECT FROM THE SCIENTIFIC

2541
01:43:00,080 --> 01:43:03,280
LITERATURE. DONORS DIVERSITY OF

2542
01:43:03,280 --> 01:43:06,880
THE DONOR POOL IS IMPORTANT FOR

2543
01:43:06,880 --> 01:43:08,240
SUFFICIENCY BUT ALSO RARE BLOODS

2544
01:43:08,240 --> 01:43:12,880
TYPES.  STUDIES IN WHICH SUCH

2545
01:43:12,880 --> 01:43:13,920
COMMUNITIES ARE

2546
01:43:13,920 --> 01:43:16,600
UNDER-REPRESENTED, MAY IDENTIFY

2547
01:43:16,600 --> 01:43:20,080
EFFICACY OF RESEARCH IN MORE

2548
01:43:20,080 --> 01:43:21,680
ADVANCE MORE ADVANTAGED

2549
01:43:21,680 --> 01:43:22,800
COMMUNITIES BUT MISIDENTIFYING

2550
01:43:22,800 --> 01:43:24,000
EFFECTS IN COMMUNITIES MOST IN

2551
01:43:24,000 --> 01:43:28,520
NEED.  STUDIES DIVERSE DONORS OR

2552
01:43:28,520 --> 01:43:31,160
POTENTIAL DONORS ARE

2553
01:43:31,160 --> 01:43:32,280
UNDER-REPRESENTED RESULT IN

2554
01:43:32,280 --> 01:43:34,160
RECRUITMENT STRATEGIES AND DONOR

2555
01:43:34,160 --> 01:43:37,480
CRITERIA THAT DON'T ADDRESS

2556
01:43:37,480 --> 01:43:38,080
RECOGNIZE IN THOSE SPECIFIC

2557
01:43:38,080 --> 01:43:44,920
COMMUNITIES.  SO WHY AN ISSUE?

2558
01:43:44,920 --> 01:43:46,760
EXCLUSION OF MINORITIES RESULTS

2559
01:43:46,760 --> 01:43:49,400
IN UNEQUAL RESOURCE ALLOCATION

2560
01:43:49,400 --> 01:43:51,200
FOR TREATMENT OR DONOR

2561
01:43:51,200 --> 01:43:52,000
RECRUITMENT APPROACHES THAT

2562
01:43:52,000 --> 01:43:53,320
BENEFIT SOME MORE THAN OTHERS

2563
01:43:53,320 --> 01:43:55,280
AND LESS EFFORT BEING PUT INTO

2564
01:43:55,280 --> 01:44:00,520
THE ALLOCATION OF TREATMENT THAT

2565
01:44:00,520 --> 01:44:03,200
BENEFIT MORE DIVERSE GROUPS. ONE

2566
01:44:03,200 --> 01:44:05,440
OF THE ISSUES, FEW WORDS

2567
01:44:05,440 --> 01:44:08,680
ABOUTIUS OF TERM MINORITIES.  IN

2568
01:44:08,680 --> 01:44:10,120
CONVERSATION WITH COMMUNITY

2569
01:44:10,120 --> 01:44:12,920
DIVERSE COMMUNITIES AND SOME

2570
01:44:12,920 --> 01:44:16,720
SPECIFIC INTERACTIONS HAVE BEEN

2571
01:44:16,720 --> 01:44:18,960
WITH THE SICKLE CELL DISEASE

2572
01:44:18,960 --> 01:44:20,400
COMMUNITY, AND COMMUNITIES THAT

2573
01:44:20,400 --> 01:44:21,960
ARE GREATER RISK FOR HAVING

2574
01:44:21,960 --> 01:44:22,960
SICKLE CELL DISEASE, THEY ARE

2575
01:44:22,960 --> 01:44:25,960
MOVING AWAY FROM SELF

2576
01:44:25,960 --> 01:44:27,840
IDENTIFYING AS MINORITY BECAUSE

2577
01:44:27,840 --> 01:44:30,200
WE KNOW THAT IN THE TERMS OF

2578
01:44:30,200 --> 01:44:33,360
POPULATION, IN THIS COUNTRY ARE

2579
01:44:33,360 --> 01:44:35,080
THE COUNTRY IS BECOMING MORE

2580
01:44:35,080 --> 01:44:37,880
DIVERSE AND WHEN THE NEXT 10 TO

2581
01:44:37,880 --> 01:44:39,280
15 YEARS THE WHITE POPULATION IN

2582
01:44:39,280 --> 01:44:40,880
THIS COUNTRY WILL NOT BE THE

2583
01:44:40,880 --> 01:44:42,840
DOMINANT CULTURE. SO WE ARE

2584
01:44:42,840 --> 01:44:46,120
ABSOLUTELY MOVING AWAY FROM

2585
01:44:46,120 --> 01:44:48,240
IDENTIFYING GROUPS, COMMUNITIES

2586
01:44:48,240 --> 01:44:50,080
OF COLOR, UNDER-REPRESENTED

2587
01:44:50,080 --> 01:44:51,520
COMMUNITIES, AS MINORITIES BUT

2588
01:44:51,520 --> 01:44:54,360
WE ARE GOING TO CONTINUE TO USE

2589
01:44:54,360 --> 01:44:54,960
THAT LANGUAGE IN THIS

2590
01:44:54,960 --> 01:44:55,960
PRESENTATION BECAUSE THAT IS THE

2591
01:44:55,960 --> 01:44:58,800
LANGUAGE MOST PEOPLE ARE USING

2592
01:44:58,800 --> 01:45:02,320
NONOW. BUT TRAJECTORY IS MOVE ON

2593
01:45:02,320 --> 01:45:03,320
FROM IDENTIFYING

2594
01:45:03,320 --> 01:45:06,360
UNDERREPRESENTED POPULATIONS AS

2595
01:45:06,360 --> 01:45:09,040
MINORITY. IN TERMS OF

2596
01:45:09,040 --> 01:45:10,440
FEASIBILITY AND BARRIERSK

2597
01:45:10,440 --> 01:45:12,560
SPECIFIC STUDIES ON DIVERSE

2598
01:45:12,560 --> 01:45:14,120
COMMUNITIES SHOULD BE FUNDED AND

2599
01:45:14,120 --> 01:45:16,040
SPECIFIC FUNDING ANNOUNCEMENTS

2600
01:45:16,040 --> 01:45:19,200
TO DEVELOP PROJECTS BY DIVERSE

2601
01:45:19,200 --> 01:45:23,640
RESEARCHERS. IF YOU DON'T KNOW

2602
01:45:23,640 --> 01:45:24,800
THESE RESEARCH PROJECTS AND

2603
01:45:24,800 --> 01:45:26,680
FUNDING IS AVAILABLING IT IS NOT

2604
01:45:26,680 --> 01:45:28,200
WIDELY PUNILY SIZED YOU DONE

2605
01:45:28,200 --> 01:45:30,400
KNOW -- PUBLICIZED YOU DON'T

2606
01:45:30,400 --> 01:45:33,000
KNOW IT IS AVAILABLE. MEMBERSHIP

2607
01:45:33,000 --> 01:45:34,280
OFTY VERSE RESEARCHERS INCLUDES

2608
01:45:34,280 --> 01:45:35,600
MENTORING FROM START TO FINISH

2609
01:45:35,600 --> 01:45:37,800
OF A PROJECTED, AND OPENNESS TO

2610
01:45:37,800 --> 01:45:39,640
DIFFERENT WAYS OF EXPRESSING

2611
01:45:39,640 --> 01:45:42,200
RESEARCH PLANS.  SO WE

2612
01:45:42,200 --> 01:45:46,600
UNDERSTAND LOOKING AT THE

2613
01:45:46,600 --> 01:45:47,600
SCIENTIFIC LITERATURE IS

2614
01:45:47,600 --> 01:45:48,920
MONOLITHIC IN TERMS HOW ARTICLES

2615
01:45:48,920 --> 01:45:50,080
ARE WRITTEN SO SO BRINGING

2616
01:45:50,080 --> 01:45:52,400
DIVERSE COMMUNITIES IN, THERE'S

2617
01:45:52,400 --> 01:45:53,080
DIVERSITY OF THOUGHT AND

2618
01:45:53,080 --> 01:45:53,880
PRESENTATION SO WE NEED TO

2619
01:45:53,880 --> 01:45:57,360
RESPECT THAT. QUALITATIVE

2620
01:45:57,360 --> 01:45:59,040
APPROACHES AND INTERDISCIPLINARY

2621
01:45:59,040 --> 01:46:00,280
COLLABORATION SUPPORTED BECAUSE

2622
01:46:00,280 --> 01:46:05,800
THESE WILL ENHANCE INCLUSIVITY. 

2623
01:46:05,800 --> 01:46:09,080
SODS ONE OF THE THINGS WE DO

2624
01:46:09,080 --> 01:46:11,440
WITH PRIORITIES IS THAT WE LIST

2625
01:46:11,440 --> 01:46:12,440
DISCUSSION QUESTIONS.  WHILE WE

2626
01:46:12,440 --> 01:46:16,840
KNOW YOU WILL ABSOLUTELY BE

2627
01:46:16,840 --> 01:46:17,680
DROPPING THOUGHTS AND QUESTIONS

2628
01:46:17,680 --> 01:46:18,840
IN THE CHAT WE WANTED

2629
01:46:18,840 --> 01:46:21,360
CONVERSATIONS STARTERS. SO WHAT

2630
01:46:21,360 --> 01:46:24,560
PART DOES MISTRUST PLAY IN THE

2631
01:46:24,560 --> 01:46:26,120
INABILITY TO RECRUIT RESEARCH

2632
01:46:26,120 --> 01:46:26,600
PARTICIPANTS FOR

2633
01:46:26,600 --> 01:46:29,040
UNDER-REPRESENTED COMMUNITIES.

2634
01:46:29,040 --> 01:46:31,960
WHAT TRUST BUILDING TECHNIQUES

2635
01:46:31,960 --> 01:46:33,240
EMPLOYED AND DOES TRUTH

2636
01:46:33,240 --> 01:46:33,800
RECONCILIATION MODEL HAVE A

2637
01:46:33,800 --> 01:46:37,120
PLACE? USING CRISPER TECHNOLOGY

2638
01:46:37,120 --> 01:46:40,320
AS AN EXAMPLE, SCIENTISTS

2639
01:46:40,320 --> 01:46:43,400
EMPLOYING THESE TECHNIQUES MAY

2640
01:46:43,400 --> 01:46:45,040
HAVE CONTACT WITH INDIVIDUALS

2641
01:46:45,040 --> 01:46:47,280
THAT MAYBE RESEARCH SUBJECTS AND

2642
01:46:47,280 --> 01:46:49,640
ULTIMATELY THE PATIENTS THAT

2643
01:46:49,640 --> 01:46:50,520
WILL BE TREAT WITH THIS

2644
01:46:50,520 --> 01:46:52,360
TECHNIQUE. IS THIS EXERTING

2645
01:46:52,360 --> 01:46:54,080
UNDUE INFLUENCE ON PATIENT?

2646
01:46:54,080 --> 01:46:55,760
AND HOW CAN THE CONFLICT OF

2647
01:46:55,760 --> 01:47:01,520
INTEREST BE ADDRESSED? PRIORITY

2648
01:47:01,520 --> 01:47:03,320
2, ACCESS TO CARE. ACCESS TO

2649
01:47:03,320 --> 01:47:04,320
APPROPRIATE TRANSFUSION CARE CAN

2650
01:47:04,320 --> 01:47:06,720
BE LIMITED BY CHURL NORMS,

2651
01:47:06,720 --> 01:47:08,360
FINANCIAL AND GEOGRAPHICAL

2652
01:47:08,360 --> 01:47:09,960
BARRIERS.  HOW CAN THESE

2653
01:47:09,960 --> 01:47:12,480
BARRIERS BE OVERCOME? WHAT IS

2654
01:47:12,480 --> 01:47:14,600
THE PROBLEM GEOGRAPHY PLAYS A

2655
01:47:14,600 --> 01:47:15,680
NEGATIVE ROLE IN ACCESS TO CARE

2656
01:47:15,680 --> 01:47:17,400
FOR PEOPLE WITH SICKLE CELL

2657
01:47:17,400 --> 01:47:20,400
DISEASE AND OTHERS WHO NEED

2658
01:47:20,400 --> 01:47:23,800
TRANSFUSION IN EMERGENCY SESSION

2659
01:47:23,800 --> 01:47:25,440
SITUATIONS.  IN 2010, 55% OF

2660
01:47:25,440 --> 01:47:27,440
BLACK AMERICANS LIVED IN SOUTH

2661
01:47:27,440 --> 01:47:29,280
AND 105 SOUTHERN COUNTIES HAD A

2662
01:47:29,280 --> 01:47:30,800
BLACK POPULATION OF 50% OR

2663
01:47:30,800 --> 01:47:34,920
GREATER. WHILE IN GENERAL,

2664
01:47:34,920 --> 01:47:37,640
COMMUNITIES WITH HIGHER

2665
01:47:37,640 --> 01:47:38,960
PERCENTAGES OF INDIVIDUALS FROM

2666
01:47:38,960 --> 01:47:41,560
UNDER-REPRESENTED UNDERRESOURCED

2667
01:47:41,560 --> 01:47:43,040
COMMUNITIES WHAT WE DO KNOW IS

2668
01:47:43,040 --> 01:47:43,960
THEY HAVE DECREASE ACCESS TO

2669
01:47:43,960 --> 01:47:48,680
CARE.  AND RURAL HEALTHCARE HAS

2670
01:47:48,680 --> 01:47:49,680
TRADITIONALLY LAGGED BEHIND THAT

2671
01:47:49,680 --> 01:47:55,480
IN URBAN AREAS.  SO THE PICTURE

2672
01:47:55,480 --> 01:47:58,560
CHANGED DRAMATICALLY OVER THE

2673
01:47:58,560 --> 01:48:01,200
PAST DECADE, DUE TO

2674
01:48:01,200 --> 01:48:03,080
TRANSFORMATION OF FINANCING,

2675
01:48:03,080 --> 01:48:05,520
INTRODUCTION OF TECHNOLOGIES AND

2676
01:48:05,520 --> 01:48:06,400
CLUSTERING OF HEALTHCARE

2677
01:48:06,400 --> 01:48:07,840
SERVICES AND RESOURCES TO

2678
01:48:07,840 --> 01:48:10,520
SYSTEMS AND NETWORKS OFTEN

2679
01:48:10,520 --> 01:48:11,880
PRIMARILY SITUATED IN URBAN

2680
01:48:11,880 --> 01:48:15,080
CENTERS. DESPITE CHANGES, RURAL

2681
01:48:15,080 --> 01:48:15,960
RESOURCES FOR RURAL HEALTH

2682
01:48:15,960 --> 01:48:17,280
SYSTEMS REMAIN RELATIVELY

2683
01:48:17,280 --> 01:48:20,640
INSUFFICIENT. AND UNCHANGED. 

2684
01:48:20,640 --> 01:48:21,960
RURAL COMMUNITIES CONTINUE TO

2685
01:48:21,960 --> 01:48:23,400
EXPERIENCE SHORTAGES OF

2686
01:48:23,400 --> 01:48:24,040
PHYSICIANS AND HEALTHCARE

2687
01:48:24,040 --> 01:48:26,680
PROVIDERS IN GENERAL. AND

2688
01:48:26,680 --> 01:48:28,040
PROPORTION OF RURAL HOSPITALS

2689
01:48:28,040 --> 01:48:29,280
UNDER FINANCIAL STRESS AND

2690
01:48:29,280 --> 01:48:31,600
STRAIN IS MUCH GREATER THAN THAT

2691
01:48:31,600 --> 01:48:33,880
URBAN HOSPITALS.  FOR PEOPLE

2692
01:48:33,880 --> 01:48:34,680
WITH SICKLE CELL DISEASE LIVING

2693
01:48:34,680 --> 01:48:38,200
IN RURAL AREAS, THERE ARE

2694
01:48:38,200 --> 01:48:41,200
CHALLENGES, GREATLY AMPLIFIED

2695
01:48:41,200 --> 01:48:42,480
UTILIZATION OF RESOURCES AND

2696
01:48:42,480 --> 01:48:45,560
SERVICES IS DIRECTLY RELATED TO

2697
01:48:45,560 --> 01:48:47,360
SOCIAL ECONOMIC CONDITIONS, THAT

2698
01:48:47,360 --> 01:48:50,320
PATIENTS FACE IN TERMS OF

2699
01:48:50,320 --> 01:48:55,240
DISTANCE TO CLINICAL SUPPORT. SO

2700
01:48:55,240 --> 01:48:57,520
WHY IS THIS AN ISSUE? HEALTH

2701
01:48:57,520 --> 01:48:59,840
OUTCOMES AS WE KNOW ARE DIRECTLY

2702
01:48:59,840 --> 01:49:01,880
IMPACTED BY ACCESS TO CARE

2703
01:49:01,880 --> 01:49:02,800
INCLUDING INDIVIDUALS WITH

2704
01:49:02,800 --> 01:49:05,560
SICKLE CELL DISEASE. WHEN

2705
01:49:05,560 --> 01:49:07,120
CONSIDERING ACCESS THE CARE AND

2706
01:49:07,120 --> 01:49:09,600
TRANSFUSION MEDICINE,

2707
01:49:09,600 --> 01:49:11,080
INDIVIDUALS WHO LIVE IN RURAL OR

2708
01:49:11,080 --> 01:49:14,280
REMOTE OR LIMITED HOSPITAL

2709
01:49:14,280 --> 01:49:16,400
LOCATIONS, HAVE DECREASE ACCESS

2710
01:49:16,400 --> 01:49:18,400
TO PATIENT AND EMERGENCY

2711
01:49:18,400 --> 01:49:20,120
TRANSFUSIONS SUCH AS

2712
01:49:20,120 --> 01:49:20,960
OBSTETRICAL, EMERGENCY

2713
01:49:20,960 --> 01:49:23,000
TRANSFUSIONS AND TRANSFUSIONS TO

2714
01:49:23,000 --> 01:49:25,240
SUPPORT CHRONIC ILLNESS. IT IS

2715
01:49:25,240 --> 01:49:26,880
IMPORTANT TO LOWER THESE ACCESS

2716
01:49:26,880 --> 01:49:29,160
BARRIERS FOR TRANSFUSION THERAPY

2717
01:49:29,160 --> 01:49:30,240
AS THIS COULD BE THE DIFFERENCE

2718
01:49:30,240 --> 01:49:31,520
BETWEEN LIFE AND DEATH FOR

2719
01:49:31,520 --> 01:49:36,240
POPULATIONS.  PATIENTS MUST

2720
01:49:36,240 --> 01:49:37,240
RECEIVE APPROPRIATE CARE WHEN

2721
01:49:37,240 --> 01:49:40,280
NECESSARY, FOR EXAMPLE, ADEQUATE

2722
01:49:40,280 --> 01:49:42,000
TRANSFUSION PHENOTYPICALLY RED

2723
01:49:42,000 --> 01:49:43,760
BLOOD CELLS AN OUTPATIENT RED

2724
01:49:43,760 --> 01:49:45,720
CELL EXCHANGESES END IT DAD AND

2725
01:49:45,720 --> 01:49:51,000
AS NEEDED.  -- EXCHANGES AS

2726
01:49:51,000 --> 01:49:52,360
NEEDED.  WHAT IS THE PROPOSED

2727
01:49:52,360 --> 01:49:54,640
APPROACH? RESEARCH FOCUSED ON

2728
01:49:54,640 --> 01:49:56,760
COMPARISON OF U.S. STATE LEVEL

2729
01:49:56,760 --> 01:49:58,400
PROGRAMS TO TREAT FOR TREATMENT

2730
01:49:58,400 --> 01:50:02,000
OF SICKLE CELL DISEASE AND OTHER

2731
01:50:02,000 --> 01:50:04,760
HEMOGLOBINOPATHIES AND COSTS

2732
01:50:04,760 --> 01:50:06,040
REIMBURSEMENT, MORBIDITY AND

2733
01:50:06,040 --> 01:50:07,320
MORAL. WHAT ARE THE --

2734
01:50:07,320 --> 01:50:10,040
MORTALITY. WHAT ARE THE BARRIERS

2735
01:50:10,040 --> 01:50:12,040
IN? PROPOSED STUDIES IDEAS WOULD

2736
01:50:12,040 --> 01:50:13,880
BE FEASIBLE THOUGH DEFINITELY

2737
01:50:13,880 --> 01:50:16,360
REQUIRE USING PUBLIC DATABASES

2738
01:50:16,360 --> 01:50:19,240
IN CONJUNCTION WITH COST OF

2739
01:50:19,240 --> 01:50:20,560
COLLECTION NEEDED TO FILL THE

2740
01:50:20,560 --> 01:50:26,400
GAPS.  NEXT SLIDE.  DISCUSSION

2741
01:50:26,400 --> 01:50:27,720
QUESTIONS, MEDICAID EXPANSION

2742
01:50:27,720 --> 01:50:32,120
MAYBE PART OF THE EQUATION

2743
01:50:32,120 --> 01:50:33,360
INCREASING ACCESS TO HEALTHCARE

2744
01:50:33,360 --> 01:50:35,280
IN URBAN AREAS AND RURAL AREAS. 

2745
01:50:35,280 --> 01:50:37,920
WHAT ARE THE PROS AN CONS TO

2746
01:50:37,920 --> 01:50:41,240
THIS EXPANSION? OVER THE LAST

2747
01:50:41,240 --> 01:50:42,640
SEVEN OR EIGHT YEARS, BECAME

2748
01:50:42,640 --> 01:50:46,080
PART OF THE LARGER CONVERSATION

2749
01:50:46,080 --> 01:50:48,600
WHEN THE AFFORDSABLE CARE ACT

2750
01:50:48,600 --> 01:50:50,920
EUPHEMISTICALLY KNOWN AS THE

2751
01:50:50,920 --> 01:50:53,600
OBAMA CARE I GUESS, MEDICAID

2752
01:50:53,600 --> 01:50:55,720
EXPANSION BECAME A HUGE ISSUE WE

2753
01:50:55,720 --> 01:50:56,920
ARE STILL TALKING NOW BECAUSE

2754
01:50:56,920 --> 01:50:58,160
SOME STATES HAVE NOT EXPANDED

2755
01:50:58,160 --> 01:51:01,320
MEDICARE.  THEN THE NEXT

2756
01:51:01,320 --> 01:51:03,960
DISCUSSION QUESTION IS, CAN

2757
01:51:03,960 --> 01:51:06,080
NON-PHYSICIAN HEALTHCARE

2758
01:51:06,080 --> 01:51:07,280
PROVIDERS FILL THE PHYSICIAN

2759
01:51:07,280 --> 01:51:14,240
GAP. PRIORITY 3 IS ACCESS TO

2760
01:51:14,240 --> 01:51:15,560
DONATE. WHAT ARE EFFECTIVE

2761
01:51:15,560 --> 01:51:16,880
STRATEGIES FOR OVERCOMING

2762
01:51:16,880 --> 01:51:18,760
BARRIERS TO BLOOD DONATION

2763
01:51:18,760 --> 01:51:19,880
EXPERIENCED BY MINORITY

2764
01:51:19,880 --> 01:51:23,800
POPULATIONS? DESCRIPTION OF THE

2765
01:51:23,800 --> 01:51:25,960
PROBLEM IS THAT A DECLINING

2766
01:51:25,960 --> 01:51:27,640
BLOOD DONOR POPULATION

2767
01:51:27,640 --> 01:51:29,640
EXACERBATES THE DISPARITIES

2768
01:51:29,640 --> 01:51:31,200
OBSERVED IN THE

2769
01:51:31,200 --> 01:51:33,040
UNDERREPRESENTATION OF MINORITY

2770
01:51:33,040 --> 01:51:34,080
DOE NO, SIR. SO WHILE STUDIES

2771
01:51:34,080 --> 01:51:36,960
HAVE SOUGHT TO UNDERSTAND THE

2772
01:51:36,960 --> 01:51:38,600
MOTIVATIONS BEHIND NON-DONOR

2773
01:51:38,600 --> 01:51:40,400
BEHAVIOR, FEWER STUDIES FOCUS ON

2774
01:51:40,400 --> 01:51:42,840
THE BARRIERS TO DONATION. ONE OF

2775
01:51:42,840 --> 01:51:44,200
THE THINGS THAT IS COMMONLY SEEN

2776
01:51:44,200 --> 01:51:48,080
IN THE LITERATURE AROUND LACK OF

2777
01:51:48,080 --> 01:51:49,640
INVOLVEMENT OF COMMUNITIES OF

2778
01:51:49,640 --> 01:51:51,840
COLOR AND DIVERSE COMMUNITIES

2779
01:51:51,840 --> 01:51:53,360
BLOOD DONATION, THE BLAME IS

2780
01:51:53,360 --> 01:51:59,880
USUALLY PUT ON THE COMMUNITY. SO

2781
01:51:59,880 --> 01:52:01,760
THAT IS PART OF THE LITERATURE,

2782
01:52:01,760 --> 01:52:03,760
PART OF WHY PEOPLE DON'T DONATE

2783
01:52:03,760 --> 01:52:05,160
BLOOD IS THEY HAVE NEVER BEEN

2784
01:52:05,160 --> 01:52:06,560
ASKED IN WAY CONSISTENT WITH

2785
01:52:06,560 --> 01:52:07,920
THEIR CULTURE OR WITH THE WAY

2786
01:52:07,920 --> 01:52:09,040
THEY FEEL LIKE THEY NEED TO BE

2787
01:52:09,040 --> 01:52:11,960
ASKED SO WE NEED TO REALLY TAKE

2788
01:52:11,960 --> 01:52:14,920
A LOOK AT THAT. MINORITIES ARE

2789
01:52:14,920 --> 01:52:17,360
UNDER-REPRESENTED, IN THE DONOR

2790
01:52:17,360 --> 01:52:19,440
POPULATION, DUE IN PART O TO

2791
01:52:19,440 --> 01:52:21,240
EDUCATIONAL BARRIERS, LACK OF

2792
01:52:21,240 --> 01:52:22,880
ACCESS TO BLOOD DRIVES

2793
01:52:22,880 --> 01:52:25,000
PHYSIOLOGIC BARRIERS AN LACK OF

2794
01:52:25,000 --> 01:52:26,360
ENGAGEMENT DUE TO PERCEPTIONS OF

2795
01:52:26,360 --> 01:52:34,800
CULTURAL RELEVANCE. SO WHY AN

2796
01:52:34,800 --> 01:52:37,160
ISSUE IN THE DONOR CRITERIA

2797
01:52:37,160 --> 01:52:39,720
CREATE A BARRIER DUE TO

2798
01:52:39,720 --> 01:52:40,640
PHYSIOLOGICAL CHARACTERISTICS

2799
01:52:40,640 --> 01:52:42,560
INCLUDING LOWER HEMOGLOBIN

2800
01:52:42,560 --> 01:52:43,640
LEVELS AND HYPERTENSION. IN

2801
01:52:43,640 --> 01:52:46,320
TERMS OF COMMUNITIES OF COLOR,

2802
01:52:46,320 --> 01:52:50,000
HYPERTENSION CERTAINLY IS AT

2803
01:52:50,000 --> 01:52:51,280
GREATER HIGH RISK OF

2804
01:52:51,280 --> 01:52:52,280
HYPERTENSION AN SPECIFICALLY IN

2805
01:52:52,280 --> 01:52:56,280
TERMS OF AFRICAN AMERICANS, OUR

2806
01:52:56,280 --> 01:52:57,640
HEMOGLOBIN LEVELS AREN'T ON THE

2807
01:52:57,640 --> 01:53:03,520
NORMAL LOWER END OF THE

2808
01:53:03,520 --> 01:53:05,000
HEMOGLOBIN FRAMEWORK. ONE OF THE

2809
01:53:05,000 --> 01:53:06,040
OTHER ISSUES THAT CERTAINLY HAS

2810
01:53:06,040 --> 01:53:09,320
TO BE ADDRESSED IS THAT LOOK ACT

2811
01:53:09,320 --> 01:53:11,560
THE REFERENCE RANGES, IN GENERAL

2812
01:53:11,560 --> 01:53:12,960
REFERENCE RANGES WE HAVE FOR I

2813
01:53:12,960 --> 01:53:15,720
WOULD SAY MOST TESTS, PARAMETERS

2814
01:53:15,720 --> 01:53:20,320
IS BASED ON A MONOLITHIC WHITE

2815
01:53:20,320 --> 01:53:21,800
POPULATION, SO TO BE ABLE TO

2816
01:53:21,800 --> 01:53:24,200
RECTIFY THAT WE NEED TO REDO

2817
01:53:24,200 --> 01:53:25,880
THOSE RANKS TO INCLUDE ALL

2818
01:53:25,880 --> 01:53:28,040
POPULATIONS AND NORMALIZE THE

2819
01:53:28,040 --> 01:53:29,920
PHYSIOLOGIC -- PHYSIOLOGY OF ALL

2820
01:53:29,920 --> 01:53:31,040
POPULATIONS.  SO INDIVIDUALS

2821
01:53:31,040 --> 01:53:33,640
WITHIN THIS COMMUNITY ARE MORE

2822
01:53:33,640 --> 01:53:35,720
LIKELY TO HAVE RARE BLOOD TYPES

2823
01:53:35,720 --> 01:53:39,080
OR BE -- HAVE RARE BLOOD GROUPS

2824
01:53:39,080 --> 01:53:40,880
AS WELL, IN RARE BLOOD GROUPS AS

2825
01:53:40,880 --> 01:53:42,920
WELL WHICH ARE DESIRED AND

2826
01:53:42,920 --> 01:53:44,880
HELPFUL TO CLINICAL SUPPORT OF

2827
01:53:44,880 --> 01:53:46,360
COMMUNITY MEMBERS AS PATIENTS

2828
01:53:46,360 --> 01:53:53,360
WHO NEEDS BLOOD TRANSFUSION.  SO

2829
01:53:53,360 --> 01:53:54,680
WHAT ARE THE PROPOSED

2830
01:53:54,680 --> 01:53:56,760
APPROACHES? A SYSTEMIC APPROACH

2831
01:53:56,760 --> 01:53:59,640
TO UNDERSTANDING AND MITIGATING

2832
01:53:59,640 --> 01:54:01,200
EDUCATIONAL, CULTURAL,

2833
01:54:01,200 --> 01:54:03,080
PHYSIOLOGICAL AND ACCESS RELATED

2834
01:54:03,080 --> 01:54:04,840
BARRIERS TO DONATION CAN BE

2835
01:54:04,840 --> 01:54:07,760
ADDRESSED IN SINGLE OR MORE --

2836
01:54:07,760 --> 01:54:10,200
MULTI-CENTER FORMAT.  IN

2837
01:54:10,200 --> 01:54:11,800
PARTNERSHIP WITH BLOOD CENTERS

2838
01:54:11,800 --> 01:54:14,120
ALSO IN PARTNERSHIP WITH

2839
01:54:14,120 --> 01:54:16,960
ORGANIZATIONS, FOCUS ON

2840
01:54:16,960 --> 01:54:18,440
COMMUNITY OF INDIVIDUALS, THE

2841
01:54:18,440 --> 01:54:20,560
BROAD COMMUNITY, MULTI-ETHNIC

2842
01:54:20,560 --> 01:54:22,440
COMMUNITY OF INDIVIDUALS WITH

2843
01:54:22,440 --> 01:54:23,680
HIGHER RATES OF SICKLE CELL

2844
01:54:23,680 --> 01:54:26,000
DISEASE AS WELL AS OTHER

2845
01:54:26,000 --> 01:54:27,760
HEMOGLOBINOPATHIES WE LOOK AT TO

2846
01:54:27,760 --> 01:54:30,200
THE CDC, SICKLE CELL DISEASE

2847
01:54:30,200 --> 01:54:31,200
ASSOCIATION OF AMERICA SO WITH

2848
01:54:31,200 --> 01:54:33,480
OUR COMBINED EFFORTS AND

2849
01:54:33,480 --> 01:54:35,040
ACTIVITIES, CAN BE DESIGNED TO

2850
01:54:35,040 --> 01:54:37,360
IMPROVE EDUCATION,

2851
01:54:37,360 --> 01:54:38,280
COMMUNICATION, PERCEIVED

2852
01:54:38,280 --> 01:54:40,960
CULTURAL RELEVANCE AND ACCESS

2853
01:54:40,960 --> 01:54:42,280
ISSUES COULD BE DEVELOPED TO

2854
01:54:42,280 --> 01:54:43,840
DEEPEN ENGAGEMENT WITHIN THESE

2855
01:54:43,840 --> 01:54:47,280
COMMUNITIES AS WELL AS HAVE A

2856
01:54:47,280 --> 01:54:48,520
CONSISTENT LITERATURE THAT CAN

2857
01:54:48,520 --> 01:54:51,240
BE USED BY ANYONE TO INTERFACE

2858
01:54:51,240 --> 01:54:52,960
AND INTERACT WITH THESE DIVERSE

2859
01:54:52,960 --> 01:54:55,640
COMMUNITIES.  PRE AND POST

2860
01:54:55,640 --> 01:54:57,160
INTERVENTION METRICS INCLUDES

2861
01:54:57,160 --> 01:54:58,960
THE NUMBER OF PRESENTING NEW OR

2862
01:54:58,960 --> 01:55:00,800
FIRST TIME DONORS, THE RETURN

2863
01:55:00,800 --> 01:55:02,960
RATE WITHIN ONE YEAR OF

2864
01:55:02,960 --> 01:55:05,640
SUCCESSFUL DONORS, THE NUMBER OF

2865
01:55:05,640 --> 01:55:06,840
SPONSORS WITHIN THE COMMUNITY,

2866
01:55:06,840 --> 01:55:08,760
AND LOOKING AT THE RETURN RATE

2867
01:55:08,760 --> 01:55:11,000
OF DEFERRED DONORS. IN TERMS OF

2868
01:55:11,000 --> 01:55:14,520
NEW SPONSORS, BECAUSE BLOOD

2869
01:55:14,520 --> 01:55:16,760
COLLECTION ORGANIZATIONS RARELY

2870
01:55:16,760 --> 01:55:18,320
HAVE INTERNALLY WE ARE ALL

2871
01:55:18,320 --> 01:55:21,120
CERTAINLY GETTING BETTER. HAVE

2872
01:55:21,120 --> 01:55:22,440
STAFF THAT REFLECT COMMUNITIES

2873
01:55:22,440 --> 01:55:24,680
THAT WE ARE TRYING TO INTERFACE

2874
01:55:24,680 --> 01:55:26,160
WITH, OUR PARTNERS BECOME

2875
01:55:26,160 --> 01:55:27,600
IMPORTANT BECAUSE OUR PARTNERS

2876
01:55:27,600 --> 01:55:30,600
ARE THE ONES THAT BRING US ALONG

2877
01:55:30,600 --> 01:55:34,400
WITH THEM INTO THE COMMUNITY. 

2878
01:55:34,400 --> 01:55:36,440
PHYSIOLOGICAL BARRIERS APPLY

2879
01:55:36,440 --> 01:55:38,440
MOST STRONGLY AGAIN TO AFRICAN

2880
01:55:38,440 --> 01:55:41,800
AMERICAN DONORS ADDRESSING

2881
01:55:41,800 --> 01:55:42,440
WHETHER THE MINIMUM HEMOGLOBIN

2882
01:55:42,440 --> 01:55:44,680
CUTS OFFS ARE APPROPRIATE, FOR

2883
01:55:44,680 --> 01:55:45,880
POPULATION WHOSE AVERAGE LEVELS

2884
01:55:45,880 --> 01:55:47,560
AND DISTRIBUTIONS ARE CLEARLY

2885
01:55:47,560 --> 01:55:49,680
DISTINCT FROM AND LOWER THAN

2886
01:55:49,680 --> 01:55:52,880
POPULATIONS NOT OF AFRICAN

2887
01:55:52,880 --> 01:55:55,440
ANCESTRY.  OPERATIONAL METRICS

2888
01:55:55,440 --> 01:55:55,960
INCLUDE DEFERRAL RATES AND

2889
01:55:55,960 --> 01:56:00,000
RECOVERY OF HEMOGLOBIN AND

2890
01:56:00,000 --> 01:56:00,680
FERRITIN BETWEEN DONATION

2891
01:56:00,680 --> 01:56:05,160
VISITS.  SO WHAT IS THE

2892
01:56:05,160 --> 01:56:07,200
FEASIBILITY BARRIERS? STUDIES TO

2893
01:56:07,200 --> 01:56:08,480
ADDRESS THE FOREGOING BARRIERS

2894
01:56:08,480 --> 01:56:10,440
TO DONATION CAN BE CONDUCTED

2895
01:56:10,440 --> 01:56:12,080
CERTAINLY WITHIN THE NEXT THREE

2896
01:56:12,080 --> 01:56:14,160
TO TEN YEAR TIME FRAME, THOUGH

2897
01:56:14,160 --> 01:56:16,240
STUDY OF PHYSIOLOGIC BARRIERS TO

2898
01:56:16,240 --> 01:56:18,240
DONATION WOULD BE OPTIMALLY

2899
01:56:18,240 --> 01:56:19,840
STUDIED FROM THE OTHER IDENTIFY

2900
01:56:19,840 --> 01:56:24,240
BARRIERS.  THESE STUDIES INFORM

2901
01:56:24,240 --> 01:56:27,320
WHETHER DONOR CRITERIA BENEFIT

2902
01:56:27,320 --> 01:56:28,680
FOR MODIFICATIONS.  ONE GREAT

2903
01:56:28,680 --> 01:56:29,920
THING THAT HAPPENED THIS YEAR IN

2904
01:56:29,920 --> 01:56:32,360
MAY OF 2022, DRAFT GUIDANCE WAS

2905
01:56:32,360 --> 01:56:34,160
ISSUED BY THE FDA TO THE

2906
01:56:34,160 --> 01:56:35,720
INDUSTRY, TO LOOK AT BLOOD

2907
01:56:35,720 --> 01:56:39,400
PRESSURE AND PULSE ELIGIBILITY

2908
01:56:39,400 --> 01:56:43,360
REQUIREMENTS AND GIVE BLOOD

2909
01:56:43,360 --> 01:56:44,400
COLLECTION RELATED TO ASSESSMENT

2910
01:56:44,400 --> 01:56:51,080
OF THESE PARAMETERS.  DISCUSSION

2911
01:56:51,080 --> 01:56:54,480
QUESTIONS WILL RISK-BASED

2912
01:56:54,480 --> 01:56:55,280
ELIGIBILITY QUESTIONS UP CREASE

2913
01:56:55,280 --> 01:56:58,080
ACCESS TO DONATION.  AND THE

2914
01:56:58,080 --> 01:56:59,520
OPERATING MARGINS FOR BLOOD

2915
01:56:59,520 --> 01:57:03,520
CENTERS, IS SMALL.  HOW DOES

2916
01:57:03,520 --> 01:57:04,280
INDUSTRY FUND NECESSARY

2917
01:57:04,280 --> 01:57:12,560
RESEARCH. SO PRIORITY 4, ADVERSE

2918
01:57:12,560 --> 01:57:14,120
EVANS. WHAT ARE EFFECTIVE

2919
01:57:14,120 --> 01:57:16,640
MEASURES TO LOWER THE RATE OF

2920
01:57:16,640 --> 01:57:20,840
ADVERSE EVENTS FROM PRODUCT

2921
01:57:20,840 --> 01:57:21,640
TRANSFUSION, BLOOD PRODUCT

2922
01:57:21,640 --> 01:57:23,320
TRANSFUSION AS WELL AS PREVENT

2923
01:57:23,320 --> 01:57:24,520
FURTHER DEVELOPMENT OF ADVERSE

2924
01:57:24,520 --> 01:57:27,200
EVANS IN PATIENTS OF MINORITY

2925
01:57:27,200 --> 01:57:29,080
DIVERSE BACKGROUNDS. ONE OF THE

2926
01:57:29,080 --> 01:57:30,680
THINGS WE HAVE SEEN WITH THE

2927
01:57:30,680 --> 01:57:32,960
2020 CENSUS IS THAT OUR

2928
01:57:32,960 --> 01:57:34,200
POPULATIONS BECOMING MORE

2929
01:57:34,200 --> 01:57:36,000
DIVERSE THAN EVER. THE

2930
01:57:36,000 --> 01:57:37,480
POPULATION, SEGMENT OF

2931
01:57:37,480 --> 01:57:39,360
POPULATION THAT HAD HIGHEST

2932
01:57:39,360 --> 01:57:40,800
PERCENTAGE GROWTH WERE THOSE

2933
01:57:40,800 --> 01:57:42,400
INDIVIDUALS THAT SELF-IDENTIFIED

2934
01:57:42,400 --> 01:57:44,840
AS MIXED RACE. SO WE CERTAINLY

2935
01:57:44,840 --> 01:57:45,720
KNOW THAT WE HAVE TO PAY

2936
01:57:45,720 --> 01:57:47,600
ATTENTION TO THIS. IN TERMS OF

2937
01:57:47,600 --> 01:57:50,680
DIVERSE BACKGROUNDS.  THE

2938
01:57:50,680 --> 01:57:51,720
DESCRIPTION OF PROBLEM IS

2939
01:57:51,720 --> 01:57:52,960
PATIENTS FROM DIVERSE

2940
01:57:52,960 --> 01:57:54,400
BACKGROUNDS EXPERIENCE HIGHER

2941
01:57:54,400 --> 01:57:56,160
RATE OF TRANSFUSION RELATED

2942
01:57:56,160 --> 01:57:59,360
ADVERSE EVENTS, IN PART TO

2943
01:57:59,360 --> 01:58:01,400
GENETIC DIFFERENCES AND RED

2944
01:58:01,400 --> 01:58:04,080
CELLS PLATELET AND HLA ANTIGENS 

2945
01:58:04,080 --> 01:58:06,720
ADVERSE EVENTS INCLUDES ALLO

2946
01:58:06,720 --> 01:58:10,840
IMMUNIZATION, DTHTR, AND CELL

2947
01:58:10,840 --> 01:58:14,240
ENGRAPHMENT WHICH LED TO

2948
01:58:14,240 --> 01:58:15,160
SIGNIFICANT MORTALITY AND

2949
01:58:15,160 --> 01:58:16,600
MORBIDITY AND MAY PRECLUDE LIFE

2950
01:58:16,600 --> 01:58:21,200
SAVING INTERVENTIONS. SEW WHY IS

2951
01:58:21,200 --> 01:58:24,160
THIS AN ISSUE? PATIENTS OF

2952
01:58:24,160 --> 01:58:24,880
AFRICAN DESCENT LIVING MANY THE

2953
01:58:24,880 --> 01:58:27,640
UNITED STATES HAVE HIGHER RATE

2954
01:58:27,640 --> 01:58:29,400
OF RED CELL ALLO

2955
01:58:29,400 --> 01:58:30,240
SENTENCETYIZATION TRANSFUSED

2956
01:58:30,240 --> 01:58:32,280
FROM A DONOR POPULATION

2957
01:58:32,280 --> 01:58:33,880
PRIMARILY CAUCASIAN DESCENT. 

2958
01:58:33,880 --> 01:58:35,120
PATIENTS WITH SICKLE CELL

2959
01:58:35,120 --> 01:58:37,000
DISEASE ARE DISPROPORTIONATELY

2960
01:58:37,000 --> 01:58:38,920
AFFECTED BY ALLO IMMUNIZATION

2961
01:58:38,920 --> 01:58:43,040
AND DHCRs, THOUGH LESS WELL

2962
01:58:43,040 --> 01:58:46,920
DOCUMENTED THIS SIMILARLY

2963
01:58:46,920 --> 01:58:50,760
AFFECTS HISPANIC POPULATIONS.

2964
01:58:50,760 --> 01:58:55,640
ALLO IMMUNIZATION AND DTHRs

2965
01:58:55,640 --> 01:58:59,640
ARE FUTURE SAFE BLOOD

2966
01:58:59,640 --> 01:59:01,440
TRANSFUSIONS PROPHYLACTIC RED

2967
01:59:01,440 --> 01:59:03,000
CELL ANTIGEN IS RECOMMENDED TO

2968
01:59:03,000 --> 01:59:05,200
REDUCE RISK BUT GENETIC MATCHING

2969
01:59:05,200 --> 01:59:07,640
MAYBE REQUIRED TO MITIGATE THE

2970
01:59:07,640 --> 01:59:09,200
RISK SUBSTANTIALLY. ALLO

2971
01:59:09,200 --> 01:59:10,640
SENSITIZATION MAYBE PREVENTED

2972
01:59:10,640 --> 01:59:13,840
WHEN HIGHER LEVELS OF MATCH

2973
01:59:13,840 --> 01:59:16,000
BLOOD REQUIRES FURTHER STUDY. WE

2974
01:59:16,000 --> 01:59:18,720
KNOW THAT THERE ARE LOTS OF

2975
01:59:18,720 --> 01:59:20,360
APPROACHES TO THIS ALLO

2976
01:59:20,360 --> 01:59:23,560
SENSITIZATION ISSUE, SOME

2977
01:59:23,560 --> 01:59:25,800
CLINICIANS, PHENOTYPE THE

2978
01:59:25,800 --> 01:59:27,640
PATIENT RIGHT UP FRONT BEFORE

2979
01:59:27,640 --> 01:59:29,600
FIRST TRANSFUSION IF POSSIBLE.

2980
01:59:29,600 --> 01:59:32,160
THEN THE OTHER APPROACHES, WAIT

2981
01:59:32,160 --> 01:59:35,120
AND SEE IF THIS PATIENT BECOMES

2982
01:59:35,120 --> 01:59:37,120
ALLO IMMUNIZED AND WE WILL DEAL

2983
01:59:37,120 --> 01:59:38,600
WITH IT AFTER THE FACT. SO

2984
01:59:38,600 --> 01:59:39,640
STRATEGIES TO MANAGE PATIENTS

2985
01:59:39,640 --> 01:59:48,000
ARE NOT WELL STUDIED.  SO WHAT

2986
01:59:48,000 --> 01:59:52,360
IS THE PROPOSED APPROACH? FIRST

2987
01:59:52,360 --> 01:59:54,360
PREVENTION. STUDY PROSPECTIVE

2988
01:59:54,360 --> 01:59:57,760
MATCHING FOR PATIENTS RECEIVING

2989
01:59:57,760 --> 01:59:59,400
CHRONIC TRANSFUSION USING

2990
01:59:59,400 --> 02:00:02,840
ADVANCE TECHNOLOGY AN MATCHING

2991
02:00:02,840 --> 02:00:05,200
ALGORITHMS. DIVERSE ADD MIXED

2992
02:00:05,200 --> 02:00:06,720
BACKGROUNDS, THAT POPULATION

2993
02:00:06,720 --> 02:00:07,840
GROWING, MORE PRECISE MATCHING

2994
02:00:07,840 --> 02:00:10,400
FURTHER REDUCE RISK OF ALLO

2995
02:00:10,400 --> 02:00:12,160
ANTIBODY FORMATI FORMATION. USEF

2996
02:00:12,160 --> 02:00:14,520
GENOMICS IN MEDICINE EXPANDS AND

2997
02:00:14,520 --> 02:00:17,640
EVER EXPANDING AREA, FOR TRANTAS

2998
02:00:17,640 --> 02:00:18,200
FUSION MEDICINE RED CELL

2999
02:00:18,200 --> 02:00:20,000
PLATELETS AND HLA GENOTYPING

3000
02:00:20,000 --> 02:00:22,920
PROVIDES AN AL TERM TEAR GNAT OR

3001
02:00:22,920 --> 02:00:26,560
HL -- ALTERNATE OR HL ASSAY TO

3002
02:00:26,560 --> 02:00:28,160
IMPROVE MATCHING OF DONORS AND

3003
02:00:28,160 --> 02:00:30,240
RECIPIENTS. IN TERMS OF

3004
02:00:30,240 --> 02:00:31,720
OUTCOMES, MEASURE ALLO

3005
02:00:31,720 --> 02:00:33,800
IMMUNIZATION AND DHTR RATES,

3006
02:00:33,800 --> 02:00:35,240
TRANSFUSION DELAYS DUE TO

3007
02:00:35,240 --> 02:00:37,400
DIFFICULTY IDENTIFYING

3008
02:00:37,400 --> 02:00:39,760
COMPATIBLE BLOOD AND WHETHER HLA

3009
02:00:39,760 --> 02:00:42,400
IMMUNIZATION IMPACTS THE

3010
02:00:42,400 --> 02:00:44,200
ELIGIBILITY FOR CURATIVE STEM

3011
02:00:44,200 --> 02:00:45,920
CELL TRANSPLANT AND GENE

3012
02:00:45,920 --> 02:00:50,560
THERAPY. FURTHER PREVENTION, FOR

3013
02:00:50,560 --> 02:00:55,400
THOSE ALLO IMMUNIZED HIGH RISK

3014
02:00:55,400 --> 02:00:57,520
OF FURTHER ALLO IMMUNIZATION

3015
02:00:57,520 --> 02:00:58,920
FEASIBLE STUDIES MANAGEMENT MAY

3016
02:00:58,920 --> 02:01:02,760
INCLUDE INTENSIFIED MATCHING,

3017
02:01:02,760 --> 02:01:04,880
PROPHYLACTIC SUPPRESSION FROM

3018
02:01:04,880 --> 02:01:07,640
FUTURE TRANSFUSION AND USE OF

3019
02:01:07,640 --> 02:01:09,120
ANTI-COMPLIMENT OR OTHER AGENT

3020
02:01:09,120 --> 02:01:17,240
TO HALT HEMOLYSIS DURING DHTR. 

3021
02:01:17,240 --> 02:01:19,680
SO IN TERMS OF FEASIBILITY AND

3022
02:01:19,680 --> 02:01:21,840
BARRIERS, SYSTEMIC APPROACH TO

3023
02:01:21,840 --> 02:01:24,280
STUDY PROPHYLACTIC RH AN

3024
02:01:24,280 --> 02:01:26,040
EXTENDED RED CELL ANTIGEN

3025
02:01:26,040 --> 02:01:28,560
MATCHING BY GENOTYPE SICKLE CELL

3026
02:01:28,560 --> 02:01:31,240
DISEASE WOULD BE FEASIBLE IN THE

3027
02:01:31,240 --> 02:01:34,560
NEXT TEN YEARS. WITH SINGLE OR

3028
02:01:34,560 --> 02:01:36,080
MULTI-INSTITUTIONAL STUDY DESIGN

3029
02:01:36,080 --> 02:01:38,280
TO DEMONSTRATE CLINICAL IMPACT,

3030
02:01:38,280 --> 02:01:39,840
AS PERFORM PREVIOUSLY IN OTHER

3031
02:01:39,840 --> 02:01:42,400
PATIENT POPULATION. THIS

3032
02:01:42,400 --> 02:01:43,760
REQUIRES COLLABORATION BETWEEN

3033
02:01:43,760 --> 02:01:45,640
TRANSFUSION SERVICES AND BLOOD

3034
02:01:45,640 --> 02:01:48,040
DONOR CENTERS. NEW SEQUENCING

3035
02:01:48,040 --> 02:01:51,200
TOOLS ARE CONSTANTLY EMERGING AS

3036
02:01:51,200 --> 02:01:52,960
STUDIES AT NOVEL METHODS OF RED

3037
02:01:52,960 --> 02:01:55,440
BLOOD CELL ANTIGEN GENOTYPING

3038
02:01:55,440 --> 02:02:01,320
ARE FEASIBLE. SO DISCUSSION

3039
02:02:01,320 --> 02:02:03,200
QUESTIONS. HOW CAN ADDRESSING

3040
02:02:03,200 --> 02:02:04,880
HEALTH DISPARITIES AND HEALTH

3041
02:02:04,880 --> 02:02:06,760
INEQUITIES IN UNDER-REPRESENTED

3042
02:02:06,760 --> 02:02:09,120
RECIPIENT POPULATIONS DECREASE

3043
02:02:09,120 --> 02:02:11,720
RECIPIENT ADVERSE REACTIONS? AND

3044
02:02:11,720 --> 02:02:14,160
HOW CAN THE CHANGE IN ADVERSE

3045
02:02:14,160 --> 02:02:22,240
REACTION RATES BE QUANTIFIED?

3046
02:02:22,240 --> 02:02:25,640
SO THE FIFTH PRIORITY STRUCTURAL

3047
02:02:25,640 --> 02:02:27,680
BARRIERS. WHAT ARE THE

3048
02:02:27,680 --> 02:02:29,080
STRUCTURAL SOCIETAL ELEMENTS

3049
02:02:29,080 --> 02:02:30,720
THAT IMPACT ACCESS TO

3050
02:02:30,720 --> 02:02:32,440
TRANSFUSION ME SIN THERAPIES?

3051
02:02:32,440 --> 02:02:34,520
AND HOW CAN THESE BARRIERS BE

3052
02:02:34,520 --> 02:02:37,800
OVERCOME TO ACHIEVE EQUITABLE

3053
02:02:37,800 --> 02:02:39,480
HEALTHCARE? SO IN TERMS OF

3054
02:02:39,480 --> 02:02:42,280
DESCRIPTION OF THE PROBLEM,

3055
02:02:42,280 --> 02:02:44,600
ACCESS TO HEALTH INSURANCE,

3056
02:02:44,600 --> 02:02:45,720
CONSTRAINTS OF HEALTH INSURANCE

3057
02:02:45,720 --> 02:02:48,680
POLICIES CAN PREVENT ACCESS TO

3058
02:02:48,680 --> 02:02:50,640
TRANSFUSION MEDICINE CARE

3059
02:02:50,640 --> 02:02:52,200
THERAPY, THERAPY AND

3060
02:02:52,200 --> 02:02:54,480
DIAGNOSTICS.  FOR INSTANCE THERE

3061
02:02:54,480 --> 02:02:57,360
IS A HIGHER MATERNAL MORTALITY

3062
02:02:57,360 --> 02:02:59,680
AMONG AFRICAN AMERICAN WOMEN,

3063
02:02:59,680 --> 02:03:01,320
HOWEVER, THE ROLE TRANSFUSION

3064
02:03:01,320 --> 02:03:04,080
MEDICINE PLAYS IS NOT WELL

3065
02:03:04,080 --> 02:03:06,400
UNDERSTOOD. IN ADDITION, THE

3066
02:03:06,400 --> 02:03:10,360
IMPACT OF RACIAL CULTURAL

3067
02:03:10,360 --> 02:03:12,120
LINGUISTIC INCONGRUENCE WEAN

3068
02:03:12,120 --> 02:03:14,120
PATIENTS AND DONORS AND THE

3069
02:03:14,120 --> 02:03:16,440
TRANSFUSION MEDICINE WORK FORCE

3070
02:03:16,440 --> 02:03:17,680
REQUIRES EXAMINATION ALONG WITH

3071
02:03:17,680 --> 02:03:19,320
THE STUDY OF STRUCTURAL FACTORS

3072
02:03:19,320 --> 02:03:25,880
THAT SUSTAIN IT.  SO WHY IS THIS

3073
02:03:25,880 --> 02:03:28,440
AN ISSUE? THE LINK BETWEEN

3074
02:03:28,440 --> 02:03:30,640
HEALTHCARE DISPARITIES, AND

3075
02:03:30,640 --> 02:03:33,400
STRUCTURAL FACTORS WITHIN

3076
02:03:33,400 --> 02:03:35,000
INSTITUTIONS, ORGANIZATIONS,

3077
02:03:35,000 --> 02:03:37,400
PROCESSES IN OUR SOCIETY, IS

3078
02:03:37,400 --> 02:03:38,720
ESTABLISHED THROUGHOUT THE

3079
02:03:38,720 --> 02:03:40,800
LITERATURE. MOSTLY IN THE PUBLIC

3080
02:03:40,800 --> 02:03:42,480
HEALTH LITERATURE BECAUSE THE

3081
02:03:42,480 --> 02:03:46,640
SCIENTIFIC LITERATURE UNTIL THE

3082
02:03:46,640 --> 02:03:47,920
LAST TWO OR THREE YEARS SINCE WE

3083
02:03:47,920 --> 02:03:49,520
HAVE BEEN IN THIS COUNTRY WE

3084
02:03:49,520 --> 02:03:52,920
HAVE BEEN IN THIS CONVERSATION

3085
02:03:52,920 --> 02:03:55,000
ABOUT SOCIAL CHANGES AND SOCIAL

3086
02:03:55,000 --> 02:03:56,720
INJUSTICE AND HEALTH DISPARITIES

3087
02:03:56,720 --> 02:03:59,280
AND HEALTH INEQUITIES THERE'S A

3088
02:03:59,280 --> 02:04:01,280
DERTH OF LITERATURE IN THIS

3089
02:04:01,280 --> 02:04:03,640
SPACE BUT LOOK AT THE LAST TWO

3090
02:04:03,640 --> 02:04:04,840
YEARS TREMENDOUS AMOUNT OF

3091
02:04:04,840 --> 02:04:05,680
CONVERSATION AROUND HEALTH

3092
02:04:05,680 --> 02:04:07,880
DISPARITIES.  HEALTH DISPARITIES

3093
02:04:07,880 --> 02:04:09,120
AMONG RACIALIZED GROUPS HAVE

3094
02:04:09,120 --> 02:04:10,560
BEEN DOCUMENTED CONSISTENTLY

3095
02:04:10,560 --> 02:04:14,400
MANY THE U.S. FOR MANY DECADES.

3096
02:04:14,400 --> 02:04:15,760
REGRETTABLY THERE IS SCARCITY OF

3097
02:04:15,760 --> 02:04:17,240
LITERATURE ADDRESSING STRUCTURAL

3098
02:04:17,240 --> 02:04:19,360
BARRIERS INCLUDING STRUCTURAL

3099
02:04:19,360 --> 02:04:21,040
RACISM WITHIN TRANSFUSION

3100
02:04:21,040 --> 02:04:23,400
MEDICINE FIELD. DEFINE QUANTIFY

3101
02:04:23,400 --> 02:04:23,960
THESE STRUCTURAL BARRIERS

3102
02:04:23,960 --> 02:04:26,840
FOLLOWED BY THE DESIGN AND

3103
02:04:26,840 --> 02:04:28,120
IMPLEMENTATION OF INTERVENTION

3104
02:04:28,120 --> 02:04:30,440
STRATEGIES IS IMPERATIVE TO

3105
02:04:30,440 --> 02:04:36,240
ACHIEVE TRUE HEALTH EQUITY. 

3106
02:04:36,240 --> 02:04:37,680
SO WHAT IS THE PROPOSED

3107
02:04:37,680 --> 02:04:40,480
APPROACH? MULTI-CENTER AND

3108
02:04:40,480 --> 02:04:41,240
MULTI-DISCIPLINARY COLLABORATION

3109
02:04:41,240 --> 02:04:43,600
AS WELL AS PUBLIC PRIVATE

3110
02:04:43,600 --> 02:04:45,320
PARTNERSHIPS, INCLUDING HEALTH

3111
02:04:45,320 --> 02:04:46,480
INSURANCE COMPANIES AN

3112
02:04:46,480 --> 02:04:47,280
GOVERNMENT INSURANCE

3113
02:04:47,280 --> 02:04:48,640
STAKEHOLDERS WITH COMMUNITY AS

3114
02:04:48,640 --> 02:04:51,280
VISERY BOARDS ARE ABSOLUTELY IN

3115
02:04:51,280 --> 02:04:52,480
COVERAGE. OBJECTIVE

3116
02:04:52,480 --> 02:04:54,320
IDENTIFICATION OF STRUCTURAL

3117
02:04:54,320 --> 02:04:55,600
BARRIERS, SHOULD BE FOLLOWED

3118
02:04:55,600 --> 02:04:57,240
CLOSELY BY IMPLEMENTATION OF

3119
02:04:57,240 --> 02:05:00,600
RESEARCH TO EVALUATE POSSIBLE

3120
02:05:00,600 --> 02:05:01,640
INTERVENTIONS AND CORRECTED

3121
02:05:01,640 --> 02:05:03,560
ACTIONS SHOULD BE IMPLEMENTED

3122
02:05:03,560 --> 02:05:08,240
WITHOUT DELAY. FACTORS THAT

3123
02:05:08,240 --> 02:05:09,240
MERIT INVESTIGATION INCLUDE

3124
02:05:09,240 --> 02:05:10,680
CHARACTERIZATION, CHARACTERIZING

3125
02:05:10,680 --> 02:05:12,120
THE VARIATION AND ACCESS AND

3126
02:05:12,120 --> 02:05:13,720
QUALITY IN TERMS OF TRANSFUSION

3127
02:05:13,720 --> 02:05:16,680
CARE BY RACE, ETHNICITY, GENDER

3128
02:05:16,680 --> 02:05:20,320
IDENTITY, GEOGRAPHIC RESIDENCE,

3129
02:05:20,320 --> 02:05:21,680
SOCIOECONOMIC STRATA AS WELL AS

3130
02:05:21,680 --> 02:05:26,800
OTHER DEMOGRAPHIC ATTRIBUTES. IN

3131
02:05:26,800 --> 02:05:28,480
TERMS OF FEASIBILITY AND

3132
02:05:28,480 --> 02:05:30,760
BARRIERS, RESEARCH PRIORITIES

3133
02:05:30,760 --> 02:05:32,040
REPRESENT IMPORTANT WORK THAT

3134
02:05:32,040 --> 02:05:35,440
BUILDS UPON ITSELF AND CONTINUE

3135
02:05:35,440 --> 02:05:36,560
TO STRONG CORRECT TESTIFY

3136
02:05:36,560 --> 02:05:37,920
MEASURES DEMONSTRATED OR ARE

3137
02:05:37,920 --> 02:05:41,200
FIRMLY IN PLACE. IT CANNOT BE

3138
02:05:41,200 --> 02:05:42,120
UNDERESTIMATED HOW IMPORTANT

3139
02:05:42,120 --> 02:05:43,360
COMMUNITY BASED PARTICIPATORY

3140
02:05:43,360 --> 02:05:45,920
RESEARCH IS, IN TERMS OF USEFUL

3141
02:05:45,920 --> 02:05:47,880
TOOL, THAT IS BEING USED TO

3142
02:05:47,880 --> 02:05:49,640
IDENTIFY SOCIAL, STRUCTURAL AND

3143
02:05:49,640 --> 02:05:50,960
ENVIRONMENTAL BARRIERS AND

3144
02:05:50,960 --> 02:05:52,960
IDENTIFY SOLUTIONS.  CHANGES TO

3145
02:05:52,960 --> 02:05:54,720
HEALTH POLICY REIMBURSEMENT TO

3146
02:05:54,720 --> 02:05:56,600
ENSURE HEALTH EQUITY AND

3147
02:05:56,600 --> 02:05:57,320
TRANSFUSION MEDICINE WILL BE

3148
02:05:57,320 --> 02:06:03,840
NECESSARY.  SO THE DISCUSSION

3149
02:06:03,840 --> 02:06:06,080
QUESTIONS ARE ACKNOWLEDGING

3150
02:06:06,080 --> 02:06:08,040
STRUCTURAL NATURE OF RACISM AND

3151
02:06:08,040 --> 02:06:11,600
BIAS IN HEALTHCARE IS THE

3152
02:06:11,600 --> 02:06:13,160
INITIAL STEP IN DETERMINING

3153
02:06:13,160 --> 02:06:14,160
SOLUTIONS.  HOW IS THIS

3154
02:06:14,160 --> 02:06:16,720
ACCOMPLISHED ON NATIONAL BASIS?

3155
02:06:16,720 --> 02:06:18,600
WHERE WOULD ACCOUNTABILITY FOR

3156
02:06:18,600 --> 02:06:21,960
EXECUTION REST? HEALTHCARE IS A

3157
02:06:21,960 --> 02:06:24,840
FACET OF SOCIAL DETERMINANTS OF

3158
02:06:24,840 --> 02:06:25,600
HEALTH WHICH AFFECT HOW

3159
02:06:25,600 --> 02:06:27,760
INDIVIDUALS AN COMMUNITIES

3160
02:06:27,760 --> 02:06:28,840
ACHIEVE FULL HEALTH AND WELL

3161
02:06:28,840 --> 02:06:30,600
BEING. ARE COMMUNITY BASED

3162
02:06:30,600 --> 02:06:31,920
MODELS THAT CAN BE SCALED TO BE

3163
02:06:31,920 --> 02:06:38,720
USED IN VARIOUS COMMUNITIES.  

3164
02:06:38,720 --> 02:06:40,600
FINAL SLIDE RESTATING OUR

3165
02:06:40,600 --> 02:06:42,160
PRIORITIES. AND AGAIN NOT ANY

3166
02:06:42,160 --> 02:06:44,320
PARTICULAR ORDER, HOW CAN

3167
02:06:44,320 --> 02:06:45,640
DIVERSITY RESEARCH PARTICIPANTS

3168
02:06:45,640 --> 02:06:48,040
BE INCREASED FOR BOTH BLOOD

3169
02:06:48,040 --> 02:06:49,560
DONOR STUDIES AND CLINICAL

3170
02:06:49,560 --> 02:06:51,760
STUDIES.  ACCESS TO APPROPRIATE

3171
02:06:51,760 --> 02:06:53,480
TRANSFUSION CAN BE LIMITED BY

3172
02:06:53,480 --> 02:06:57,560
CULTURAL NORMS, FINANCIAL AND

3173
02:06:57,560 --> 02:06:58,160
GEOGRAPHICAL BARRIERS HOW CAN

3174
02:06:58,160 --> 02:06:58,680
BARRIERS BE OVERCOME.

3175
02:06:58,680 --> 02:07:00,560
WHAT ARE THE EFFECTIVE

3176
02:07:00,560 --> 02:07:01,560
STRATEGIES FOR OVERCOMING

3177
02:07:01,560 --> 02:07:02,920
BARRIERS TO BLOOD DONATION

3178
02:07:02,920 --> 02:07:04,240
EXPERIENCED BY MINORITY

3179
02:07:04,240 --> 02:07:05,720
POPULATIONS.  WHAT ARE EFFECTIVE

3180
02:07:05,720 --> 02:07:07,240
MEASURES TO LOWER THE RATE OF

3181
02:07:07,240 --> 02:07:08,720
ADVERSE EVENTS FROM BLOOD

3182
02:07:08,720 --> 02:07:10,440
PRODUCT TRANSFUSION, AS WELL AS

3183
02:07:10,440 --> 02:07:13,200
PREVENTS FURTHER DEVELOPMENT OF

3184
02:07:13,200 --> 02:07:16,520
ADVERSE EVENTS IN PATIENTS WITH

3185
02:07:16,520 --> 02:07:18,320
MINORITY DIVERSE BACKGROUNDS AND

3186
02:07:18,320 --> 02:07:20,320
WHAT ARE THE STRUCTURAL SOCIETAL

3187
02:07:20,320 --> 02:07:23,280
ELEMENTS THAT IMPACT ACCESS TO

3188
02:07:23,280 --> 02:07:25,000
TRANSFUSION MEDICINE THERAPY AND

3189
02:07:25,000 --> 02:07:27,080
HOW BARRIERS OVERCOME TO ACHIEVE

3190
02:07:27,080 --> 02:07:28,000
EQUITABLE HEALTHCARE. SO THANK

3191
02:07:28,000 --> 02:07:30,280
YOU SO MUCH FOR YOUR ATTENTION.

3192
02:07:30,280 --> 02:07:32,440
CONTINUE TO DROP YOUR THOUGHTS

3193
02:07:32,440 --> 02:07:35,640
AND QUESTIONS IN TO THE CHAT.

3194
02:07:35,640 --> 02:07:37,840
AGAIN, THANK YOU FOR OUR ENTIRE

3195
02:07:37,840 --> 02:07:39,880
GROUP AND CO-CHAIR DR. MEGHAN

3196
02:07:39,880 --> 02:07:50,040
DELANEY.

3197
02:07:51,360 --> 02:07:52,680
>> THANK YOU VERY MUCH,
YVETTE.

3198
02:07:52,680 --> 02:07:55,760
WONDERFUL PRESENTATION.  WE

3199
02:07:55,760 --> 02:07:57,440
COMPLETED THE PRESENTATIONS OF

3200
02:07:57,440 --> 02:07:59,240
THE WORKING GROUP CO-CHAIRS FOR

3201
02:07:59,240 --> 02:08:01,440
THE GENERAL SESSION AND WE ARE

3202
02:08:01,440 --> 02:08:06,600
IN OUR LUNCH BREAK NOW. PLEASE

3203
02:08:06,600 --> 02:08:09,560
RETURN, HALF AN HOUR LUNCH

3204
02:08:09,560 --> 02:08:13,720
BREAK. WE WILL RETURN, HEAR SAYS

3205
02:08:13,720 --> 02:08:15,480
12:30, BUT A LITTLE EARLIER IF

3206
02:08:15,480 --> 02:08:19,760
YOU LIKE DIRECTION IN FINDING

3207
02:08:19,760 --> 02:08:22,000
THE BREAK OUT SESSION LINK ON

3208
02:08:22,000 --> 02:08:27,360
THE ZOOM CHAT BAR. THANK YOU. 

3209
02:08:27,360 --> 02:08:28,880
>>I WANT TO WELCOME
EVERYBODY

3210
02:08:28,880 --> 02:08:35,920
BACK FROM THE BREAK. THE NEXT

3211
02:08:35,920 --> 02:08:40,840
PAR OF OUR AGENDA IS RECAP OF

3212
02:08:40,840 --> 02:08:45,800
THE BREAK OUT SESSIONS THAT THE

3213
02:08:45,800 --> 02:08:47,800
CO-CHAIRS HAVE THE UNENVIABLE --

3214
02:08:47,800 --> 02:08:50,200
>> IF I MAY INTERRUPT. I
THINK

3215
02:08:50,200 --> 02:08:52,200
WE ARE STILL WAITING FOR SOME

3216
02:08:52,200 --> 02:08:55,080
PEOPLE AT THE BREAK OUTS. JUST

3217
02:08:55,080 --> 02:09:05,320
20 SECONDS. 

3218
02:09:24,240 --> 02:09:25,840
>> WELCOME BACK, EVERYONE.
LOOKS

3219
02:09:25,840 --> 02:09:30,600
LIKE MAJORITY OF HAD A CHANCE TO

3220
02:09:30,600 --> 02:09:33,080
REJOIN THE SESSION. NEXT PART OF

3221
02:09:33,080 --> 02:09:35,600
OUR AGENDA IS FOR EACH OF THE

3222
02:09:35,600 --> 02:09:40,000
WORKING GROUP CO-CHAIRS TO

3223
02:09:40,000 --> 02:09:41,920
SUMMARIZE IN RAPID FASHION

3224
02:09:41,920 --> 02:09:43,120
DISCUSSION OF THE BREAK OUT

3225
02:09:43,120 --> 02:09:45,800
SESSION OVER THE LAST HOUR.

3226
02:09:45,800 --> 02:09:54,160
FIRST TO DO SO IS ELDAD AND

3227
02:09:54,160 --> 02:09:54,600
ANGELO.

3228
02:09:54,600 --> 02:09:56,280
>> WE HAVE A LOT OF TIME
TO

3229
02:09:56,280 --> 02:09:57,880
PREPARE FOR THIS BUT WE WILL DO

3230
02:09:57,880 --> 02:10:00,080
THE BEST WE CAN AS WE HAD LIVELY

3231
02:10:00,080 --> 02:10:01,640
DISCUSSION FOR AN HOUR WITH A

3232
02:10:01,640 --> 02:10:05,160
WONDERFUL GROUP OF PEOPLE WHO

3233
02:10:05,160 --> 02:10:08,480
SHARED THEIR THOUGHTS REGARDING

3234
02:10:08,480 --> 02:10:09,840
PRIORITIES. SO I FEEL LIKE WE

3235
02:10:09,840 --> 02:10:12,960
SPENT A LOT OF TIME DISCUSSING

3236
02:10:12,960 --> 02:10:16,320
THE STORAGE LESION AND THE

3237
02:10:16,320 --> 02:10:17,920
CLINICAL TRIALS SURROUNDING THE

3238
02:10:17,920 --> 02:10:22,640
CLINICAL IMPACT OF THE STORAGE

3239
02:10:22,640 --> 02:10:25,280
LESION. WHAT I GOT FROM THE --

3240
02:10:25,280 --> 02:10:27,880
WHAT WE THINK WE GOT FROM THE

3241
02:10:27,880 --> 02:10:29,400
DISCUSSION IS THAT CLEARLY MORE

3242
02:10:29,400 --> 02:10:33,200
RESEARCH IS NEEDED AND THAT MORE

3243
02:10:33,200 --> 02:10:37,200
SYSTEMATIC APPROACH GOING FROM

3244
02:10:37,200 --> 02:10:39,120
THE BENCH BACK O THE -- FROM THE

3245
02:10:39,120 --> 02:10:40,880
BENCH TO BEDSIDE AND BACK AGAIN

3246
02:10:40,880 --> 02:10:43,560
IS STILL NEEDED. WE ARE PROBABLY

3247
02:10:43,560 --> 02:10:45,920
NOT GOING TO REPEAT THE CLINICAL

3248
02:10:45,920 --> 02:10:48,640
TRIALS THAT HAVE ALREADY DONE

3249
02:10:48,640 --> 02:10:52,320
SURROUNDING THE AGE OF BLOOD BUT

3250
02:10:52,320 --> 02:10:56,240
WE STILL NEED TO FIND, LOOK FOR

3251
02:10:56,240 --> 02:10:58,480
ADDITIONAL RECIPIENT POPULATIONS

3252
02:10:58,480 --> 02:11:03,080
OR ADDITIONAL BIOMARKERS

3253
02:11:03,080 --> 02:11:06,120
CAPTURED METABOLIC AGE OF THE

3254
02:11:06,120 --> 02:11:07,880
OPPOSED TO THE CHRONOLOGICAL AGE

3255
02:11:07,880 --> 02:11:09,600
USED TO RANDOMIZE ON AND SO

3256
02:11:09,600 --> 02:11:12,160
THERE'S STILL ADDITIONAL WORK

3257
02:11:12,160 --> 02:11:13,160
FROM PRE-CLINICAL STAGE THAT

3258
02:11:13,160 --> 02:11:16,720
NEEDS TO GET DONE TO THEN FUTURE

3259
02:11:16,720 --> 02:11:21,400
TAKE IT TO THE THE CLINICAL

3260
02:11:21,400 --> 02:11:24,080
TRIALS. THERE WAS SOME MENTION

3261
02:11:24,080 --> 02:11:28,480
MORE RIGOROUS VALIDATION OF

3262
02:11:28,480 --> 02:11:30,920
BIOMARKERS NEEDS TO BE DONE AND

3263
02:11:30,920 --> 02:11:32,640
WE HEARD THERE ARE SOME

3264
02:11:32,640 --> 02:11:36,480
AVAILABLE BIOMARKERS AND TOOLS

3265
02:11:36,480 --> 02:11:39,120
THAT EXIST THAT WE MIGHT BE

3266
02:11:39,120 --> 02:11:41,120
UNDERUTILIZING AND THOSE COULD

3267
02:11:41,120 --> 02:11:47,800
BE UTILIZED MORE SUCH AS NEERS

3268
02:11:47,800 --> 02:11:49,760
AND OTHER PUBLIC THINGS. WHAT

3269
02:11:49,760 --> 02:11:53,520
ELSE? THERE WAS ALSO SOME TALK

3270
02:11:53,520 --> 02:11:55,280
ABOUT AND THIS MAYBE OVERLAPS

3271
02:11:55,280 --> 02:11:57,600
WITH ONE OF THE SESSIONS FROM

3272
02:11:57,600 --> 02:12:00,520
YESTERDAY BUT DIFFERENT CLINICAL

3273
02:12:00,520 --> 02:12:02,440
TRIAL DESIGNS THAT MAY ALLOW US

3274
02:12:02,440 --> 02:12:04,800
TO LOOK AT BIOMARKERS AND IMPACT

3275
02:12:04,800 --> 02:12:06,480
SUCH AS ADAPTIVE TRIAL DESIGNS

3276
02:12:06,480 --> 02:12:11,960
AND THINGS LIKE THAT.  ANOTHER

3277
02:12:11,960 --> 02:12:14,000
AREA IS ADDITIONAL RECIPIENT

3278
02:12:14,000 --> 02:12:15,920
FACTORS THAT WE SHOULD TAKE INTO

3279
02:12:15,920 --> 02:12:18,920
ACCOUNT SUCH AS RECIPIENT ANEMIA

3280
02:12:18,920 --> 02:12:21,760
OR RECIPIENT INFLAMMATION THAT

3281
02:12:21,760 --> 02:12:24,360
MAY IMPACT OUTCOMES OF PLATELET

3282
02:12:24,360 --> 02:12:25,800
OR RED CELL TRANSFUGS AND THOSE

3283
02:12:25,800 --> 02:12:29,200
SHOULD BE INCORPORATED TO

3284
02:12:29,200 --> 02:12:31,400
PRIORITIES SO WE ADHERE THAT.

3285
02:12:31,400 --> 02:12:32,840
CERTAINLY THE INTERACTION WITH

3286
02:12:32,840 --> 02:12:34,320
VARIOUS THINGS WE DO IN BLOOD

3287
02:12:34,320 --> 02:12:35,880
BANK OR CENTER LIKE IRRADIATION

3288
02:12:35,880 --> 02:12:37,440
AND THINGS LIKE THAT AND IMPACT

3289
02:12:37,440 --> 02:12:40,680
OF THOSE MODIFICATIONS AND HOW

3290
02:12:40,680 --> 02:12:43,520
THEY IMPACT RECIPIENT. WE ALSO

3291
02:12:43,520 --> 02:12:48,080
HAD A LITTLE DISCUSSION AROUND

3292
02:12:48,080 --> 02:12:50,720
ARE THERE -- NOW -- AT LEAST FOR

3293
02:12:50,720 --> 02:12:54,240
COLD STORED PLATELETS, WE KNOW

3294
02:12:54,240 --> 02:12:56,760
MECHANISM OF CLEARANCE AND THERE

3295
02:12:56,760 --> 02:12:59,640
ARE DRUGS AVAILABLE THAT CAN

3296
02:12:59,640 --> 02:13:01,840
BLOCK THOSE SHOULD WE DO MORE

3297
02:13:01,840 --> 02:13:05,800
STUDIES TO LOOK AT THERAPEUTIC

3298
02:13:05,800 --> 02:13:07,440
INTERVENTIONS THAT COULD PREVENT

3299
02:13:07,440 --> 02:13:09,440
CLEARANCE OF PLATELETS OR IF WE

3300
02:13:09,440 --> 02:13:11,600
UNDERSTOOD THE MECHANISM OF RED

3301
02:13:11,600 --> 02:13:13,480
CELL CLEARANCE BETTER CAN WE

3302
02:13:13,480 --> 02:13:15,000
DESIGN DRUGS THAT WOULD PREVENT

3303
02:13:15,000 --> 02:13:19,000
THAT AS WELL. SO WE HEARD THAT

3304
02:13:19,000 --> 02:13:23,040
AS WELL. AND TRY TO INCORPORATE

3305
02:13:23,040 --> 02:13:24,840
THAT INTO PRIORITIES. FINAL

3306
02:13:24,840 --> 02:13:26,360
THING I HAD IN MY NOTES WAS

3307
02:13:26,360 --> 02:13:29,680
RELATING TO LONGER TERM

3308
02:13:29,680 --> 02:13:33,520
STUDIESs ESPECIALLY NEONATES

3309
02:13:33,520 --> 02:13:36,600
AND TRANSFUSIONS, INTERUTERINE

3310
02:13:36,600 --> 02:13:38,160
TRANSFUGS DURING PREGNANCY AND

3311
02:13:38,160 --> 02:13:40,400
WE DON'T KNOW WHAT THE LONGER

3312
02:13:40,400 --> 02:13:42,440
TERM IMMUNOLOGIC OR OTHER

3313
02:13:42,440 --> 02:13:44,640
CLINICAL OUTCOMES ARE OF THESE

3314
02:13:44,640 --> 02:13:47,000
TRANSFUSIONS ESPECIALLY IN YOUNG

3315
02:13:47,000 --> 02:13:51,600
AND CLEARLY YOU NEED LONGER --

3316
02:13:51,600 --> 02:13:54,400
AS WE HAD IN PRIORITY WE NEED

3317
02:13:54,400 --> 02:13:56,480
LONGER TERM STUDIES TO FOLLOW-UP

3318
02:13:56,480 --> 02:13:58,040
ADVERSE CONSEQUENCES ESPECIALLY

3319
02:13:58,040 --> 02:13:59,120
IN THE YOUNGER POPULATIONS SO

3320
02:13:59,120 --> 02:14:00,960
THERE WAS GOOD DISCUSSION AROUND

3321
02:14:00,960 --> 02:14:05,880
THAT. I KNOW WE WERE SUPPOSED TO

3322
02:14:05,880 --> 02:14:08,400
-- WE HAD UP TO 20 MINUTES BUT

3323
02:14:08,400 --> 02:14:09,880
TOLD WE DIDN'T HAVE TO USE THE

3324
02:14:09,880 --> 02:14:13,960
FULL 20 MINUTES BUT ANGELO IF

3325
02:14:13,960 --> 02:14:15,160
YOU HAD ADDITIONAL THINGS TO

3326
02:14:15,160 --> 02:14:15,920
ADD.

3327
02:14:15,920 --> 02:14:17,680
>> TWO ADDITIONAL POINTS,
AS

3328
02:14:17,680 --> 02:14:19,320
SOMEBODY WITH NO TIME PRETTY

3329
02:14:19,320 --> 02:14:21,480
MUCMUCH. THE ONLY TWO OTHER THIS

3330
02:14:21,480 --> 02:14:24,640
I HAVE ARE COMMENTS THAT CAME

3331
02:14:24,640 --> 02:14:26,320
DURING THE PRESENTATION THAT

3332
02:14:26,320 --> 02:14:27,760
PERTAIN TO OPPORTUNITY TO SELECT

3333
02:14:27,760 --> 02:14:32,320
DONORS BASED ON FOR EXAMPLE

3334
02:14:32,320 --> 02:14:37,440
KNOWING WHETHER CASE DONORS

3335
02:14:37,440 --> 02:14:40,720
PARTICULARLY IF (INAUDIBLE)

3336
02:14:40,720 --> 02:14:42,200
WHETHER WE KNOW THEY ARE GOING

3337
02:14:42,200 --> 02:14:44,400
TO STORE POORLY, WHETHER WE CAN

3338
02:14:44,400 --> 02:14:49,040
IDENTIFY PERSONALIZE THE

3339
02:14:49,040 --> 02:14:55,080
APPROACH AND DONORS BE COLD

3340
02:14:55,080 --> 02:14:58,600
STORE, ROOM TEMPERATURE AND USE

3341
02:14:58,600 --> 02:15:00,320
PLATELETS DEPENDING ON

3342
02:15:00,320 --> 02:15:03,920
ACTIVATION PROFILES FOR SPECIFIC

3343
02:15:03,920 --> 02:15:05,400
INDICATIONS.  THIS COMMENT

3344
02:15:05,400 --> 02:15:07,760
WITHIN THE FRAMEWORK OF

3345
02:15:07,760 --> 02:15:09,200
POTENTIAL APPLICATION OF MORE

3346
02:15:09,200 --> 02:15:12,680
LIKE PERMIZED APPROACHES --

3347
02:15:12,680 --> 02:15:13,600
PERSONALIZED APPROACHES THAT

3348
02:15:13,600 --> 02:15:18,360
TOOK INTO ACCOUNT THE PHENOTYPES

3349
02:15:18,360 --> 02:15:21,240
AND THE NEEDS. THAT'S THE AMOUNT

3350
02:15:21,240 --> 02:15:25,600
I HAVE IN TERMS OF NOTES, AND I

3351
02:15:25,600 --> 02:15:34,920
SEE THERE IS A HAN HAND RAISED 

3352
02:15:34,920 --> 02:15:37,760
>> STEVE I DON'T KNOW IF
YOU

3353
02:15:37,760 --> 02:15:39,000
MEANT TO HAVE YOUR HAND RAISED.

3354
02:15:39,000 --> 02:15:42,760
>> I WANT TO ASK A
QUESTION TO

3355
02:15:42,760 --> 02:15:45,480
ELDAD. IS YOUR GROUP ADVOCATING

3356
02:15:45,480 --> 02:15:47,400
NEW CLINICAL TRIALS ON RED CELL

3357
02:15:47,400 --> 02:15:50,200
TRANTAS FUSION THRESHOLDS NOW?

3358
02:15:50,200 --> 02:15:51,840
OR ARE YOU SAYING WE NEED BETTER

3359
02:15:51,840 --> 02:15:53,520
TOOLS TO DETERMINE THE METABOLIC

3360
02:15:53,520 --> 02:15:56,120
AGE OF RED CELLS AND ONCE WE DO

3361
02:15:56,120 --> 02:15:57,720
THAT THEN MAYBE CLINICAL TRIALS

3362
02:15:57,720 --> 02:15:59,120
COULD FOLLOW. I WASN'T SURE WHAT

3363
02:15:59,120 --> 02:16:04,200
THE CONCLUSION WAS. 

3364
02:16:04,200 --> 02:16:07,960
>> SO I'M NOT SURE WE ARE

3365
02:16:07,960 --> 02:16:09,720
ADVOCATING EITHER. WE ARE

3366
02:16:09,720 --> 02:16:11,160
ADVOCATING FOR MORE RESEARCH

3367
02:16:11,160 --> 02:16:14,040
RELATING TO BIOMARKERS THAT

3368
02:16:14,040 --> 02:16:19,080
MIGHT LEAD TO FUTURE CLINICAL

3369
02:16:19,080 --> 02:16:21,120
TRIALS. YOU ARE ASKING REGARDING

3370
02:16:21,120 --> 02:16:23,400
THRESHOLDS OR AGE OF BLOOD? OUR

3371
02:16:23,400 --> 02:16:25,240
DISCUSSION WAS RELATING TO THE

3372
02:16:25,240 --> 02:16:29,000
AGE OF BLOOD NOT SO MUCH THE

3373
02:16:29,000 --> 02:16:30,120
THRESHOLD:  TO THE EXTENT THERE

3374
02:16:30,120 --> 02:16:31,880
IS A RECIPIENT POPULATION THAT

3375
02:16:31,880 --> 02:16:34,440
HAS NOT BEEN STUDIED, THERE IS

3376
02:16:34,440 --> 02:16:36,560
ENOUGH PRELIMINARY DATA TO

3377
02:16:36,560 --> 02:16:37,800
SUPPORT A CLINICAL TRIAL THEN WE

3378
02:16:37,800 --> 02:16:39,520
WOULD ADVOCATE FOR THERE TO BE

3379
02:16:39,520 --> 02:16:41,320
FUNDING OR FOR THERE NOT FUNDING

3380
02:16:41,320 --> 02:16:43,240
BUT THERE TO BE A CLINICAL TRIAL

3381
02:16:43,240 --> 02:16:44,160
PROPOSED. 

3382
02:16:44,160 --> 02:16:46,960
>> THIS IS WHERE I'M COR
ARE I

3383
02:16:46,960 --> 02:16:48,520
FOR PERSEVERATING. THIS IS WHERE

3384
02:16:48,520 --> 02:16:51,560
I'M CONFUSED.  IN THE ABSENCE OF

3385
02:16:51,560 --> 02:16:55,800
BETTER BIOMARKERS WHERE THE NOT

3386
02:16:55,800 --> 02:16:57,360
BOLLIC AGE OF RED CELLS YOU ARE

3387
02:16:57,360 --> 02:17:00,040
STILL ADVOCATING FOR CLINICAL

3388
02:17:00,040 --> 02:17:01,680
STUDY IN SUBGROUP OF PATIENTS

3389
02:17:01,680 --> 02:17:03,920
WHO HAVE NOT YET BEEN STUDIED?

3390
02:17:03,920 --> 02:17:06,800
WHO MAY ACTUALLY -- IF YOU DID

3391
02:17:06,800 --> 02:17:08,240
THAT WITHOUT THE METABOLIC

3392
02:17:08,240 --> 02:17:10,120
MARKER THEN YOU WOULD JUST BE

3393
02:17:10,120 --> 02:17:13,680
EVALUATING STORAGE AGE VERSUS

3394
02:17:13,680 --> 02:17:15,760
OUTCOME IN A GROUP THAT WAS IN A

3395
02:17:15,760 --> 02:17:17,120
SUBSET OF PATIENTS THAT YOU

3396
02:17:17,120 --> 02:17:20,200
THOUGHT HAD NOT BEEN STUDIED

3397
02:17:20,200 --> 02:17:22,200
ADEQUATELY?

3398
02:17:22,200 --> 02:17:25,920
>> I THINK WE NEED TO
THINK

3399
02:17:25,920 --> 02:17:27,240
ABOUT DIFFERENT TYPE OF CLINICAL

3400
02:17:27,240 --> 02:17:30,000
DESIGNS THAN I HAVE DONE IN THE

3401
02:17:30,000 --> 02:17:34,680
PAST.  I THINK THAT -- THERE ARE

3402
02:17:34,680 --> 02:17:35,840
CERTAINLY CERTAIN PATIENT

3403
02:17:35,840 --> 02:17:38,880
POPULATIONS THAT HAVE NOT BEEN

3404
02:17:38,880 --> 02:17:40,200
STUDIED, AGAIN ONE EXAMPLE WE

3405
02:17:40,200 --> 02:17:41,960
KEEP COMING BACK TO ARE

3406
02:17:41,960 --> 02:17:43,640
CHRONICALLY TRANSFUSED PATIENTS

3407
02:17:43,640 --> 02:17:45,920
WHERE CLEARLY THE SURVIVAL OF

3408
02:17:45,920 --> 02:17:47,680
THE RED CELLS HAS GREATER IMPACT

3409
02:17:47,680 --> 02:17:50,800
BUT OUTCOME THERE IS NOT

3410
02:17:50,800 --> 02:17:52,640
MORTALITY, THEY ARE CHRONICALLY

3411
02:17:52,640 --> 02:17:54,080
TRANSFUSED SO DIFFERENT OUTCOMES

3412
02:17:54,080 --> 02:17:59,040
YOU CAN LOOK AT. AND I MOW WE

3413
02:17:59,040 --> 02:18:00,720
ARE STUDYING THAT THROUGH

3414
02:18:00,720 --> 02:18:01,560
OBSERVATION, THERE MAYBE OTHER

3415
02:18:01,560 --> 02:18:03,240
CLINICAL TRIAL DESIGNS THAT ONE

3416
02:18:03,240 --> 02:18:05,920
COULD APPROACH TO DO

3417
02:18:05,920 --> 02:18:07,440
INTERVENTIONS TO LOOK IN

3418
02:18:07,440 --> 02:18:08,360
DIFFERENT POPULATIONS WHETHER

3419
02:18:08,360 --> 02:18:10,040
THAT MIGHT IMPROVE DIFFERENT

3420
02:18:10,040 --> 02:18:12,760
OUTCOMES THAN THOSE THAT HAVE

3421
02:18:12,760 --> 02:18:13,880
BEEN LOOKED AT SO NOT

3422
02:18:13,880 --> 02:18:15,320
NECESSARILY PROPOSING THAT WE

3423
02:18:15,320 --> 02:18:17,680
NEED BIOMARKERS, IT WOULD BE

3424
02:18:17,680 --> 02:18:20,520
GREAT IF -- IF THERE WERE

3425
02:18:20,520 --> 02:18:22,720
BIOMARKERS IF SOMEONE HAD ONE

3426
02:18:22,720 --> 02:18:23,760
THAT THERE WAS SUFFICIENT

3427
02:18:23,760 --> 02:18:25,200
PRE-CLINICAL DATA TO SUPPORT A

3428
02:18:25,200 --> 02:18:29,160
CLINICAL TRIAL THEN SURE LET US

3429
02:18:29,160 --> 02:18:30,560
PROPOSE ONE BUT THERE MAYBE

3430
02:18:30,560 --> 02:18:31,840
OTHER CLINICAL TRIAL DESIGNS

3431
02:18:31,840 --> 02:18:36,800
SOMEONE MIGHT PROPOSE.

3432
02:18:36,800 --> 02:18:47,440
>> THANKS FOR THE
CLARIFICATION 

3433
02:18:48,040 --> 02:18:54,600
>> OTHER QUESTIONS OR
COMMENTS? 

3434
02:18:54,600 --> 02:18:57,720
>> I HAVE ONE QUICK
COMMENT

3435
02:18:57,720 --> 02:19:01,560
WHICH WAS I THINK IT WAS A VERY

3436
02:19:01,560 --> 02:19:03,640
HELPFUL DISCUSSION IN THAT LAST

3437
02:19:03,640 --> 02:19:05,440
SESSION ABILITY STUFF THAT WAS

3438
02:19:05,440 --> 02:19:08,400
SUMMARIZED BUT WHAT WE DIDN'T

3439
02:19:08,400 --> 02:19:11,400
GET TO WAS I HOPE WILL BE

3440
02:19:11,400 --> 02:19:12,440
INCLUDED IN SUMMARY STATEMENT, I

3441
02:19:12,440 --> 02:19:15,320
THINK SUMMARIZED BY THE WORKING

3442
02:19:15,320 --> 02:19:20,400
GROUP, ISSUES SURROUNDING

3443
02:19:20,400 --> 02:19:23,800
ALLOIZATION, THE NEED TO STUDY

3444
02:19:23,800 --> 02:19:24,360
UNDERSTANDING, EVIDENCE

3445
02:19:24,360 --> 02:19:26,360
NECESSARY SENSE, ALL THOSE

3446
02:19:26,360 --> 02:19:28,120
DIDN'T COME UP BECAUSE OF ROBUST

3447
02:19:28,120 --> 02:19:29,320
DISCUSSION AROUND OTHER SUBJECTS

3448
02:19:29,320 --> 02:19:33,480
BUT I WOULD ENCOURAGE ELDAD AND

3449
02:19:33,480 --> 02:19:34,840
ANGELO TO INCLUDE THOSE IN YOUR

3450
02:19:34,840 --> 02:19:36,560
GENERAL DISCUSSION AS THIS GOES

3451
02:19:36,560 --> 02:19:37,840
FORWARD TO THE NIH.

3452
02:19:37,840 --> 02:19:44,240
>> OF COURSE. 

3453
02:19:44,240 --> 02:19:47,760
>> THESE ARE DRAFT
PRIORITIES

3454
02:19:47,760 --> 02:19:50,440
AND STILL TIME BEFORE

3455
02:19:50,440 --> 02:19:51,880
FINALIZATION AND THERE COULD BE

3456
02:19:51,880 --> 02:19:53,960
OPPORTUNITIES TO SHARE INPUT AND

3457
02:19:53,960 --> 02:20:04,560
THEY WILL TALK ABOUT THAT LATER 

3458
02:20:06,320 --> 02:20:10,000
>> OTHER QUESTIONS OR
COMMENTS? 

3459
02:20:10,000 --> 02:20:12,960
THANK YOU ELDAD AND ANGELA. I

3460
02:20:12,960 --> 02:20:17,120
CERTAINLY CHALLENGE TRYING TO

3461
02:20:17,120 --> 02:20:19,640
DIGEST WHAT COMMENTS AND

3462
02:20:19,640 --> 02:20:22,080
CONVERSATION OF THE BREAK OUT

3463
02:20:22,080 --> 02:20:24,200
AND BEING FIRST STEP. THANK YOU

3464
02:20:24,200 --> 02:20:26,360
FOR THAT. NEXT RUCHIKA AND

3465
02:20:26,360 --> 02:20:28,600
JANSENISM

3466
02:20:28,600 --> 02:20:36,520
>> I LIKE TO SHARE MY
SCREEN. IF

3467
02:20:36,520 --> 02:20:42,440
THAT'S OKAY. SO WE HAD A LIVELY

3468
02:20:42,440 --> 02:20:44,960
DISCUSSION, OUR RECORD SUBGROUP,

3469
02:20:44,960 --> 02:20:47,240
JAN SON AND I WERE TRYING TO

3470
02:20:47,240 --> 02:20:51,640
COMPILE ON OUR INFORMATION

3471
02:20:51,640 --> 02:20:52,920
FEEDBACK INTO SLIDES AN

3472
02:20:52,920 --> 02:20:54,840
COMMENTS, SO HERE WHAT WE HAVE

3473
02:20:54,840 --> 02:20:56,160
IS FEEDBACK RECEIVED BY

3474
02:20:56,160 --> 02:20:58,680
PARTICIPANTS. SO GOING BY THE

3475
02:20:58,680 --> 02:20:59,920
PRIORITY, FOR THE INFORMATION

3476
02:20:59,920 --> 02:21:01,240
COMMUNICATION TECHNOLOGY AND

3477
02:21:01,240 --> 02:21:05,920
SOCIAL MEDIA TO UNDERSTAND THE

3478
02:21:05,920 --> 02:21:08,840
BEHAVIOR OUR KNOWLEDGE POWER OF

3479
02:21:08,840 --> 02:21:11,720
CLUCK AND ACCESSIBILITY DIVERSE

3480
02:21:11,720 --> 02:21:13,360
CONCERNS RAISED FOR EXAMPLE IN

3481
02:21:13,360 --> 02:21:14,680
UNITED STATES WITH DIFFERENT

3482
02:21:14,680 --> 02:21:16,440
ORGANIZATIONS, AS THE COLLECTORS

3483
02:21:16,440 --> 02:21:18,560
HOW WOULD LIKE NOTIFICATION

3484
02:21:18,560 --> 02:21:22,440
SYSTEM BE ABLE TO FAIRLY DIRECT

3485
02:21:22,440 --> 02:21:25,760
DONOR WITH COMPUTATION AMONG

3486
02:21:25,760 --> 02:21:27,320
COLLECTORS, THAT'S MISWRITTEN

3487
02:21:27,320 --> 02:21:29,200
THERE. IS THERE A WAY TO MAKE

3488
02:21:29,200 --> 02:21:30,640
THE PLATFORM NEUTRAL FOR AN

3489
02:21:30,640 --> 02:21:32,040
INTERVENTION LIKE THAT. WE ALSO

3490
02:21:32,040 --> 02:21:33,920
DISCUSS IN RELEVANCE TO ANOTHER

3491
02:21:33,920 --> 02:21:35,360
QUESTION THAT SOMETHING LIKE

3492
02:21:35,360 --> 02:21:37,680
THIS IN CANADA, THERE IS ONLY

3493
02:21:37,680 --> 02:21:39,360
TWO COLLECTORS PRIMARILY, MAY

3494
02:21:39,360 --> 02:21:43,520
NOT BE A PROBLEM SO BEFORE A

3495
02:21:43,520 --> 02:21:45,440
TOOL LIKE THIS IS IMPLEMENTED,

3496
02:21:45,440 --> 02:21:47,880
APPLICATION IN THE UNITED

3497
02:21:47,880 --> 02:21:49,520
STATES, SOMETHING THAT NEEDS TO

3498
02:21:49,520 --> 02:21:51,320
BE LOOKED INTO WE DISCUSSED THE

3499
02:21:51,320 --> 02:21:53,360
ROLE OF EVENTS FOR THE MASS

3500
02:21:53,360 --> 02:21:56,840
CASUALTY EVENTS, AND BUT THERE

3501
02:21:56,840 --> 02:22:00,360
ARE CURRENTLY THE INFORMATION

3502
02:22:00,360 --> 02:22:02,560
LACKS AUTOMATION. FOLLOW-UP ON

3503
02:22:02,560 --> 02:22:04,360
DOCUMENTING THE EFFECTIVENESS OF

3504
02:22:04,360 --> 02:22:08,760
INTERVENTION LIKE THIS. CAN BE

3505
02:22:08,760 --> 02:22:11,680
HARD BECAUSE SOMETIMES THE BLOOD

3506
02:22:11,680 --> 02:22:13,320
ESTABLISHMENTS DON'T USE IN REAL

3507
02:22:13,320 --> 02:22:17,320
NAME ON LINE AND THEY MAY BE USE

3508
02:22:17,320 --> 02:22:21,280
NON-SPECIFIC NAMES SO THAT COULD

3509
02:22:21,280 --> 02:22:23,520
LEAD TO DOCUMENTING

3510
02:22:23,520 --> 02:22:25,000
EFFECTIVENESS, NOT AN EASY TASK 

3511
02:22:25,000 --> 02:22:27,960
THERE WAS CONCERN RAIDED FOR

3512
02:22:27,960 --> 02:22:30,200
SOME OUTCOME LIKE THIS WITH

3513
02:22:30,200 --> 02:22:32,000
NON-DONORS NOT RESPOND THAT MUCH

3514
02:22:32,000 --> 02:22:33,880
SO INVERTED RISK OF SYSTEMIC

3515
02:22:33,880 --> 02:22:38,720
BIAS AS WE ASSESS THESE

3516
02:22:38,720 --> 02:22:40,240
INTERVENTIONS, WHILE WILL CAN BE

3517
02:22:40,240 --> 02:22:41,920
BENEFIT OF CAUSATIVE DONATION

3518
02:22:41,920 --> 02:22:44,360
EXPERIENCE, THE NEGATIVE IMPACT

3519
02:22:44,360 --> 02:22:46,600
OF -- IT CAN BE MORE NEGATIVE,

3520
02:22:46,600 --> 02:22:48,280
SOMEONE HAD NEGATIVE DONATION,

3521
02:22:48,280 --> 02:22:51,720
IN THE BLOOD CENTER REALLY HARD.

3522
02:22:51,720 --> 02:22:53,760
CAN IT ADVERSELY AFFECT

3523
02:22:53,760 --> 02:22:56,200
COLLECTIONS LIKE NEGATIVE REVIEW

3524
02:22:56,200 --> 02:22:58,120
POSTED. IF WE CAN USE THIS IN

3525
02:22:58,120 --> 02:23:00,960
THE FUTURE TO INCORPORATE MORE

3526
02:23:00,960 --> 02:23:02,800
SYSTEMATIC FEEDBACK WITH BLOOD

3527
02:23:02,800 --> 02:23:06,240
CENTER OPERATIONS AND SOME BLOOD

3528
02:23:06,240 --> 02:23:07,600
DONORS AND COLLECTION CENTERS

3529
02:23:07,600 --> 02:23:09,360
COMMENTED THEY ARE ALREADY

3530
02:23:09,360 --> 02:23:10,680
TRACKING THE SOCIAL MEDIA

3531
02:23:10,680 --> 02:23:13,280
COMMENTARY FAIRLY CLOSELY. SOFT

3532
02:23:13,280 --> 02:23:15,920
THAT IS FIRST, PRIORITY. FOR OUR

3533
02:23:15,920 --> 02:23:18,800
SECOND PRIORITY ABOUT

3534
02:23:18,800 --> 02:23:20,120
MULTI-DIMENSIONAL DATABASES AND

3535
02:23:20,120 --> 02:23:24,040
DATA VISUALIZATION, WE HAD VERY

3536
02:23:24,040 --> 02:23:26,320
HEATED INTENSE DISCUSSION. SO

3537
02:23:26,320 --> 02:23:31,560
SOME IMPORTANT CONCERNS ABOUT

3538
02:23:31,560 --> 02:23:35,040
THE DATA COLLECTION MODEL IS IT

3539
02:23:35,040 --> 02:23:36,520
SUFFICIENT FOR RELATED RESEARCH

3540
02:23:36,520 --> 02:23:38,600
AND GIVE SUFFICIENT DETAIL. SO

3541
02:23:38,600 --> 02:23:40,400
CERTAINLY WE ACKNOWLEDGE AS WE

3542
02:23:40,400 --> 02:23:43,960
ARE DOING MAPPING FROM EHR TO

3543
02:23:43,960 --> 02:23:46,840
OMOP STANDARDS THERE'S LOSS OF

3544
02:23:46,840 --> 02:23:48,040
SPECIFICITY AND NOT EXACT

3545
02:23:48,040 --> 02:23:49,960
MATCHES ARE FOUND SO ONE DOES

3546
02:23:49,960 --> 02:23:52,320
HAVE TO SELECT THE BEST

3547
02:23:52,320 --> 02:23:53,280
AVAILABLE SO THERE ARE TRADE

3548
02:23:53,280 --> 02:23:55,280
OFFS. HOWEVER, JUST WE GOT SOME

3549
02:23:55,280 --> 02:23:58,920
RECENT EXPERIENCES HERE FROM

3550
02:23:58,920 --> 02:24:02,640
ADAPTIVE RED 4P AND OMOP IS

3551
02:24:02,640 --> 02:24:05,600
EVOLVING AND OVER THE YEARS THE

3552
02:24:05,600 --> 02:24:06,960
REACH HAS GROWN. SO AT LEAST

3553
02:24:06,960 --> 02:24:11,120
FROM CURRENT UNDERSTANDING FOR

3554
02:24:11,120 --> 02:24:12,680
APPLICATION TO MEDICINE THE

3555
02:24:12,680 --> 02:24:14,920
PRODUCT AND POSSIBLE SIDE OF

3556
02:24:14,920 --> 02:24:17,000
RECIPIENT COVERAGE IT LOOKS

3557
02:24:17,000 --> 02:24:18,240
BETTERMENT THE QUALITY OF DATA

3558
02:24:18,240 --> 02:24:21,360
IMPROVED BUT THE DONOR SIDE OF

3559
02:24:21,360 --> 02:24:24,040
THE DATABASE MODEL IS REALLY

3560
02:24:24,040 --> 02:24:25,600
LEARNING AND THE LEARNING IS

3561
02:24:25,600 --> 02:24:27,400
GOING WITH ADOPTING DONOR AS

3562
02:24:27,400 --> 02:24:29,280
PATIENT AND USING THE SAME

3563
02:24:29,280 --> 02:24:33,440
MODEL. WE HAVE DISCUSSIONS ABOUT

3564
02:24:33,440 --> 02:24:35,760
INCLUDING DONORS AND COULD WE

3565
02:24:35,760 --> 02:24:38,440
HAVE BETTER DONOR DATA

3566
02:24:38,440 --> 02:24:42,400
INCORPORATED. THIS WAS SHARED

3567
02:24:42,400 --> 02:24:45,280
THAT FDA BEST DEVELOP OMOP --

3568
02:24:45,280 --> 02:24:48,640
WHICH ACTS AS THE ISPP CORDS TO

3569
02:24:48,640 --> 02:24:49,720
IDENTIFY TRANTAS FUSED

3570
02:24:49,720 --> 02:24:51,640
COMPONENT. SO IT IS STILL

3571
02:24:51,640 --> 02:24:53,960
REQUIRES SOME REGIONAL LEVEL

3572
02:24:53,960 --> 02:24:54,680
WORK, SIMILAR BUT IT IS A

3573
02:24:54,680 --> 02:24:57,840
POSSIBILITY. ONE IMPORTANT

3574
02:24:57,840 --> 02:24:59,600
CONCERN AND FEEDBACK THAT CAME

3575
02:24:59,600 --> 02:25:02,120
WAS FOR THE -- ANY WAY TO

3576
02:25:02,120 --> 02:25:03,240
MAINTAIN DATA AND ITS

3577
02:25:03,240 --> 02:25:05,040
APPLICABILITY WAS THE REAL TIME

3578
02:25:05,040 --> 02:25:07,040
DATA AGGREGATION BECAUSE DATA

3579
02:25:07,040 --> 02:25:09,000
TENDS TO LAG BY YEARS AND

3580
02:25:09,000 --> 02:25:12,120
MONTHS. SO WE HAVE SOME -- THAT

3581
02:25:12,120 --> 02:25:15,360
SOMETHING AS WE WORK ON SEVERAL

3582
02:25:15,360 --> 02:25:20,200
DATABASES CURRENTLY, WE DISCUSS

3583
02:25:20,200 --> 02:25:22,960
NOVEL STRATEGIES LIKE NLP

3584
02:25:22,960 --> 02:25:24,360
NATURAL LANGUAGE PROCESSING FOR

3585
02:25:24,360 --> 02:25:26,640
POPULATING ELEMENTS FROM THE HIV

3586
02:25:26,640 --> 02:25:27,720
DATA. A LOT OF THIS IS

3587
02:25:27,720 --> 02:25:30,680
EXPERIMENTAL BUT THERE IS SOME

3588
02:25:30,680 --> 02:25:32,080
RESEARCH UPCOMING THAT SHOULD BE

3589
02:25:32,080 --> 02:25:33,240
PRESENT IN THE NEAR FUTURE

3590
02:25:33,240 --> 02:25:37,640
LOOKING HOW THIS IS IMPLEMENTED 

3591
02:25:37,640 --> 02:25:39,640
FOR ANY DATA FIDELITY OF DATA,

3592
02:25:39,640 --> 02:25:43,600
IT REALLY DOES ALWAYS COME DOWN

3593
02:25:43,600 --> 02:25:46,840
TO HOW TRUE THE DATA, ANYTHING

3594
02:25:46,840 --> 02:25:48,640
DERIVED INDEPENDENT OF DATA, SO

3595
02:25:48,640 --> 02:25:50,880
WE DISCUSS TIME STAMPS WHEN

3596
02:25:50,880 --> 02:25:51,800
TRANSFUSION HAPPEN WHEN WAS

3597
02:25:51,800 --> 02:25:54,880
PRODUCT ISSUED WAS IT ISSUED OR

3598
02:25:54,880 --> 02:25:56,880
ISSUED FROM THE BLOOD BANK, NOT

3599
02:25:56,880 --> 02:25:58,120
VALIDATION AND ARE WE PAYING

3600
02:25:58,120 --> 02:26:00,520
ATTENTION TO THOSE DETAILS AS WE

3601
02:26:00,520 --> 02:26:05,560
DO DATABASE LEVEL RESEARCH. WE

3602
02:26:05,560 --> 02:26:07,440
ALSO SPOKE ABOUT COLLABORATION

3603
02:26:07,440 --> 02:26:09,680
WITH THE HHS OFFICE OF NATIONAL

3604
02:26:09,680 --> 02:26:11,680
COORDINATOR TO GET BIOLOGICALLY

3605
02:26:11,680 --> 02:26:13,960
DERIVED PRODUCTS INTO THE U.S.

3606
02:26:13,960 --> 02:26:15,400
CORE DATA FOR INTEROPERABILITY.

3607
02:26:15,400 --> 02:26:18,480
THAT CAN BE REALLY A LOT OF

3608
02:26:18,480 --> 02:26:19,320
COMMUNICATION BETWEEN BLOOD BANK

3609
02:26:19,320 --> 02:26:23,600
SOFTWARE AND EHR. SO SOME USEFUL

3610
02:26:23,600 --> 02:26:24,400
DISCUSSIONS HERE BETWEEN WOULD

3611
02:26:24,400 --> 02:26:27,160
LIKE TO TAKE BACK TO OUR WORKING

3612
02:26:27,160 --> 02:26:29,520
GROUP. FOR THE DATA DRIVEN

3613
02:26:29,520 --> 02:26:32,720
APPROACHES ABOUT THE ECONOMIC

3614
02:26:32,720 --> 02:26:35,920
EVALUATIONS, THIS POINT CAME UP

3615
02:26:35,920 --> 02:26:38,280
THAT RECENTLY FOCUS IS ON

3616
02:26:38,280 --> 02:26:39,960
INFECTIOUS DISEASE SCREENING AND

3617
02:26:39,960 --> 02:26:41,320
EFFICIENCY AND THE EFFICACY AND

3618
02:26:41,320 --> 02:26:45,160
THAT IS VERY IMPORTANT. HOWEVER

3619
02:26:45,160 --> 02:26:46,960
DATA FROM THE HOSPITALS

3620
02:26:46,960 --> 02:26:48,160
RECIPIENTS AND DOWNSTREAM

3621
02:26:48,160 --> 02:26:53,600
CLINICAL IMPACT IS LIMITED. SO

3622
02:26:53,600 --> 02:26:56,000
WE DID DISCUSS IT EARLIER IN

3623
02:26:56,000 --> 02:26:56,800
PRESENTATION HOWEVER

3624
02:26:56,800 --> 02:26:58,280
NON-INFECTIOUS OUTCOMES AND

3625
02:26:58,280 --> 02:26:59,520
ADVERSE EVENTS NEED TO BE

3626
02:26:59,520 --> 02:27:00,840
FOCUSED ON AND THIS IS A

3627
02:27:00,840 --> 02:27:03,360
CHALLENGE. WE DISCUSS SCENARIOS

3628
02:27:03,360 --> 02:27:05,040
WHERE ECONOMIC EVALUATIONS WOULD

3629
02:27:05,040 --> 02:27:07,720
BE HELPFUL FOR EXAMPLE USE OF

3630
02:27:07,720 --> 02:27:10,360
MACHINE COMPATIBLE PLATELETS AND

3631
02:27:10,360 --> 02:27:12,800
DEVELOPMENT OF UNIFIED DATABASE

3632
02:27:12,800 --> 02:27:14,240
TO UNDERSTAND SOME RESOURCE

3633
02:27:14,240 --> 02:27:18,640
INTENSE PRACTICES LIKE SIMPLY

3634
02:27:18,640 --> 02:27:20,040
DONOR MATCH COMPATIBLE DATA HOW

3635
02:27:20,040 --> 02:27:22,040
WE DO THAT FOR A SELECT

3636
02:27:22,040 --> 02:27:25,800
POPULATION.  MOVING ON FOR OUR

3637
02:27:25,800 --> 02:27:29,080
MACHINE LEARNING AND ARTIFICIAL

3638
02:27:29,080 --> 02:27:30,800
INTELLIGENCE SEVERAL FEEDBACK

3639
02:27:30,800 --> 02:27:35,840
AND COMMENTS, BASICALLY WE HAVE

3640
02:27:35,840 --> 02:27:38,640
SOME SEVERAL STUDIES COMING BUT

3641
02:27:38,640 --> 02:27:40,200
HOW CLINICAL TOOLS APPLICABLE.

3642
02:27:40,200 --> 02:27:45,040
WE NEED ONGOING DEMONSTRATION OF

3643
02:27:45,040 --> 02:27:46,160
GENERALIZABILITY SCALABILITY AND

3644
02:27:46,160 --> 02:27:48,280
ROBUSTNESS SO THESE STUDIES ARE

3645
02:27:48,280 --> 02:27:50,320
NOT REACHING CLINICAL GRADE

3646
02:27:50,320 --> 02:27:51,720
APPLICATION LEVEL. WE HAVE TO BE

3647
02:27:51,720 --> 02:27:54,160
MORE SPECIFIC ABOUT THE USE

3648
02:27:54,160 --> 02:27:56,960
CASES. WHERE ARE TECHNIQUES

3649
02:27:56,960 --> 02:27:59,360
APPROPRIATE, HOW ARE WE

3650
02:27:59,360 --> 02:28:00,840
ADDRESSING THE IMPLEMENTATION

3651
02:28:00,840 --> 02:28:04,960
GAP. I THINK ONE CONCERN WAS

3652
02:28:04,960 --> 02:28:08,040
THAT THE PREDICTIVE MODEL BEYOND

3653
02:28:08,040 --> 02:28:12,400
MODELING STAGE, IMPLEMENTATION

3654
02:28:12,400 --> 02:28:15,120
STAGES NASCENT STAGE HOW ARE WE

3655
02:28:15,120 --> 02:28:16,160
MONITORING THAT IS IMPORTANT,

3656
02:28:16,160 --> 02:28:20,280
KEY METRICS FOR THAT. THE

3657
02:28:20,280 --> 02:28:22,600
QUESTION OF EQUITY VERSUS

3658
02:28:22,600 --> 02:28:25,920
EQUALITY, A MODEL THAT IS

3659
02:28:25,920 --> 02:28:27,000
DERIVED FROM ANOTHER TRAINING

3660
02:28:27,000 --> 02:28:28,760
DATA SET, IS IT GENERALIZABLE

3661
02:28:28,760 --> 02:28:31,120
AND DEPLOYABLE IN PATIENT

3662
02:28:31,120 --> 02:28:32,200
POPULATION WHICH WAS INDEPENDENT

3663
02:28:32,200 --> 02:28:34,440
OF THAT, THE INTENDED USE

3664
02:28:34,440 --> 02:28:39,600
POPULATION IS IT THE SAME SO

3665
02:28:39,600 --> 02:28:44,440
COULD BE MAKING ERRORS IN THE

3666
02:28:44,440 --> 02:28:47,240
APPLICATION VERY TRAINING

3667
02:28:47,240 --> 02:28:48,560
DEPLOYMENT, THE APPLICATION CAN

3668
02:28:48,560 --> 02:28:51,680
BE DEPENDENT ON TRAINING DATA SO

3669
02:28:51,680 --> 02:28:54,400
MAKING SURE THAT FOR TRAINING

3670
02:28:54,400 --> 02:28:57,520
DATABASE SETS MULTI-CENTER DATA

3671
02:28:57,520 --> 02:28:58,880
DIVERSITY IS INCLUDED AS

3672
02:28:58,880 --> 02:29:02,880
IMPORTANT. THAT TAKES INTO

3673
02:29:02,880 --> 02:29:04,120
ACCOUNT CURRENT IMPLEMENTATIONS

3674
02:29:04,120 --> 02:29:06,160
ARE NOT ACCURATE, COULD WE BE

3675
02:29:06,160 --> 02:29:07,600
CONCERNED ABOUT POTENTIAL HARM

3676
02:29:07,600 --> 02:29:10,040
ESPECIALLY FOR UNDER-REPRESENTED

3677
02:29:10,040 --> 02:29:12,400
GROUPS OR WHERE IT RESULTS

3678
02:29:12,400 --> 02:29:13,400
APPLIED NOT ENOUGH DIVERSITY IN

3679
02:29:13,400 --> 02:29:15,320
OUR DEVELOPMENT IN THE TRAINING

3680
02:29:15,320 --> 02:29:20,680
DATABASES.  FOR GENOMICS WORKING

3681
02:29:20,680 --> 02:29:22,680
GROUP INTEGRATING GENOMICS TO

3682
02:29:22,680 --> 02:29:25,360
CLINICAL TRANSFUSION WORK FLOWS,

3683
02:29:25,360 --> 02:29:29,560
WE DISCUSSED REGULATORY VALUES

3684
02:29:29,560 --> 02:29:32,720
INHIBITED ADOPTION OR USING THE

3685
02:29:32,720 --> 02:29:35,360
GENOTYPING AND INTERESTING

3686
02:29:35,360 --> 02:29:38,920
PERSPECTIVE FROM SELENA SERVICES

3687
02:29:38,920 --> 02:29:40,800
FOR EXAMPLE THE DIFFERENCE

3688
02:29:40,800 --> 02:29:43,400
BETWEEN U.S. AND CANADA IS THAT

3689
02:29:43,400 --> 02:29:44,840
BECAUSE THERE ARE FOR THE ENTIRE

3690
02:29:44,840 --> 02:29:46,520
COUNTRY BASICALLY TWO BLOOD

3691
02:29:46,520 --> 02:29:50,200
COLLECTORS WITHIN THAT ONE BEING

3692
02:29:50,200 --> 02:29:53,040
MORE PRIMARY IT IS EASIER TO

3693
02:29:53,040 --> 02:29:54,280
ESTABLISH WORK FLOWS THE

3694
02:29:54,280 --> 02:29:55,920
INTEROPERABILITY IS EASIER,

3695
02:29:55,920 --> 02:29:57,080
SHARING INFORMATION

3696
02:29:57,080 --> 02:29:57,840
STANDARDIZATION WHICH IS GOING

3697
02:29:57,840 --> 02:30:01,200
TO BE A CHALLENGE FOR REALLY

3698
02:30:01,200 --> 02:30:04,520
WIDE SCALE GENOMICS

3699
02:30:04,520 --> 02:30:05,840
IMPLEMENTATION IN US.  WE DO

3700
02:30:05,840 --> 02:30:08,720
NEED TO TAP INTO THE BLOOD DONOR

3701
02:30:08,720 --> 02:30:11,040
DIVERSITY AS WE TRY TO MAKE

3702
02:30:11,040 --> 02:30:14,800
GENOMICS WORK SUCCESSFUL AND SO

3703
02:30:14,800 --> 02:30:17,200
THE PROGRAM HAS ESTABLISHED

3704
02:30:17,200 --> 02:30:18,640
PROGRAM GENOTYPE FOR DONORS AND

3705
02:30:18,640 --> 02:30:21,000
PATIENTS IS USED TO PROVIDE

3706
02:30:21,000 --> 02:30:24,200
COMPATIBLE PRODUCTS FOR PATIENTS

3707
02:30:24,200 --> 02:30:26,280
WITH ALLO ANTIBODIES. SO THERE'S

3708
02:30:26,280 --> 02:30:28,520
SOME BACKGROUND ON WHAT PROGRAMS

3709
02:30:28,520 --> 02:30:32,080
ARE IN PLACE AND HOW CAN WE MAKE

3710
02:30:32,080 --> 02:30:36,120
IT WIDER MORE ACCESSIBLE

3711
02:30:36,120 --> 02:30:37,520
DISCUSSED. VERY LIVELY

3712
02:30:37,520 --> 02:30:38,920
DISCUSSION WE GOT THROUGH PRETTY

3713
02:30:38,920 --> 02:30:44,560
MUCH ALL OUR PRIORITIES.  I

3714
02:30:44,560 --> 02:30:52,880
WOULD LIKE TO STOP HERE. 

3715
02:30:52,880 --> 02:30:54,600
>> FEW COMMENTS IN THE
CHAT FROM

3716
02:30:54,600 --> 02:30:57,840
AMANDA HESS. AARP LAUNCHING A

3717
02:30:57,840 --> 02:31:00,840
WEBSITE TO HELP SUPPORT WORK OF

3718
02:31:00,840 --> 02:31:08,120
PRIORITY NUMBER ONE. THEN FROM

3719
02:31:08,120 --> 02:31:10,680
DARRELL CORE, THE PROMISE OF AI

3720
02:31:10,680 --> 02:31:13,280
ML IS EXCITING IN THIS SPACE.

3721
02:31:13,280 --> 02:31:15,680
AND ECHOING COMMENTS WE RAISED

3722
02:31:15,680 --> 02:31:19,720
DURING THE BREAK OUT SESSION.

3723
02:31:19,720 --> 02:31:23,760
>> I REACHED OUT TO
AMANDA,

3724
02:31:23,760 --> 02:31:26,000
PROBABLY AS WE TRY TO FINE TUNE

3725
02:31:26,000 --> 02:31:28,640
THAT PRIORITY 1, TO DARRELL'S

3726
02:31:28,640 --> 02:31:30,080
POINT THAT WAS THE OBJECTIVE OF

3727
02:31:30,080 --> 02:31:31,320
HAVING PRIORITY FOCUS ON

3728
02:31:31,320 --> 02:31:34,120
IMPLEMENTATION. RATHER THAN JUST

3729
02:31:34,120 --> 02:31:36,680
RESEARCH INTO USE CASES FOR AI

3730
02:31:36,680 --> 02:31:39,520
ML. THE REAL CHALLENGE IS

3731
02:31:39,520 --> 02:31:41,560
IMPLEMENTING A MODEL AFTER IT'S

3732
02:31:41,560 --> 02:31:43,800
BUILT. THEN CREATING BETTER

3733
02:31:43,800 --> 02:31:45,920
DATABASES FACILITATES THE FRONT

3734
02:31:45,920 --> 02:31:47,920
END WHICH IS CLEANING DATA

3735
02:31:47,920 --> 02:31:49,360
MANIPULATING DATA, DATA

3736
02:31:49,360 --> 02:31:51,480
ENGINEERING IN GENERAL. SO WE

3737
02:31:51,480 --> 02:31:53,280
TRIED TO HAVE PRIORITIES THAT

3738
02:31:53,280 --> 02:31:55,280
FOCUS ON THE FRONT AND BACK END

3739
02:31:55,280 --> 02:31:59,240
AND NOT JUST AI ML USE CASES. 

3740
02:31:59,240 --> 02:32:03,600
>> AS WE DO OUR FINAL
WRITE UP

3741
02:32:03,600 --> 02:32:07,000
THESE ARE IMPORTANT FEEDBACK TO

3742
02:32:07,000 --> 02:32:12,120
INCORPORATE.  THANK YOU. 

3743
02:32:12,120 --> 02:32:13,880
>> I HAVEN'T ABLE TO JOIN
THIS

3744
02:32:13,880 --> 02:32:15,520
BREAK OUT BUT WONDER IF OFTEN

3745
02:32:15,520 --> 02:32:17,080
TIMES ONE OF THE CHALLENGES IS

3746
02:32:17,080 --> 02:32:19,360
WE LIKE TO CREATE MODELS USING

3747
02:32:19,360 --> 02:32:21,320
STATIC RELATIONAL DATA THAT

3748
02:32:21,320 --> 02:32:24,680
MIGHT EXIST IN OMOP DATA MODEL

3749
02:32:24,680 --> 02:32:27,480
BUT REALITY USING THE MODEL

3750
02:32:27,480 --> 02:32:28,840
UTILIZES IN WORK FLOWS NEEDS TO

3751
02:32:28,840 --> 02:32:32,600
BE BUILT ON TRANSACTIONAL DATA

3752
02:32:32,600 --> 02:32:34,480
MODEL THAT LOOKS DIFFERENT FROM

3753
02:32:34,480 --> 02:32:35,840
OMOP DATA MODEL.  HOW DO YOU

3754
02:32:35,840 --> 02:32:37,440
ADDRESS THE GAP OF CREATING

3755
02:32:37,440 --> 02:32:40,000
MODELS USING A STATIC RELATIONAL

3756
02:32:40,000 --> 02:32:40,960
DATA ENVIRONMENT WHEN MODELS

3757
02:32:40,960 --> 02:32:44,440
HAVE TO BE IMPLEMENTED ON A VERY

3758
02:32:44,440 --> 02:32:45,520
DIFFERENT ENVIRONMENT AND

3759
02:32:45,520 --> 02:32:46,520
CHALLENGES ARE AROUND THAT

3760
02:32:46,520 --> 02:32:47,320
IMPLEMENTATION. 

3761
02:32:47,320 --> 02:32:49,200
>> WE DISCUSSED THAT WHEN
IT

3762
02:32:49,200 --> 02:32:50,760
CAME TO DATABASES.  HOW DO WE

3763
02:32:50,760 --> 02:32:52,960
MOVE FROM THIS STATIC DATABASE

3764
02:32:52,960 --> 02:32:56,040
AGGREGATION TO REAL TIME DATA

3765
02:32:56,040 --> 02:32:58,160
AGGREGATION. WHAT YOU ARE

3766
02:32:58,160 --> 02:33:00,040
TALKING ABOUT AS WELL IS THE

3767
02:33:00,040 --> 02:33:02,120
FIELDS WE USE THE TRAIN THE

3768
02:33:02,120 --> 02:33:06,280
MODEL MAY NOT BE ACCESSIBLE FOR

3769
02:33:06,280 --> 02:33:08,040
REAL TIME. THAT DID NOT COME UP

3770
02:33:08,040 --> 02:33:09,720
AND WE WILL ADD TO LIST OF

3771
02:33:09,720 --> 02:33:19,680
COMMENTS AS WELL. 

3772
02:33:19,680 --> 02:33:21,240
>> OTHER QUESTIONS OR
COMMENTS

3773
02:33:21,240 --> 02:33:31,760
FROM WORKING GROUP CHAIRS? THANK

3774
02:33:32,760 --> 02:33:34,840
YOU VERY MUCH, RUCHIKA AND

3775
02:33:34,840 --> 02:33:35,560
JANSEN, WONDERFUL JOB.

3776
02:33:35,560 --> 02:33:38,760
>> THANK YOU. 

3777
02:33:38,760 --> 02:33:43,160
>> GO NOW INTRODUCE YVETTE

3778
02:33:43,160 --> 02:33:44,600
MEGHAN TO PRESENT SUMMARY OF

3779
02:33:44,600 --> 02:33:47,840
THEIR BREAK OUT SESSION.

3780
02:33:47,840 --> 02:33:52,560
>> THANK YOU SO MUCH,
NAREG.

3781
02:33:52,560 --> 02:33:53,920
SHOW YOU COUPLE OF SLIDES THEN

3782
02:33:53,920 --> 02:33:58,640
WE WILL CONTINUE TO TALK WITH

3783
02:33:58,640 --> 02:34:09,160
THOSE SLIDES. I WILL START BY

3784
02:34:14,320 --> 02:34:16,560
SHOWING -- FIRST I -- BEFORE I

3785
02:34:16,560 --> 02:34:20,440
SAY ANYTHING ELSE I WILL SAY

3786
02:34:20,440 --> 02:34:22,880
THIS GROUP AND OUR DISCUSSION

3787
02:34:22,880 --> 02:34:26,000
THAT WE JUST HAD AS WELL AS THE

3788
02:34:26,000 --> 02:34:28,120
WHOLE PAST YEAR WORKING TOGETHER

3789
02:34:28,120 --> 02:34:34,280
HAS BEEN A LEARNING EXPERIENCE.

3790
02:34:34,280 --> 02:34:37,240
EYE OPENING AND ALSO VERY

3791
02:34:37,240 --> 02:34:39,080
ENGAGING, JUST SO INSPIRING TO

3792
02:34:39,080 --> 02:34:40,160
HAVE SO MANY WANTING TO COME

3793
02:34:40,160 --> 02:34:42,400
FORWARD AND TALK ABOUT THESE

3794
02:34:42,400 --> 02:34:44,480
ISSUES THAT ARE UNFORTUNATELY

3795
02:34:44,480 --> 02:34:46,680
PART OF THE FABRIC OF OUR

3796
02:34:46,680 --> 02:34:50,120
SOCIETY THAT WE HAVE TO CALL OUT

3797
02:34:50,120 --> 02:34:52,440
AND WORK TOGETHER TO IMPROVE

3798
02:34:52,440 --> 02:34:54,920
HEALTHCARE FOR ALL PEOPLE. SO

3799
02:34:54,920 --> 02:34:59,680
THE FIVE PRIORITIES THAT WE HAVE

3800
02:34:59,680 --> 02:35:01,480
HERE, WE FEEL -- I WANT TO

3801
02:35:01,480 --> 02:35:04,600
CLARIFY, THEY ARE NOT IN ORDER

3802
02:35:04,600 --> 02:35:06,360
THEY ARE ALL IMPORTANT AND WE

3803
02:35:06,360 --> 02:35:08,480
HAVE THEM NUMBERED ONE TO FIVE

3804
02:35:08,480 --> 02:35:10,240
AND WE DON'T THINK -- THEY ARE

3805
02:35:10,240 --> 02:35:11,920
QUITE BROAD IN GENERAL AND WE

3806
02:35:11,920 --> 02:35:15,600
LIKE THEM THAT WAY.  THOUGH WE

3807
02:35:15,600 --> 02:35:17,200
HAVE MORE TO ADD ABOUT THEM AS

3808
02:35:17,200 --> 02:35:18,600
WELL THAT CAME UP ESPECIALLY

3809
02:35:18,600 --> 02:35:20,840
DURING THE BREAK OUT SESSION. SO

3810
02:35:20,840 --> 02:35:23,000
SHOW THIS ONE SLIDE TO EMPHASIZE

3811
02:35:23,000 --> 02:35:25,640
SOME MAJOR THEMES AND THEN I

3812
02:35:25,640 --> 02:35:28,840
WILL TALK MORE ABOUT SOME OF THE

3813
02:35:28,840 --> 02:35:30,280
REALLY INTERESTING COMMENTS THAT

3814
02:35:30,280 --> 02:35:32,480
WERE BROUGHT UP. SO THINKING

3815
02:35:32,480 --> 02:35:35,000
ABOUT WHY WE WERE CALLED

3816
02:35:35,000 --> 02:35:38,120
TOGETHER BY THE NIH, SO OUR

3817
02:35:38,120 --> 02:35:40,880
RESPONSE BACK IS WE FEEL THE

3818
02:35:40,880 --> 02:35:44,160
FUNDING FROM NIH SPECIFICALLY

3819
02:35:44,160 --> 02:35:44,680
ALLOCATED TO STRENGTHEN

3820
02:35:44,680 --> 02:35:45,880
HEALTHCARE SYSTEMS DELIVERY AND

3821
02:35:45,880 --> 02:35:49,600
UNDERSTANUNDERSTANDING THE NEEDF

3822
02:35:49,600 --> 02:35:51,200
COMMUNITIES AND WE HAVE TO FACE

3823
02:35:51,200 --> 02:35:52,880
RACISM AND WORK TOGETHER TO CALL

3824
02:35:52,880 --> 02:35:54,440
IT OUT AND MOVE FORWARD

3825
02:35:54,440 --> 02:35:55,640
TRANSPARENTLY AND

3826
02:35:55,640 --> 02:35:56,880
COLLABORATIVELY. ONE THING THAT

3827
02:35:56,880 --> 02:35:58,640
CAME OUT FOR REALLY ALL OF THE

3828
02:35:58,640 --> 02:36:02,040
PRIORITIES THAT WE JUST PUT ON

3829
02:36:02,040 --> 02:36:03,960
THE SCREEN IS FIRST STEP FOR

3830
02:36:03,960 --> 02:36:06,280
MANY OR ALL OF THEM, IT'S

3831
02:36:06,280 --> 02:36:07,480
COMMUNITY BASED RESEARCH AND

3832
02:36:07,480 --> 02:36:10,000
WHAT WE MEAN BY THAT, IS TO TALK

3833
02:36:10,000 --> 02:36:14,440
TO THE COMMUNITIES THEMSELVES,

3834
02:36:14,440 --> 02:36:16,960
AND TO LET THEM TELL US WHAT

3835
02:36:16,960 --> 02:36:21,040
THEY NEED, WHAT THEY WANT, WITH

3836
02:36:21,040 --> 02:36:22,200
RESPECT TO PARTICIPATION IN

3837
02:36:22,200 --> 02:36:23,560
RESEARCH, ACCESS AND NEEDS FROM

3838
02:36:23,560 --> 02:36:28,000
THE HEALTHCARE SYSTEM. WANTING

3839
02:36:28,000 --> 02:36:29,960
TO DONATE BLOOD AND WHAT THEY

3840
02:36:29,960 --> 02:36:33,840
MIGHT WANT FROM A BLOOD DONOR

3841
02:36:33,840 --> 02:36:37,120
CENTER. SO THERE ARE ALREADY

3842
02:36:37,120 --> 02:36:38,320
MULTIPLE DIFFERENT GROUPS

3843
02:36:38,320 --> 02:36:39,360
BECAUSE SOCIAL DETERMINANTS OF

3844
02:36:39,360 --> 02:36:41,560
HEALTH IS NOT JUST THE

3845
02:36:41,560 --> 02:36:42,760
HEALTHCARE SYSTEM, IT IS ACCESS

3846
02:36:42,760 --> 02:36:45,120
TO HEALTHY FOOD AND THE

3847
02:36:45,120 --> 02:36:48,120
ENVIRONMENT PEOPLE LIVE IN. AS

3848
02:36:48,120 --> 02:36:50,000
WELL AS EMPLOYMENT

3849
02:36:50,000 --> 02:36:51,520
OPPORTUNITIES, MANY, MANY THINGS

3850
02:36:51,520 --> 02:36:54,040
THAT IMPACT SOCIAL DETERMINANTS

3851
02:36:54,040 --> 02:36:56,960
OF HEALTH. SO WE THINK THAT OUR

3852
02:36:56,960 --> 02:36:59,000
FIELD NEEDS TO PARTNER WITH

3853
02:36:59,000 --> 02:37:00,520
GROUPS AND LEARN FROM GROUPS

3854
02:37:00,520 --> 02:37:02,920
ALREADY WORKING IN THE

3855
02:37:02,920 --> 02:37:05,200
COMMUNITY. TO HAVE AN ENTRE INTO

3856
02:37:05,200 --> 02:37:09,600
THE COMMUNITY TO TRY TO LEARN

3857
02:37:09,600 --> 02:37:11,880
WHAT THEY NEED, WHAT THEY WANT. 

3858
02:37:11,880 --> 02:37:16,640
WE NEED TO BE PREPARED FOR LACK

3859
02:37:16,640 --> 02:37:21,960
OF TRUST AND HEARING THINGS THE

3860
02:37:21,960 --> 02:37:26,040
HEALTHCARE SYSTEM OUR FIELD, OUR

3861
02:37:26,040 --> 02:37:28,200
APPROACH TO DONOR RECRUITMENT

3862
02:37:28,200 --> 02:37:30,080
AND TOUGH THINGS ABOUT HOW THOSE

3863
02:37:30,080 --> 02:37:32,200
THINGS MAY HAVE OR HAD EXCLUDED

3864
02:37:32,200 --> 02:37:32,840
MEMBERS OF DIFFERENT

3865
02:37:32,840 --> 02:37:38,920
COMMUNITIES.  BECAUSE THERE IS

3866
02:37:38,920 --> 02:37:40,680
DESIRE AND KNOWN INTEREST TO

3867
02:37:40,680 --> 02:37:43,920
INCREASING BLOOD DONOR RECRU

3868
02:37:43,920 --> 02:37:45,200
RECRUITMENT, OF ALL TYPES OF

3869
02:37:45,200 --> 02:37:48,080
PEOPLE, ETHNIC GROUPS, DIFFERENT

3870
02:37:48,080 --> 02:37:51,040
GROUPS DIFFERENT GEOGRAPHIES

3871
02:37:51,040 --> 02:37:52,600
ANCESTRAL BACKGROUND WE THINK

3872
02:37:52,600 --> 02:37:53,760
HAVING BLOOD DONOR CENTERS AND

3873
02:37:53,760 --> 02:37:56,880
REPRESENTATIVE THE BLOOD DONOR

3874
02:37:56,880 --> 02:37:57,880
CENTERS IS PARTICIPANTS IN THIS

3875
02:37:57,880 --> 02:38:03,200
TYPE OF LISTENING AND LEARNING

3876
02:38:03,200 --> 02:38:05,400
WOULD BE ADVANTAGEOUS. WHEN WE

3877
02:38:05,400 --> 02:38:09,120
TALKED ABOUT PATIENT OUTCOMES,

3878
02:38:09,120 --> 02:38:11,240
THERE IS A LOT OF INTEREST IN

3879
02:38:11,240 --> 02:38:14,880
PRIORITY FOUR AS WELL, WHICH IS

3880
02:38:14,880 --> 02:38:19,600
TO REALLY BETTER CLASSIFY, KEEP

3881
02:38:19,600 --> 02:38:23,680
TRACK OF AND LEARN HOW TO

3882
02:38:23,680 --> 02:38:28,160
PREVENT AND TREAT ADVERSE EVENTS

3883
02:38:28,160 --> 02:38:29,200
RELATED TO TRANSFUSION

3884
02:38:29,200 --> 02:38:30,440
EXPERIENCED IN HIGHER PROPORTION

3885
02:38:30,440 --> 02:38:35,880
OF PATIENTS OF MINORITY GROUPS.

3886
02:38:35,880 --> 02:38:37,560
HOWEVER, THAT LOW -- THE LAST

3887
02:38:37,560 --> 02:38:39,200
BULLET THERE, WE THINK RIGHT NOW

3888
02:38:39,200 --> 02:38:42,320
WE KIND OF CONSIDER THOSE THINGS

3889
02:38:42,320 --> 02:38:46,040
RARE. BUT MANY DON'T THINK THEY

3890
02:38:46,040 --> 02:38:47,960
ARE RARE BECAUSE THEY ARE

3891
02:38:47,960 --> 02:38:50,520
UNDERSTUDIED, UNDERCLASSIFIED,

3892
02:38:50,520 --> 02:38:51,600
THERE'S NOT A LARGE FUNDING

3893
02:38:51,600 --> 02:38:55,920
MECHANISM TO STUDY AD VERSION

3894
02:38:55,920 --> 02:38:57,440
EVENTS SUCH AS TRANSFUSION

3895
02:38:57,440 --> 02:38:58,640
REACTIONS SO THIS IS

3896
02:38:58,640 --> 02:39:03,080
MULTI-CENTER AND QUITE LONG TERM

3897
02:39:03,080 --> 02:39:04,600
STUDY, NOT JUST SHORT TERM STUDY

3898
02:39:04,600 --> 02:39:05,960
SO FUNDING MECHANISMS HAVE TO

3899
02:39:05,960 --> 02:39:11,200
SUPPORT THAT. COOPERATION WITH

3900
02:39:11,200 --> 02:39:14,080
BLOOD DONOR CENTERS, COMMUNITY

3901
02:39:14,080 --> 02:39:17,640
ORGANIZERS, POLITICIAN, CHURCH,

3902
02:39:17,640 --> 02:39:19,040
THIS GOES BACK TO RESEARCH, WE

3903
02:39:19,040 --> 02:39:23,400
IN OUR OFFICES AND -- ARE NOT

3904
02:39:23,400 --> 02:39:24,840
ABLE TO SAY WHAT COMMUNITY

3905
02:39:24,840 --> 02:39:29,840
NEEDS, WE NEED TO HAVE THEM AND

3906
02:39:29,840 --> 02:39:31,360
ANYONE THAT WANTS TO TALK AND

3907
02:39:31,360 --> 02:39:34,400
HELP US BETTER UNDERSTAND

3908
02:39:34,400 --> 02:39:35,840
PATIENT OUTCOMES.  THE PATIENT

3909
02:39:35,840 --> 02:39:42,760
OUTCOMES COULD BE LACK OF

3910
02:39:42,760 --> 02:39:44,120
TRANSFUSION WE CALLED OUT ON THE

3911
02:39:44,120 --> 02:39:47,320
GROUP, WHERE A PATIENT LIVES,

3912
02:39:47,320 --> 02:39:54,640
ACCESS TO TERTIARY AND

3913
02:39:54,640 --> 02:39:56,240
QUARTERNARY CARE, GENE THERAPIES

3914
02:39:56,240 --> 02:39:59,120
AND OTHER NEW TREATMENTS IS NOT

3915
02:39:59,120 --> 02:40:01,320
AVAILABLE EVERYWHERE. SO THAT

3916
02:40:01,320 --> 02:40:04,320
NEEDS TO BE RECOGNIZED STUDIED

3917
02:40:04,320 --> 02:40:05,920
AND THOUGHT HOW IT COULD BE

3918
02:40:05,920 --> 02:40:09,000
DELIVERED IN -- EVERYWHERE IN A

3919
02:40:09,000 --> 02:40:14,960
MORE EQUITABLE WAY. THE LACK OF

3920
02:40:14,960 --> 02:40:17,720
TRANSFUSION CAN BE FOR

3921
02:40:17,720 --> 02:40:20,240
EMERGENCIES. SO FOR TRAUMA BASED

3922
02:40:20,240 --> 02:40:25,360
CARE AS WELL AS BLEEDING, BOTH

3923
02:40:25,360 --> 02:40:28,000
OF THOSE NEED TRANSFUSION CARE

3924
02:40:28,000 --> 02:40:29,920
QUICKLY AND NOT ALL HOSPITALS OR

3925
02:40:29,920 --> 02:40:30,760
HEALTHCARE FACILITIES ARE

3926
02:40:30,760 --> 02:40:37,120
EQUIPPED FOR THAT. THERE IS RECK

3927
02:40:37,120 --> 02:40:39,480
NICHE, WHAT CARE PATIENTS

3928
02:40:39,480 --> 02:40:40,360
EXPERIENCE FOR THOSE EMERGENCIES

3929
02:40:40,360 --> 02:40:42,160
DOES DEPEND WHERE THEY ARE AND

3930
02:40:42,160 --> 02:40:45,200
WHO THEY ARE. SO THAT NEEDS TO

3931
02:40:45,200 --> 02:40:47,520
BE ADDRESSED BOTH WITH

3932
02:40:47,520 --> 02:40:48,320
HEALTHCARE SYSTEMS STRENGTHENING

3933
02:40:48,320 --> 02:40:50,400
AND RESEARCH TO SUPPORT

3934
02:40:50,400 --> 02:40:53,280
HEALTHCARE SYSTEM STRENGTHENING 

3935
02:40:53,280 --> 02:40:57,600
SO THOSE ARE BROAD THEMES THAT

3936
02:40:57,600 --> 02:41:00,360
CAME OUT FROM OUR SESSION. I

3937
02:41:00,360 --> 02:41:02,360
WANT TO THANK SO MANY PEOPLE WHO

3938
02:41:02,360 --> 02:41:04,160
ALSO SPOKE UP AND GAVE REALLY

3939
02:41:04,160 --> 02:41:07,000
SPECIFIC EXAMPLES. ONE THING

3940
02:41:07,000 --> 02:41:10,840
THAT WAS DISCUSSED IN DETAIL WAS

3941
02:41:10,840 --> 02:41:15,040
THE INFORMED CONSENT PROCESS.

3942
02:41:15,040 --> 02:41:17,600
HOW THE LENGTH OF IT, THE DETAIL

3943
02:41:17,600 --> 02:41:20,880
OF THE WRITTEN WORD AND HOW THAT

3944
02:41:20,880 --> 02:41:23,320
DISUADES PEOPLE FROM

3945
02:41:23,320 --> 02:41:26,000
PARTICIPATING IN RESEARCH. OTHER

3946
02:41:26,000 --> 02:41:27,560
POINTS SPOKEN ABOUT IN TERMS OF

3947
02:41:27,560 --> 02:41:29,320
SOCIAL DETERMINANTS OF HEALTH

3948
02:41:29,320 --> 02:41:30,880
AND BLOOD CENTERS, THERE WAS A

3949
02:41:30,880 --> 02:41:35,080
NICE CONNECTION MADE BY SEVERAL

3950
02:41:35,080 --> 02:41:37,200
FOLKS ABOUT HOW NIH STARTING TO

3951
02:41:37,200 --> 02:41:42,560
VIEW BLOOD CENTERS AS A PLACE

3952
02:41:42,560 --> 02:41:44,160
WHERE CHRONIC DISEASES THAT

3953
02:41:44,160 --> 02:41:48,480
IMPACT MANY PEOPLE, CAN BE TOUCH

3954
02:41:48,480 --> 02:41:50,320
POINT FOR THE FIRST POINT OF

3955
02:41:50,320 --> 02:41:53,400
CARE. AS WELL AS FOR YOUNG

3956
02:41:53,400 --> 02:41:54,800
DONORS WHICH ARE OFTEN A TARGET

3957
02:41:54,800 --> 02:41:56,800
OF DONATION RECRUITMENT IN TERMS

3958
02:41:56,800 --> 02:41:59,680
OF ADOLESCENT BASED HEALTH. SO

3959
02:41:59,680 --> 02:42:01,560
INCLUDING IN TERMS OF THE WHOLE

3960
02:42:01,560 --> 02:42:05,960
COMMUNITY OF CARE FOR ALL

3961
02:42:05,960 --> 02:42:07,280
DIFFERENT REPRESENTATIONS OF

3962
02:42:07,280 --> 02:42:09,280
COMMUNITIES AND MINORITY GROUPS

3963
02:42:09,280 --> 02:42:11,280
TO INCLUDE THOSE BLOOD CENTERS

3964
02:42:11,280 --> 02:42:15,360
AND STUDY THAT TO BE ABLE TO

3965
02:42:15,360 --> 02:42:18,000
BOTH LEARN AND TEACH AND

3966
02:42:18,000 --> 02:42:19,440
POTENTIALLY RETAIN BLOOD DONORS

3967
02:42:19,440 --> 02:42:23,760
BUT ALSO PROVIDE ACCESS TO

3968
02:42:23,760 --> 02:42:26,160
HEALTHCARE OR AT LEAST THE ENTRE

3969
02:42:26,160 --> 02:42:30,920
POINT OF HEALTHCARE. THERE ARE

3970
02:42:30,920 --> 02:42:31,600
MANY OTHER POINTS, TRYING TO

3971
02:42:31,600 --> 02:42:33,040
THINK OF WHAT OTHERS TO CALL

3972
02:42:33,040 --> 02:42:43,560
OUT.  THE -- BACK TO MY FIRST

3973
02:42:47,720 --> 02:42:52,680
POINT, THEN I WILL SEND IT TO

3974
02:42:52,680 --> 02:42:54,000
YVETTE. ABOUT COMMUNITY BASED

3975
02:42:54,000 --> 02:42:55,360
RESEARCH AND COMMUNITY BASED

3976
02:42:55,360 --> 02:43:00,640
LISTENING AND LEARNING, THERE

3977
02:43:00,640 --> 02:43:02,080
WAS AN INTERESTING ANECDOTE

3978
02:43:02,080 --> 02:43:04,440
SHARED ABOUT HOW ADVANCE STUDY

3979
02:43:04,440 --> 02:43:08,640
BEGAN IN FLORIDA AND HOW GOING

3980
02:43:08,640 --> 02:43:11,400
TO COMMUNITY AT LGBTQ COMMUNITY

3981
02:43:11,400 --> 02:43:14,240
CENTER TO DESCRIBE STUDY AND

3982
02:43:14,240 --> 02:43:17,240
LISTEN, WAS A REAL TURNING POINT

3983
02:43:17,240 --> 02:43:20,600
FOR UNDERSTANDING HOW THE

3984
02:43:20,600 --> 02:43:23,920
COMMUNITY WOULD RECEIVE STUDY

3985
02:43:23,920 --> 02:43:25,360
AND ALSO THE POINT THE INITIAL

3986
02:43:25,360 --> 02:43:26,760
DESCRIPTION OF THE STUDY WAS MET

3987
02:43:26,760 --> 02:43:32,040
WITH A GREAT DEAL OF NOT

3988
02:43:32,040 --> 02:43:36,320
TRUSTING SCIENTIFIC COMMUNITY.

3989
02:43:36,320 --> 02:43:37,800
SO THOSE HAVE TO BE WORKED

3990
02:43:37,800 --> 02:43:40,000
THROUGH TO MOVE FORWARD TO THIS

3991
02:43:40,000 --> 02:43:41,240
IDEAL OF BROAD DIVERSITY

3992
02:43:41,240 --> 02:43:45,240
INCLUDED IN OUR STUDY AS WELL AS

3993
02:43:45,240 --> 02:43:46,840
INCLUDED IN OUR RESEARCHERS

3994
02:43:46,840 --> 02:43:48,480
THEMSELVES. MY LAST POINT WILL

3995
02:43:48,480 --> 02:43:52,040
BE THE RESEARCH PIPELINE BRING

3996
02:43:52,040 --> 02:43:54,160
OF EDUCATING OUR YOUNG FOLKS IN

3997
02:43:54,160 --> 02:43:57,720
ALL COMMUNITIES ABOUT SCIENCE,

3998
02:43:57,720 --> 02:43:59,840
COMMUNITY BASED HEALTHCARE AND

3999
02:43:59,840 --> 02:44:02,480
ADVOCACY AND ALL THESE TOPICS

4000
02:44:02,480 --> 02:44:04,000
START YOUNG AND THERE ARE

4001
02:44:04,000 --> 02:44:05,440
ALREADY PROGRAMS THAT MANY OF

4002
02:44:05,440 --> 02:44:07,240
YOU ALSO LEAD AND PARTICIPATE IN

4003
02:44:07,240 --> 02:44:09,400
AND SOME THAT OUR PROFESSIONAL

4004
02:44:09,400 --> 02:44:10,800
SOCIETIES DO AND THOSE ARE

4005
02:44:10,800 --> 02:44:12,200
INCREDIBLY IMPORTANT AND

4006
02:44:12,200 --> 02:44:13,320
CONTINUE TO BE FUNDED IF NOT

4007
02:44:13,320 --> 02:44:16,840
STUDIED TO SHOW THE IMPORTANCE

4008
02:44:16,840 --> 02:44:18,480
OF FILLING THE PIPELINE WITH A

4009
02:44:18,480 --> 02:44:20,040
VERY DIVERSE GROUP OF

4010
02:44:20,040 --> 02:44:22,520
INDIVIDUALS THAT WILL ALSO MAKE

4011
02:44:22,520 --> 02:44:24,640
THE FUTURE RESEARCH ON MORE

4012
02:44:24,640 --> 02:44:27,320
INCLUSIVE. SO YVETTE, ANYTHING

4013
02:44:27,320 --> 02:44:29,520
ELSE? I TRIED TO SUMMARIZE A LOT

4014
02:44:29,520 --> 02:44:33,280
OF STUFF STUFF. IN A FEW MOMENT.

4015
02:44:33,280 --> 02:44:35,640
>> MEGHAN, YOU DID AN
EXCELLENT

4016
02:44:35,640 --> 02:44:37,920
JOB. AGAIN, I WANT TO DO SOME OF

4017
02:44:37,920 --> 02:44:41,120
THE SAME THINGS, THANK OUR

4018
02:44:41,120 --> 02:44:41,880
CERTAINLY THE GROUP OF

4019
02:44:41,880 --> 02:44:43,080
INDIVIDUALS THAT ATTENDED THE

4020
02:44:43,080 --> 02:44:46,320
BREAK OUT SESSION BUT JUST

4021
02:44:46,320 --> 02:44:49,400
HARDLY WORDS TO DESCRIBE REALLY

4022
02:44:49,400 --> 02:44:52,480
HOW MUCH FUN IT WAS. TO WORK

4023
02:44:52,480 --> 02:44:58,640
WITH OUR WORK GROUP TEAM.

4024
02:44:58,640 --> 02:45:00,080
PERSONALITIES THAT MELD IT

4025
02:45:00,080 --> 02:45:01,080
TOGETHER AND IT BECAME VERY

4026
02:45:01,080 --> 02:45:02,400
COMFORTABLE FOR US TO WORK WITH

4027
02:45:02,400 --> 02:45:05,480
EACH OTHER AND SHARE INFORMATION

4028
02:45:05,480 --> 02:45:07,040
AND PARTNERSHIP. ALL OF US HAVE

4029
02:45:07,040 --> 02:45:08,440
CERTAINLY NOW HAVE A NEW GROUP

4030
02:45:08,440 --> 02:45:09,360
OF COLLEAGUES THAT WE CAN CALL

4031
02:45:09,360 --> 02:45:13,160
ON. FOR YEARS AND YEARS TO COME

4032
02:45:13,160 --> 02:45:14,480
AND GET THEIR OPINIONS AND

4033
02:45:14,480 --> 02:45:16,800
THOUGHTS BECAUSE OF THE GREAT

4034
02:45:16,800 --> 02:45:18,000
RESPECT WE HAVE FOR EACH OTHER.

4035
02:45:18,000 --> 02:45:20,640
THE LAST THING I WANT TO ADD IS

4036
02:45:20,640 --> 02:45:23,640
THAT BEING IN THIS SPECIFIC WORK

4037
02:45:23,640 --> 02:45:28,280
GROUP, WE BEGAN TO ADDRESS AREAS

4038
02:45:28,280 --> 02:45:29,680
IN RELATIONSHIP TO HEALTH

4039
02:45:29,680 --> 02:45:31,320
DISPARITIES AND HEALTH

4040
02:45:31,320 --> 02:45:33,440
INEQUITIES IN TRANSFUSION

4041
02:45:33,440 --> 02:45:34,680
MEDICINE WHICH MANY NEVER

4042
02:45:34,680 --> 02:45:35,920
DISCUSSED AT THIS LEVEL BEFORE.

4043
02:45:35,920 --> 02:45:38,920
SO FOR MANY OF US, THIS IS NEW

4044
02:45:38,920 --> 02:45:40,360
PLACE AND NEW SPACE AND NEW

4045
02:45:40,360 --> 02:45:44,560
PLACE TO START THINKING SO NOW

4046
02:45:44,560 --> 02:45:49,480
THAT THIS OPPORTUNITY HAS OPENED

4047
02:45:49,480 --> 02:45:51,000
UP FOR US TO THINK DIFFERENTLY

4048
02:45:51,000 --> 02:45:52,240
ABOUT WORK THAT WE DO, THE

4049
02:45:52,240 --> 02:45:53,440
POPULATIONS WE WORK WITH AS WELL

4050
02:45:53,440 --> 02:45:55,800
AS HAVE A COMPLETELY DIFFERENT

4051
02:45:55,800 --> 02:45:58,120
VIEW OF OURSELVES, AND OUR

4052
02:45:58,120 --> 02:45:59,920
ABILITY TO STEP UP AND STAND OUT

4053
02:45:59,920 --> 02:46:01,920
AND ADVOCATE ON BEHALF OF OUR

4054
02:46:01,920 --> 02:46:03,280
PATIENTS, THIS IS A NEW SPACE

4055
02:46:03,280 --> 02:46:05,080
THAT MANY OF US HAVE NEVER BEEN

4056
02:46:05,080 --> 02:46:09,480
IN BEFORE TO THIS EXTENT. WE ALL

4057
02:46:09,480 --> 02:46:11,320
KNOW OUR RESPONSIBILITY TO WANT

4058
02:46:11,320 --> 02:46:13,240
TO DO BEST FOR OUR PATIENTS BUT

4059
02:46:13,240 --> 02:46:14,800
WE ARE THINKING ABOUT

4060
02:46:14,800 --> 02:46:16,560
COMMUNITIES NOW. SO THE WORK

4061
02:46:16,560 --> 02:46:19,640
THAT WE HAVE TO DO IN FRONT OF

4062
02:46:19,640 --> 02:46:21,800
US IS VERY BROAD. BUT WE KNOW WE

4063
02:46:21,800 --> 02:46:23,840
CAN DO IT. THIS IS OUR SPACE TO

4064
02:46:23,840 --> 02:46:25,680
INHABIT. SO THAT IS THE ONLY

4065
02:46:25,680 --> 02:46:27,800
THING I WANT TO ADD AND AGAIN,

4066
02:46:27,800 --> 02:46:30,440
JUST THANK MY TEAM AND WORKING

4067
02:46:30,440 --> 02:46:35,080
WITH MEGHAN HAS BEEN PURE JOY.

4068
02:46:35,080 --> 02:46:37,480
WE WOULD JUST ENCOURAGE AND

4069
02:46:37,480 --> 02:46:38,480
SUPPORT EVERYONE IN THIS WORK

4070
02:46:38,480 --> 02:46:41,520
AND AGAIN THIS IS JUST THE FIRST

4071
02:46:41,520 --> 02:46:43,200
SCENE OF THIS PLAY. SO WE HAVE A

4072
02:46:43,200 --> 02:46:44,520
LOT OF WORK LEFT TO DO. THANK

4073
02:46:44,520 --> 02:46:46,920
YOU.

4074
02:46:46,920 --> 02:46:50,760
>> THANK YOU, YVETTE. 
BRIAN AND

4075
02:46:50,760 --> 02:46:52,680
NAREG BACK OVER TO YOU OR ANY

4076
02:46:52,680 --> 02:46:54,360
COMMENTS OF COURSE. I SEE SOME

4077
02:46:54,360 --> 02:46:56,040
PEOPLE COMING OFF -- PUTTING

4078
02:46:56,040 --> 02:46:56,600
THEIR CAMERAS ON.

4079
02:46:56,600 --> 02:47:00,520
>> THANK YOU VERY MUCH.
YOU TAKE

4080
02:47:00,520 --> 02:47:03,960
A POSITIVE WAY TO END THE RECAP,

4081
02:47:03,960 --> 02:47:05,520
ECHOING IN THE SPIRIT OF

4082
02:47:05,520 --> 02:47:06,520
COLLABORATION AND THIS NEW

4083
02:47:06,520 --> 02:47:10,160
UNIQUE FACET TO THE PART OF THE

4084
02:47:10,160 --> 02:47:12,080
STATE OF THE SCIENCE, I CAN FOR

4085
02:47:12,080 --> 02:47:13,280
SEE THAT CONTINUING TO THE

4086
02:47:13,280 --> 02:47:17,720
FUTURE AS WELL. SO I WILL STOP

4087
02:47:17,720 --> 02:47:21,800
AND SEE IF ANYONE HAS COMMENTS

4088
02:47:21,800 --> 02:47:22,800
OR QUESTIONS.

4089
02:47:22,800 --> 02:47:25,800
>> BEFORE YOU DO JUMP IN
WITH

4090
02:47:25,800 --> 02:47:26,960
ANY COMMENT FEEL FREE TO RAISE

4091
02:47:26,960 --> 02:47:28,040
YOUR HAND OR USE THE CHAT BOX. 

4092
02:47:28,040 --> 02:47:31,240
THIS IS TIME FOR US NOT ONLY FOR

4093
02:47:31,240 --> 02:47:33,040
COMMENTS FOR MEGHAN AND YVETTE

4094
02:47:33,040 --> 02:47:34,400
BUT THE TWO OTHER WORKING GROUPS

4095
02:47:34,400 --> 02:47:38,480
THAT PRESENTED TODAY. PLEASE

4096
02:47:38,480 --> 02:47:40,280
FEEL FREE WE RECOGNIZE EACH OF

4097
02:47:40,280 --> 02:47:41,760
YOU ONLY ABLE TO JOIN A SINGLE

4098
02:47:41,760 --> 02:47:42,400
BRAINING OUT SESSION. WE

4099
02:47:42,400 --> 02:47:43,840
PROBABLY WANTED TO ATTEND MANY

4100
02:47:43,840 --> 02:47:45,600
MORE THAN JUST TWO OVER THE LAST

4101
02:47:45,600 --> 02:47:47,480
TWO DAYS. WE DO HAVE A LITTLE

4102
02:47:47,480 --> 02:47:50,120
BIT OF TIME. UPWARDS OF 20

4103
02:47:50,120 --> 02:47:51,440
MINUTES, WE WANT TO HAVE SOME

4104
02:47:51,440 --> 02:47:52,880
FURTHER DISCUSSION. AND WE WANT

4105
02:47:52,880 --> 02:47:55,400
TO TALK ACROSS GROUPS, FEEL FREE

4106
02:47:55,400 --> 02:47:57,080
TO DO SO. THIS IS AN OPPORTUNITY

4107
02:47:57,080 --> 02:48:01,000
FOR ALL OF TO HEAR EACH OTHER'S

4108
02:48:01,000 --> 02:48:01,840
THOUGHTS TOGETHER.

4109
02:48:01,840 --> 02:48:05,800
>> I WOULD SAY IF WE CAN
FOCUS

4110
02:48:05,800 --> 02:48:08,360
INITIALLY ON THE SIX WORKING

4111
02:48:08,360 --> 02:48:10,360
GROUPS, IF THERE IS DESIRE TO

4112
02:48:10,360 --> 02:48:13,320
PROCEED TO THE BROADER OPENNESS

4113
02:48:13,320 --> 02:48:18,960
COURSE WE CAN DO SO PRIOR TO MY

4114
02:48:18,960 --> 02:48:22,920
PUSH THIS PRESENTATION IN 20

4115
02:48:22,920 --> 02:48:29,560
MINUTES. -- MIKE BUSCH'S

4116
02:48:29,560 --> 02:48:38,000
PRESENTATION IN 20 MINUTES. 

4117
02:48:38,000 --> 02:48:38,720
OPERATOR:  QUENTIN.

4118
02:48:38,720 --> 02:48:40,440
>> I WANT TO MAKE A BRIEF

4119
02:48:40,440 --> 02:48:41,800
COMMENT, MEGHAN KNOWS THIS

4120
02:48:41,800 --> 02:48:43,000
BECAUSE SHE WORKS WITH THE

4121
02:48:43,000 --> 02:48:44,040
GLOBAL TRANSFUSION FORUM, THERE

4122
02:48:44,040 --> 02:48:46,040
IS A LOT OF OVERLAP BETWEEN YOUR

4123
02:48:46,040 --> 02:48:47,800
WORKING GROUP AND WHAT IS GOING

4124
02:48:47,800 --> 02:48:49,520
ON IN LOW AND MIDDLE INCOME

4125
02:48:49,520 --> 02:48:52,080
COUNTRIES. I THINK WE SHOULD

4126
02:48:52,080 --> 02:48:53,840
EXPLORE OVERLAPS AND WHAT WE CAN

4127
02:48:53,840 --> 02:48:56,560
LEARN FROM EACH OTHER BY

4128
02:48:56,560 --> 02:48:58,640
DIRECTIONALLY, BIDIRECTIONALLY

4129
02:48:58,640 --> 02:48:59,760
PARTICULARLY WITH DONOR PROGRAMS

4130
02:48:59,760 --> 02:49:02,320
IN THESE SETTINGS MANY WHICH

4131
02:49:02,320 --> 02:49:04,120
WERE INNOVATIVE IN AFRICA AND

4132
02:49:04,120 --> 02:49:06,080
SURE YOU ARE AWARE BUT WE SHOULD

4133
02:49:06,080 --> 02:49:07,880
LOOK INTO THAT, IT IS NOT JUST

4134
02:49:07,880 --> 02:49:10,200
AS A WORD WE USE NOW IN GLOBAL

4135
02:49:10,200 --> 02:49:13,840
HEALTH I'M IMMERSED IN, GLOBAL,

4136
02:49:13,840 --> 02:49:17,040
LOCAL, GLOCAL STANDS FOR GLOBAL

4137
02:49:17,040 --> 02:49:21,160
AND LOCAL. AND THIS IS CERTAINLY

4138
02:49:21,160 --> 02:49:23,400
AN INCIDENCE OF SO TO SPEAK

4139
02:49:23,400 --> 02:49:24,640
GLOCAL. THERE IS A LOT TO BE

4140
02:49:24,640 --> 02:49:26,720
LEARNED FROM THE LOW AND MIDDLE

4141
02:49:26,720 --> 02:49:29,040
INCOME COUNTRY SETTINGS AND PUT

4142
02:49:29,040 --> 02:49:29,720
THE GROUPS IN TOUCH WITH EACH

4143
02:49:29,720 --> 02:49:33,800
OTHER.

4144
02:49:33,800 --> 02:49:35,520
>> BRIAN, OKAY IF I
RESPOND?

4145
02:49:35,520 --> 02:49:36,760
>> PLEASE.

4146
02:49:36,760 --> 02:49:40,360
>> QUENTIN THANK YOU. WE
WORK

4147
02:49:40,360 --> 02:49:43,200
TOGETHER ON -- TWO COMMENTS I

4148
02:49:43,200 --> 02:49:46,600
WANT TO BRING UP. ON OUR BREAK

4149
02:49:46,600 --> 02:49:48,960
OUT SESSION BERNARDO PYATT

4150
02:49:48,960 --> 02:49:50,960
BROUGHT UP USE OF WHAT'S APP AND

4151
02:49:50,960 --> 02:49:52,840
THINKING FROM THE COMMUNITY

4152
02:49:52,840 --> 02:49:54,640
BASED PERSPECTIVE, HOW DO

4153
02:49:54,640 --> 02:49:58,280
COMMUNITIES TALK TO EACH OTHER?

4154
02:49:58,280 --> 02:50:00,480
AND IS IT THESE DIFFERENT

4155
02:50:00,480 --> 02:50:02,320
MODALITIES AND SHOULD THEY BE

4156
02:50:02,320 --> 02:50:06,880
STUDIED. I PUT IN A PLUG THE

4157
02:50:06,880 --> 02:50:08,720
BLOOD BASE PROGRAM IS INCREASING

4158
02:50:08,720 --> 02:50:11,320
ACCESS TO SAVE TRANSFUSION IN

4159
02:50:11,320 --> 02:50:12,880
LOW AND MIDDLE INCOME COUNTRIES

4160
02:50:12,880 --> 02:50:15,080
SPECIFICALLY FOCUSED AT

4161
02:50:15,080 --> 02:50:17,080
SUB-SAHARAN AFRIC AFRICA. ONE OE

4162
02:50:17,080 --> 02:50:19,520
STUDIES LOOKS AT THE

4163
02:50:19,520 --> 02:50:23,280
INTERVENTION FOR BLOOD DONATION

4164
02:50:23,280 --> 02:50:24,360
RECRUITMENT AND GETTING PEOPLE

4165
02:50:24,360 --> 02:50:27,960
IN IMMUNITY TO DONATE.  ON A

4166
02:50:27,960 --> 02:50:30,680
MORE GENERAL EXAMPLE, SORT OF

4167
02:50:30,680 --> 02:50:32,640
EMPHASIZING WHAT QUINTON IS

4168
02:50:32,640 --> 02:50:34,000
SAYING, THAT PROGRAM IN

4169
02:50:34,000 --> 02:50:37,080
PARTICULAR IS A WAY THE NIH BY

4170
02:50:37,080 --> 02:50:39,120
DOING IMPLEMENTATION SCIENCE

4171
02:50:39,120 --> 02:50:41,720
RESEARCH IS STRENGTHENING THE

4172
02:50:41,720 --> 02:50:42,600
HEALTHCARE SYSTEM WHERE THOSE

4173
02:50:42,600 --> 02:50:46,320
ARE OCCURRING AND TRYING TO SHOW

4174
02:50:46,320 --> 02:50:52,400
RESEARCH LEVEL METHODOLOGY THAT

4175
02:50:52,400 --> 02:50:54,200
OPTION A OR B ARE TWO STUDY ARM,

4176
02:50:54,200 --> 02:50:55,480
WHAT IS THE BETTER WAY TO

4177
02:50:55,480 --> 02:50:56,360
INCREASE ACCESS TO BLOOD

4178
02:50:56,360 --> 02:50:58,000
TRANSFUSION WHICH IS THE GOEL OF

4179
02:50:58,000 --> 02:51:04,680
THOSE PROJECTS.  SO THERE IS A

4180
02:51:04,680 --> 02:51:06,120
PATHWAY THAT RESEARCH

4181
02:51:06,120 --> 02:51:08,600
ORGANIZATION AND FUNDING CAN

4182
02:51:08,600 --> 02:51:11,800
VERY CLEARLY PROVIDE HEALTHCARE

4183
02:51:11,800 --> 02:51:13,520
SYSTEM STRENGTHENING, WHICH IS

4184
02:51:13,520 --> 02:51:14,480
STILL NOT EVERYTHING THAT WE

4185
02:51:14,480 --> 02:51:15,800
TALKED ABOUT IN OUR SUBGROUP BUT

4186
02:51:15,800 --> 02:51:22,640
PART OF IT. SUPPORT, KNOWLEDGE,

4187
02:51:22,640 --> 02:51:23,920
GENERALIZABLE INCREASE IN

4188
02:51:23,920 --> 02:51:30,960
HEALTHCARE RECRUITMENT. THANKS. 

4189
02:51:30,960 --> 02:51:32,880
>> CASSANDRA.

4190
02:51:32,880 --> 02:51:35,120
>> I WAS THINKING ABOUT

4191
02:51:35,120 --> 02:51:36,240
COMMUNITY AND I WAS THINKING

4192
02:51:36,240 --> 02:51:37,440
ABOUT HOW TO GET INTO THE

4193
02:51:37,440 --> 02:51:38,560
COMMUNITY AND I WAS THINKING

4194
02:51:38,560 --> 02:51:43,760
ABOUT PEDIATRICS AND FAMILIES.

4195
02:51:43,760 --> 02:51:45,640
AND SO MANY CHILDREN IN

4196
02:51:45,640 --> 02:51:48,360
DIFFERENT WAYS NEED BLOOD AND IT

4197
02:51:48,360 --> 02:51:52,800
IS VERY HARD TO FIGURE HOW TO

4198
02:51:52,800 --> 02:51:55,560
CONNECT TO THE COMMUNITIES AND

4199
02:51:55,560 --> 02:51:57,200
THEY ARE ALL DIFFERENT TYPES OF

4200
02:51:57,200 --> 02:51:59,280
COMMUNITIES OF PATIENTS THAT

4201
02:51:59,280 --> 02:52:00,960
NEED BLOOD IN EITHER CHILDREN'S

4202
02:52:00,960 --> 02:52:02,240
HOSPITAL OR IN -- WITH CHILDREN

4203
02:52:02,240 --> 02:52:06,760
IN AN ADULT HOSPITAL. I WAS

4204
02:52:06,760 --> 02:52:09,040
THINKING THAT ONE UNIQUE WAY

4205
02:52:09,040 --> 02:52:10,280
MIGHT BE TO GET INTO THE

4206
02:52:10,280 --> 02:52:13,760
COMMUNITIES BY HAVING -- LOOKING

4207
02:52:13,760 --> 02:52:16,720
AT FAMILIES AND SOCIOECONOMIC

4208
02:52:16,720 --> 02:52:17,960
DETERMINANTS OF HEALTH AND

4209
02:52:17,960 --> 02:52:19,200
LOOKING AT IT BECAUSE SO MANY

4210
02:52:19,200 --> 02:52:21,400
CHILDREN ARE ON MEDICAID AND

4211
02:52:21,400 --> 02:52:22,920
THERE IS JUST -- SEEMS LIKE THAT

4212
02:52:22,920 --> 02:52:24,760
WOULD BE AN INROAD TO TALK WITH

4213
02:52:24,760 --> 02:52:27,920
FAMILIES AND TALK WITH VERY HARD

4214
02:52:27,920 --> 02:52:29,280
TORR PARENTS TO GET PLACES, AND

4215
02:52:29,280 --> 02:52:36,760
VERY HARD FOR THEM TO UNDERSTAND

4216
02:52:36,760 --> 02:52:38,760
ABOUT BLOOD TRANSFUG. WE SPEAK

4217
02:52:38,760 --> 02:52:40,240
TO LOTS OF FAMILIES HOW BLOOD

4218
02:52:40,240 --> 02:52:41,440
GETS TO HOSPITALS.  SOME

4219
02:52:41,440 --> 02:52:42,960
CHILDREN HOSPITALS HAVE A BLOOD

4220
02:52:42,960 --> 02:52:44,840
CENTER BUT MOST DONE. AND THEN I

4221
02:52:44,840 --> 02:52:47,280
WAS JUST THINKING SOMEHOW

4222
02:52:47,280 --> 02:52:49,320
SETTING UP WITH COMMUNITY, WHERE

4223
02:52:49,320 --> 02:52:50,040
THERE ARE CHILDREN HOSPITALS

4224
02:52:50,040 --> 02:52:52,480
MIGHT BE A WAY TO BRING BRING

4225
02:52:52,480 --> 02:52:55,400
COMMUNITY CLOSER AND EDUCATE

4226
02:52:55,400 --> 02:53:00,000
THEM ABOUT WHAT BLOOD

4227
02:53:00,000 --> 02:53:01,200
TRANSFUSION IS ABOUT AND THEN

4228
02:53:01,200 --> 02:53:02,680
FIND OUT WHAT THE BARRIERS ARE

4229
02:53:02,680 --> 02:53:04,120
TO PEOPLE IN THE COMMUNITY BEING

4230
02:53:04,120 --> 02:53:06,320
ABLE TO DONATE BLOOD. SO I WAS

4231
02:53:06,320 --> 02:53:09,040
THINKING THAT WAS ONE AVENUE

4232
02:53:09,040 --> 02:53:10,840
THAT MIGHT NOT HAVE BEEN

4233
02:53:10,840 --> 02:53:11,560
HIGHLIGHTED THAT IS I THINK AN

4234
02:53:11,560 --> 02:53:18,160
OPPORTUNITY.

4235
02:53:18,160 --> 02:53:20,440
>> THANK YOU, CASSANDRA.
GO

4236
02:53:20,440 --> 02:53:22,840
AHEAD MIKE.

4237
02:53:22,840 --> 02:53:24,760
>> OBVIOUSLY I WILL
PRESENT

4238
02:53:24,760 --> 02:53:27,240
LATER AND LAYING THE FOUNDATION

4239
02:53:27,240 --> 02:53:30,760
FOR WHAT -- WHY I BELIEVE LARGE

4240
02:53:30,760 --> 02:53:32,880
IMPORTANTLY SUSTAINABLE LINK

4241
02:53:32,880 --> 02:53:35,640
DONOR RECIPIENT AND DISEASE

4242
02:53:35,640 --> 02:53:36,400
REGISTRY DAY BASES ARE SO

4243
02:53:36,400 --> 02:53:38,440
IMPORTANT OPTIMALLY LINKED TO

4244
02:53:38,440 --> 02:53:40,000
REPOSITORIES. BUT PLEASED TO SEE

4245
02:53:40,000 --> 02:53:41,120
PARTICIPATION IN THE MEETING OF

4246
02:53:41,120 --> 02:53:44,800
SOME LEADERSHIP FROM SENIOR

4247
02:53:44,800 --> 02:53:46,440
PEOPLE FROM RED CROSS AND LARGE

4248
02:53:46,440 --> 02:53:48,800
TESTING LABS. I THINK IN MY

4249
02:53:48,800 --> 02:53:52,080
DISCUSSION HISTORICALLY WITH

4250
02:53:52,080 --> 02:53:54,120
NHLBI AND LEADERSHIP, NIH IS

4251
02:53:54,120 --> 02:53:56,560
REALLY NOT THERE TO SUPPORT

4252
02:53:56,560 --> 02:53:58,120
ESTABLISHING THE LARGE SCALE

4253
02:53:58,120 --> 02:54:00,960
INFRASTRUCTURE NEEDED TO

4254
02:54:00,960 --> 02:54:03,360
MAINTAIN AND ESTABLISH AND

4255
02:54:03,360 --> 02:54:05,160
MAINTAIN THESE LARGE LINK BLOOD

4256
02:54:05,160 --> 02:54:07,040
ORGANIZATIONS AND THE U.S. WE

4257
02:54:07,040 --> 02:54:10,000
ARE SEEING OTHER COUNTRIES ARE

4258
02:54:10,000 --> 02:54:11,880
LEAP FROGGING THOUGH SOME CASES

4259
02:54:11,880 --> 02:54:14,000
YOU CAN ARGUE WE DEVELOP THE

4260
02:54:14,000 --> 02:54:17,240
ORIGINAL PROGRAMS TO EARLY

4261
02:54:17,240 --> 02:54:19,040
REGISTER PROGRAMS BECAUSE OF THE

4262
02:54:19,040 --> 02:54:20,200
FRAGMENTATION OF THE U.S. BLOOD

4263
02:54:20,200 --> 02:54:22,080
COLLECTION PROGRAMS, WE DON'T

4264
02:54:22,080 --> 02:54:25,160
HAVE THE SYSTEMS LIKE THEY HAVE

4265
02:54:25,160 --> 02:54:26,680
FOR EXAMPLE MILLION CANADA OR

4266
02:54:26,680 --> 02:54:28,800
AUSTRALIA OR DENMARK THAT ALLOW

4267
02:54:28,800 --> 02:54:31,320
A NATIONAL LONG TERM DEVELOPMENT

4268
02:54:31,320 --> 02:54:33,320
OF SUCH DATABASES AND

4269
02:54:33,320 --> 02:54:36,560
REPOSITORIES SO JUST TO PLANT

4270
02:54:36,560 --> 02:54:38,320
THE IDEA THE BLOOD COLLECTION

4271
02:54:38,320 --> 02:54:39,720
ORGANIZATIONS THEMSELVES AND THE

4272
02:54:39,720 --> 02:54:42,400
LARGE TESTING LABS THEY OWN AND

4273
02:54:42,400 --> 02:54:44,720
OPERATE, THEY HAVE A CERTAIN

4274
02:54:44,720 --> 02:54:48,680
OBLIGATION. SOME OF THEM -- THEY

4275
02:54:48,680 --> 02:54:51,840
JUST ESTABLISHED VETALIN

4276
02:54:51,840 --> 02:54:54,680
INNOVATION CENTER, FOR

4277
02:54:54,680 --> 02:54:56,480
ACTIVITIES TO MOVE RESEARCH

4278
02:54:56,480 --> 02:54:58,040
FINDINGS TO REAL WORLD. I WOULD

4279
02:54:58,040 --> 02:55:02,520
LIKE TO LAY THE GROUND WORK FOR

4280
02:55:02,520 --> 02:55:03,440
ORGANIZATIONAL FUNDING THAT THEN

4281
02:55:03,440 --> 02:55:05,840
IS COMPLIMENTED BY NIH AND OTHER

4282
02:55:05,840 --> 02:55:16,160
EXTERNAL FUNDING.

4283
02:55:17,760 --> 02:55:19,040
>> I WANT THE THEY CAN THE

4284
02:55:19,040 --> 02:55:20,400
ORGANIZERS FOR THIS MEETING. ONE

4285
02:55:20,400 --> 02:55:21,760
THING IMPRESS WITH MY MIND WITH

4286
02:55:21,760 --> 02:55:23,640
THIS MEETING AND GENERAL

4287
02:55:23,640 --> 02:55:26,000
TRANSFUSION DESPITE THE FACT

4288
02:55:26,000 --> 02:55:27,200
TRANSFUSION IS A SMALL FIELD THE

4289
02:55:27,200 --> 02:55:29,480
TALKS ARE INCREDIBLY DIVERSE YOU

4290
02:55:29,480 --> 02:55:31,280
GO DOWN THE RABBIT HOLE AND

4291
02:55:31,280 --> 02:55:33,120
REALIZE SO MANY AREAS FROM DONOR

4292
02:55:33,120 --> 02:55:35,480
ASPECT OF GETTING THE

4293
02:55:35,480 --> 02:55:36,560
ANTHROPOLOGY BEHIND IT TO

4294
02:55:36,560 --> 02:55:37,640
ACTUALLY CHARACTERIZING IT TO

4295
02:55:37,640 --> 02:55:39,800
WHAT HAPPENS IN DIFFERENT

4296
02:55:39,800 --> 02:55:40,880
RECIPIENTS AND PATIENT

4297
02:55:40,880 --> 02:55:42,680
POPULATIONS.S.  ONE THOUGHT I HD

4298
02:55:42,680 --> 02:55:44,200
TALKING ABOUT THIS, BASED ON A

4299
02:55:44,200 --> 02:55:44,880
COMMENTS STEVE MADE AT THE

4300
02:55:44,880 --> 02:55:47,520
BEGINNING OF THE MEETING IS THE

4301
02:55:47,520 --> 02:55:49,960
TRAINING, TRANSFUSION IS UNIQUE

4302
02:55:49,960 --> 02:55:51,400
ONE YEAR CLINICAL FELLOWSHIP

4303
02:55:51,400 --> 02:55:54,520
WITH LITTLE RESEARCH EMBEDDED

4304
02:55:54,520 --> 02:55:55,640
UNLIKE CARDIOLOGY OR OTHER

4305
02:55:55,640 --> 02:55:57,000
SPECIALTIES IN MEDICINE WHERE

4306
02:55:57,000 --> 02:55:58,400
THEY HAVE SIGNIFICANT RESEARCH

4307
02:55:58,400 --> 02:56:01,720
TRAINING THAT YOU CAN ARGUE IS

4308
02:56:01,720 --> 02:56:05,880
INSUFFICIENT TO BE ABLE TO PLAY

4309
02:56:05,880 --> 02:56:08,120
FOR GRANTS. WONDER IF WILL IS

4310
02:56:08,120 --> 02:56:09,680
OVERARCHING ASPECT THAT MAYBE

4311
02:56:09,680 --> 02:56:14,200
BENEFIT BY HAVING -- NOT

4312
02:56:14,200 --> 02:56:15,640
SPECIFICS IN TERMS OF HOW NIH

4313
02:56:15,640 --> 02:56:17,640
SHOULD TO THIS BUT WHETHER THERE

4314
02:56:17,640 --> 02:56:19,400
IS A BENEFIT FROM A PROGRAM. I

4315
02:56:19,400 --> 02:56:21,480
TRAIN IN GLYCO BIOLOGY WHICH IS

4316
02:56:21,480 --> 02:56:24,400
VERY ORGANIC CHEMISTRY AND

4317
02:56:24,400 --> 02:56:27,000
INTENSE FIELD, WEIRDLY, AND

4318
02:56:27,000 --> 02:56:30,760
NHLBI JUST FUNDED A K 12 PROGRAM

4319
02:56:30,760 --> 02:56:32,520
FOR GLYCO BIOLOGY, WE HAVE A

4320
02:56:32,520 --> 02:56:35,080
FOLLOW IN OUR LAB DOING THAT AND

4321
02:56:35,080 --> 02:56:36,600
THERE'S BUNCH OF GREAT

4322
02:56:36,600 --> 02:56:39,320
SCIENTISTS HERE AND NOT ON THIS

4323
02:56:39,320 --> 02:56:41,040
CALL BUT POINTED OUT IF THAT

4324
02:56:41,040 --> 02:56:43,720
WOULD BE USEFUL OVER ARCHING AND

4325
02:56:43,720 --> 02:56:46,040
JUST ANOTHER COMMENT IN GENERAL

4326
02:56:46,040 --> 02:56:48,240
FOR APHERESIS, NOT REALLY

4327
02:56:48,240 --> 02:56:49,680
DISCUSSING NOT A SPECIFIC

4328
02:56:49,680 --> 02:56:51,800
RESEARCH INTEREST OF MINE PER SE

4329
02:56:51,800 --> 02:56:53,240
BUT SOMETHING WE ALL DEAL WITH

4330
02:56:53,240 --> 02:56:54,160
CLINICALLY AND YOU CAN SEE

4331
02:56:54,160 --> 02:56:55,600
PATIENTS ARE JUST NO DATA FOR

4332
02:56:55,600 --> 02:56:58,000
MOST OF WHAT WE DO

4333
02:56:58,000 --> 02:57:00,080
MECHANISTICALLY OR OTHERWISE SO

4334
02:57:00,080 --> 02:57:01,280
JUST ANOTHER EXAMPLE OF

4335
02:57:01,280 --> 02:57:02,440
SOMETHING I DON'T SUGGEST ANY

4336
02:57:02,440 --> 02:57:04,000
WAY NEEDS TO PRIORITIZE ABOUT

4337
02:57:04,000 --> 02:57:05,520
THINGS WE TALK ABOUT TODAY BUT

4338
02:57:05,520 --> 02:57:06,840
SO MANY OPPORTUNITIES RESEARCH

4339
02:57:06,840 --> 02:57:08,840
ONE LIMITATION IS JUST DON'T

4340
02:57:08,840 --> 02:57:10,200
HAVE RESEARCH EMBEDDED IN

4341
02:57:10,200 --> 02:57:11,880
TRAINING, SO I THINK THAT DOES

4342
02:57:11,880 --> 02:57:13,720
LIMIT SOME OF THESE DIFFERENT

4343
02:57:13,720 --> 02:57:17,320
ASPECTS OF DONOR SCIENCE, OTHER

4344
02:57:17,320 --> 02:57:19,320
THINGS THAT MAY BE LEFT TO SITES

4345
02:57:19,320 --> 02:57:20,640
BECAUSE THERE IS A STRUCTURE IN

4346
02:57:20,640 --> 02:57:22,160
PLACE TO TRAIN PEOPLE. COULD BE

4347
02:57:22,160 --> 02:57:23,360
WRONG BUT JUST A THOUGHT ON THAT

4348
02:57:23,360 --> 02:57:29,680
IN GENERAL.

4349
02:57:29,680 --> 02:57:32,680
>> RUCHIKA.

4350
02:57:32,680 --> 02:57:38,200
>> HI. I STRONGLY -- EVERY
TIME

4351
02:57:38,200 --> 02:57:39,560
YOU GO THROUGH THE PROCESS THE

4352
02:57:39,560 --> 02:57:41,880
QUESTION OF HOW CAN WE INTEGRATE

4353
02:57:41,880 --> 02:57:45,960
THIS INTO TEACHING OUR --

4354
02:57:45,960 --> 02:57:47,080
WHETHER NEXT GENERATION OR

4355
02:57:47,080 --> 02:57:48,840
FELLOWSHIP GRADUATES, TRAINEES,

4356
02:57:48,840 --> 02:57:50,760
SOME WAY TO HAVE A MORE

4357
02:57:50,760 --> 02:57:52,880
SYNCHRONIZE WAY OF MENTORSHIP,

4358
02:57:52,880 --> 02:57:57,160
SOMETHING THAT THEY COULD DO

4359
02:57:57,160 --> 02:57:59,960
START DURING THE TRANS--

4360
02:57:59,960 --> 02:58:00,840
INDEPENDENT, (INAUDIBLE) PEOPLE

4361
02:58:00,840 --> 02:58:03,200
COMING FROM HEMATOLOGY,

4362
02:58:03,200 --> 02:58:05,600
PULMONARY, ANESTHESIA,

4363
02:58:05,600 --> 02:58:06,680
TRANSFUSION MEDICINE RESEARCH.

4364
02:58:06,680 --> 02:58:10,960
BUT HAVING SOME PATHWAY THERE

4365
02:58:10,960 --> 02:58:12,880
COULD BE UNDER ONE UMBRELLA. IF

4366
02:58:12,880 --> 02:58:14,400
YOU HAVE AN INTEREST SOME WAY TO

4367
02:58:14,400 --> 02:58:16,520
CONNECT TO MENTOR, STUFF CAN BE

4368
02:58:16,520 --> 02:58:21,360
DONE REMOTELY, NOT EVERYTHING

4369
02:58:21,360 --> 02:58:22,360
BUT (INAUDIBLE) HAS MENTORING

4370
02:58:22,360 --> 02:58:23,560
PROGRAM, WE HAD DISCUSSION WITH

4371
02:58:23,560 --> 02:58:27,960
CLAUDIA RECENTLY, WE WERE ON A

4372
02:58:27,960 --> 02:58:30,640
CALL USING THE DEEP DIVE ABB

4373
02:58:30,640 --> 02:58:33,760
DATA GROUP PROJECTS AND WE

4374
02:58:33,760 --> 02:58:34,760
THOUGHT WE COULD USE IT TO

4375
02:58:34,760 --> 02:58:37,600
ANNOUNCE AND SEE IF THERE ARE

4376
02:58:37,600 --> 02:58:39,560
OTHER TRAINEES LOOKING FOR

4377
02:58:39,560 --> 02:58:42,040
MENTORSHIP OR JUNIOR FACULTY OR

4378
02:58:42,040 --> 02:58:43,640
SENIOR LOOKING FOR MENTORING, I

4379
02:58:43,640 --> 02:58:46,480
THINK HAVING SOME INFRASTRUCTURE

4380
02:58:46,480 --> 02:58:48,200
WOULD BE AMAZINGS. SOMETHING

4381
02:58:48,200 --> 02:58:50,600
SIMILAR COULD BE DONE FOR SOME

4382
02:58:50,600 --> 02:58:52,560
OF THE DATA SCIENCE AT LEAST

4383
02:58:52,560 --> 02:58:55,680
SOME BASIC EDUCATION AS WELL

4384
02:58:55,680 --> 02:58:58,600
WHICH WILL MAKE FOLKS MUCH MORE

4385
02:58:58,600 --> 02:58:59,120
COMFORTABLE THAT EVEN

4386
02:58:59,120 --> 02:59:01,080
UNDERSTANDING WHEN THE NEW

4387
02:59:01,080 --> 02:59:02,360
PAPERS COME OUT SO YES, I THINK

4388
02:59:02,360 --> 02:59:06,160
THAT IS A GREAT IDEA, SOME POINT

4389
02:59:06,160 --> 02:59:07,600
BUILDING INTO TRANSFUSION

4390
02:59:07,600 --> 02:59:18,160
MEDICINE EDUCATION IS HELPFUL.

4391
02:59:21,360 --> 02:59:25,720
>> THANK YOU, RUCHIKA.
YVETTE.

4392
02:59:25,720 --> 02:59:28,680
>>S IN A GREAT
CONVERSATION

4393
02:59:28,680 --> 02:59:32,960
AROUND HOW DO WE EMBED RESEARCH

4394
02:59:32,960 --> 02:59:36,320
IN TRAINING BUT THE I GUESS THE

4395
02:59:36,320 --> 02:59:38,640
BROAD THINKING AROUND APHERESIS

4396
02:59:38,640 --> 02:59:41,080
MEDICINE, WHEN YOU COME TO

4397
02:59:41,080 --> 02:59:43,400
APHERESIS MEDICINE TOLUENE FROG

4398
02:59:43,400 --> 02:59:47,840
OR PATHOLOGY OR HEMATOLOGY. SO

4399
02:59:47,840 --> 02:59:50,720
USING APHERESIS MEDICINE HOW

4400
02:59:50,720 --> 02:59:52,840
THOSE MULTIPLE MEDICAL

4401
02:59:52,840 --> 02:59:55,840
SPECIALTIES CAN GET, SPECIFIC

4402
02:59:55,840 --> 02:59:56,400
RESEARCH P P INFORMATION IN

4403
02:59:56,400 --> 02:59:58,600
RELATIONSHIP TO THOSE

4404
02:59:58,600 --> 02:59:59,600
POPULATIONS, PAINT DIVERSE

4405
02:59:59,600 --> 03:00:00,880
POPULATIONS OF PATIENTS WHO NEED

4406
03:00:00,880 --> 03:00:04,760
THIS ONE PROCEDURE APHERESIS.  

4407
03:00:04,760 --> 03:00:06,120
SO JUST RECENTLY THIS WAS LAST

4408
03:00:06,120 --> 03:00:11,280
WEEK WE HAD A JOURNAL CLUB

4409
03:00:11,280 --> 03:00:12,480
TALKING ABOUT DIFFERENT

4410
03:00:12,480 --> 03:00:16,240
OBJECTIVE MEASURES OF TRAINING

4411
03:00:16,240 --> 03:00:17,720
PHYSICIANS IN APHERESIS MEDICINE

4412
03:00:17,720 --> 03:00:19,600
COMING FROM ALL THE MEDICAL

4413
03:00:19,600 --> 03:00:22,240
SPECIALTIES AND HOW TO HAVE

4414
03:00:22,240 --> 03:00:24,360
STANDARDIZED OBJECTIVES IN TERMS

4415
03:00:24,360 --> 03:00:28,320
OF TRAINING. USING APHERESIS

4416
03:00:28,320 --> 03:00:33,440
MEDICINE AS AN OPPORTUNITY TO

4417
03:00:33,440 --> 03:00:36,760
BRING FORTH INTO ONE PARTICULAR

4418
03:00:36,760 --> 03:00:38,640
PIECE OF DEALING WITH OR ONE

4419
03:00:38,640 --> 03:00:40,400
PARTICULAR PROCEDURE OR ASPECT

4420
03:00:40,400 --> 03:00:42,560
OF TREATMENT APHERESIS MEDICINE,

4421
03:00:42,560 --> 03:00:43,960
AND THEN HAVE ALL OF THOSE

4422
03:00:43,960 --> 03:00:45,400
MEDICAL SPECIALTIES THAT USE

4423
03:00:45,400 --> 03:00:51,120
THIS PROCEDURE TALK ABOUT HOW

4424
03:00:51,120 --> 03:00:52,200
THEY COULD COME TOGETHER IN

4425
03:00:52,200 --> 03:00:53,800
RELATIONSHIP TO FUNDING, AND

4426
03:00:53,800 --> 03:00:55,600
TRAINING AND RESEARCH AROUND

4427
03:00:55,600 --> 03:00:58,440
APHERESIS MEDICINE WHICH IS IN

4428
03:00:58,440 --> 03:01:01,720
MANY CASES TRANSFUSION, FALSE

4429
03:01:01,720 --> 03:01:12,280
TRANSFUSION AS WELL.  WE STARTED

4430
03:01:20,080 --> 03:01:21,400
TA TALK TOWARD THEND OF THE

4431
03:01:21,400 --> 03:01:22,760
MEETING AND THERE'S GOOD

4432
03:01:22,760 --> 03:01:24,400
COMMENTS IN THE CHAT BOX AROUND

4433
03:01:24,400 --> 03:01:26,320
DIFFERENT INITIATIVES. BECAUSE

4434
03:01:26,320 --> 03:01:27,400
WE HAVEN'T HAD A CHANCE TO TALK

4435
03:01:27,400 --> 03:01:29,280
ABOUT THIS AND THINK THROUGH

4436
03:01:29,280 --> 03:01:31,720
WHAT SHOULD WE ASK FOR NIH AND

4437
03:01:31,720 --> 03:01:35,480
NHLBI TO DO TO HELP SUPPORT NEXT

4438
03:01:35,480 --> 03:01:38,240
GENERATION. AGAIN RECOGNIZING

4439
03:01:38,240 --> 03:01:39,160
EVERYBODY'S EFFORT AND INTEREST

4440
03:01:39,160 --> 03:01:41,920
IN THIS AREA, THANK YOU, FOR

4441
03:01:41,920 --> 03:01:43,240
SURFACING IT AND GIVING A CHANCE

4442
03:01:43,240 --> 03:01:45,120
TO RECORD IT AS A PARTS OF THE

4443
03:01:45,120 --> 03:01:46,800
PROCEEDINGS FOR THE STATE OF THE

4444
03:01:46,800 --> 03:01:57,320
SCIENCE TRANSFUSION MEDICINE. 

4445
03:02:02,440 --> 03:02:03,720
THOSE CHAT MESSAGES WILL BE

4446
03:02:03,720 --> 03:02:05,280
CAPTURED.  I WILL TRANSITION TO

4447
03:02:05,280 --> 03:02:07,200
GIVE INTRODUCTION FOR MIKE

4448
03:02:07,200 --> 03:02:08,560
BUSCH, AT LEAST MORE ME IT IS

4449
03:02:08,560 --> 03:02:10,640
CERTAINLY A VERY STRANGE TO SEE

4450
03:02:10,640 --> 03:02:13,400
HIM CLASSIFIED AS DIRECTOR

4451
03:02:13,400 --> 03:02:15,160
EMERITUS OF THE RESEARCH

4452
03:02:15,160 --> 03:02:16,320
INSTITUTE BUT WE ARE VERY

4453
03:02:16,320 --> 03:02:18,760
HONORED TO HAVE HIM AS WELL AS

4454
03:02:18,760 --> 03:02:21,360
WE HAVE DR. DEVINE SPEAKING ON

4455
03:02:21,360 --> 03:02:24,120
HIS PERSPECTIVE FOR A RESEARCH

4456
03:02:24,120 --> 03:02:26,240
CAREER IN BLOOD SAFETY AND

4457
03:02:26,240 --> 03:02:27,400
TRANSFUSION MEDICINE. WHAT HE

4458
03:02:27,400 --> 03:02:30,480
THINKS THE FUTURE BRINGS. SO HE

4459
03:02:30,480 --> 03:02:32,760
HAS AN ESTEEMED CAREER WITH OVER

4460
03:02:32,760 --> 03:02:35,360
600 PEER REVIEWED PUBLICATIONS

4461
03:02:35,360 --> 03:02:37,920
AS WELL AS 150 COMMENTARIES OR

4462
03:02:37,920 --> 03:02:41,040
EDITORIAL PIECES ON THAT. SO HE

4463
03:02:41,040 --> 03:02:42,560
DOESN'T NEED ANY MORE

4464
03:02:42,560 --> 03:02:43,360
INTRODUCTION FROM ME, I WILL

4465
03:02:43,360 --> 03:02:45,040
TURN IT TO MIKE. THANK YOU VERY

4466
03:02:45,040 --> 03:02:46,400
MUCH FOR CLOSING OUT THE MEETING

4467
03:02:46,400 --> 03:02:56,880
WITH YOUR KEYNOTE ADDRESS. 

4468
03:02:57,680 --> 03:02:58,960
>> THANK YOU. IT'S BEEN A

4469
03:02:58,960 --> 03:03:03,040
TERRIFIC MEETING AND I WANT TO

4470
03:03:03,040 --> 03:03:03,760
COMPLIMENT THE EXCELLENT

4471
03:03:03,760 --> 03:03:05,120
PRESENTATIONS AND I'M HONORED TO

4472
03:03:05,120 --> 03:03:06,560
GIVE THIS TALK. I ENJOYED ALL

4473
03:03:06,560 --> 03:03:08,120
THE WORKING GROUP PRESENTATIONS.

4474
03:03:08,120 --> 03:03:11,600
I THINK THIS IS EXTRAORDINARILY

4475
03:03:11,600 --> 03:03:12,480
SUCCESSFUL, APPRECIATE STEVE'S

4476
03:03:12,480 --> 03:03:13,360
COMMENTS AT THE BEGINNING

4477
03:03:13,360 --> 03:03:15,520
LOOKING BACK AT THE LAST STATE

4478
03:03:15,520 --> 03:03:16,760
OF THE SCIENCE MEETING AND I

4479
03:03:16,760 --> 03:03:18,480
BELIEVE AS HE NOTED THAT WE HAVE

4480
03:03:18,480 --> 03:03:20,600
MADE ENORMOUS PROGRESS ON THE

4481
03:03:20,600 --> 03:03:24,560
IDEAS AND PROJECTS THAT WERE

4482
03:03:24,560 --> 03:03:25,960
DELINEATED. SO SURE WE WILL DO

4483
03:03:25,960 --> 03:03:27,920
THE SAME. IN MY TALK I WANT TO

4484
03:03:27,920 --> 03:03:29,520
STEP BACK AND SHARE PERSPECTIVE

4485
03:03:29,520 --> 03:03:31,960
OF STUDIES, DID BASIC RESEARCH,

4486
03:03:31,960 --> 03:03:33,760
LAB RESEARCH, Ph.D. IN

4487
03:03:33,760 --> 03:03:35,040
RESIDENCY BUT THEN I WAS

4488
03:03:35,040 --> 03:03:36,280
FORTUNATE TO GET INVOLVED VERY

4489
03:03:36,280 --> 03:03:38,400
EARLY IN MY CAREER IN THE EARLY

4490
03:03:38,400 --> 03:03:39,840
'80s WITH AIDS AND SOME BIG

4491
03:03:39,840 --> 03:03:41,640
STUDIES AND I WILL SHARE COUPLE

4492
03:03:41,640 --> 03:03:46,640
OF THOSE BUT THEN TALK ABOUT THE

4493
03:03:46,640 --> 03:03:49,360
EVOLUTION OF STUDIES AND IMPACT

4494
03:03:49,360 --> 03:03:53,120
OF BIG DATA ON THE FIELD. NEXT

4495
03:03:53,120 --> 03:03:57,880
SLIDE, I WANT TO RECOGNIZE TWO

4496
03:03:57,880 --> 03:04:01,560
MENTORS AND TED KATE FOUNDING

4497
03:04:01,560 --> 03:04:03,760
SCIENTIST SCIENTIFIC DIRECTOR

4498
03:04:03,760 --> 03:04:06,160
RESEARCH PROGRAM AT THE IRWIN

4499
03:04:06,160 --> 03:04:07,400
MEMORIAL BLOOD BANK WHICH I

4500
03:04:07,400 --> 03:04:10,000
JOINED AND PASSED AWAY ABOUT

4501
03:04:10,000 --> 03:04:11,440
NINE YEARS AGO A AND GEORGE NIMO

4502
03:04:11,440 --> 03:04:13,800
WHO RECENTLY PASSED AWAY. I MET

4503
03:04:13,800 --> 03:04:16,200
BOTH HERB AND GEORGE ALMOST

4504
03:04:16,200 --> 03:04:18,840
EXACTLY THE IMSAME TIME IN 1983

4505
03:04:18,840 --> 03:04:20,200
AT THE BLOOD BANK IN SAN

4506
03:04:20,200 --> 03:04:21,360
FRANCISCO AND TRANSFUSION AIDS

4507
03:04:21,360 --> 03:04:22,880
CRISIS WAS JUST BEGINNING TO BE

4508
03:04:22,880 --> 03:04:24,000
APAREN. AND GEORGE AT THE TIME

4509
03:04:24,000 --> 03:04:25,560
HAD JUST TAKEN OVER THE

4510
03:04:25,560 --> 03:04:28,880
TRANSFUSION MEDICINE BRANCH AT

4511
03:04:28,880 --> 03:04:30,320
NHLBI AND LEADING THE FUNDING

4512
03:04:30,320 --> 03:04:32,400
PROCESS FOR THE BIG STUDIES THAT

4513
03:04:32,400 --> 03:04:36,720
I WILL TALK ABOUT. SO MANY OF US

4514
03:04:36,720 --> 03:04:40,280
INCLUDING SIMONE AND RECRUITED

4515
03:04:40,280 --> 03:04:43,040
HER TO NHLBI AND NEXT SLIDE IS A

4516
03:04:43,040 --> 03:04:44,840
PHOTO WITH THE CONCLUDING

4517
03:04:44,840 --> 03:04:46,320
CEREMONY AROUND THE RED TREE

4518
03:04:46,320 --> 03:04:48,280
PROGRAM WHICH CHOSE GEORGE AND

4519
03:04:48,280 --> 03:04:50,000
SIMONE AND ALSO STEVE KLINEMAN

4520
03:04:50,000 --> 03:04:51,440
WHO HAS BEEN A LIFE LONG

4521
03:04:51,440 --> 03:04:53,240
COLLEAGUE, I MET HIM AT THE SAME

4522
03:04:53,240 --> 03:04:55,760
TIME BACK IN 1984 AND WE HAVE

4523
03:04:55,760 --> 03:04:58,240
BEEN CLOSE FRIENDS AND

4524
03:04:58,240 --> 03:04:59,240
COLLEAGUES COLLABORATORS

4525
03:04:59,240 --> 03:05:01,120
THROUGHOUT THE DECADES. SO THE

4526
03:05:01,120 --> 03:05:02,520
NEXT SLIDE IS THE FINAL

4527
03:05:02,520 --> 03:05:05,720
RECOGNITION WHICH IS TO BRIAN

4528
03:05:05,720 --> 03:05:07,600
AND NAREG, VERY PROUD OBVIOUSLY

4529
03:05:07,600 --> 03:05:09,720
THAT BRIAN IS SUCCEEDING ME AS

4530
03:05:09,720 --> 03:05:10,840
DIRECTOR. AND PROUD THAT BOTH

4531
03:05:10,840 --> 03:05:12,280
BRIAN AND NAREG ARE THE

4532
03:05:12,280 --> 03:05:13,960
CO-CHAIRS OF THIS SYMPOSIUM

4533
03:05:13,960 --> 03:05:16,000
BECAUSE THEY BOTH HAVE BEEN

4534
03:05:16,000 --> 03:05:18,200
COLLABORATORS AT MY -- OUR

4535
03:05:18,200 --> 03:05:19,880
INSTITUTE FOR LAST 10 TO 20

4536
03:05:19,880 --> 03:05:22,320
YEARS, WONDERFUL TO SEE YOUNG

4537
03:05:22,320 --> 03:05:24,840
PEOPLE SUCCEED WITHIN OUR

4538
03:05:24,840 --> 03:05:26,240
INSTITUTE STAY BUT ALSO TO MOVE

4539
03:05:26,240 --> 03:05:28,240
ELSEWHERE AND BE SUCCESSFUL SO

4540
03:05:28,240 --> 03:05:30,440
THAT RECENT DISCUSSION, IF THAT

4541
03:05:30,440 --> 03:05:32,040
WAS APPROPRIATE,S THE CRITICAL

4542
03:05:32,040 --> 03:05:34,120
VALUE OF TRAINING AND THE NEXT

4543
03:05:34,120 --> 03:05:36,120
GENERATION OF SCIENTISTS TO

4544
03:05:36,120 --> 03:05:40,520
ADVANCE THE FIELD.  MOVING TO

4545
03:05:40,520 --> 03:05:43,080
THE NEXT SLIDE, COUPLE OF EARLY

4546
03:05:43,080 --> 03:05:45,480
STUDIES, I STARTED BACK IN 1984

4547
03:05:45,480 --> 03:05:48,800
AND I GOT INVOLVED WITH SAFETY

4548
03:05:48,800 --> 03:05:51,480
STUDY TSS WHICH MEASURED RATE OF

4549
03:05:51,480 --> 03:05:54,240
HIV INFECTION IN DONATION

4550
03:05:54,240 --> 03:05:56,120
COLLECTED PRIOR TO HIV ANN BODY

4551
03:05:56,120 --> 03:06:00,240
TESTING SO NHLBI HAD FORE SITE

4552
03:06:00,240 --> 03:06:03,760
AND JIM MOSLEY AND STEVE AND

4553
03:06:03,760 --> 03:06:06,320
GEORGE AND HERB PER KENS

4554
03:06:06,320 --> 03:06:08,480
ESTABLISH AD REPOSITORY OF

4555
03:06:08,480 --> 03:06:10,520
COUPLE OF HUNDRED THOUSAND

4556
03:06:10,520 --> 03:06:11,520
DONATIONS COLLECTED PRIOR TO

4557
03:06:11,520 --> 03:06:13,280
AVAILABILITY OF SCREENING IN

4558
03:06:13,280 --> 03:06:14,560
1985.  WHEN WESTERED WITH EARLY

4559
03:06:14,560 --> 03:06:17,160
GENERATION ANTIBODY TESTS ABOUT

4560
03:06:17,160 --> 03:06:18,280
.8% DONATIONS IN SAN FRANCISCO

4561
03:06:18,280 --> 03:06:19,600
AT THE TIME WERE ANTIBODY

4562
03:06:19,600 --> 03:06:22,600
POSITIVE. AND THAT GAVE US

4563
03:06:22,600 --> 03:06:24,240
INSIGHT TO THE RATE OF INFECTION

4564
03:06:24,240 --> 03:06:26,880
PRIOR TO SCREENING BUT WE ARE

4565
03:06:26,880 --> 03:06:28,560
REQUIRED THE REAL UNDERSTANDING

4566
03:06:28,560 --> 03:06:30,640
OF THE PRE-SCREENING RISK WAS

4567
03:06:30,640 --> 03:06:32,680
INTEGRATION OF THAT DATA WITH

4568
03:06:32,680 --> 03:06:35,440
DATA ON RATE OF DONATION BY

4569
03:06:35,440 --> 03:06:38,640
PRIOR HIGH RISK INDIVIDUALS

4570
03:06:38,640 --> 03:06:40,000
IDENTIFIED AS AIDS CASES AND

4571
03:06:40,000 --> 03:06:41,760
TRACK TO LOOK BACK AND THEN

4572
03:06:41,760 --> 03:06:43,560
RATES OF INFECTION OVER TIME IN

4573
03:06:43,560 --> 03:06:45,640
SAN FRANCISCO BASED ON HEPATITIS

4574
03:06:45,640 --> 03:06:47,360
VACCINE TRIALS CONDUCTED, BY

4575
03:06:47,360 --> 03:06:48,360
INTEGRATING ALL THOSE DATA WE

4576
03:06:48,360 --> 03:06:49,960
WERE ABLE TO GENERATE THE CURVE

4577
03:06:49,960 --> 03:06:52,160
AT THE BOTTOM, WHICH IS THE RISK

4578
03:06:52,160 --> 03:06:54,240
OVER TIME AND DEMONSTRATE THE

4579
03:06:54,240 --> 03:06:56,200
EARLY IMPLEMENTATION OF DONOR

4580
03:06:56,200 --> 03:06:57,200
DEFERRAL CRITERIA WITH THE

4581
03:06:57,200 --> 03:06:59,400
REALIZATION OF TRANSFUSION AIDS

4582
03:06:59,400 --> 03:07:01,000
FIRST CASE REPORTED FROM SAN

4583
03:07:01,000 --> 03:07:04,240
FRANCISCO DECEMBER OF '82 LED TO

4584
03:07:04,240 --> 03:07:05,880
DROP AND PROGRESSIVE ENHANCEMENT

4585
03:07:05,880 --> 03:07:08,640
OF THOSE DEFERRALS, ABOUT A

4586
03:07:08,640 --> 03:07:10,480
TENFOLD REDUCTION OF HIV RISK

4587
03:07:10,480 --> 03:07:11,960
PRIOR TO THE AVAILABILITY OF

4588
03:07:11,960 --> 03:07:13,680
SCREENING SO A STRONG INDICATION

4589
03:07:13,680 --> 03:07:16,560
OF THE IMPACT OF DONOR SAFETY

4590
03:07:16,560 --> 03:07:21,080
SELECTION CRITERIA. SO ONE FIRST

4591
03:07:21,080 --> 03:07:22,760
BIG STUDY BUT THE NEXT ONE I

4592
03:07:22,760 --> 03:07:26,760
WILL SHARE IS A STUDY THAT WE

4593
03:07:26,760 --> 03:07:29,440
FUNDED EARLY ON FROM NHLBI IN

4594
03:07:29,440 --> 03:07:31,240
THE UPPER RIGHT, ANOTHER LONG

4595
03:07:31,240 --> 03:07:34,440
TERM MENTOR. THIS WAS A STUDY OF

4596
03:07:34,440 --> 03:07:35,360
AFTER SCREENING WAS IMPLEMENTED

4597
03:07:35,360 --> 03:07:36,720
WE REALIZE THE TRANSMISSIONS

4598
03:07:36,720 --> 03:07:40,120
WERE STILL HAPPENING SO IN

4599
03:07:40,120 --> 03:07:42,880
COLLABORATION WITH TEAM I MOVED

4600
03:07:42,880 --> 03:07:45,600
TO THE BLOOD BANK WE SAVED

4601
03:07:45,600 --> 03:07:49,400
75,000 IDENTIFIED PURIFIED

4602
03:07:49,400 --> 03:07:50,960
PBMCs FROM 25,000 SERO

4603
03:07:50,960 --> 03:07:52,840
NEGATIVE DONATION P AND DID POOL

4604
03:07:52,840 --> 03:07:54,240
TESTING SO CONCEPT OF POOL

4605
03:07:54,240 --> 03:07:55,360
TESTING WHICH IS OF COURTS

4606
03:07:55,360 --> 03:07:57,120
EMPLOYED IN THE U.S., -- OF

4607
03:07:57,120 --> 03:07:58,160
COURSE EMPLOYED IN THE U.S.

4608
03:07:58,160 --> 03:08:00,040
BEGAN IN A SENSE CREATING POOLS

4609
03:08:00,040 --> 03:08:02,720
OF PBMCs FROM DONORS AND PCR

4610
03:08:02,720 --> 03:08:04,600
AND CULTURE TESTING ENDED UP

4611
03:08:04,600 --> 03:08:06,400
BEING PERFORMED ON THOSE POOL

4612
03:08:06,400 --> 03:08:10,640
SAMPLES AND IDENTIFYING VIE

4613
03:08:10,640 --> 03:08:11,280
REAMIC INFECTIOUS UNITS MISSED

4614
03:08:11,280 --> 03:08:13,640
BY SCREENING. SO TO BEGIN MY

4615
03:08:13,640 --> 03:08:17,520
CAREER, I WAS LUCKY TO GET INTO

4616
03:08:17,520 --> 03:08:19,840
BIG STUDIES. SERIES OF SLIDES TO

4617
03:08:19,840 --> 03:08:24,560
MAKE A POINT HERE, EVERYTHING WE

4618
03:08:24,560 --> 03:08:26,800
DO IN MY EXPERIENCE HAS

4619
03:08:26,800 --> 03:08:28,040
RAMIFICATIONS WELL BEYOND

4620
03:08:28,040 --> 03:08:31,280
TRANSFUSION SAFETY. WITH HIV,

4621
03:08:31,280 --> 03:08:32,960
EARLY WORK WINDOW PERIOD AND HOW

4622
03:08:32,960 --> 03:08:34,400
TO CLOSE THE BIN DOE PERIOD FROM

4623
03:08:34,400 --> 03:08:35,880
A BLOOD SAFETY PERSPECTIVE LED

4624
03:08:35,880 --> 03:08:40,080
TO DEVELOPMENT OF STAGING SYSTEM

4625
03:08:40,080 --> 03:08:41,680
FOR IDENTIFYING CATEGORIZING

4626
03:08:41,680 --> 03:08:43,720
NEWLY DIAGNOSED PEOPLE TO WHAT

4627
03:08:43,720 --> 03:08:45,200
STAGE OF INFECTION THEY ARE IN

4628
03:08:45,200 --> 03:08:46,800
AT THE TIME OF DIAGNOSIS AND

4629
03:08:46,800 --> 03:08:49,360
THIS IS STILL USED GLOBALLY AS

4630
03:08:49,360 --> 03:08:51,080
THE STAGING SYSTEM USED IN IF

4631
03:08:51,080 --> 03:08:53,880
ALL CURE TRIALS, ET CETERA.  FOR

4632
03:08:53,880 --> 03:08:55,400
IDENTIFYING WHEN PEOPLE

4633
03:08:55,400 --> 03:08:56,680
CATEGORIZE WHEN PEOPLE ARE

4634
03:08:56,680 --> 03:08:59,080
INFECTED. WE ALSO DEVELOPED

4635
03:08:59,080 --> 03:09:00,440
EARLY ON IN ORDER TO MEASURE

4636
03:09:00,440 --> 03:09:02,200
RISK IN DONORS WE DEVELOP

4637
03:09:02,200 --> 03:09:03,760
INCIDENCE ASSAYS WHICH ARE

4638
03:09:03,760 --> 03:09:06,640
INITIALLY DETUNED LESS SENSITIVE

4639
03:09:06,640 --> 03:09:09,080
BUT NOW THERE IS A BATTERY OF

4640
03:09:09,080 --> 03:09:10,720
ALTERNATIVE APPROACH TO DETECT

4641
03:09:10,720 --> 03:09:12,480
RECENTLY INFECTED PEOPLE BASED

4642
03:09:12,480 --> 03:09:14,720
ON ANTIBODY MATURATION DYNAMICS.

4643
03:09:14,720 --> 03:09:16,720
SO THESE ARE EXTENSIVELY USED

4644
03:09:16,720 --> 03:09:20,120
ALL OVER THE WORLD TO MEASURE

4645
03:09:20,120 --> 03:09:21,360
HIV INCIDENCE WITH MUCH MORE

4646
03:09:21,360 --> 03:09:23,120
PRECISION AND CAN BE ACHIEVED

4647
03:09:23,120 --> 03:09:25,400
WITH MORE TRADITIONAL INCIDENCE

4648
03:09:25,400 --> 03:09:27,520
MEASUREMENT METHODS SO EXAMPLES

4649
03:09:27,520 --> 03:09:29,720
HERE HOW STUDIES IN BLOOD BANKS

4650
03:09:29,720 --> 03:09:31,960
CAN HAVE RAMIFICATIONS IN THIS

4651
03:09:31,960 --> 03:09:33,960
-- TELL THE SAME STORY FOR MANY

4652
03:09:33,960 --> 03:09:37,880
OTHER VIRUSES AND INFECTIOUS

4653
03:09:37,880 --> 03:09:41,800
DISEASE. JUST TO RECOGNIZE THE

4654
03:09:41,800 --> 03:09:43,880
REDS PROGRAM, I'M FORTUNATE AS

4655
03:09:43,880 --> 03:09:45,440
STEVE TO BE PEOPLE WHO HAVE BEEN

4656
03:09:45,440 --> 03:09:47,800
IN ALL THESE PROGRAMS. REDS 1

4657
03:09:47,800 --> 03:09:49,440
STARTED IN '88 YOU CAN SEE THE

4658
03:09:49,440 --> 03:09:53,520
FOLKS THERE AND REDS 2 IN 2004.

4659
03:09:53,520 --> 03:09:55,000
ALL THESE PROGRAMS RAN INITIALLY

4660
03:09:55,000 --> 03:09:57,480
FUNDED FOR FIVE YEARS BUT THEY

4661
03:09:57,480 --> 03:10:00,200
TYPICALLY RUN FEW MORE IN

4662
03:10:00,200 --> 03:10:01,480
EXTENSION BASIS EXTRAORDINARILY

4663
03:10:01,480 --> 03:10:03,040
PRODUCTIVE, YOU CAN SEE THE

4664
03:10:03,040 --> 03:10:05,240
CITATION AFTER THE REDS 1 AND 2

4665
03:10:05,240 --> 03:10:07,880
PAPERS REVIEW PAPER THAT STEVE

4666
03:10:07,880 --> 03:10:12,080
LED. NEXT SLIDE.  THE REDS 3

4667
03:10:12,080 --> 03:10:13,960
PROGRAM FOR THE FIRST TIME

4668
03:10:13,960 --> 03:10:15,680
INCLUDED NOT ONLY DOMESTIC BUT

4669
03:10:15,680 --> 03:10:18,360
INTERNATIONAL SITES. SO AGAIN

4670
03:10:18,360 --> 03:10:20,360
CITATION HERE TO THE REVIEW

4671
03:10:20,360 --> 03:10:23,440
PAPER FOR THE REDS PROGRAM AND

4672
03:10:23,440 --> 03:10:25,400
DOMESTIC TEAM ABOVE LEFT AND

4673
03:10:25,400 --> 03:10:26,840
INTERNATIONAL GROUP LOWER RIGHT

4674
03:10:26,840 --> 03:10:31,720
YOU SEE SIMONE HAS JOINED IN

4675
03:10:31,720 --> 03:10:33,840
REDS 2S WETAT THEN TO NHLBI AND

4676
03:10:33,840 --> 03:10:36,040
TOOK OVER FOR GEORGE AND LED THE

4677
03:10:36,040 --> 03:10:38,560
PROGRAMS FROM ALL THOSE YEARS

4678
03:10:38,560 --> 03:10:40,040
AND INTERNATIONAL AND NATIONAL

4679
03:10:40,040 --> 03:10:41,520
COLLEAGUES ON THIS CALL. NEXT

4680
03:10:41,520 --> 03:10:48,720
SLIDE.  THIS IS THE REDS 4 TEAM

4681
03:10:48,720 --> 03:10:50,200
STILL ACTIVE AND PRODUCTIVE. ALL

4682
03:10:50,200 --> 03:10:51,600
ARE EXTRAORDINARILY PRODUCTIVE

4683
03:10:51,600 --> 03:10:53,080
WITH MANY DIFFERENT PROJECTS

4684
03:10:53,080 --> 03:10:56,200
GOING ON SIMULTANEOUSLY,

4685
03:10:56,200 --> 03:10:59,680
ENORMOUS WORK BUT ENORMOUS

4686
03:10:59,680 --> 03:11:03,280
SUCCESS. SO THE REDS 1 PROGRAM

4687
03:11:03,280 --> 03:11:06,080
JUST TO MENTION EARLY ON FOCUSED

4688
03:11:06,080 --> 03:11:09,360
ON BLOOD SAFETY, SO DEALING WITH

4689
03:11:09,360 --> 03:11:10,720
OBVIOUSLY HIV AND EARLY FINDINGS

4690
03:11:10,720 --> 03:11:16,440
WITH HEPATITIS C AND D WORK ON

4691
03:11:16,440 --> 03:11:18,760
ASSESSMENT AND SOME WORK ON NEW

4692
03:11:18,760 --> 03:11:20,680
TRANSFUSION ON DONOR

4693
03:11:20,680 --> 03:11:23,520
EPIDEMIOLOGY AND BLOOD

4694
03:11:23,520 --> 03:11:25,240
AVAILABILITY NO SIGNIFICANT

4695
03:11:25,240 --> 03:11:26,600
STUDIES IN TRANSFUSION

4696
03:11:26,600 --> 03:11:32,000
RECIPIENTS.  THE NEXT SLIDE.  

4697
03:11:32,000 --> 03:11:34,680
ONE EARLY AGAIN COMMITMENTS OF

4698
03:11:34,680 --> 03:11:36,080
THE NHLBI WAS ESTABLISH

4699
03:11:36,080 --> 03:11:37,640
REPOSITORIES.  I MENTIONED

4700
03:11:37,640 --> 03:11:40,080
TRANSFUSION SAFETY STUDY

4701
03:11:40,080 --> 03:11:41,440
REPOSITORY IN EARLY ON HARVEY

4702
03:11:41,440 --> 03:11:44,280
WALTER HAD HIS LARGE

4703
03:11:44,280 --> 03:11:46,600
REPOSITORIES VIRUS STUDY SO A

4704
03:11:46,600 --> 03:11:49,400
FEW CITATIONS TO REVIEW ARTICLES

4705
03:11:49,400 --> 03:11:51,880
THAT DISCUSSED THE INCREDIBLE

4706
03:11:51,880 --> 03:11:53,880
VALUE OF SPECIMEN BANKS BUILT

4707
03:11:53,880 --> 03:11:56,200
OFF OF DONOR SAMPLES ARE NOW

4708
03:11:56,200 --> 03:11:58,200
LINKED DONOR RECIPIENT SAMPLES

4709
03:11:58,200 --> 03:12:00,080
SO INCREDIBLY IMPORTANT IS TO

4710
03:12:00,080 --> 03:12:02,520
SAVE SAMPLES FROM BLOOD

4711
03:12:02,520 --> 03:12:03,880
DONATION, SOMETHING I WISH WE

4712
03:12:03,880 --> 03:12:06,800
COULD DO MORE AND WE DO IN A

4713
03:12:06,800 --> 03:12:08,680
STRATEGIC WAY NOW AS I WILL TALK

4714
03:12:08,680 --> 03:12:10,280
ABOUT A LITTLE BIT LATER BUT A

4715
03:12:10,280 --> 03:12:12,400
FEW CITATIONS INCLUDING ONE WITH

4716
03:12:12,400 --> 03:12:13,680
SIMONE ON THE IMPORTANCE OF

4717
03:12:13,680 --> 03:12:15,320
REPOSITORIES AND UTILITY. AND

4718
03:12:15,320 --> 03:12:18,240
THEN THE NEXT SLIDE -- THEY ARE

4719
03:12:18,240 --> 03:12:20,680
GLOBAL NOW, THE BIOLINK PROGRAM

4720
03:12:20,680 --> 03:12:23,920
IS IMPORTANT NHLBI RESOURCE THAT

4721
03:12:23,920 --> 03:12:25,960
SAVES THESE. SO NOT ONLY DOES

4722
03:12:25,960 --> 03:12:28,320
NHLBI FUND ESTABLISHMENT OF

4723
03:12:28,320 --> 03:12:29,640
RESPOSITORIES BUT IN A STRATEGIC

4724
03:12:29,640 --> 03:12:31,080
WAY THEY MAINTAIN THE SAMPLES

4725
03:12:31,080 --> 03:12:33,600
FOR DECADES AND MAKE AVAILABLE

4726
03:12:33,600 --> 03:12:37,240
TO BIOLINK INCLUDING FUNDING

4727
03:12:37,240 --> 03:12:38,440
OPPORTUNITIES TO DO STUDIES

4728
03:12:38,440 --> 03:12:40,040
USING ARCHIVE SAMPLES WHICH

4729
03:12:40,040 --> 03:12:41,760
BECAME VALUE IN DECADES LATER.

4730
03:12:41,760 --> 03:12:46,080
NEXT SLIDE.  IN TERMS OF

4731
03:12:46,080 --> 03:12:47,760
TRANSFUSION RISK WE HAVE HAD

4732
03:12:47,760 --> 03:12:50,080
INCREDIBLE SUCCESS WITH

4733
03:12:50,080 --> 03:12:52,800
IMPLEMENTATION OF DONOR

4734
03:12:52,800 --> 03:12:53,920
CRITERIA, ILLEGIBILITY CRITERIA

4735
03:12:53,920 --> 03:12:55,600
BUT IMPORTANTLY THE FURTHER

4736
03:12:55,600 --> 03:12:57,040
ADVANCEMENTS IN SERO LOGIC

4737
03:12:57,040 --> 03:12:58,280
NUCLEIC ACID TESTING DRIVING

4738
03:12:58,280 --> 03:13:00,080
DOWN THE RISK OF THE MAJOR

4739
03:13:00,080 --> 03:13:02,440
TRANSFUSION VIRUSES, ON THE

4740
03:13:02,440 --> 03:13:04,360
LINES BUT THEN EVERY YEAR SEEMS

4741
03:13:04,360 --> 03:13:08,320
WE FACE A NEW EIV THREAT SO

4742
03:13:08,320 --> 03:13:09,560
NHLBI THROUGH THE REDS PROGRAM

4743
03:13:09,560 --> 03:13:11,440
AND OTHER GRANT FUND HAS

4744
03:13:11,440 --> 03:13:13,440
RESPONDED TO VIRTUALLY ALL OF

4745
03:13:13,440 --> 03:13:14,440
THESE THREATS AND ESTABLISHED

4746
03:13:14,440 --> 03:13:16,480
WHETHER THEY REALLY HAVE

4747
03:13:16,480 --> 03:13:17,840
TRANSFUSION PATHOGENS, WHETHER

4748
03:13:17,840 --> 03:13:20,880
SCREENING IS INDICATED OR

4749
03:13:20,880 --> 03:13:22,120
WHETHER THEY ARE TRULY

4750
03:13:22,120 --> 03:13:23,600
INFECTIOUS DISEASE BUT WE DON'T

4751
03:13:23,600 --> 03:13:25,280
SEE TRANSMITTED BY TRANSFUSION

4752
03:13:25,280 --> 03:13:27,040
OR CAUSING DISEASE OR SOME CASES

4753
03:13:27,040 --> 03:13:29,440
FALSE ALARMS. SO THINGS LIKE

4754
03:13:29,440 --> 03:13:31,760
XMRV, A DECADE OR SO AGO,

4755
03:13:31,760 --> 03:13:33,400
ALLEGED ASSOCIATED WITH CHRONIC

4756
03:13:33,400 --> 03:13:35,840
FATIGUE SYNDROME BUT PROVEN

4757
03:13:35,840 --> 03:13:38,000
CONTAMINATION EVENT. SO HUGE

4758
03:13:38,000 --> 03:13:39,000
PROGRESS BUT NEVER ENDING

4759
03:13:39,000 --> 03:13:41,080
CHALLENGE OBVIOUSLY AS WE NOW

4760
03:13:41,080 --> 03:13:43,080
DEAL WITH SARS 2. THERE IS

4761
03:13:43,080 --> 03:13:48,040
CRITICAL PAPERS COMING OUT SOON

4762
03:13:48,040 --> 03:13:49,640
PAPER LED BY (INDISCERNIBLE)

4763
03:13:49,640 --> 03:13:51,400
WILL BE APPEARING THIS WEEK THAT

4764
03:13:51,400 --> 03:13:55,360
FULLY DISPROVES ANY RISK OF SARS

4765
03:13:55,360 --> 03:13:57,320
COV-2 FROM TRANSFUSIONS AND NOW

4766
03:13:57,320 --> 03:13:58,840
DEALING WITH MONKEY POX DO WE

4767
03:13:58,840 --> 03:14:00,120
NEED TO ADDRESS THAT SO NEVER

4768
03:14:00,120 --> 03:14:04,160
ENDING NEED TO RESPOND TO

4769
03:14:04,160 --> 03:14:05,440
THREATS AND DO SO IN A

4770
03:14:05,440 --> 03:14:08,560
SCIENTIFICALLY RIGOROUS FASHION.

4771
03:14:08,560 --> 03:14:10,000
SUMMARIZE AS WE EVOLVE OUR

4772
03:14:10,000 --> 03:14:16,120
THINKING OVER DECADES TO ADDRESS

4773
03:14:16,120 --> 03:14:16,760
TRANSFUSION THREATS WE ARE

4774
03:14:16,760 --> 03:14:19,120
BUILDING A PROCESS TO CRANK THE

4775
03:14:19,120 --> 03:14:24,320
WHEEL, SAVE SAMPLES WE ESTABLISH

4776
03:14:24,320 --> 03:14:26,640
PREVALENCE AND RNAEMIA OR

4777
03:14:26,640 --> 03:14:29,120
DNAEMIA AND ESTABLISH

4778
03:14:29,120 --> 03:14:30,520
INFECTIVITY OF, VIS-A-VIS ANIMAL

4779
03:14:30,520 --> 03:14:34,000
MODEL TRANSMISSION STUDIES AND

4780
03:14:34,000 --> 03:14:36,480
HUMAN LINK DONOR RECIPIENT

4781
03:14:36,480 --> 03:14:39,240
TRANSFUSION STUDIES, STUDIES ON

4782
03:14:39,240 --> 03:14:40,320
CONSEQUENCES OF THESE DISEASES

4783
03:14:40,320 --> 03:14:45,640
IN PATIENTSES. THIS PROCESS HOW

4784
03:14:45,640 --> 03:14:47,400
TO ASSESS WHETHER NEWLY

4785
03:14:47,400 --> 03:14:48,800
IDENTIFIED POTENTIAL TRANSFUSION

4786
03:14:48,800 --> 03:14:49,880
THREAT IS A PROBLEM AND HOW TO

4787
03:14:49,880 --> 03:14:52,960
RESPONDS TO IT IS SOMETHING THAT

4788
03:14:52,960 --> 03:14:54,480
WE THINK OVER DECADES LEARN HOW

4789
03:14:54,480 --> 03:14:58,360
TO DO, IT TAKES TIME AND MONEY

4790
03:14:58,360 --> 03:14:59,600
BUT IT IS SOMETHING WE

4791
03:14:59,600 --> 03:15:00,480
EFFECTIVELY ACHIEVE AND THE

4792
03:15:00,480 --> 03:15:04,320
BLOOD SUPPLY IS EXTRAORDINARILY

4793
03:15:04,320 --> 03:15:06,280
SAFE THE MOST RECENT FUNDING,

4794
03:15:06,280 --> 03:15:09,000
ALWAYS THROUGHOUT DECADES THE

4795
03:15:09,000 --> 03:15:10,480
REDS PROGRAM HAS BEEN

4796
03:15:10,480 --> 03:15:11,800
FOUNDATIONAL PROGRAM THOUGH THE

4797
03:15:11,800 --> 03:15:16,480
BULK OF THE SCIENCE EXECUTED HAS

4798
03:15:16,480 --> 03:15:19,240
OVER TWO DECADES FOCUS ON DONOR

4799
03:15:19,240 --> 03:15:21,040
ISSUES AND DONOR RECIPIENT

4800
03:15:21,040 --> 03:15:23,920
EFFICACY QUESTIONS, THE PROGRAM

4801
03:15:23,920 --> 03:15:27,360
ON WHICH NHLBI ADDS RESOURCES TO

4802
03:15:27,360 --> 03:15:28,840
ADDRESS NEW THREATS, WITH

4803
03:15:28,840 --> 03:15:32,960
RESPECT TO SARS COV-2 WHERE THE

4804
03:15:32,960 --> 03:15:34,960
RESPONSE PROGRAM WAS SUPPLEMENT

4805
03:15:34,960 --> 03:15:36,320
TO REDS SPORE PROGRAM TO

4806
03:15:36,320 --> 03:15:38,720
ESTABLISH FREQUENCIES OF RNAEMIA

4807
03:15:38,720 --> 03:15:41,560
DONATIONS TO DO TRANSFUSION

4808
03:15:41,560 --> 03:15:43,160
STUDIES AND INCLUDING ANIMAL

4809
03:15:43,160 --> 03:15:47,360
MODEL STUDIES. SO THIS IS A

4810
03:15:47,360 --> 03:15:49,280
SUMMARY OF THE KINDS OF STUDIES

4811
03:15:49,280 --> 03:15:50,720
THAT WE HAVE DONE OVER THE LAST

4812
03:15:50,720 --> 03:15:54,600
FEW YEARS WITH RESPECT TO SARS

4813
03:15:54,600 --> 03:15:59,160
COV-2COV-2. ONE STUDY WAS SERO

4814
03:15:59,160 --> 03:16:02,000
PREVALENCE THAT STARTED AS REDS

4815
03:16:02,000 --> 03:16:04,160
4 STUDY IN FIVE CITIES ACROSS

4816
03:16:04,160 --> 03:16:06,160
THE U.S. AND EXPANDED TO THE

4817
03:16:06,160 --> 03:16:07,680
BLOOD DONOR PROVIDENCE STUDY, SO

4818
03:16:07,680 --> 03:16:11,800
A BIG STUDY WE ESTABLISHED THAT

4819
03:16:11,800 --> 03:16:12,920
INCLUDES 50 STATES AND PUERTO

4820
03:16:12,920 --> 03:16:17,080
RICO AND WASHINGTON D.C.

4821
03:16:17,080 --> 03:16:18,560
TRACKING EVOLUTION OF BOTH

4822
03:16:18,560 --> 03:16:20,360
INFECTION AND VACCINATION OVER

4823
03:16:20,360 --> 03:16:24,840
THE LAST TWO AND A HALF YEARS NO

4824
03:16:24,840 --> 03:16:27,320
DETAIL ON THE FINDINGS BUT TO

4825
03:16:27,320 --> 03:16:28,920
ILLUSTRATE WE CAN ACHIEVE THESE

4826
03:16:28,920 --> 03:16:30,600
STUDIES THROUGH REACHING OUT TO

4827
03:16:30,600 --> 03:16:31,480
BLOOD ORGANIZATIONS THROUGHOUT

4828
03:16:31,480 --> 03:16:33,000
THE U.S. WHO ARE ALWAYS

4829
03:16:33,000 --> 03:16:34,640
COLLABORATIVE AND COOPERATIVE

4830
03:16:34,640 --> 03:16:37,040
WITH RESPECT TO PROVIDING

4831
03:16:37,040 --> 03:16:38,000
SAMPLES AND LINKING TOGETHER

4832
03:16:38,000 --> 03:16:40,680
THOSE SAMPLES WITH NEW

4833
03:16:40,680 --> 03:16:42,520
TECHNOLOGY TESTS, IN THIS CASE

4834
03:16:42,520 --> 03:16:45,840
SERO SURVEILLANCE. WORKING WITH

4835
03:16:45,840 --> 03:16:47,120
EXPERT GROUPS IN THIS CASES

4836
03:16:47,120 --> 03:16:51,440
WETAT TO EXECUTE WAITING --

4837
03:16:51,440 --> 03:16:54,440
WESTAT WAITING TO INFER FROM

4838
03:16:54,440 --> 03:16:57,080
BLOOD DATA THE RATINGS AND

4839
03:16:57,080 --> 03:16:59,720
IMPACT OF VACCINATIONS AND

4840
03:16:59,720 --> 03:17:01,280
IMPACT OF VARIANTS ON

4841
03:17:01,280 --> 03:17:03,200
TRANSMISSION OVER TIME. SO THIS

4842
03:17:03,200 --> 03:17:04,640
WAS MONTHLY CROSS SECTIONAL

4843
03:17:04,640 --> 03:17:06,920
TESTING OF 170,000 SAMPLES PER

4844
03:17:06,920 --> 03:17:08,680
MONTH, BUT WE REALIZE THE END OF

4845
03:17:08,680 --> 03:17:10,800
LAST YEAR THAT APPROACH WAS

4846
03:17:10,800 --> 03:17:12,600
REACHING SATURATION, COULDN'T

4847
03:17:12,600 --> 03:17:14,720
MAKE MUCH SENSE OF IT SO THAT IS

4848
03:17:14,720 --> 03:17:16,200
WHY WE MOVE TO THIS NEW

4849
03:17:16,200 --> 03:17:17,800
APPROACH, A REPEAT DONOR COHORT

4850
03:17:17,800 --> 03:17:21,120
SO THIS INVOLVES ABOUT 160,000

4851
03:17:21,120 --> 03:17:24,440
DONORS FROM RED CROSS AND VITALA

4852
03:17:24,440 --> 03:17:26,120
FREQUENT REPEAT DONORS HAD

4853
03:17:26,120 --> 03:17:28,040
SAMPLES SAVED DURING PERIODS

4854
03:17:28,040 --> 03:17:29,000
WHEN UNIVERSAL SCREENING WAS

4855
03:17:29,000 --> 03:17:31,800
GOING ON AND WE FLAGGED DONORS

4856
03:17:31,800 --> 03:17:33,360
IDENTITIES ANDTURING SAMPLES

4857
03:17:33,360 --> 03:17:35,640
EVERY TIME THESE DONORS DONATE

4858
03:17:35,640 --> 03:17:37,520
GOING FORWARD FROM JULY 2021,

4859
03:17:37,520 --> 03:17:39,440
CAPTURING SAMPLES AND STUDYING

4860
03:17:39,440 --> 03:17:41,240
THEM FOR CONTINUED EVOLUTION OF

4861
03:17:41,240 --> 03:17:45,600
THEIR INFECTION. THIS ALLOWS US

4862
03:17:45,600 --> 03:17:47,120
TO DETECT VACCINE BREAK THROUGH

4863
03:17:47,120 --> 03:17:48,920
INFECTION AND REINFECTION,

4864
03:17:48,920 --> 03:17:50,520
FUNDED FOR ANOTHER YEAR BUT

4865
03:17:50,520 --> 03:17:53,440
HOPEFULLY GO ON BEYOND THAT.

4866
03:17:53,440 --> 03:17:58,000
WITH THE VISION JUST TO MENTION

4867
03:17:58,000 --> 03:18:01,200
THIS CONCEPT OF A GLOBAL

4868
03:18:01,200 --> 03:18:03,400
IMMUNOLOGIC OBSERVATORY SO USING

4869
03:18:03,400 --> 03:18:05,360
SERIAL SAMPLES FROM REPEAT BLOOD

4870
03:18:05,360 --> 03:18:06,760
DONORS AND FLAG AND CAPTURE

4871
03:18:06,760 --> 03:18:08,600
SAMPLES FROM THE TESTING LABS

4872
03:18:08,600 --> 03:18:11,200
ARCHIVE THOSE SAMPLES AWAY, THAT

4873
03:18:11,200 --> 03:18:15,760
GETS US THE ABILITY TO RAPIDLY

4874
03:18:15,760 --> 03:18:16,880
RESPOND TO FUTURE PANDEMIC

4875
03:18:16,880 --> 03:18:17,760
THREATS AND UNDERSTAND WHEN

4876
03:18:17,760 --> 03:18:18,520
VIRUSES ENTERED THE BLOOD

4877
03:18:18,520 --> 03:18:24,760
SUPPLY.  SO THE REDS PROGRAM

4878
03:18:24,760 --> 03:18:26,560
EVOLVED, I APOLOGIZE IT SHOULD

4879
03:18:26,560 --> 03:18:28,320
SAY REDS 2 AND 3 IN THE UPPER

4880
03:18:28,320 --> 03:18:30,160
BARS HERE. BUT THE REDS 2

4881
03:18:30,160 --> 03:18:31,680
PROGRAM BEGAN TO LOOK AT DONOR

4882
03:18:31,680 --> 03:18:35,360
SAFETY ISSUES, THINGS LIKE

4883
03:18:35,360 --> 03:18:36,880
TROLLY AND TACO BUT THE REDS 3

4884
03:18:36,880 --> 03:18:40,320
PROGRAM NEXT SLIDE REALLY DID

4885
03:18:40,320 --> 03:18:42,200
SOMETHING NEW AT THE TIME, TO

4886
03:18:42,200 --> 03:18:44,200
LINK DONORS AND RECIPIENTS AND

4887
03:18:44,200 --> 03:18:45,880
BUILD FOR THE FIRST TIME A LINK

4888
03:18:45,880 --> 03:18:47,240
DONOR COMPONENT RECIPIENT

4889
03:18:47,240 --> 03:18:49,040
DATABASE. THAT IS WHERE AGAIN I

4890
03:18:49,040 --> 03:18:51,520
WANT TO FOCUS MOST OF MY

4891
03:18:51,520 --> 03:18:53,200
SUBSEQUENT COMMENTS,S THE POWER

4892
03:18:53,200 --> 03:18:55,680
AND THE IMPORTANCE OF THOSE

4893
03:18:55,680 --> 03:18:57,480
LINKED DONOR RECIPIENT DATABASE,

4894
03:18:57,480 --> 03:18:58,720
A LOT COME OUT THROUGH THE

4895
03:18:58,720 --> 03:19:00,000
WORKING GROUP DISCUSSION IN THE

4896
03:19:00,000 --> 03:19:04,560
PAST COUPLE OF DAYS.  SO IN IS

4897
03:19:04,560 --> 03:19:07,760
EARLY STUDY DANA SHOWED VERSION

4898
03:19:07,760 --> 03:19:11,840
OF THIS THATNA READ ROUBINIAN

4899
03:19:11,840 --> 03:19:13,320
SHOWED WHERE E H LINKED THE

4900
03:19:13,320 --> 03:19:15,040
BLOOD DONOR CHARACTERISTICS

4901
03:19:15,040 --> 03:19:16,840
EPIDEMIOLOGIC FACTORS GENDER

4902
03:19:16,840 --> 03:19:18,240
AGE, COMPONENT CHARACTERISTICS

4903
03:19:18,240 --> 03:19:19,640
IN TERMS OF THINGS LIKE

4904
03:19:19,640 --> 03:19:22,080
IRRADIATION AND STORAGE, WITH

4905
03:19:22,080 --> 03:19:23,640
RECIPIENT OUTCOME VARIABILITIES

4906
03:19:23,640 --> 03:19:28,280
AND DEMOGRAPHICS. AND WAS ABLE

4907
03:19:28,280 --> 03:19:28,880
TO SHOW CERTAIN DONOR

4908
03:19:28,880 --> 03:19:29,880
CHARACTERISTICS COMPONENT

4909
03:19:29,880 --> 03:19:31,680
CHARACTERISTICS IMPACT THE

4910
03:19:31,680 --> 03:19:34,720
EFFICACY. THAT LED TO A

4911
03:19:34,720 --> 03:19:35,920
FOLLOW-UP LARGE PROGRAM

4912
03:19:35,920 --> 03:19:39,440
TRIGGERED BY MARK AND TAMIR IN

4913
03:19:39,440 --> 03:19:42,440
THE WORK THEY DEMONSTRATED HIGH

4914
03:19:42,440 --> 03:19:46,320
BOTH SIDESSED DONOR VARIATION

4915
03:19:46,320 --> 03:19:48,680
INCLUDING GENDER AND AGE BUT

4916
03:19:48,680 --> 03:19:51,160
GENETIC VARIATION AFFECT

4917
03:19:51,160 --> 03:19:52,600
HEMOLYTIC PROPENSITY AND

4918
03:19:52,600 --> 03:19:54,040
CONSEQUENCE RECOVERY AND

4919
03:19:54,040 --> 03:19:56,280
EFFICACY OF TRANSFUSION. THE

4920
03:19:56,280 --> 03:19:57,960
NEXT SLIDE IS THE STUDY WE BUILT

4921
03:19:57,960 --> 03:19:59,920
ONE BIGGEST THING WE HAVE DONE

4922
03:19:59,920 --> 03:20:03,080
IS RBC OMICS STUDY, INVOLVED IN

4923
03:20:03,080 --> 03:20:04,600
ENROLLING 14,000 DONORS

4924
03:20:04,600 --> 03:20:08,080
PERSPECTIVELY USING DIVERSION

4925
03:20:08,080 --> 03:20:10,200
SAMPLES TO CAPTURE ALLOQUATS OF

4926
03:20:10,200 --> 03:20:12,760
THE PRODUCED RED CELLS, USING

4927
03:20:12,760 --> 03:20:15,000
THE REDUCTION FILTERS TO CAPTURE

4928
03:20:15,000 --> 03:20:17,200
WHITE CELLS AND CHARACTERIZING

4929
03:20:17,200 --> 03:20:18,360
PHENOTYPICALLY THE PROPERTIES OF

4930
03:20:18,360 --> 03:20:20,000
STORED RED CELLS STORED IN

4931
03:20:20,000 --> 03:20:22,920
SPECIAL TRANSFER BAGS AND

4932
03:20:22,920 --> 03:20:24,480
CHARACTERIZE END OF STORAGE,

4933
03:20:24,480 --> 03:20:28,480
WITH RESPECT TO HEMOLYTIC TO

4934
03:20:28,480 --> 03:20:31,080
PROSENSITIVE WE RECALL LARGE SUB

4935
03:20:31,080 --> 03:20:34,000
OAT AND SHOWED PHENOTYPE

4936
03:20:34,000 --> 03:20:35,440
REPRODUCIBLE WINDOW NORS SO

4937
03:20:35,440 --> 03:20:37,600
HERITABLE AND EXECUTED A LARGE

4938
03:20:37,600 --> 03:20:40,200
GWAS STUDY TO IDENTIFY LARGE

4939
03:20:40,200 --> 03:20:42,000
NUMBER OF TRAITS CORRELATED WITH

4940
03:20:42,000 --> 03:20:44,760
THE HEMOLYTIC PROPENSITY OF

4941
03:20:44,760 --> 03:20:47,320
THOSE RED CELLS THAT HAD BEEN

4942
03:20:47,320 --> 03:20:49,320
STORED FOR 42 DAYS.  THOSE

4943
03:20:49,320 --> 03:20:51,120
SAMPLES HAVE NOW BEEN

4944
03:20:51,120 --> 03:20:53,280
EXTENSIVELY CHARACTERIZED BY

4945
03:20:53,280 --> 03:20:55,920
ANGELO D'ALESSANDRO'S TEAM BY

4946
03:20:55,920 --> 03:20:57,680
METABOLOMICS AND WE LOOK AT

4947
03:20:57,680 --> 03:20:59,080
TRANSFUSION EFFICACY IN TERMS OF

4948
03:20:59,080 --> 03:21:00,440
PRODUCTS DERIVED FROM THE UNITS

4949
03:21:00,440 --> 03:21:05,440
-- THESE CHARACTERIZED DONORS. 

4950
03:21:05,440 --> 03:21:07,680
NEXT SLIDE. THIS SUMMARIZES NO

4951
03:21:07,680 --> 03:21:09,000
DETAIL HERE BUT THIS IS

4952
03:21:09,000 --> 03:21:12,080
PUBLISHED IN RECENTLY IN JCI BY

4953
03:21:12,080 --> 03:21:14,640
PAIGE STATISTICIAN OVERSEEING

4954
03:21:14,640 --> 03:21:17,720
THIS WORK AT RTI. THESE ARE

4955
03:21:17,720 --> 03:21:21,160
MAJOR GENE FINDINGS, MANY TURNED

4956
03:21:21,160 --> 03:21:24,000
OUT TO BE PROTEINS EXPRESSED ON

4957
03:21:24,000 --> 03:21:25,560
SURFACE OF RED CELLS, AND

4958
03:21:25,560 --> 03:21:28,400
FUNCTIONAL AND INVOLVED IN

4959
03:21:28,400 --> 03:21:30,080
PATHOLOGICAL CONDITIONS. IN A

4960
03:21:30,080 --> 03:21:31,640
SENSE NO SURPRISE THESE PROTEINS

4961
03:21:31,640 --> 03:21:33,760
AND POLYMORPHISMS WITHIN THESE

4962
03:21:33,760 --> 03:21:35,200
PROTEINS INFLUENCE ABILITY OF

4963
03:21:35,200 --> 03:21:40,160
RED CELLS TO TOLERATE STORAGE.

4964
03:21:40,160 --> 03:21:41,800
IMPORTANT NEW CAPACITY TO

4965
03:21:41,800 --> 03:21:45,840
UNDERSTAND MECHANISTIC REASONS

4966
03:21:45,840 --> 03:21:46,880
WHY RED CELLS FUNCTION

4967
03:21:46,880 --> 03:21:53,760
DIFFERENTLY.  NEXT SLIDE PLEASE.

4968
03:21:53,760 --> 03:21:55,760
ANOTHER FOLLOW-UP FROM NAREG,

4969
03:21:55,760 --> 03:21:57,680
PUBLISHED IN JCI WHICH TOOK

4970
03:21:57,680 --> 03:21:59,560
GENETIC FINDINGS FROM THE GWAS

4971
03:21:59,560 --> 03:22:01,680
AND ADDED THOSE TO HIS ANALYSIS

4972
03:22:01,680 --> 03:22:05,640
OF TRANSFUSION EFFICACY. 

4973
03:22:05,640 --> 03:22:06,960
EFFICACY DEFINED BASED ON

4974
03:22:06,960 --> 03:22:08,320
CHANGES POST TRANSFUSION CHANGES

4975
03:22:08,320 --> 03:22:10,560
AND HEMOGLOBIN CREATININE AND

4976
03:22:10,560 --> 03:22:12,880
BILIRUBIN.  AND A NUMBER OF HITS

4977
03:22:12,880 --> 03:22:16,160
IDENTIFIED BASED ON IN VITRO

4978
03:22:16,160 --> 03:22:16,840
HEMOLYSIS CHARACTERIZATION OF

4979
03:22:16,840 --> 03:22:18,720
SAMPLES URNED THE OUT

4980
03:22:18,720 --> 03:22:20,320
SIGNIFICANT WITH RESPECT TO

4981
03:22:20,320 --> 03:22:21,680
TRANSFUSION EFFICACY IN

4982
03:22:21,680 --> 03:22:22,960
MULTI-VARIANT ANALYSIS ACCOUNTED

4983
03:22:22,960 --> 03:22:25,160
FOR ALL THE OTHER BLOOD DONOR

4984
03:22:25,160 --> 03:22:35,640
COMPONENT RECIPIENT FACTORS. 

4985
03:22:39,520 --> 03:22:44,720
GREAT.  ANGELO AND TRAVIS, HAS

4986
03:22:44,720 --> 03:22:47,880
DONE ENORMOUS WORK ON THE OMICS

4987
03:22:47,880 --> 03:22:49,200
SAMPLES AND ONE INTERESTING

4988
03:22:49,200 --> 03:22:51,720
PAPER THAT HE HAS STUDIED THAT

4989
03:22:51,720 --> 03:22:53,520
HE DEVELOPED WAS RELATED TO

4990
03:22:53,520 --> 03:22:54,840
EXPOSOME SO TURNS OUT THESE

4991
03:22:54,840 --> 03:22:57,960
DONOR SAMPLES THAT WE SAVE

4992
03:22:57,960 --> 03:23:00,160
FROZEN FROM METABOLOMICS

4993
03:23:00,160 --> 03:23:01,080
ANALYSIS CHARACTERIZE TO

4994
03:23:01,080 --> 03:23:04,960
IDENTIFY EXTENSIVE DIETARY

4995
03:23:04,960 --> 03:23:06,200
MICROBIOME AND POLLUTANTS AND

4996
03:23:06,200 --> 03:23:07,960
DRUGS IN DONOR SAMPLES SO OUR

4997
03:23:07,960 --> 03:23:11,040
DONORS ARE HUMAN BEINGS AND

4998
03:23:11,040 --> 03:23:13,600
EXPOSE NOT ONLY TO GENETIC

4999
03:23:13,600 --> 03:23:16,480
CHARACTER RICKS BUT EXPOSURE

5000
03:23:16,480 --> 03:23:17,280
CHARACTERISTICS DIFFERENT FROM

5001
03:23:17,280 --> 03:23:19,680
DONOR TO DONOR. WE CAN IDENTIFY

5002
03:23:19,680 --> 03:23:23,560
THOSE COMPOUNDS IN THE

5003
03:23:23,560 --> 03:23:24,920
METABOLOMIC PROFILES AND

5004
03:23:24,920 --> 03:23:29,200
CORRELATE THE IMPACT OF

5005
03:23:29,200 --> 03:23:31,000
FUNCTIONAL PROPERTIES OF RED

5006
03:23:31,000 --> 03:23:33,000
CELLS IN VITRO CHARACTERIZATION.

5007
03:23:33,000 --> 03:23:35,760
NEXT SLIDE SHOWS ONE RECENT WORK

5008
03:23:35,760 --> 03:23:38,480
PRODUCTS OF ANGELO'S AND GRIER

5009
03:23:38,480 --> 03:23:41,600
PAGE'S EFFORTS WHICH IS TO

5010
03:23:41,600 --> 03:23:42,840
COMBINE GENETIC DATA WITH

5011
03:23:42,840 --> 03:23:44,480
METABOLOMICS DATA IN

5012
03:23:44,480 --> 03:23:45,960
QUANTITATIVE TRAIT LOCI

5013
03:23:45,960 --> 03:23:47,600
ANALYSIS, THE PAPER IS UNDER

5014
03:23:47,600 --> 03:23:48,760
REVIEW BUT FOR THE FIRST TIME

5015
03:23:48,760 --> 03:23:50,440
REALLY INTEGRATED THE FINDINGS

5016
03:23:50,440 --> 03:23:52,120
FROM THE GENETIC POLYMORPHISMS

5017
03:23:52,120 --> 03:23:55,480
WE IDENTIFIED WITH THE

5018
03:23:55,480 --> 03:23:56,920
METABOLOMICS DATA THAT IS RICH

5019
03:23:56,920 --> 03:23:58,120
AND DEMONSTRATES EVERYTHING

5020
03:23:58,120 --> 03:24:01,360
MAKES SENSE, THAT THE GENETIC

5021
03:24:01,360 --> 03:24:04,160
POLYMORPHISM IN DIFFERENT GENES,

5022
03:24:04,160 --> 03:24:06,360
INFLUENCE PROTEIN FUNCTION,

5023
03:24:06,360 --> 03:24:07,760
REFLECTED IN METABOLOMIC

5024
03:24:07,760 --> 03:24:15,520
PROFILES OF THOSE RED CELLS. THE

5025
03:24:15,520 --> 03:24:16,720
REDS 4 PORTFOLIO, NOT GOING TO

5026
03:24:16,720 --> 03:24:19,400
GO INTO BUT IT INCLUDES

5027
03:24:19,400 --> 03:24:21,280
EXTENSIVE WORK TO TRY TO

5028
03:24:21,280 --> 03:24:23,840
IDENTIFY NEW BIOMARKERS OF RED

5029
03:24:23,840 --> 03:24:26,160
CELL SEQUENCING USING OMIC

5030
03:24:26,160 --> 03:24:28,480
SAMPLES AND USES WORK TO

5031
03:24:28,480 --> 03:24:31,040
ESTABLISH BIO RBC TECHNOLOGIES

5032
03:24:31,040 --> 03:24:33,280
FOR TRACKING SURVIVAL RECOVERY

5033
03:24:33,280 --> 03:24:34,160
AND FUNCTION OF CELLS AND

5034
03:24:34,160 --> 03:24:35,520
CHARACTERIZATION OF CELLS THAT

5035
03:24:35,520 --> 03:24:39,840
DO SURVIVE. THERE IS THE VEIN TO

5036
03:24:39,840 --> 03:24:41,400
VEIN DATABASE AND LARGE

5037
03:24:41,400 --> 03:24:42,840
MULTI-SITE PROTOCOLS WHICH

5038
03:24:42,840 --> 03:24:44,920
INCLUDED PRE-TERM INFANT AND RBC

5039
03:24:44,920 --> 03:24:47,800
IMPACT STUDY WHICH WILL USE A

5040
03:24:47,800 --> 03:24:49,040
TRANSFUSION MEDICINE ARRAY THAT

5041
03:24:49,040 --> 03:24:51,840
IS DEVELOPED AND INCLUDES

5042
03:24:51,840 --> 03:24:55,000
FINDINGS FROM RBC OMICS AND

5043
03:24:55,000 --> 03:24:56,120
EXTENSIVE ADDITIONAL

5044
03:24:56,120 --> 03:24:57,920
CHARACTERIZATION OF GENETICS OF

5045
03:24:57,920 --> 03:24:59,760
DONORS AND BLOOD GROUP

5046
03:24:59,760 --> 03:25:01,840
POLYMORPHISMS. THEN THE RAPID

5047
03:25:01,840 --> 03:25:03,120
RESPONSE CAPACITY BOTH WITH

5048
03:25:03,120 --> 03:25:05,320
RESPECT TO THE CONCERNS OVER

5049
03:25:05,320 --> 03:25:08,160
PREP AND DONORS AND THE SARS

5050
03:25:08,160 --> 03:25:09,440
COV-2 RESPONSE PROGRAM, I

5051
03:25:09,440 --> 03:25:13,560
REFERENCED EARLIER. CITATION

5052
03:25:13,560 --> 03:25:14,920
AVAILABLE FOR THAT. WHAT WE HAVE

5053
03:25:14,920 --> 03:25:16,440
DONE HERE IN THE U.S., WE DON'T

5054
03:25:16,440 --> 03:25:20,360
WANT TO SAY WE ARE THE ONLY ONES

5055
03:25:20,360 --> 03:25:22,920
WHO DO THESE BY NO MEANS

5056
03:25:22,920 --> 03:25:23,920
INCREDIBLE WORK DONE IN

5057
03:25:23,920 --> 03:25:25,600
COUNTRIES PARALLELLING WHAT WE

5058
03:25:25,600 --> 03:25:26,800
ACHIEVE AND I WILL TOUCH ON A

5059
03:25:26,800 --> 03:25:28,360
FEW OF THESE OVER THE NEXT FEW

5060
03:25:28,360 --> 03:25:34,440
SLIDES.  GUSTAF IS SHOWN HERE IN

5061
03:25:34,440 --> 03:25:36,720
THE SCANDAT PROGRAM, I REMEMBER

5062
03:25:36,720 --> 03:25:38,040
WRITING WITH BRIAN EDITORIAL

5063
03:25:38,040 --> 03:25:41,080
THAT ACCOMPANIEDED THE FIRST

5064
03:25:41,080 --> 03:25:42,960
SCANDAT PAPER 15 YEARS AGO MAYBE

5065
03:25:42,960 --> 03:25:45,280
LONGER, AND THIS IS A LINKAGE OF

5066
03:25:45,280 --> 03:25:48,760
THE SWEDISH AND DANISH DONOR AND

5067
03:25:48,760 --> 03:25:50,320
TRANSFUSION DATABASES WITH THE

5068
03:25:50,320 --> 03:25:52,600
REGISTRIES, THE DISEASE

5069
03:25:52,600 --> 03:25:53,440
REGISTRIES WITHIN THOSE TWO

5070
03:25:53,440 --> 03:25:54,960
COUNTRIES SO BY NATIONAL

5071
03:25:54,960 --> 03:25:59,040
REGISTRY THAT IS NOW UPDATED AND

5072
03:25:59,040 --> 03:26:00,720
GOES BACK 20 YEARS. ALLOWS YOU

5073
03:26:00,720 --> 03:26:03,560
TO LOOK AT DONOR

5074
03:26:03,560 --> 03:26:07,080
CHARACTERISTICS.  THERE'S NO

5075
03:26:07,080 --> 03:26:08,800
SAMPLES, NO DETAIL

5076
03:26:08,800 --> 03:26:10,600
CHARACTERIZATION BEYOND ROUTINE

5077
03:26:10,600 --> 03:26:12,280
DONOR DATA BUT BECAUSE NATIONAL

5078
03:26:12,280 --> 03:26:13,840
IDEA OF ALL DONORS AND PATIENTS

5079
03:26:13,840 --> 03:26:17,360
EVERYONE IN THEIR LIVES, THEY

5080
03:26:17,360 --> 03:26:18,600
EXECUTE EXTRAORDINARY STUDIES

5081
03:26:18,600 --> 03:26:21,040
AND DOZENS OF PUBLICATIONS FROM

5082
03:26:21,040 --> 03:26:25,440
GUSTA IF AND TEAM FROM THE

5083
03:26:25,440 --> 03:26:28,600
SCANDAT PROGRAM. CHRISTIAN

5084
03:26:28,600 --> 03:26:31,920
ERICSON, THE DANISH DONOR STUDY,

5085
03:26:31,920 --> 03:26:35,240
THE SCANDAT TOOK A STEP FURTHER

5086
03:26:35,240 --> 03:26:36,280
NATIONAL BLOOD COLLECTION

5087
03:26:36,280 --> 03:26:37,640
ORGANIZATION AND ABILITY TO

5088
03:26:37,640 --> 03:26:40,800
ESSENTIALLY CONSENT ALMOST 100%

5089
03:26:40,800 --> 03:26:41,920
DANISH BLOOD DONORS TO

5090
03:26:41,920 --> 03:26:43,200
PARTICIPATE IN THE STUDY, THEY

5091
03:26:43,200 --> 03:26:44,960
HAVE BEEN ABLE TO ACQUIRE

5092
03:26:44,960 --> 03:26:47,120
LONGITUDINAL SAMPLES FROM DONORS

5093
03:26:47,120 --> 03:26:49,320
AND STUDY THEM WITH RESPECT TO

5094
03:26:49,320 --> 03:26:51,120
MANY CRITICAL QUESTIONS THAT

5095
03:26:51,120 --> 03:26:56,400
WERE ALL INTERESTED IN TERMS OF

5096
03:26:56,400 --> 03:26:59,200
IRON SUPPLEMENTATION, SO

5097
03:26:59,200 --> 03:27:03,720
EXTENSIVE GWAS DATA GENERATED

5098
03:27:03,720 --> 03:27:06,680
AND BIOMARKER STUDIES LINK DONOR

5099
03:27:06,680 --> 03:27:12,440
RECIPIENT SAMPLES. IS THE

5100
03:27:12,440 --> 03:27:14,240
AUSTRALIAN SYSTEM WHICH WAS

5101
03:27:14,240 --> 03:27:16,160
UNAWARE OF, THIS IS ERICA WOOD

5102
03:27:16,160 --> 03:27:17,120
WHO LED THE PROGRAM OF

5103
03:27:17,120 --> 03:27:20,120
ESTABLISHING THE AUSTRALIAN

5104
03:27:20,120 --> 03:27:21,720
NATIONAL TRANSFUSION DATA SET. 

5105
03:27:21,720 --> 03:27:23,320
NEXT SLIDE HAS HIGH LEVEL

5106
03:27:23,320 --> 03:27:25,600
OVERVIEW OF THAT PROGRAM BUT IT

5107
03:27:25,600 --> 03:27:27,960
IS GOLD STANDARD IN MY OPINION

5108
03:27:27,960 --> 03:27:29,840
AND BEING FINALIZED AND BUILT

5109
03:27:29,840 --> 03:27:31,400
BUT IT IS REALLY BUILDS THE

5110
03:27:31,400 --> 03:27:32,960
LINKAGE FROM THE DONORS AND

5111
03:27:32,960 --> 03:27:34,400
INCLUDING CAPTURING SAMPLES FROM

5112
03:27:34,400 --> 03:27:36,720
THE DONATIONS, THROUGH TO THE

5113
03:27:36,720 --> 03:27:37,960
HOSPITAL TRANSFUSION SERVICES,

5114
03:27:37,960 --> 03:27:40,440
AND THE RECIPIENTS AND THEN

5115
03:27:40,440 --> 03:27:43,200
LINKING THAT WITH CLINICAL

5116
03:27:43,200 --> 03:27:45,000
REGISTRIES THROUGHOUT AUSTRALIA

5117
03:27:45,000 --> 03:27:46,840
IN TERMS OF DISEASE REGISTRIES

5118
03:27:46,840 --> 03:27:48,760
AND HEALTH OUTCOME REGISTRIES.

5119
03:27:48,760 --> 03:27:51,440
SO THIS IS THE KIND OF BIG DATA

5120
03:27:51,440 --> 03:27:58,480
I THINK IS FUTURE OF THE FIELD I

5121
03:27:58,480 --> 03:28:00,800
WANT TO RECOGNIZE NANCY AND THE

5122
03:28:00,800 --> 03:28:01,800
CANADIANS HAVE BEEN FABULOUS

5123
03:28:01,800 --> 03:28:04,280
WORK AND NANCY IN PARTICULAR HAS

5124
03:28:04,280 --> 03:28:06,400
ALWAYS BEEN A CHAMPION OF

5125
03:28:06,400 --> 03:28:08,400
METHODOLOGY AND THIS IS FROM THE

5126
03:28:08,400 --> 03:28:10,200
LAST TRANSFUSION PUBLISHED

5127
03:28:10,200 --> 03:28:12,960
OUTSTANDING REVIEW OF HOW BIG

5128
03:28:12,960 --> 03:28:15,280
DATA RESEARCH TRANSFUSION

5129
03:28:15,280 --> 03:28:17,760
MEDICINE SHOULD BE DONE IN TERMS

5130
03:28:17,760 --> 03:28:20,360
OF OPPOSED HYPOTHESIS DRIVEN

5131
03:28:20,360 --> 03:28:21,920
BASED RESEARCH WHICH IS ALWAYS

5132
03:28:21,920 --> 03:28:23,200
INVESTIGATIONAL STUDIES THAT

5133
03:28:23,200 --> 03:28:26,200
INVOLVE RANDOMIZATION, THOSE ARE

5134
03:28:26,200 --> 03:28:27,120
ALWAYS IMPORTANT AND SHOULD BE

5135
03:28:27,120 --> 03:28:28,920
DONE BUT WHEN YOU CAPTURE AND

5136
03:28:28,920 --> 03:28:30,920
ACCURATELY CURATE AND ANALYZE

5137
03:28:30,920 --> 03:28:33,000
BIG DATA YOU CAN ACHIEVE

5138
03:28:33,000 --> 03:28:34,920
INCREDIBLE INSIGHTS THAT FEED

5139
03:28:34,920 --> 03:28:36,720
INTO THE NEXT FIELD OF

5140
03:28:36,720 --> 03:28:41,760
HYPOTHESIS DRIVEN RESEARCH. 

5141
03:28:41,760 --> 03:28:44,040
COMING TO THE END HERE, I WANT

5142
03:28:44,040 --> 03:28:49,120
TO SAY ALL THESE GREAT IDEAS AND

5143
03:28:49,120 --> 03:28:50,280
ACCOMPLISHMENTS, CROSS

5144
03:28:50,280 --> 03:28:54,160
FERTILIZATION COLLABORATION,

5145
03:28:54,160 --> 03:28:55,720
CONCEPTION, PASSION, DEPENDS ON

5146
03:28:55,720 --> 03:28:57,320
PEOPLE. THIS IS A SLIDE OF GROUP

5147
03:28:57,320 --> 03:29:00,320
OF PEOPLE IN THE PERKINS LIBRARY

5148
03:29:00,320 --> 03:29:02,280
THAT UNFORTUNATELY ABOUT TO BE

5149
03:29:02,280 --> 03:29:03,600
CLOSED AS WE MOVE TO A NEW

5150
03:29:03,600 --> 03:29:05,760
FACILITY BUT THIS INCLUDES STEVE

5151
03:29:05,760 --> 03:29:08,600
KLINEMAN AND GUSTAV AND NAREG

5152
03:29:08,600 --> 03:29:10,600
AND OTHERS AND I THINK PHILLIP

5153
03:29:10,600 --> 03:29:12,240
OR ANGELO ARE STANDING UP TAKING

5154
03:29:12,240 --> 03:29:14,200
THE PICTURE BUT THERE IS NO

5155
03:29:14,200 --> 03:29:16,160
SUBSTITUTE FOR HUMAN BEINGS

5156
03:29:16,160 --> 03:29:19,040
REALLY BOUNCING IDEAS OFF EACH

5157
03:29:19,040 --> 03:29:20,840
OTHER AND CONSOLIDATING STUDIES

5158
03:29:20,840 --> 03:29:22,840
AND CONCEPTUALIZING THEM INTO

5159
03:29:22,840 --> 03:29:25,600
REAL PROTOCOLS THAT NEED TO BE

5160
03:29:25,600 --> 03:29:28,480
TRANSLATED INTO MANUALS OF

5161
03:29:28,480 --> 03:29:30,720
OPERATION AND EMPOWERMENT

5162
03:29:30,720 --> 03:29:32,120
ANALYSES AND SIMONE AND WE

5163
03:29:32,120 --> 03:29:33,520
EXECUTE THOSE STUDIES AND

5164
03:29:33,520 --> 03:29:34,960
ACHIEVE WHAT IS REALLY BEEN I

5165
03:29:34,960 --> 03:29:36,080
THINK A REALLY INCREDIBLE

5166
03:29:36,080 --> 03:29:37,120
PROGRESS IN OUR FIELD THAT WE

5167
03:29:37,120 --> 03:29:40,560
HAVE ACHIEVED OVER MY CAREER AND

5168
03:29:40,560 --> 03:29:42,120
SEE IT CONTINUING WITH MY

5169
03:29:42,120 --> 03:29:44,280
SUCCESSORS AS WELL AS THE TEAM

5170
03:29:44,280 --> 03:29:46,520
ON THIS CALL. JUST THIS QUOTE

5171
03:29:46,520 --> 03:29:48,800
WHICH I SPOTTED IN A TRANTAS

5172
03:29:48,800 --> 03:29:51,400
FUSION ABB SMART BRIEF, BUT FEEL

5173
03:29:51,400 --> 03:29:52,640
STRONGLY ABOUT, HAVING PEOPLE

5174
03:29:52,640 --> 03:29:55,040
WHO ARE PASSIONATE WORKING

5175
03:29:55,040 --> 03:29:56,720
TOGETHER FOR LONG PERIODS OF

5176
03:29:56,720 --> 03:29:59,720
TIME IS THE ANSWER. LOT OF

5177
03:29:59,720 --> 03:30:02,720
PEOPLE THAT REALLY WATCHING THAT

5178
03:30:02,720 --> 03:30:04,000
IS FINE BUT PEOPLE WHO ARE

5179
03:30:04,000 --> 03:30:06,600
PASSIONATE AND ACHIEVE IT THAT I

5180
03:30:06,600 --> 03:30:08,320
THINK ALLOW US TO ACHIEVE WHAT

5181
03:30:08,320 --> 03:30:10,680
IS IN THE LAST SLIDE WHICH IS

5182
03:30:10,680 --> 03:30:11,840
THE PRODUCT OF THIS MEETING

5183
03:30:11,840 --> 03:30:15,400
WHICH IS THE EVOLUTION OF OUR

5184
03:30:15,400 --> 03:30:17,960
FIELD TO PRECISION TRANSFUSION

5185
03:30:17,960 --> 03:30:19,720
MEDICINE VISION. THANK YOU FOR

5186
03:30:19,720 --> 03:30:21,320
YOUR ATTENTION. IF THERE IS TIME

5187
03:30:21,320 --> 03:30:31,920
I WILL HAPPILY ANSWER QUESTIONS 

5188
03:30:38,080 --> 03:30:40,720
>> THERE IS TIME SO YES,
PLEASE

5189
03:30:40,720 --> 03:30:41,720
THANK YOU VERY MUCH MIKE FOR

5190
03:30:41,720 --> 03:30:42,600
YOUR COMPREHENSIVE CONVERSATION

5191
03:30:42,600 --> 03:30:46,240
ABOUT THE FUTURE AND THE PAST

5192
03:30:46,240 --> 03:30:49,800
ALL TOGETHER. HAPPY FOR PEOPLE

5193
03:30:49,800 --> 03:30:51,080
TO ASK MIKE ANY QUESTIONS THEY

5194
03:30:51,080 --> 03:31:01,280
WOULD LIKE.

5195
03:31:12,640 --> 03:31:14,120
PEOPLE MAY BE A LITTLE

5196
03:31:14,120 --> 03:31:15,720
OVERWHELMED WITH ALL THAT

5197
03:31:15,720 --> 03:31:16,760
HONESTLY BUT I WILL ASK A

5198
03:31:16,760 --> 03:31:18,160
QUESTION. IT IS A BEAUTIFUL

5199
03:31:18,160 --> 03:31:20,280
VISION. BUT THERE IS A LOT OF

5200
03:31:20,280 --> 03:31:21,760
ELEMENTS TO PRECISION

5201
03:31:21,760 --> 03:31:22,560
TRANSFUSION MEDICINE THAT WE

5202
03:31:22,560 --> 03:31:25,640
HAVE TO WORK THROUGH.  SO HOW DO

5203
03:31:25,640 --> 03:31:27,840
WE START? DO WE JUST START WITH

5204
03:31:27,840 --> 03:31:30,240
PATH OF OUR OWN OR SHOULD WE BE

5205
03:31:30,240 --> 03:31:32,000
DOING FOCUS RESEARCH THAT HELPS

5206
03:31:32,000 --> 03:31:33,880
UNDERSTAND FOR EXAMPLE, HOW MUCH

5207
03:31:33,880 --> 03:31:35,880
DONORS ARE WILLING TO

5208
03:31:35,880 --> 03:31:39,200
PARTICIPATE IN THOSE ACTIVITIES 

5209
03:31:39,200 --> 03:31:44,040
>> IT IS A BIG
MULTI-FACETED

5210
03:31:44,040 --> 03:31:45,600
PROCESS BUT I DO THINK WE HAVE

5211
03:31:45,600 --> 03:31:48,520
STARTED WELL ALONG THE PATH AND

5212
03:31:48,520 --> 03:31:49,920
IT IS CONTINUING AND AGAIN ALL

5213
03:31:49,920 --> 03:31:53,760
THE WORKING GROUPS ALL ENJOYED

5214
03:31:53,760 --> 03:31:56,840
THE WORKING GROUP 1 AND DONOR

5215
03:31:56,840 --> 03:31:59,080
WHAT DOES IT TAKE TO RECRUIT

5216
03:31:59,080 --> 03:32:00,640
INSCENT AND ENCOURAGE PEOPLE TO

5217
03:32:00,640 --> 03:32:03,040
GIVE. AS ALLUDED TO EARLIER, A

5218
03:32:03,040 --> 03:32:04,720
BIG PIECE OF THIS IN THE U.S.

5219
03:32:04,720 --> 03:32:06,240
THOUGH WE ARE INCREDIBLY

5220
03:32:06,240 --> 03:32:08,320
FORTUNATE TO HAVE THE RESOURCES

5221
03:32:08,320 --> 03:32:10,880
WE HAVE, IN TERMS OF NIH FUNDING

5222
03:32:10,880 --> 03:32:17,360
AND SUPPORT FROM OTHER NATIONAL

5223
03:32:17,360 --> 03:32:18,040
ORGANIZATIONS, THERE NEEDS TO BE

5224
03:32:18,040 --> 03:32:20,160
A COMMITMENT IN THE BLOOD

5225
03:32:20,160 --> 03:32:24,360
ORGANIZATIONS THEMSELVES.

5226
03:32:24,360 --> 03:32:26,000
OBVIOUSLY THEY CARE DEEPLY, THEY

5227
03:32:26,000 --> 03:32:27,480
NEED THE DONORS SO THEY CARE

5228
03:32:27,480 --> 03:32:30,120
ABOUT DONOR RECRUITMENT AND

5229
03:32:30,120 --> 03:32:31,800
RETENTION, RESEARCH THAT WAS

5230
03:32:31,800 --> 03:32:33,000
DISCUSSED. THEY WANT THEIR

5231
03:32:33,000 --> 03:32:35,240
PRODUCTS TO BE EFFICACIOUS, THEY

5232
03:32:35,240 --> 03:32:36,560
WANT NEXT GENERATION BETTER

5233
03:32:36,560 --> 03:32:38,760
TRANSFUSION PRODUCTS. SO I THINK

5234
03:32:38,760 --> 03:32:41,920
THEY NEED TO INVEST IN

5235
03:32:41,920 --> 03:32:44,480
ESTABLISHING CAPACITY TO CONSENT

5236
03:32:44,480 --> 03:32:47,000
DONORS ROUTINELY TO BE ABLE TO

5237
03:32:47,000 --> 03:32:49,280
CAPTURE SAMPLES FROM OPTIMALLY

5238
03:32:49,280 --> 03:32:51,640
SELECTED SUB SETS OF DONORS TO

5239
03:32:51,640 --> 03:32:54,760
BE ABLE TO LINK THAT TO

5240
03:32:54,760 --> 03:32:57,000
TRANSFUSION OUTCOMES OPTIMALLY,

5241
03:32:57,000 --> 03:32:59,000
CAPTURING SAMPLES AND SAVING

5242
03:32:59,000 --> 03:33:03,120
THEM AND THAT COULD BE ACHIEVED

5243
03:33:03,120 --> 03:33:04,480
THROUGH THE NATIONAL CENTRALIZED

5244
03:33:04,480 --> 03:33:07,920
TESTING LABS. SO WE CAN'T EXPECT

5245
03:33:07,920 --> 03:33:09,440
THE NIH AND THE CHALLENGE THAT I

5246
03:33:09,440 --> 03:33:11,400
FELT OVER TIME IS EVERY TIME WE

5247
03:33:11,400 --> 03:33:14,160
BUILD GREAT REPOSITORIES AND

5248
03:33:14,160 --> 03:33:15,840
GREAT LINK DATA SETS THAT THE

5249
03:33:15,840 --> 03:33:18,280
STUDIES EXPIRE. THERE'S NO MORE

5250
03:33:18,280 --> 03:33:21,360
FUNDING TO SUSTAIN THOSE

5251
03:33:21,360 --> 03:33:23,840
DATABASES FROM REDS 2, TO REDS 3

5252
03:33:23,840 --> 03:33:26,080
OR 4. SO I FEEL LIKE IN A

5253
03:33:26,080 --> 03:33:27,520
CHAMPIONING TO THE HIGHER

5254
03:33:27,520 --> 03:33:29,600
ORGANIZATION AND OTHERS THAT THE

5255
03:33:29,600 --> 03:33:31,400
BLOOD COLLECTION ORGANIZATIONS

5256
03:33:31,400 --> 03:33:33,800
AND TESTING LABORATORIES IN THE

5257
03:33:33,800 --> 03:33:36,600
U.S. NEED TO PARTNER TOGETHER

5258
03:33:36,600 --> 03:33:37,600
AND SUPPORT INFRASTRUCTURE ON

5259
03:33:37,600 --> 03:33:41,800
WHICH THEN RESEARCH PROGRAMS CAN

5260
03:33:41,800 --> 03:33:46,760
BUILD AND EXECUTE THE SCIENCE,

5261
03:33:46,760 --> 03:33:49,440
DISCOVERY WORK AND THEN THE

5262
03:33:49,440 --> 03:33:51,720
TRANSLATIONAL WORK TO MOVE THESE

5263
03:33:51,720 --> 03:33:53,160
PRECISION TRANSFUSION MEDICINE

5264
03:33:53,160 --> 03:33:58,320
TOOLS INTO ACTUAL PRACTICE. 

5265
03:33:58,320 --> 03:34:00,480
>> THANK YOU, MIC. LOOKS
LIKE

5266
03:34:00,480 --> 03:34:02,480
SUNNY, YOU HAVE A COMMENT? FEEL

5267
03:34:02,480 --> 03:34:02,840
FREE.

5268
03:34:02,840 --> 03:34:06,280
>> I DO, I HAVE A COMMENT
AND A

5269
03:34:06,280 --> 03:34:13,200
QUESTION FOR MIKE. FIRST IT IS

5270
03:34:13,200 --> 03:34:15,720
REALLY HARD TO FOLLOW MIKE WITH

5271
03:34:15,720 --> 03:34:17,480
ANYTHING. YOU LISTEN TO A

5272
03:34:17,480 --> 03:34:19,440
PRESENTATION WITH MIKE IT IS

5273
03:34:19,440 --> 03:34:20,960
ALWAYS IN A CLASS BY ITSELF. SO

5274
03:34:20,960 --> 03:34:22,440
IT IS AN OPPORTUNITY JUST TO SAY

5275
03:34:22,440 --> 03:34:24,080
THE OBVIOUS, WHICH IS TO

5276
03:34:24,080 --> 03:34:27,880
CONGRATULATE YOU ON A JUST

5277
03:34:27,880 --> 03:34:31,000
STUNNING CAREER EVERY TIME YOU

5278
03:34:31,000 --> 03:34:31,880
SUMMARIZE ONE-TENTH OF WHAT YOU

5279
03:34:31,880 --> 03:34:34,960
HAVE DONE, IT IS MIND BOGGLING.

5280
03:34:34,960 --> 03:34:36,600
BUT ANYWAY THAT IS NOT WHAT I

5281
03:34:36,600 --> 03:34:38,080
NEEDED.  ONE THING THAT CAME UP

5282
03:34:38,080 --> 03:34:39,840
IN TOWARD THE END OF THE SOS, I

5283
03:34:39,840 --> 03:34:42,560
THINK WAS REALLY IMPORTANT, YOU

5284
03:34:42,560 --> 03:34:46,680
TOUCHED ON IT MIKE. WITH YOUR

5285
03:34:46,680 --> 03:34:48,640
COMMENTS TRYING TO PREPARE NEXT

5286
03:34:48,640 --> 03:34:50,320
GENERATION.  WE HEARD A LOT OF

5287
03:34:50,320 --> 03:34:51,960
INTERESTING COMMENTS ABOUT THE

5288
03:34:51,960 --> 03:34:53,840
IMPORTANCE OF TRANSFUSION

5289
03:34:53,840 --> 03:34:57,920
MEDICINE EDUCATION ESPECIALLY IN

5290
03:34:57,920 --> 03:35:00,040
TRAINING RESEARCH IN TRANSFUSION

5291
03:35:00,040 --> 03:35:02,320
MEDICINE. THE INADEQUACY OF A

5292
03:35:02,320 --> 03:35:05,920
ONE YEAR FELLOWSHIP TRAINING

5293
03:35:05,920 --> 03:35:08,480
PROGRAM. CLINICAL TRANTAS FUSION

5294
03:35:08,480 --> 03:35:09,920
MEDICINE IN ONE YEAR GOD FORD BY

5295
03:35:09,920 --> 03:35:12,440
ALSO DOING RESEARCH TECHNIQUES

5296
03:35:12,440 --> 03:35:14,120
AND HOW TO POOL OFF RESEARCH SO

5297
03:35:14,120 --> 03:35:17,000
YOU SAID YOU WERE INCREDIBLY

5298
03:35:17,000 --> 03:35:18,720
LUCKY TO HAVE FALLEN IN THE

5299
03:35:18,720 --> 03:35:20,280
CIRCUMSTANCES THAT FOSTERED YOUR

5300
03:35:20,280 --> 03:35:22,600
RESEARCH. AND I TAKE THAT POINT.

5301
03:35:22,600 --> 03:35:26,000
I SEE THE ELEMENT OF LUCK THAT

5302
03:35:26,000 --> 03:35:27,560
WAS THERE BUT WE KNOW IT WASN'T

5303
03:35:27,560 --> 03:35:31,200
JUST LUCK, RIGHT? THERE WAS

5304
03:35:31,200 --> 03:35:32,000
SOMETHING ABOUT YOU AND

5305
03:35:32,000 --> 03:35:33,600
SOMETHING ABOUT THE PEOPLE WHO

5306
03:35:33,600 --> 03:35:38,440
HELPED TRAIN YOU AND GUIDE YOU. 

5307
03:35:38,440 --> 03:35:40,560
I WOULD BE INTERESTED IN

5308
03:35:40,560 --> 03:35:41,720
REFLECTING ON YOU REFLECTING

5309
03:35:41,720 --> 03:35:43,480
YOUR OWN CAREER. IF YOU COULD

5310
03:35:43,480 --> 03:35:46,560
HAVE ANYTHING, WITH RESPECT TO

5311
03:35:46,560 --> 03:35:48,400
TRAINING FUTURE TRANSFUSION

5312
03:35:48,400 --> 03:35:51,600
MEDICINE RESEARCHERS, WHAT WOULD

5313
03:35:51,600 --> 03:35:54,080
THAT BE? HOW DO YOU THINK WE

5314
03:35:54,080 --> 03:35:55,800
SHOULD CHANGE WHAT WE DO TO

5315
03:35:55,800 --> 03:35:56,840
IMPROVE GENERATION OF

5316
03:35:56,840 --> 03:35:59,000
RESEARCHERS?

5317
03:35:59,000 --> 03:36:01,080
>> THANKS FOR THE
COMMENTS. I

5318
03:36:01,080 --> 03:36:03,320
FEEL THE SAME ABOUT YOU AND YOUR

5319
03:36:03,320 --> 03:36:07,200
CAREER. FABULOUS. I DID I GUESS

5320
03:36:07,200 --> 03:36:09,320
STUMBLE IN TO A SITUATION BUT I

5321
03:36:09,320 --> 03:36:11,000
PUT MY HEART AND SOUL INTO IT

5322
03:36:11,000 --> 03:36:13,920
FOR THE SUBSEQUENT 40 YEARS. I

5323
03:36:13,920 --> 03:36:15,920
DID IT WITH PEOPLE WHO ARE

5324
03:36:15,920 --> 03:36:20,560
PASSIONATE AND COMMITTED. SO HE

5325
03:36:20,560 --> 03:36:22,120
CAME INTO WORK UNTIL A WEEK

5326
03:36:22,120 --> 03:36:24,320
BEFORE HE DIED IN '92. LOVED

5327
03:36:24,320 --> 03:36:26,040
EVERY MINUTE OF TRAINING PEOPLE,

5328
03:36:26,040 --> 03:36:27,240
HE CONTINUED TO TRAIN ALL THE

5329
03:36:27,240 --> 03:36:29,680
FELLOWS AND LEAD THE TRANSFUSION

5330
03:36:29,680 --> 03:36:32,160
MEDICINE FELLOWSHIP PROGRAM.

5331
03:36:32,160 --> 03:36:34,040
USDS IS STILL ACTIVE TRYING TO

5332
03:36:34,040 --> 03:36:37,200
GET MONEY SUCCESSFULLY BUT JUST

5333
03:36:37,200 --> 03:36:39,280
BEEN EXAMPLE OF SOMEONE WHO HAS

5334
03:36:39,280 --> 03:36:42,880
JUST PUT THE METAL ALL THE TIME.

5335
03:36:42,880 --> 03:36:44,760
SO I FEEL LIKE I WAS FORTUNATE

5336
03:36:44,760 --> 03:36:46,680
AND AGAIN WITH NIH AND PEOPLE

5337
03:36:46,680 --> 03:36:48,680
LIKE GEORGE AND SIMONE ON MY

5338
03:36:48,680 --> 03:36:51,680
SIDE.  BUT I THINK WHAT IS ALSO

5339
03:36:51,680 --> 03:36:54,440
TRUE IS I CARE DEEPLY AND

5340
03:36:54,440 --> 03:36:56,000
SURROUNDED -- BEEN FORTUNATE TO

5341
03:36:56,000 --> 03:36:57,560
RECRUIT AND SURROUND MYSELF WITH

5342
03:36:57,560 --> 03:36:59,120
YOUNG PEOPLE WHO DID STAY ON.

5343
03:36:59,120 --> 03:37:00,640
THEY DID THE TRANSFUSION

5344
03:37:00,640 --> 03:37:04,040
MEDICINE FELLOWSHIP AND THEN

5345
03:37:04,040 --> 03:37:06,240
THEY EITHER STAYED OUR INSTITUTE

5346
03:37:06,240 --> 03:37:08,640
FOR BRIEF PERIOD, MANY OTHERS

5347
03:37:08,640 --> 03:37:10,120
WHO BECOME GREAT LEADERS IN THE

5348
03:37:10,120 --> 03:37:13,000
FIELD, OR THEY STAYED ON AND

5349
03:37:13,000 --> 03:37:15,920
BECOME INCREDIBLY PRODUCTIVE AND

5350
03:37:15,920 --> 03:37:17,160
COLLABORATIVE IN OUR INSTITUTE.

5351
03:37:17,160 --> 03:37:21,720
THAT REQUIRED THE INSTITUTE.

5352
03:37:21,720 --> 03:37:23,480
WHAT WE HAVE SEEN UNFORTUNATELY

5353
03:37:23,480 --> 03:37:26,720
IS DEMICE OF ALMOST ALL WHAT

5354
03:37:26,720 --> 03:37:28,320
USED TO BE SUCCESSFUL

5355
03:37:28,320 --> 03:37:29,400
TRANSFUSION MEDICINE RESEARCH

5356
03:37:29,400 --> 03:37:31,000
PROGRAMS IN THE US.  I WON'T

5357
03:37:31,000 --> 03:37:34,040
NAME NAMES BUT MANY OF THEM HAVE

5358
03:37:34,040 --> 03:37:37,600
EITHER STOPPED COMPLETELY OFFER

5359
03:37:37,600 --> 03:37:39,040
STRUGGLING TO MAINTAIN INTERNAL

5360
03:37:39,040 --> 03:37:42,520
FUNDING TO SUPPORT RESEARCH

5361
03:37:42,520 --> 03:37:44,880
PROGRAMS. THIS IS A TRAGEDY. THE

5362
03:37:44,880 --> 03:37:48,920
PROGRAMS LIKE OURS THAT ARE ABLE

5363
03:37:48,920 --> 03:37:50,600
TO CONTINUE TO BENEFIT FROM

5364
03:37:50,600 --> 03:37:53,120
INTRAMURAL FUNDING IS WHAT IS

5365
03:37:53,120 --> 03:37:55,360
CRITICAL, WE JUST MOVING INTO A

5366
03:37:55,360 --> 03:37:59,040
BRAND NEW INSTITUTE FACILITY.

5367
03:37:59,040 --> 03:38:00,680
THE INVESTMENT OF OUR TALENT TO

5368
03:38:00,680 --> 03:38:03,000
DO THAT IS WONDERFUL. A

5369
03:38:03,000 --> 03:38:04,720
COMMITMENT TO SUPPORT

5370
03:38:04,720 --> 03:38:06,040
INVESTIGATORS AT ALL STAGES TO

5371
03:38:06,040 --> 03:38:09,160
SUPPORT SUMMER INTERNSHIPS AND

5372
03:38:09,160 --> 03:38:11,800
FELLOWSHIP PROGRAMS, WE CAN'T

5373
03:38:11,800 --> 03:38:13,880
EXPECT AND WE ARE A SMALL FIELD

5374
03:38:13,880 --> 03:38:16,200
SO WE CAN'T SUCCESSFULLY COMPETE

5375
03:38:16,200 --> 03:38:18,320
IN MANY CASES FOR LARGE SCALE

5376
03:38:18,320 --> 03:38:20,840
TRAINING GRANTS, THE ONE WE HAD

5377
03:38:20,840 --> 03:38:22,080
HISTORICALLY THAT ARE BROOD BANK

5378
03:38:22,080 --> 03:38:24,040
FOCUSED UCSF NOW MOVED TO

5379
03:38:24,040 --> 03:38:27,920
CELLULAR THERAPY FOCUS.  THEY

5380
03:38:27,920 --> 03:38:30,320
CHANGE TACK. SO IT REQUIRES

5381
03:38:30,320 --> 03:38:32,080
COMMITMENT BACK TO EARLIER

5382
03:38:32,080 --> 03:38:33,200
COMMENTS, IT REQUIRES

5383
03:38:33,200 --> 03:38:35,080
COMMITMENTS OF THE NATIONAL

5384
03:38:35,080 --> 03:38:45,640
BLOOD ORGANIZATIONS THAT WE NEED

5385
03:38:46,280 --> 03:38:47,600
TO SUSTAIN AND RECOGNIZE THE

5386
03:38:47,600 --> 03:38:48,880
INSTITUTES, WE LIKE TO SEE

5387
03:38:48,880 --> 03:38:51,280
TRAINING GO ON EVERYWHERE

5388
03:38:51,280 --> 03:38:53,440
RESEARCH OPPORTUNITIES, NATIONAL

5389
03:38:53,440 --> 03:38:56,440
THANKS TO LARGE PROGRAMS NHLBI

5390
03:38:56,440 --> 03:38:59,080
FUNDED, THAT BECOMES

5391
03:38:59,080 --> 03:39:00,520
COLLABORATIVE ACTIVITY THAT

5392
03:39:00,520 --> 03:39:01,840
DISSEMINATES OUT BEYOND THE

5393
03:39:01,840 --> 03:39:03,720
HANDFUL OF INSTITUTES THAT LEAD

5394
03:39:03,720 --> 03:39:05,280
IT AND DRIVE IT.  BUT I THINK IT

5395
03:39:05,280 --> 03:39:07,440
IS THAT LONG TERM COMMITMENT OF

5396
03:39:07,440 --> 03:39:10,680
THE BLOOD ORGANIZATIONS THAT I

5397
03:39:10,680 --> 03:39:13,240
FEEL LIKE WE MANAGE TO MAINTAIN

5398
03:39:13,240 --> 03:39:16,360
BUT BARELY AND WE NEED TO KEEP

5399
03:39:16,360 --> 03:39:18,520
ON THEM TO SUPPORT RESEARCH AND

5400
03:39:18,520 --> 03:39:24,520
SUPPORT INFRASTRUCTURE. 

5401
03:39:24,520 --> 03:39:26,200
>> DR. YOUNG, WOULD YOU
LIKE TO

5402
03:39:26,200 --> 03:39:27,320
MAKE A COMMENT?

5403
03:39:27,320 --> 03:39:30,880
>> HI. FIRST OF ALL,

5404
03:39:30,880 --> 03:39:35,560
CONGRATULATIONS ON JUST SUCH

5405
03:39:35,560 --> 03:39:38,560
INCREDIBLE CAREER. IT IS GREAT

5406
03:39:38,560 --> 03:39:40,000
TO HAVE LUMINARIES LIKE YOU TO

5407
03:39:40,000 --> 03:39:44,800
LOOK UP TO AND THANK YOU FOR THE

5408
03:39:44,800 --> 03:39:46,400
GREAT TALK. ONE THING I HAVE

5409
03:39:46,400 --> 03:39:49,520
BEEN THINKING ABOUT AS I LISTEN

5410
03:39:49,520 --> 03:39:51,480
TO YOUR TALK AS WELL AS OTHERS

5411
03:39:51,480 --> 03:39:57,280
IN THIS AFTERNOON, AND MORNING

5412
03:39:57,280 --> 03:40:01,240
MUCH OF TRANSFUSION MEDICINE IS

5413
03:40:01,240 --> 03:40:06,520
NOT ISN'T AMENABLE TO HYPOTH 

5414
03:40:06,520 --> 03:40:07,520
HYPOTHESIS.  HYPOTHESIS BASED

5415
03:40:07,520 --> 03:40:10,600
RESEARCH, A LOT IS QUITE

5416
03:40:10,600 --> 03:40:13,760
EXPLORATORY. LOOKING AT DONOR

5417
03:40:13,760 --> 03:40:15,520
MOTIVATION IS EXPLORATORY

5418
03:40:15,520 --> 03:40:18,280
RESEARCH. NOT HYPOTHESIS DRIVEN.

5419
03:40:18,280 --> 03:40:18,400
.

5420
03:40:18,400 --> 03:40:21,400
AS IS SORT OF THE DONOR

5421
03:40:21,400 --> 03:40:24,160
RECIPIENT DATABASE, REALLY LENDS

5422
03:40:24,160 --> 03:40:26,920
ITSELF TO LOT OF EXPLORATORY

5423
03:40:26,920 --> 03:40:30,120
RESEARCH, NOT NECESSARILY

5424
03:40:30,120 --> 03:40:31,240
HYPOTHESIS DRIVEN AT THIS STAGE,

5425
03:40:31,240 --> 03:40:36,160
NOT A LOT OF MECHANISTIC

5426
03:40:36,160 --> 03:40:37,160
QUESTIONS, AVAILABLE IN OUR

5427
03:40:37,160 --> 03:40:38,760
FIELD WHICH IS DIFFERENT THAN

5428
03:40:38,760 --> 03:40:42,400
MAYBE SOME OTHER AREAS OF

5429
03:40:42,400 --> 03:40:46,240
MEDICINE. I GUESS MY QUESTION

5430
03:40:46,240 --> 03:40:52,840
IS, HOW WILLING IS NIH TO

5431
03:40:52,840 --> 03:40:56,160
SUPPORT THIS FIELD AND THIS TYPE

5432
03:40:56,160 --> 03:40:58,720
OF APPROACH BECAUSE THAT IS IN

5433
03:40:58,720 --> 03:41:02,160
MY EXPERIENCE BEEN ONE OF THE

5434
03:41:02,160 --> 03:41:05,000
CHALLENGES IN PROPOSING AND

5435
03:41:05,000 --> 03:41:09,200
GETTING FUNDED

5436
03:41:09,200 --> 03:41:13,960
>> THAT MIGHT BE A
QUESTION

5437
03:41:13,960 --> 03:41:15,520
FORESI MOAN. I THINK THE OTHER

5438
03:41:15,520 --> 03:41:20,480
POINT TO MAKE IN RESPONSE THINGS

5439
03:41:20,480 --> 03:41:22,040
HAVE EVOLVED SO DRAMATICALLY

5440
03:41:22,040 --> 03:41:23,480
WITH COVID-19 THE LAST TWO DAYS

5441
03:41:23,480 --> 03:41:24,880
HAVE BEEN A STRUGGLE BECAUSE

5442
03:41:24,880 --> 03:41:27,960
FROM MIDNIGHT MY TIME UNTIL 8

5443
03:41:27,960 --> 03:41:29,200
A.M. OVERLAPPING BEGINNING OF

5444
03:41:29,200 --> 03:41:31,440
THIS MEETING THERE'S BEEN A WHO

5445
03:41:31,440 --> 03:41:32,800
WONDERFUL MEETING ABOUT HOW TO

5446
03:41:32,800 --> 03:41:37,320
BE READY FOR THE NEXT PANDEMIC

5447
03:41:37,320 --> 03:41:39,880
X, IT IS JUST -- BUT IT IS

5448
03:41:39,880 --> 03:41:41,240
CHANGED OUR LIVES PRETTY

5449
03:41:41,240 --> 03:41:42,440
DRAMATICALLY AND I THINK IT IS

5450
03:41:42,440 --> 03:41:44,320
CHANGED RESEARCH. VIRTUALLY

5451
03:41:44,320 --> 03:41:46,000
EVERYONE WHO IS DOING ANY KIND

5452
03:41:46,000 --> 03:41:51,080
OF RESEARCH FROM BASIC THROUGH

5453
03:41:51,080 --> 03:41:53,240
TRANSLATIONAL AND EPIDEMIOLOGIC

5454
03:41:53,240 --> 03:41:54,480
OBSERVATIONAL RESEARCH PIVOTED

5455
03:41:54,480 --> 03:41:57,800
TO WORK ON COVID-19. A LOT OF

5456
03:41:57,800 --> 03:41:59,600
INCREDIBLE PRODUCTIVITY HAS BEEN

5457
03:41:59,600 --> 03:42:01,760
ACHIEVED THROUGH OBSERVATIONAL

5458
03:42:01,760 --> 03:42:04,040
STUDIES AND JUST RESPONDING

5459
03:42:04,040 --> 03:42:06,720
URGENTLY TO CRISIS WE HAVE LIVED

5460
03:42:06,720 --> 03:42:08,600
THROUGH. SO I HI IT IS KIND OF

5461
03:42:08,600 --> 03:42:12,280
AN OPPORTUNITY FOR RESET AND I

5462
03:42:12,280 --> 03:42:15,640
WOULD LIKE TO HEAR NHLBI

5463
03:42:15,640 --> 03:42:18,320
RESPONSE AND OTHERS, I FEEL LIKE

5464
03:42:18,320 --> 03:42:20,440
RESEARCH WE DO IS REAL RESEARCH

5465
03:42:20,440 --> 03:42:22,360
AS STEVE SAID AT THE BEGINNING

5466
03:42:22,360 --> 03:42:24,200
THERE'S ALL DIFFERENT KINDS OF

5467
03:42:24,200 --> 03:42:26,160
RESEARCH AND IT HAS TO BE GOOD

5468
03:42:26,160 --> 03:42:28,280
RESEARCH AND HAS TO BE IMPACTFUL

5469
03:42:28,280 --> 03:42:30,440
BUT THERE IS VALUE TO THE KIND

5470
03:42:30,440 --> 03:42:34,760
OF RESEARCH YOU JUST SUMMARIZED

5471
03:42:34,760 --> 03:42:36,000
INCLUDING OPERATIONAL ISSUES

5472
03:42:36,000 --> 03:42:39,440
LIKE DONOR MOTIVATION RETENTION

5473
03:42:39,440 --> 03:42:41,800
THIS IS CRITICAL. SIMILAR MOAN

5474
03:42:41,800 --> 03:42:42,240
ARE YOU ON?

5475
03:42:42,240 --> 03:42:48,280
>> I'M ON AND I WANT TO
SAY THAT

5476
03:42:48,280 --> 03:42:49,360
ABSOLUTELY I THINK THOSE LAST

5477
03:42:49,360 --> 03:42:56,320
TWO DAYS HAVE SHOWN ACTUALLY THE

5478
03:42:56,320 --> 03:42:58,360
VERY IMPORTANT RESEARCH

5479
03:42:58,360 --> 03:43:03,200
QUESTIONS THE FIELD HAS. SO OF

5480
03:43:03,200 --> 03:43:05,120
COURSE THIS IS FOR THE WHOLE

5481
03:43:05,120 --> 03:43:07,960
COMMUNITY TO CONSIDER. AS YOU

5482
03:43:07,960 --> 03:43:11,000
KNOW, BUT OF COURSE NHLBI WILL

5483
03:43:11,000 --> 03:43:15,320
ALSO LOOK AT THOSE PRIORITIES.

5484
03:43:15,320 --> 03:43:17,800
CLEARLY, I'M PERSONALLY ALTHOUGH

5485
03:43:17,800 --> 03:43:20,560
AS YOU KNOW I REALLY LOVE THIS

5486
03:43:20,560 --> 03:43:26,120
FIELD, BUT I'M STILL IN AWE

5487
03:43:26,120 --> 03:43:30,120
ABOUT BREADTH OF THE RESEARCH

5488
03:43:30,120 --> 03:43:31,720
AND POSSIBILITIES YOU HAVE IN

5489
03:43:31,720 --> 03:43:38,320
FRONT OF YOU. I ENCOURAGE YOU TO

5490
03:43:38,320 --> 03:43:41,440
WHEN YOU HAVE A RESEARCH IDEA IN

5491
03:43:41,440 --> 03:43:46,400
MIND YOU COME UP WITH SOME AIMS

5492
03:43:46,400 --> 03:43:53,160
AND CALL US. 

5493
03:43:53,160 --> 03:43:54,560
>> ALL RIGHT, THANK YOU
VERY

5494
03:43:54,560 --> 03:43:57,280
MUCH DR. GLYNN. ENCOURAGEMENT, I

5495
03:43:57,280 --> 03:43:58,720
THINK YOU WILL HEAR FROM PERHAPS

5496
03:43:58,720 --> 03:44:02,720
MORE THAN A FEW PEOPLE. I MAKE

5497
03:44:02,720 --> 03:44:06,160
ONE COMMENT, MIKE. LINKING TO

5498
03:44:06,160 --> 03:44:11,440
WHAT YOU SAID. I THINK ADMIRAL

5499
03:44:11,440 --> 03:44:12,920
LEVINE OPENING COMMENTS AT

5500
03:44:12,920 --> 03:44:14,680
HIGHEST LEVEL OF HHS THERE IS A

5501
03:44:14,680 --> 03:44:15,840
CURRENT CLEAR INTEREST THAT, IS

5502
03:44:15,840 --> 03:44:16,840
A LEVERAGE POINT FOR US SO WE

5503
03:44:16,840 --> 03:44:19,440
NEED TO TAKE ADVANTAGE OF THAT.

5504
03:44:19,440 --> 03:44:23,240
WE WILL DO OUR BEST AS CO-CHAIRS

5505
03:44:23,240 --> 03:44:24,440
AND ORGANIZING COMMITTEE OF THE

5506
03:44:24,440 --> 03:44:25,600
STATE OF THE SCIENCE TRANSFUSION

5507
03:44:25,600 --> 03:44:29,560
MEDICINE TO DO THAT. WHAT WE

5508
03:44:29,560 --> 03:44:32,720
WILL DO NOW IS TURN TO SOME WRAP

5509
03:44:32,720 --> 03:44:33,920
UP COMMENTS THAT NAREG AND I

5510
03:44:33,920 --> 03:44:35,840
WILL MAKE ABOUT WHAT WE HEARD

5511
03:44:35,840 --> 03:44:37,280
THE LAST COUPLE OF DAYS AND

5512
03:44:37,280 --> 03:44:38,440
WHERE WE GO FROM HERE. SO TURN

5513
03:44:38,440 --> 03:44:44,200
IT TO YOU TO START NAREG.

5514
03:44:44,200 --> 03:44:47,120
>> CAN YOU SEE MY SCREEN?

5515
03:44:47,120 --> 03:44:48,240
>> YES.

5516
03:44:48,240 --> 03:44:53,760
>> THANK YOU MIKE FOR THE

5517
03:44:53,760 --> 03:44:58,520
PRESENTATION ONE SEGUE. AS A

5518
03:44:58,520 --> 03:45:00,240
PULMONOLOGIST BROUGHT INTO FIELD

5519
03:45:00,240 --> 03:45:03,040
OF TRANSFUSION MEDICINE, REALLY

5520
03:45:03,040 --> 03:45:05,360
WAS BEING SURROUNDED BY GREAT

5521
03:45:05,360 --> 03:45:06,840
MENTORS, BY PEOPLE AROUND YOU

5522
03:45:06,840 --> 03:45:08,120
MADE THE DIFFERENCE FOR ME

5523
03:45:08,120 --> 03:45:14,640
PERSONALLY.  FEW COMMENTS, THE

5524
03:45:14,640 --> 03:45:15,760
ORGANIZING COMMITTEE PICKED A

5525
03:45:15,760 --> 03:45:18,240
FEW EXAMPLES OF COMMON THEMES

5526
03:45:18,240 --> 03:45:19,320
RESEARCH PRY YOURS ACROSS THE

5527
03:45:19,320 --> 03:45:24,800
WORKING GROUPS THAT

5528
03:45:24,800 --> 03:45:28,000
INDEPENDENTLY IDENTIFIED AREAS

5529
03:45:28,000 --> 03:45:30,440
OF FOCUS. AREAS OF FOCUS TO

5530
03:45:30,440 --> 03:45:35,160
BRING US BACK TO THE LET ME MOVE

5531
03:45:35,160 --> 03:45:37,240
MY SCREEN, I AM LOOKING. THERE

5532
03:45:37,240 --> 03:45:39,880
IS A FOCUS FOR THE 2022 STATE OF

5533
03:45:39,880 --> 03:45:41,880
SCIENCE TRANSFUSION MEDICINE,

5534
03:45:41,880 --> 03:45:44,320
INCLUDE INCREASING DIVERSIFYING

5535
03:45:44,320 --> 03:45:47,560
THE BLOOD DONOR POOL IDENTIFYING

5536
03:45:47,560 --> 03:45:48,960
WHICH BLOOD PRODUCTS WIDOW NORS

5537
03:45:48,960 --> 03:45:50,880
BEST MEET THE CLINICAL NEEDS OF

5538
03:45:50,880 --> 03:45:52,400
SPECIFIC RECIPIENT POPULATIONS

5539
03:45:52,400 --> 03:45:56,240
HELPING ENSURE SAFE EFFECTIVE

5540
03:45:56,240 --> 03:45:58,480
TRANSFUSION STRATEGIES

5541
03:45:58,480 --> 03:45:59,600
RECOGNIZING THESE MAY DIFFER FOR

5542
03:45:59,600 --> 03:46:01,440
DIFFERENT RECIPIENT POPULATIONS.

5543
03:46:01,440 --> 03:46:03,320
SO I THINK OVER THE PAST TWO

5544
03:46:03,320 --> 03:46:05,760
DAYS WE HAVE TOUCHED ON NUMBER

5545
03:46:05,760 --> 03:46:08,680
OF THESE CONCEPTS ACROSS THE SIX

5546
03:46:08,680 --> 03:46:11,080
WORKING GROUPS. MAINTAINING

5547
03:46:11,080 --> 03:46:14,240
ROBUST DIVERSE BLOOD DONOR POOL,

5548
03:46:14,240 --> 03:46:16,400
THIS IS AS NOTED RECENTLY BEEN

5549
03:46:16,400 --> 03:46:17,960
AMPLIFIED IN SETTING OF BLOOD

5550
03:46:17,960 --> 03:46:22,600
SHORTAGE INCLUDING PART OF

5551
03:46:22,600 --> 03:46:24,240
COVID-19 AS WELL AS NEEDS FOR

5552
03:46:24,240 --> 03:46:26,480
SPECIAL POPULATIONS. WE HAVE

5553
03:46:26,480 --> 03:46:28,400
SPOKEN ABOUT NEEDS FOR

5554
03:46:28,400 --> 03:46:30,120
COMPONENTS AND RECIPIENTS, WIDOW

5555
03:46:30,120 --> 03:46:31,800
NORS WHICH PRODUCTS FOR BROAD

5556
03:46:31,800 --> 03:46:34,240
RANGE OF RECIPIENTS ACROSS THE

5557
03:46:34,240 --> 03:46:37,000
RANGE INCLUDING NEONATE AS WELL

5558
03:46:37,000 --> 03:46:39,520
AS FOR VARIOUS CLINICAL

5559
03:46:39,520 --> 03:46:42,480
SCENARIOS, BE IT SURGICAL,

5560
03:46:42,480 --> 03:46:44,240
NON-SURGICAL, SITUATIONS OF

5561
03:46:44,240 --> 03:46:46,360
HEMORRHAGE, PATIENTS WITH

5562
03:46:46,360 --> 03:46:48,920
MALIGNANT CONDITIONS. THEN WITH

5563
03:46:48,920 --> 03:46:50,680
OVERLAP FOCUSED ON BLOOD SAFETY

5564
03:46:50,680 --> 03:46:53,160
AND EFFECTIVENESS, MINIMIZING

5565
03:46:53,160 --> 03:46:57,400
MITIGATING RISK. IDENTIFYING

5566
03:46:57,400 --> 03:46:59,040
EXPANDING UPON EFFICACY

5567
03:46:59,040 --> 03:47:00,520
EFFECTIVENESS OUTCOMES AND AGAIN

5568
03:47:00,520 --> 03:47:04,240
IN VARIOUS PARTICULAR

5569
03:47:04,240 --> 03:47:05,200
POPULATIONS, WITH EVEN COMMENTS

5570
03:47:05,200 --> 03:47:07,600
DURING THE BREAK OUT ABOUT RED

5571
03:47:07,600 --> 03:47:11,120
CELL OR PLATELET EFFECTIVENESS

5572
03:47:11,120 --> 03:47:14,640
OR CLEARANCE NOT JUST POST

5573
03:47:14,640 --> 03:47:16,440
TRANSFUSION BUT DOWNSTREAM. WITH

5574
03:47:16,440 --> 03:47:17,320
MIKE'S PRESENTATION, FOR

5575
03:47:17,320 --> 03:47:18,920
BRINGING THIS TOGETHER THIS

5576
03:47:18,920 --> 03:47:20,520
VISION OF PRECISION TRANSFUSION

5577
03:47:20,520 --> 03:47:24,000
MEDICINE. CAN WE INTERFACE

5578
03:47:24,000 --> 03:47:26,640
BETWEEN BASIC CLINICAL SCIENCE

5579
03:47:26,640 --> 03:47:30,800
TO IDENTIFY WIDOW NORS USING FOR

5580
03:47:30,800 --> 03:47:34,400
EXAMPLE, GENOMIC OR GENOTYPING

5581
03:47:34,400 --> 03:47:35,440
METABOLOMICS OR HEMOLYSIS

5582
03:47:35,440 --> 03:47:37,680
MEASURES OR OTHER BIOMARKERS

5583
03:47:37,680 --> 03:47:40,120
MEET THE NEED FOR SPECIFIC

5584
03:47:40,120 --> 03:47:41,640
RECIPIENTS ACROSS THE AGE

5585
03:47:41,640 --> 03:47:43,280
SPECTRUM BY TRANSFUSION

5586
03:47:43,280 --> 03:47:47,320
INDICATION OR CO-MORBIDITY. THAT

5587
03:47:47,320 --> 03:47:48,800
INCLUDES DONOR OUTREACH

5588
03:47:48,800 --> 03:47:50,600
SELECTION AND RETENTION IN MANY

5589
03:47:50,600 --> 03:47:54,320
CASES SO THIS IS CONCEPT OF

5590
03:47:54,320 --> 03:47:57,400
PERSONALIZED PRECISION MEDICINE

5591
03:47:57,400 --> 03:48:00,080
IS ONE THAT HAS COME UP OVER

5592
03:48:00,080 --> 03:48:03,240
PAST FEW DAYS ACROSS THE THREAD

5593
03:48:03,240 --> 03:48:04,920
OF SIX WORKING GROUPS AND JUST

5594
03:48:04,920 --> 03:48:06,880
WANTED TO TOUCH ON THAT AS WELL

5595
03:48:06,880 --> 03:48:10,120
AS LET BRIAN DO SO.

5596
03:48:10,120 --> 03:48:12,520
>> THANK YOU, I AM GOING
TO

5597
03:48:12,520 --> 03:48:15,480
BUILD ON WHAT NAREG SAID. SO WE

5598
03:48:15,480 --> 03:48:16,960
HAVE VISION FOR PRECISION

5599
03:48:16,960 --> 03:48:18,760
TRANSFUSION MEDICINE. SOME MIGHT

5600
03:48:18,760 --> 03:48:21,520
CALL IT PERSONAL TRANSFUSION

5601
03:48:21,520 --> 03:48:23,440
MEDICINE. WHAT I THINK RAISES IS

5602
03:48:23,440 --> 03:48:25,120
AN OPPORTUNITY BUT WE SEE IT AS

5603
03:48:25,120 --> 03:48:26,520
DIRECTLY MEETING THE CHALLENGES

5604
03:48:26,520 --> 03:48:28,720
THAT WE HAVE TO FACE HEAD ON

5605
03:48:28,720 --> 03:48:30,760
WITH RESPECT TO HEALTH

5606
03:48:30,760 --> 03:48:32,080
DISPARITIES. CAN WE HAVE THEM

5607
03:48:32,080 --> 03:48:33,920
BOTH. SO NO, WE CAN'T HAVE THEM

5608
03:48:33,920 --> 03:48:36,560
BOTH.  WE HAVE TO FIGURE HOW TO

5609
03:48:36,560 --> 03:48:38,120
OVERCOME HEALTH DISPARITIES AND

5610
03:48:38,120 --> 03:48:43,400
ACCESSING DONORS, TO PROVIDE

5611
03:48:43,400 --> 03:48:44,720
COMPONENTS TO RECIPIENTS BUT

5612
03:48:44,720 --> 03:48:46,160
DOING SO IN WAYS THAT ARE

5613
03:48:46,160 --> 03:48:48,160
APPROPRIATE TO THE COMMUNITIES

5614
03:48:48,160 --> 03:48:51,800
THAT WE SERVE. I SEE THIS AS A

5615
03:48:51,800 --> 03:48:53,520
HUGE OPPORTUNITY BUT PERHAPS

5616
03:48:53,520 --> 03:48:55,960
EVEN MORE REALLY IMPORTANT

5617
03:48:55,960 --> 03:48:58,720
CHALLENGE WE FACE. THERE IS A

5618
03:48:58,720 --> 03:49:00,800
LOT TO UNPACK AROUND THAT.

5619
03:49:00,800 --> 03:49:02,560
CLEARLY WE WILL BE TRYING TO DO

5620
03:49:02,560 --> 03:49:04,800
SO AS PART OF THE PROCEEDINGS OF

5621
03:49:04,800 --> 03:49:07,920
THIS MEETING. THAT IS ALL TO SAY

5622
03:49:07,920 --> 03:49:09,640
ABOUT THAT. I WILL GO ON TO

5623
03:49:09,640 --> 03:49:20,360
SIMPLER TOPICS WHICH ARE EASIER 

5624
03:49:20,360 --> 03:49:23,920
JUST TO START TO SUMMARIZE NAREG

5625
03:49:23,920 --> 03:49:25,480
SHARED THOUGHTS ON COMMON THEMES

5626
03:49:25,480 --> 03:49:27,480
AND I WILL SHARE A COUPLE BEFORE

5627
03:49:27,480 --> 03:49:29,520
WE TALK NEXT STEPS. SO WE HAD

5628
03:49:29,520 --> 03:49:32,120
DISCUSSIONS AROUND INCREASING

5629
03:49:32,120 --> 03:49:33,440
DIVERSIFYING THE BLOOD DONOR

5630
03:49:33,440 --> 03:49:35,040
POOL AND SPECIFIC WORKING GROUPS

5631
03:49:35,040 --> 03:49:36,520
FOCUSED ON DIFFERENT ASPECTS OF

5632
03:49:36,520 --> 03:49:38,360
THAT. HONESTLY THAT WAS MY

5633
03:49:38,360 --> 03:49:39,800
INTENTION, WE WANTED PEOPLE

5634
03:49:39,800 --> 03:49:41,080
THINKING ABOUT HOW WE BRING

5635
03:49:41,080 --> 03:49:43,200
DONORS IN, WHAT ARE THE ISSUES

5636
03:49:43,200 --> 03:49:44,880
RELATED TO SUFFICIENCY OF THE

5637
03:49:44,880 --> 03:49:47,320
SUPPLY BUT WE ALSO WANTED AN

5638
03:49:47,320 --> 03:49:48,400
INDEPENDENT VOICE, WHAT DO WE

5639
03:49:48,400 --> 03:49:50,480
HAVE WITH RESPECT TO DONOR

5640
03:49:50,480 --> 03:49:51,600
RECIPIENT DISPARITIES AND HOW

5641
03:49:51,600 --> 03:49:53,320
IMPORTANT ARE THOSE. BUT THERE

5642
03:49:53,320 --> 03:49:58,520
ARE THOSE THEMES THAT CLEARLY

5643
03:49:58,520 --> 03:49:59,280
ARE VERY CLOSE CONNECTED WITH

5644
03:49:59,280 --> 03:50:00,520
THE WORK THOSE TWO DIFFERENT

5645
03:50:00,520 --> 03:50:03,440
WORKING GROUPS DONE, ONE ARE

5646
03:50:03,440 --> 03:50:05,240
MOTIVATORS AND BARRIERS TO

5647
03:50:05,240 --> 03:50:08,000
INITIAL AND REPEAT DONATION.

5648
03:50:08,000 --> 03:50:09,120
PARTICULARLY AMONG YOUNGER

5649
03:50:09,120 --> 03:50:11,360
INDIVIDUALS AN PEOPLE WITH

5650
03:50:11,360 --> 03:50:12,680
DIVERSE BACKGROUNDS CURRENTLY

5651
03:50:12,680 --> 03:50:14,240
UNDERREPRESENTED IN DONOR POOL

5652
03:50:14,240 --> 03:50:16,640
AND WHAT ARE EFFECTIVE

5653
03:50:16,640 --> 03:50:18,360
STRATEGIES FOR OVERCOMING

5654
03:50:18,360 --> 03:50:19,440
BARRIERS PARTICULARLY DIVERSE

5655
03:50:19,440 --> 03:50:25,080
POPULATIONS OR COMMUNITY OF

5656
03:50:25,080 --> 03:50:26,840
COLOR. SO WORK TOGETHER TO MELD

5657
03:50:26,840 --> 03:50:28,480
TWO WORKING GROUP PRIORITIES

5658
03:50:28,480 --> 03:50:30,280
INTO RESEARCH AGENDA THAT

5659
03:50:30,280 --> 03:50:31,840
ADDRESSES ALL THAT

5660
03:50:31,840 --> 03:50:34,280
SIMULTANEOUSLY OR WE WON'T BE

5661
03:50:34,280 --> 03:50:35,920
SUCCESSFUL. WE HAVE THIS BROADER

5662
03:50:35,920 --> 03:50:38,120
OR ADDITIONAL ASPECT OF THE

5663
03:50:38,120 --> 03:50:39,880
SOCIAL MILIEU OR THE SITUATION

5664
03:50:39,880 --> 03:50:41,760
WE FIND OURSELVES IN IN.

5665
03:50:41,760 --> 03:50:42,720
UNRELATED TO RESEARCH

5666
03:50:42,720 --> 03:50:43,800
PARTICIPANTS AND WILLINGNESS TO

5667
03:50:43,800 --> 03:50:47,360
BE PART OF STUDIES, THAT IS MUCH

5668
03:50:47,360 --> 03:50:48,560
MORE THAN JUST INDIVIDUAL

5669
03:50:48,560 --> 03:50:50,800
CONVERSATION THAT IS ALL OF

5670
03:50:50,800 --> 03:50:51,720
THOSE OTHER FACTORS THAT

5671
03:50:51,720 --> 03:50:52,880
CONTRIBUTE TO WILLINGNESS TO

5672
03:50:52,880 --> 03:50:54,480
PARTICIPATE OR NOT AND WORK WITH

5673
03:50:54,480 --> 03:50:56,000
US SO WE FACE CHALLENGES BUT

5674
03:50:56,000 --> 03:51:04,600
OPPORTUNITIES. THIS IS

5675
03:51:04,600 --> 03:51:05,840
RECOGNIZING TWO VERY DIFFERENT

5676
03:51:05,840 --> 03:51:07,440
WORKING GROUPS FOCUSED ON

5677
03:51:07,440 --> 03:51:10,920
THINKING ABOUT THESE THEMES BUT

5678
03:51:10,920 --> 03:51:12,200
COMMON IDEA HOW THE USE SOCIAL

5679
03:51:12,200 --> 03:51:13,760
MEDIA, OR DIGITAL COMMUNICATIONS

5680
03:51:13,760 --> 03:51:15,400
TO BE MORE EFFECTIVE

5681
03:51:15,400 --> 03:51:20,720
COMMUNICATORS WITH BLOOD DONORS 

5682
03:51:20,720 --> 03:51:23,040
OBVIOUSLY DATA SCIENCE UNDERPINS

5683
03:51:23,040 --> 03:51:24,400
THAT HOW THE FIELD IS GOING BUT

5684
03:51:24,400 --> 03:51:28,240
THERE IS MORE DIRECT HOY IS IT

5685
03:51:28,240 --> 03:51:29,800
EFFECTIVE AND HOW TO MEASURE

5686
03:51:29,800 --> 03:51:31,040
EFFECTIVENESS IN DONORS

5687
03:51:31,040 --> 03:51:33,840
THEMSELVES SO NO ANSWERS JUST

5688
03:51:33,840 --> 03:51:38,320
COMMON THEMES THAT ALLOW US TO

5689
03:51:38,320 --> 03:51:39,560
PROPOSE RESEARCH QUESTIONS AND

5690
03:51:39,560 --> 03:51:41,240
STUDIES THAT CAN LOOK AT THIS IN

5691
03:51:41,240 --> 03:51:45,640
MORE DETAIL. 

5692
03:51:45,640 --> 03:51:48,320
>> PARALLEL ACROSS THREE
WORKING

5693
03:51:48,320 --> 03:51:50,960
GROUPS WE SAW COMMON THEMES

5694
03:51:50,960 --> 03:51:55,160
RELATED TO VEIN TO VEIN DATAB 

5695
03:51:55,160 --> 03:51:56,800
DATABASES, THE DATA METHODS

5696
03:51:56,800 --> 03:51:58,920
GROUP MULTI-DIMENSIONAL VEIN TO

5697
03:51:58,920 --> 03:52:01,120
VEIN DATABASES CURATED TO ANSWER

5698
03:52:01,120 --> 03:52:02,320
SPECIFIC RESEARCH QUESTIONS AND

5699
03:52:02,320 --> 03:52:04,040
SPECIFIC FOCUS ON SPECIAL

5700
03:52:04,040 --> 03:52:07,480
POPULATIONS OR RARE OUTCOMES

5701
03:52:07,480 --> 03:52:09,840
WHERE LARGE SCALE DATABASES IS

5702
03:52:09,840 --> 03:52:17,280
PERHAPS NECESSARY. OPTIMIZING

5703
03:52:17,280 --> 03:52:18,640
FOCUS ON EFFECTIVENESS BUT

5704
03:52:18,640 --> 03:52:20,840
LINKING IN WHAT THE ROLE OF

5705
03:52:20,840 --> 03:52:22,720
DONOR COMPONENTS WERE AS PART OF

5706
03:52:22,720 --> 03:52:27,200
VEIN TO VEIN DATABASE.  ONE CAN

5707
03:52:27,200 --> 03:52:29,840
VIEW ROLE OF CONVALESCENT PLASMA

5708
03:52:29,840 --> 03:52:32,200
AS ANOTHER FORM OF VEIN TO VEIN

5709
03:52:32,200 --> 03:52:33,400
DATABASE RECOGNIZED IN

5710
03:52:33,400 --> 03:52:34,560
OBSERVATIONAL STUDIES THAT THERE

5711
03:52:34,560 --> 03:52:37,840
WERE FACETS OF THE DONOR

5712
03:52:37,840 --> 03:52:40,040
INCLUDING THEIR IMMUNE TITERS,

5713
03:52:40,040 --> 03:52:41,840
ANTIBODY TITERS RELEVANT TO

5714
03:52:41,840 --> 03:52:43,400
OUTCOME OF RECIPIENT AND HOW

5715
03:52:43,400 --> 03:52:46,160
THIS WAS NEEDED TO BE STUDIED IN

5716
03:52:46,160 --> 03:52:47,240
CLINICAL TRIAL AND OBSERVATIONAL

5717
03:52:47,240 --> 03:52:53,240
FASHIONS.  INTEGRATING GENOMICS

5718
03:52:53,240 --> 03:52:56,440
INTO CLINICAL TRANSFUSION WORK

5719
03:52:56,440 --> 03:52:58,760
FLOW, THIS IS RECOGNIZED AN

5720
03:52:58,760 --> 03:53:00,280
APPROACH TO RARE GENOTYPES BUT

5721
03:53:00,280 --> 03:53:02,960
IDENTIFYING THE BEST DONOR FOR

5722
03:53:02,960 --> 03:53:05,040
RECIPIENT IS ANOTHER FACET OF

5723
03:53:05,040 --> 03:53:12,960
THIS CONCEPT.  THE EVER PRESENT

5724
03:53:12,960 --> 03:53:17,120
FOCUS ON BLOOD SAFETY IS --

5725
03:53:17,120 --> 03:53:18,800
REMAINS HIGHLY RELEVANT. THIS

5726
03:53:18,800 --> 03:53:21,880
CAME UP IN FOUR WORKING GROUPS. 

5727
03:53:21,880 --> 03:53:22,880
IN THE BREAK OUT SESSION THIS

5728
03:53:22,880 --> 03:53:26,440
WAS RAISED TO SOME EXTENT

5729
03:53:26,440 --> 03:53:29,880
OPTIMIZING CLINICAL OUTCOMES

5730
03:53:29,880 --> 03:53:31,320
NON-INFECTIOUS HAZARDS OF

5731
03:53:31,320 --> 03:53:32,880
TRANSFUSION PART OF THE EMERGING

5732
03:53:32,880 --> 03:53:35,120
INFECTIONS WORKING GROUP ROLE OF

5733
03:53:35,120 --> 03:53:38,000
PATHOGEN REDUCED BLOOD PRODUCTS

5734
03:53:38,000 --> 03:53:43,920
TO MITIGATE EMERGING PATHOGENS.

5735
03:53:43,920 --> 03:53:44,760
MECHANISTICALLY SPEAKING

5736
03:53:44,760 --> 03:53:46,440
RECOGNIZING THESE ADVERSE

5737
03:53:46,440 --> 03:53:48,440
OUTCOMES AND RECIPIENTS HOW WE

5738
03:53:48,440 --> 03:53:50,880
MORE BROADLY UNDERSTAND

5739
03:53:50,880 --> 03:53:54,600
PATHOYENSIS OF ADVERSE EVENTS

5740
03:53:54,600 --> 03:53:55,960
AND BETTER UNDERSTAND QUALITY IN

5741
03:53:55,960 --> 03:54:00,320
TERMS OF MITIGATING EVENTS.

5742
03:54:00,320 --> 03:54:01,000
RECOGNIZING THERE ARE

5743
03:54:01,000 --> 03:54:02,720
DISPARITIES IN MINORITY DIVERSE

5744
03:54:02,720 --> 03:54:03,960
BACKGROUND POPULATIONS WHERE WE

5745
03:54:03,960 --> 03:54:06,560
SEE HIGHER ADVERSE EVENT RATES

5746
03:54:06,560 --> 03:54:08,080
AND HOW CAN WE BETTER STUDY

5747
03:54:08,080 --> 03:54:09,680
THOSE AND MITIGATE THOSE IN THE

5748
03:54:09,680 --> 03:54:17,680
FUTURE.  THEN MEASURING

5749
03:54:17,680 --> 03:54:21,560
EFFECTIVENESS, ACROSS MULTIPLE

5750
03:54:21,560 --> 03:54:24,240
WORK GROUP GROUP GROUPS. CLINICN

5751
03:54:24,240 --> 03:54:25,920
MAKING FOR RED BLOOD CELL

5752
03:54:25,920 --> 03:54:28,160
TRANSFUSION WAS EVER PRESENT

5753
03:54:28,160 --> 03:54:30,600
TOPIC IN THE OPTIMIZING CLINICAL

5754
03:54:30,600 --> 03:54:34,520
OUTCOMES GROUP. THIS IS AN AREA

5755
03:54:34,520 --> 03:54:36,600
OF FOCUS TRYING TO UNDERSTAND

5756
03:54:36,600 --> 03:54:39,040
HEMOSTATIC AND NON-HEMOSTATIC

5757
03:54:39,040 --> 03:54:41,560
PROCESSES FOR PLATELET

5758
03:54:41,560 --> 03:54:43,160
TRANSFUSION IMMUNE ASPECT OF THE

5759
03:54:43,160 --> 03:54:43,920
TRANSFUSION THAT ARE NOT WELL

5760
03:54:43,920 --> 03:54:48,320
UNDERSTOOD. CLEARLY

5761
03:54:48,320 --> 03:54:50,080
MECHANISTICALLY APPROACHES TO

5762
03:54:50,080 --> 03:54:51,440
BETTER UNDERSTANDING WHAT WE ARE

5763
03:54:51,440 --> 03:54:53,040
DOING, HOW WE ARE DOING IT AND

5764
03:54:53,040 --> 03:54:56,440
WHY WE ARE DOING IT FOCUSING ON

5765
03:54:56,440 --> 03:54:58,680
METHODS AND STRATEGIES FOR

5766
03:54:58,680 --> 03:54:59,920
UNDERSTANDING BOTH BLOOD PRODUCT

5767
03:54:59,920 --> 03:55:02,880
EFFECTIVENESS AND EFFICACY.

5768
03:55:02,880 --> 03:55:05,640
MECHANISMS FOR TRANSFUSION.

5769
03:55:05,640 --> 03:55:07,880
LASTLY, FOR THE FOCUS ON NEW

5770
03:55:07,880 --> 03:55:13,040
RESEARCH METHODS, THE USE OF BIG

5771
03:55:13,040 --> 03:55:16,240
DATA OR SCALABLE TECHNOLOGIES

5772
03:55:16,240 --> 03:55:17,800
ARTIFICIAL INTELLIGENCE, MACHINE

5773
03:55:17,800 --> 03:55:19,040
LEARNING BLOOD FLOWS ON THE

5774
03:55:19,040 --> 03:55:20,600
BLOOD BANKING SIDE AS WELL AS

5775
03:55:20,600 --> 03:55:23,000
TRANSFUSION MEDICINE, THIS TOPIC

5776
03:55:23,000 --> 03:55:25,000
ALSO CAME UP IN BREAK OUT

5777
03:55:25,000 --> 03:55:27,120
SESSION FOR OPTIMIZING CLINICAL

5778
03:55:27,120 --> 03:55:29,640
OUTCOMES RECOGNIZING PERHAPS

5779
03:55:29,640 --> 03:55:31,000
LABORATORY TRANSFUSION

5780
03:55:31,000 --> 03:55:32,680
THRESHOLDS SUCH AS

5781
03:55:32,680 --> 03:55:33,400
PRE-TRANSFUSION HEMOBLOW BIN

5782
03:55:33,400 --> 03:55:36,440
LEVEL OR PLATELET COUNTS ARE NOT

5783
03:55:36,440 --> 03:55:38,760
THE MOST EFFECTIVE APPROACH TO

5784
03:55:38,760 --> 03:55:40,720
TRANSFUSION DECISION MAKING AND

5785
03:55:40,720 --> 03:55:44,920
MAY TAKE USE OF LARGER SCALE

5786
03:55:44,920 --> 03:55:46,360
HEMODYNAMIC OR PHYSIOLOGIC

5787
03:55:46,360 --> 03:55:48,280
DAYTIME ON PATIENTS AND

5788
03:55:48,280 --> 03:55:49,520
UNDERSTANDING -- DATA ON

5789
03:55:49,520 --> 03:55:50,600
PATIENTS AND WHICH IS CLINICAL

5790
03:55:50,600 --> 03:55:52,200
DECISION MAKING AND

5791
03:55:52,200 --> 03:55:53,400
EFFECTIVENESS OF WHAT THAT

5792
03:55:53,400 --> 03:55:54,880
TRANSFUSION IS, USING LARGER

5793
03:55:54,880 --> 03:56:02,000
SCALE DATA.  SO THIS IS THE

5794
03:56:02,000 --> 03:56:06,320
FIRST STEP OF PROCESS. WE HAD

5795
03:56:06,320 --> 03:56:08,280
THE OPPORTUNITY TO PRESENT DRAFT

5796
03:56:08,280 --> 03:56:10,880
RESEARCH PRIORITIES AND RECEIVE

5797
03:56:10,880 --> 03:56:12,640
YOUR FEEDBACK AND INPUT.  NEXT

5798
03:56:12,640 --> 03:56:14,920
IS TO HAVE WORKING GROUPS

5799
03:56:14,920 --> 03:56:16,840
RECONVENE TO DIGEST AND THINK

5800
03:56:16,840 --> 03:56:19,040
THROUGH COMMENTS RECEIVED AND

5801
03:56:19,040 --> 03:56:20,960
HOW THAT MAYBE MAY FORMALLY

5802
03:56:20,960 --> 03:56:25,040
REVISE PRIORITIES. WE HAVE

5803
03:56:25,040 --> 03:56:26,200
OPPORTUNITY FOR ADDITIONAL

5804
03:56:26,200 --> 03:56:27,760
DIALOGUE AND FEEDBACK DURING THE

5805
03:56:27,760 --> 03:56:31,720
UP COMING AABB MEETING IN

5806
03:56:31,720 --> 03:56:35,320
OCTOBER. WE ALSO HAVE AN EMAIL

5807
03:56:35,320 --> 03:56:38,000
ADDRESS WHICH WILL BE PROVIDED

5808
03:56:38,000 --> 03:56:42,680
DIRECTLY TO REGISTRANTS BUT LET

5809
03:56:42,680 --> 03:56:44,560
YOU KNOW ADDRESS WILL DIRECTLY

5810
03:56:44,560 --> 03:56:46,480
REACH MEMBERS OF THE ORGANIZING

5811
03:56:46,480 --> 03:56:48,240
COMMITTEE AND MEMBER OF NHLBI

5812
03:56:48,240 --> 03:56:50,960
AND OASH. AS HAS BEEN DONE IN

5813
03:56:50,960 --> 03:56:53,840
THE PAST, THERE MAY BE SPECIFIC

5814
03:56:53,840 --> 03:56:57,080
WORKSHOPS OR SYMPOSIUM THAT

5815
03:56:57,080 --> 03:56:59,000
BASED UPON THIS DISCUSSION, WILL

5816
03:56:59,000 --> 03:57:02,560
BE HELD IN THE FUTURE BY NHLBI

5817
03:57:02,560 --> 03:57:10,160
AND OASH.

5818
03:57:10,160 --> 03:57:13,280
>> SO YES, AS INDICATED
THERE IS

5819
03:57:13,280 --> 03:57:14,600
AN OPPORTUNITY FOR FURTHER

5820
03:57:14,600 --> 03:57:17,200
DIALOGUE SO WE DO ALL RECOGNIZE

5821
03:57:17,200 --> 03:57:18,440
THE EXPERIENCE OF HAVING TO TRY

5822
03:57:18,440 --> 03:57:19,920
TO HAVE THE STATE OF THE SCIENCE

5823
03:57:19,920 --> 03:57:23,120
IN TRANSFUSION MEDICINE AS

5824
03:57:23,120 --> 03:57:24,560
VIRTUAL MEETING, NOT HAD NEARLY

5825
03:57:24,560 --> 03:57:28,600
THE TIME TO REALLY HAVE SIDE BAR

5826
03:57:28,600 --> 03:57:29,840
CONVERSATIONS AND OPPORTUNITIES

5827
03:57:29,840 --> 03:57:31,960
FOR SPARK IDEAS. SO WE ARE VERY

5828
03:57:31,960 --> 03:57:34,040
HAPPY TO BE ABLE TO SAY WILL IS

5829
03:57:34,040 --> 03:57:35,760
ONE MORE IN PERSON OPPORTUNITY

5830
03:57:35,760 --> 03:57:38,040
FOR PEOPLE TO GET TOGETHER AND

5831
03:57:38,040 --> 03:57:41,760
TALK ABOUT THE WORK DONE HERE BY

5832
03:57:41,760 --> 03:57:42,840
ALL WORKING GROUPS AND WHAT IS

5833
03:57:42,840 --> 03:57:44,040
PRESENTED THE LAST COUPLE OF

5834
03:57:44,040 --> 03:57:46,480
DAYS. THAT IS GOING TO BE THE

5835
03:57:46,480 --> 03:57:48,280
AABB NATIONAL BLOOD FOUNDATION

5836
03:57:48,280 --> 03:57:49,960
RESEARCH AND DEVELOPMENT FORUM

5837
03:57:49,960 --> 03:57:51,520
THAT WILL TAKE PLACE AT THE

5838
03:57:51,520 --> 03:57:54,520
ANNUAL MEETING. TO BE HELD

5839
03:57:54,520 --> 03:57:57,040
OCTOBER 3 FROM 7 A.M. TO 8:30,

5840
03:57:57,040 --> 03:57:58,280
NOT A LONG PERIOD BUT IT IS

5841
03:57:58,280 --> 03:58:01,360
GOING TO ALLOW US SIX

5842
03:58:01,360 --> 03:58:02,760
SIMULTANEOUS ROUND TABLE

5843
03:58:02,760 --> 03:58:04,760
DISCUSSIONS LED BY ONE OR MORE

5844
03:58:04,760 --> 03:58:06,960
WORK GROUP CHAIRS AND MEMBERS.

5845
03:58:06,960 --> 03:58:08,960
SO AGAIN PEOPLE WILL MEET

5846
03:58:08,960 --> 03:58:10,000
SIMULTANEOUSLY, THIS MEANS YOU

5847
03:58:10,000 --> 03:58:11,440
WILL HAVE TO CHOOSE SPECIFIC

5848
03:58:11,440 --> 03:58:13,640
GROUP IF YOU CHOOSE TO

5849
03:58:13,640 --> 03:58:16,200
PARTICIPATE IN THE MEETING

5850
03:58:16,200 --> 03:58:18,720
ITSELF, BUT WHAT IT ALSO WILL BE

5851
03:58:18,720 --> 03:58:21,240
IS AN OPPORTUNITY FOR ADDITIONAL

5852
03:58:21,240 --> 03:58:22,120
60 MINUTES OF CONVERSATION ABOUT

5853
03:58:22,120 --> 03:58:25,360
EACH OF THE RESEARCH PRIORITIES 

5854
03:58:25,360 --> 03:58:27,000
SO WHAT YOU CAN DO IS IF YOU DO

5855
03:58:27,000 --> 03:58:30,000
SIGN UP FOR THE AABB ANNUAL

5856
03:58:30,000 --> 03:58:31,680
MEETING YOU CAN SELECT ONE OF

5857
03:58:31,680 --> 03:58:33,920
THE ACTUAL ACTIVITIES YOU WILL

5858
03:58:33,920 --> 03:58:35,360
ATTEND SO IT IS IMPORTANT FOR

5859
03:58:35,360 --> 03:58:36,800
YOU TO BE ABLE TO -- IF YOU WANT

5860
03:58:36,800 --> 03:58:38,680
TO PARTICIPATE IN THAT SIGN UP

5861
03:58:38,680 --> 03:58:39,800
SO THEY CAN MAKE SURE TO

5862
03:58:39,800 --> 03:58:41,040
ACCOMMODATE ALL INTERESTED

5863
03:58:41,040 --> 03:58:42,600
INDIVIDUALS WHO WANT TO

5864
03:58:42,600 --> 03:58:50,120
PARTICIPATE.  IN ADDITION TO

5865
03:58:50,120 --> 03:58:53,560
THAT DIALOGUE, BETWEEN NOW AND

5866
03:58:53,560 --> 03:58:56,120
BEGINNING OF OCTOBER IS A CHANCE

5867
03:58:56,120 --> 03:58:58,720
FOR THE WORKING GROUPS TO

5868
03:58:58,720 --> 03:58:59,960
RECONVENE AND THINK HOW THEY

5869
03:58:59,960 --> 03:59:03,280
MIGHT MODIFY OR LISTEN TO AND

5870
03:59:03,280 --> 03:59:04,360
REFLECT ON THE COMMENTS

5871
03:59:04,360 --> 03:59:06,360
RECEIVED. THEN THERE IS THE

5872
03:59:06,360 --> 03:59:07,040
LISTENING SESSION AND

5873
03:59:07,040 --> 03:59:08,400
OPPORTUNITY FOR THE ROUND TABLE

5874
03:59:08,400 --> 03:59:11,840
DISCUSSIONS AS PARTS OF THE

5875
03:59:11,840 --> 03:59:14,080
FORUM, WHAT HAPPENS WITH ALL

5876
03:59:14,080 --> 03:59:15,840
THAT INFORMATION? THERE IS

5877
03:59:15,840 --> 03:59:17,120
DIFFERENT REPORTS GENERATED, OF

5878
03:59:17,120 --> 03:59:19,840
COURSE VERY MUCH IN KEEPING WITH

5879
03:59:19,840 --> 03:59:21,240
PREVIOUS STATE OF THE SCIENCE

5880
03:59:21,240 --> 03:59:23,200
AND TRANSFUSION MEDICINE. FIRST

5881
03:59:23,200 --> 03:59:24,440
REPORT WILL BE WRITTEN REPORT

5882
03:59:24,440 --> 03:59:25,960
PRIORITIES DEVELOPED AND WORK

5883
03:59:25,960 --> 03:59:27,920
CLOSELY TO DEFINE NHLBI WEBSITE

5884
03:59:27,920 --> 03:59:29,160
AND SHARED WITH OTHER

5885
03:59:29,160 --> 03:59:30,280
ORGANIZATIONS. THIS WILL BE THE

5886
03:59:30,280 --> 03:59:31,920
FIRST FORMAL REPORT OF THE

5887
03:59:31,920 --> 03:59:34,600
PROCEEDINGS, OF THE 2022 SOS

5888
03:59:34,600 --> 03:59:36,720
TRANSFUSION MEDICINE. IT WILL

5889
03:59:36,720 --> 03:59:39,280
INCLUDE OVERARCHING INTRODUCTORY

5890
03:59:39,280 --> 03:59:40,840
COMMENTS WE WILL WRITE AS

5891
03:59:40,840 --> 03:59:41,840
ORGANIZING COMMITTEE AND HIGH

5892
03:59:41,840 --> 03:59:43,560
LEVEL SUMMARY OF THE LIST OF

5893
03:59:43,560 --> 03:59:44,680
PRIORITIES DEVELOPED BY EACH

5894
03:59:44,680 --> 03:59:47,480
WORKING GROUP. WE ALSO WILL

5895
03:59:47,480 --> 03:59:49,280
FOCUS ON CROSS CUTTING THEMES

5896
03:59:49,280 --> 03:59:50,720
IDENTIFIED BY MORE THAN ONE

5897
03:59:50,720 --> 03:59:53,040
GROUP WHAT WE THINK THAT MEANS,

5898
03:59:53,040 --> 03:59:54,960
EXPECTED TIME LINE FOR THIS IS

5899
03:59:54,960 --> 03:59:57,840
LATE OCTOBER TO EARLY NOVEMBER.

5900
03:59:57,840 --> 03:59:59,280
WHERE THIS WOULD BE AVAILABLE ON

5901
03:59:59,280 --> 04:00:01,080
THE WEBSITE SO WE HAVE TO WORK

5902
04:00:01,080 --> 04:00:02,520
THROUGH THAT BUT THAT IS THE

5903
04:00:02,520 --> 04:00:04,240
EXPECTED TIME LINE SO IT WILL BE

5904
04:00:04,240 --> 04:00:06,120
ABOUT A MONTH AFTER THE MEETING

5905
04:00:06,120 --> 04:00:08,840
THAT THIS IS AVAILABLE. IN

5906
04:00:08,840 --> 04:00:10,480
ADDITION THERE IS A FORMAL

5907
04:00:10,480 --> 04:00:11,920
PUBLICATION THAT WILL BE -- THE

5908
04:00:11,920 --> 04:00:15,680
TRUE PROCEEDINGS AS REPORTED,

5909
04:00:15,680 --> 04:00:16,560
MANUSCRIPT DEVELOPED COMBINING

5910
04:00:16,560 --> 04:00:18,720
ALL THE DIFFERENT PRIORITIES AND

5911
04:00:18,720 --> 04:00:21,360
ALSO INCLUDING REFLECTION ON

5912
04:00:21,360 --> 04:00:23,200
PROGRESS WE HAVE MADE AS A

5913
04:00:23,200 --> 04:00:25,360
SCIENTIFIC COMMUNITY SINCE 2015

5914
04:00:25,360 --> 04:00:26,600
STATE OF SCIENCE TRANSFUSION

5915
04:00:26,600 --> 04:00:28,480
MEDICINE. SO WHATEVER WE

5916
04:00:28,480 --> 04:00:30,200
ACHIEVE, WHAT WE HAVE YET TO

5917
04:00:30,200 --> 04:00:32,480
ACHIEVE AND HOW THE NEW

5918
04:00:32,480 --> 04:00:34,840
PRIORITIES LINK TO PREVIOUS

5919
04:00:34,840 --> 04:00:36,560
STATES IN THE SCIENCE. IN

5920
04:00:36,560 --> 04:00:37,960
ADDITION, ONE OF THE THINGS WE

5921
04:00:37,960 --> 04:00:39,200
HAVE BEEN EXCITED TO BE ABLE TO

5922
04:00:39,200 --> 04:00:43,360
TELL ALL THE WORKING GROUP

5923
04:00:43,360 --> 04:00:45,360
MEMBERS AND PARTICIPANTS IS THE

5924
04:00:45,360 --> 04:00:47,560
OPPORTUNITY FOR TRUE DEEP DIVE

5925
04:00:47,560 --> 04:00:49,040
THEY HAVE DONE THINKING WHAT THE

5926
04:00:49,040 --> 04:00:51,680
RESEARCH PRIORITIES SHOULD BE,

5927
04:00:51,680 --> 04:00:53,040
AND OPPORTUNITY TO WITHIN THAT

5928
04:00:53,040 --> 04:00:54,800
WORKING GROUP PUBLISH ALL NOSE

5929
04:00:54,800 --> 04:00:56,920
PRIORITIES ALLOWING MORE

5930
04:00:56,920 --> 04:01:00,640
INFORMATION OPT PRIORITIES

5931
04:01:00,640 --> 04:01:02,760
THEMSELVES, THEY HAVE DEVELOPED

5932
04:01:02,760 --> 04:01:05,360
AND EXTANT LITERATURE THAT

5933
04:01:05,360 --> 04:01:06,560
UNDERPINS, SO THAT IS AVAILABLE

5934
04:01:06,560 --> 04:01:08,200
BUT NOT A REQUIREMENT FOR EACH

5935
04:01:08,200 --> 04:01:10,840
WORKING GROUP TO BE ABLE TO TAKE

5936
04:01:10,840 --> 04:01:13,360
ON OR TACKLE. I SUSPECT ALL SIX

5937
04:01:13,360 --> 04:01:15,280
WORKING GROUPS MAY END UP

5938
04:01:15,280 --> 04:01:16,320
DEVELOPING THE -- THERE WILL BE

5939
04:01:16,320 --> 04:01:18,200
SOME CRITICAL PUBLICATIONS THAT

5940
04:01:18,200 --> 04:01:22,560
FELLOWS HERE IN 2022 OR

5941
04:01:22,560 --> 04:01:23,680
REALICSICLY 2023 STATE OF THE

5942
04:01:23,680 --> 04:01:25,000
SCIENCE WITH RESPECT TO EACH SIX

5943
04:01:25,000 --> 04:01:26,440
PRIMARY TOPICS THAT HAVE BEEN

5944
04:01:26,440 --> 04:01:27,800
THE THEMES FOR THE DIFFERENT

5945
04:01:27,800 --> 04:01:35,360
WORKING GROUPS.  WE HAVE COVERED

5946
04:01:35,360 --> 04:01:37,240
A LOT. IN THE LAST COUPLE OF

5947
04:01:37,240 --> 04:01:39,480
DAYS AND WE WANT TO THANK

5948
04:01:39,480 --> 04:01:40,720
EVERYONE OF YOU FOR

5949
04:01:40,720 --> 04:01:43,440
PARTICIPATING IN THE 2022 STOT

5950
04:01:43,440 --> 04:01:44,000
OF THE SCIENCE TRANSFUSION

5951
04:01:44,000 --> 04:01:45,720
MEDICINE AND FOR ALL THE

5952
04:01:45,720 --> 04:01:48,400
COMMENTS AND DIALOGUE EVEN

5953
04:01:48,400 --> 04:01:50,720
THOUGH THIS VIRTUAL FORMAT IS

5954
04:01:50,720 --> 04:01:52,320
NEW FOR EXCHANGING SCIENTIFIC

5955
04:01:52,320 --> 04:01:55,000
IDEAS WE HAVE HAD A FANTASTIC

5956
04:01:55,000 --> 04:01:57,400
INPUT FROM WORKING GROUP

5957
04:01:57,400 --> 04:02:00,000
PARTICIPANTS AND PEOPLE WHO

5958
04:02:00,000 --> 04:02:01,960
PARTICIPATED AS JUST BEING PART

5959
04:02:01,960 --> 04:02:04,000
OF THIS TWO DAY INTERACTION.

5960
04:02:04,000 --> 04:02:05,680
AGAIN, THANK YOU ALL VERY MUCH. 

5961
04:02:05,680 --> 04:02:12,920
I ALSO WANT TO THANK DR. NAREG

5962
04:02:12,920 --> 04:02:15,480
ROUBINIAN FOR BEING CO-CHAIR,

5963
04:02:15,480 --> 04:02:17,560
DR. GLENN FOR THE SUPPORT FROM

5964
04:02:17,560 --> 04:02:19,720
THE ORGANIZING COMMITTEE, THE IT

5965
04:02:19,720 --> 04:02:21,160
STAFF AND EVERYBODY ELSE AT

5966
04:02:21,160 --> 04:02:22,600
NHLBI, THANK YOU SO MUCH. L WE

5967
04:02:22,600 --> 04:02:26,040
ARE NOT DONE. WE ARE JUST

5968
04:02:26,040 --> 04:02:28,360
BEGINNING P DIALOGUE BUT YOU CAN

5969
04:02:28,360 --> 04:02:29,560
SEE WHAT I PRESENTED ON THE LAST

5970
04:02:29,560 --> 04:02:30,160
SLIDE WHAT THE NEXT STEPS WILL

5971
04:02:30,160 --> 04:02:31,360
BE OVER THE COUPLE OF COMING

5972
04:02:31,360 --> 00:00:00,000
MONTHS.  THANK YOU, EVERYBODY.